[
  {
    "chunk_id": "roche_2023_001",
    "content": "annual report 2023 sustainable innovation at our core innovation is at the core of everything we do. we are committed to transform lives. pushing boundaries, we pursue ground-breaking solutions across all our functions. doing now what patients need next, we look ahead to create a healthy and stable future for people and the planet. with pharmaceuticals and diagnostics under one roof , we are uniquely positioned to improve care along the patient journey. by investing in cutting-edge research and collaborative partnerships, we continue to transform ideas into life-changing solutions for people and communities worldwide. 2  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report letters to shareholders 4 sustainability report 14 how we contribute 96 corporate governance 122 remuneration report 148contents roche.comreportingannual report 2023  roche 3 4  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report letters to shareholdersletters to shareholders  roche 5 dr severin schwan6  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report dear shareholders at roche, the year 2023 was marked by significant management changes. i am very pleased that my successor as ceo, thomas schinecker, and his leadership team have already embarked on a series of important initiatives. roche is characterised by its ability to combine continuity and change. we remain committed to our values and our strategy, and at the same time, we evolve as an organisation, and initiate necessary changes accordingly. we are convinced that our strategy, which is focused on innovation in pharmaceuticals and diagnostics, ensures we remain in a strong position. our consistent ability to successfully bring new products to patients is a hallmark of our company  particularly last year when we were able to offset the expected significant decline in the covid-19 business with new products. our ability to innovate will remain the key success factor for roche in the future. for this, we need the courage to take risks. in our industry, only a handful of molecules make the leap from development to approved medicine. and roche is no exception: we have also had to overcome some setbacks in recent times, such as with a new compound against alzheimers. the patients are at the heart of all our endeavours. and that is exactly what motivates us to keep creating a better framework in order to maintain, foster and strengthen the creativity and innovative spirit at roche. this starts with the companys culture and the incredibly talented people who work here. yet, at the same time, we must keep looking for opportunities to make our work even more efficient along the entire value chain. this includes, for instance, testing and developing new methods in research and development. one great example of this is the foundation of the institute of human biology ihb in basel last year.",
    "word_count": 467,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_002",
    "content": "this includes, for instance, testing and developing new methods in research and development. one great example of this is the foundation of the institute of human biology ihb in basel last year. the institute is focused on, among other things, research on organoids  miniature models of organs or tissues that are grown in the laboratory and used for researching diseases without having to rely on real organs. this also means we can reduce animal testing even further while accelerating and improving the development of much needed innovative treatments. as important as our own innovative strength is, a large proportion of innovation takes place outside our company. for that reason, securing even more long-term partnerships with academic institutions, hospitals and other companies remains an essential part of our strategy. for example, the recent acquisition of telavant provides the opportunity for us to combat various autoimmune diseases with a promising new mechanism of action. and with the acquisition of carmot, we are able to tap into potential new medicines in obesity and other metabolic diseases. after all, innovation is only sustainable if it reaches the patients who need it most. one of our key priorities therefore remains to facilitate and improve worldwide access to our medicines and diagnostic tests.chairmans shareholder letter  roche 7 roche board of directors on 31 december 2023 dr severin schwan 1967, chairman, d, e andr\u00e9 hoffmann 1958, vice-chairman, representative of the shareholder group with pooled voting rights, a, c, d, e, g dr j\u00f6rg duschmal\u00e9 1984, representative of the shareholder group with pooled voting rights, b, c, e, g dr patrick frost 1968, b, e, g anita hauser 1969, c, d, e, g prof. dr akiko iwasaki 1970, a, e, g prof. dr richard p . lifton 1953, c, e, g dr jemilah mahmood 1959, a, e, g bernard poussot 1952, c, e, g dr mark schneider 1965, b, e, g dr claudia suessmuth dyckerhoff 1967, a, b, e, g a corporate governance and sustainability committee  b audit committee  c remuneration committee  d chairmansnomination committee e non-executive director  f executive director  currently no member   g independent member of the board of directors   committee chairperson8  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report from a results perspective, 2023 was again a good year for roche. in spite of the expected decline in sales from our covid-19 products of chf 4.3 billion, total sales rose by 1 at constant exchange rates, and ifrs net income came to chf 12.4 billion. the board of directors therefore proposes to the annual general meeting an increase in the dividend of 1 to chf 9.60 per share. if approved, this will be the 37th consecutive increase. lastly, the past year was also marked by geopolitical uncertainties, major conflicts, war, terror and the dreadful impact these events had on those affected. in such situations, it becomes even more important to ensure that patients continue to receive our medicines and diagnostic tests.",
    "word_count": 491,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "om a results perspective, 2023 was again a good year for roche. in spite of the expected decline in sales from our covid-19 products of chf 4.3 billion, total sales rose by 1 at constant exchange rates, an",
            "position": 2441,
            "sentence": "in spite of the expected decline in sales from our covid-19 products of chf 4.3 billion, total sales rose by 1 at constant exchange rates, and ifrs net income came to chf 12.4 billion."
          },
          {
            "keyword": "sales",
            "context": "che. in spite of the expected decline in sales from our covid-19 products of chf 4.3 billion, total sales rose by 1 at constant exchange rates, and ifrs net income came to chf 12.4 billion. the board of di",
            "position": 2500,
            "sentence": "in spite of the expected decline in sales from our covid-19 products of chf 4.3 billion, total sales rose by 1 at constant exchange rates, and ifrs net income came to chf 12.4 billion."
          },
          {
            "keyword": "net income",
            "context": "ur covid-19 products of chf 4.3 billion, total sales rose by 1 at constant exchange rates, and ifrs net income came to chf 12.4 billion. the board of directors therefore proposes to the annual general meeting a",
            "position": 2553,
            "sentence": "in spite of the expected decline in sales from our covid-19 products of chf 4.3 billion, total sales rose by 1 at constant exchange rates, and ifrs net income came to chf 12.4 billion."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_003",
    "content": "lastly, the past year was also marked by geopolitical uncertainties, major conflicts, war, terror and the dreadful impact these events had on those affected. in such situations, it becomes even more important to ensure that patients continue to receive our medicines and diagnostic tests. our employees devote themselves to achieving this goal with great passion and dedication every single day. i would like to thank them for their tireless efforts. and thank you, dear shareholders, for placing your trust in us. dr severin schwan chairman unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf.chairmans shareholder letter  roche 9 dr thomas schinecker10  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report dear shareholders 2023 was both a demanding and a successful year for roche  with strong business performance, promising medical advances and key partnerships and acquisitions. this was also the year in which the world health organization declared the end of the coronavirus pandemic. we at roche are proud of the significant contributions we made towards achieving this objective. the return to normality consequently led to a decline in our covid-19 sales. given this, our annual result is all the more impressive: with sales of chf 58.7 billion  an increase of 1 at constant exchange rates  we more than offset the decline in covid-19 sales and the impact of biosimilargeneric erosion. overall, we were able to compensate more than chf 6.4 billion  which is more than 10 of our sales. this success is rooted in our strong base business without cov id -19 products, which grew by 8 thanks to the high demand for our newer diagnostics and medicines. one particular highlight is vabysmo, an innovative medicine for the treatment of eye diseases that can lead to blindness. around 70 million people worldwide currently suffer from wet age-related macular degeneration, diabetic macular oedema or retinal vein occlusion. for many elderly people, vabysmo already offers new hope: it may help them to maintain  or even regain  eyesight and thus independence. vabysmo made a significant contribution to the companys growth in 2023 and has been one of the most successful product launches in roches history.we have also achieved other important milestones for patients in 2023. our innovative immunotherapies columvi and lunsumio, both bispecific antibodies aimed at activating the bodys own immune system, opened up new avenues in the combat against blood cancer. columvi has shown promising results for people with an aggressive form of blood cancer who have already received several treatments and are in urgent need of new options. lunsumio offers new promise to patients with a special type of follicular lymphoma, a disease that progresses slowly and has been incurable until now. the positive phase iii data for alecensa and inavolisib in lung and breast cancer, respectively, are further highlights.",
    "word_count": 484,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "rds achieving this objective. the return to normality consequently led to a decline in our covid-19 sales. given this, our annual result is all the more impressive: with sales of chf 58.7 billion  an incre",
            "position": 1353,
            "sentence": "the return to normality consequently led to a decline in our covid-19 sales."
          },
          {
            "keyword": "sales",
            "context": "to a decline in our covid-19 sales. given this, our annual result is all the more impressive: with sales of chf 58.7 billion  an increase of 1 at constant exchange rates  we more than offset the decline i",
            "position": 1423,
            "sentence": "given this, our annual result is all the more impressive: with sales of chf 58.7 billion  an increase of 1 at constant exchange rates  we more than offset the decline in covid-19 sales and the impact of biosimilargeneric erosion."
          },
          {
            "keyword": "sales",
            "context": "7 billion  an increase of 1 at constant exchange rates  we more than offset the decline in covid-19 sales and the impact of biosimilargeneric erosion. overall, we were able to compensate more than chf 6.4",
            "position": 1539,
            "sentence": "given this, our annual result is all the more impressive: with sales of chf 58.7 billion  an increase of 1 at constant exchange rates  we more than offset the decline in covid-19 sales and the impact of biosimilargeneric erosion."
          },
          {
            "keyword": "sales",
            "context": "rosion. overall, we were able to compensate more than chf 6.4 billion  which is more than 10 of our sales. this success is rooted in our strong base business without cov id -19 products, which grew by 8 th",
            "position": 1682,
            "sentence": "overall, we were able to compensate more than chf 6.4 billion  which is more than 10 of our sales."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_004",
    "content": "lunsumio offers new promise to patients with a special type of follicular lymphoma, a disease that progresses slowly and has been incurable until now. the positive phase iii data for alecensa and inavolisib in lung and breast cancer, respectively, are further highlights. alecensa  which is already effective in a specific form of advanced lung cancer  now offers the chance of cure to those in the early stages of the disease. inavolisib could prove to be a medical breakthrough for a form of advanced, hard-to-treat breast cancer. at roche, we have a long tradition of complementing our own research and development activities with external partnerships. 2023 was no different: by partnering with alnylam, we gained access to an investigational therapeutic for treating high blood pressure, a disease that affects 1.2 billion people and cannot be adequately controlled with treatments currently available. with telavant, we acquired a potential treatment for inflammatory bowel disease and other immune-m ediated diseases. in addition, our acquisition of carmot has the potential to enrich our portfolio with a range of programmes in obesity and other metabolic disorders. unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf. biosimilarsgenerics for avastin, herceptin, mabtherarituxan, lucentis and esbrietshareholder letter ceo roche group  roche 11 roche corporate executive committee on 31 december 2023 dr thomas schinecker 1975, ceo roche group teresa graham 1973, ceo roche pharmaceuticals matt sause 1977, ceo roche diagnostics dr alan hippe 1967, chief financial and information officer cristina a. wilbur 1967, chief people officer claudia b\u00f6ckstiegel 1964, general counsel prof. dr hans clevers 1957, head roche pharma research and early development pred dr levi garraway 1968, head global product development and chief medical officer silke h\u00f6rnstein 1975, head corporate strategy and sustainability dr aviv regev 1971, head genentech research and early development gred dr james h. sabry 1958, global head pharma partnering barbara sch\u00e4dler 1962, head group communications  member of the enlarged corporate executive committee12  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report it is well-known that you can only treat what you know. patient care always begins with a diagnosis  its importance is immense. modern diagnostics are pivotal for early detection of diseases and targeted treatments, for example in infection- related conditions such as sepsis. often called blood poisoning, sepsis is a leading cause of death in newborns. with elecsys il -6, the worlds first immunoassay for the diagnosis of sepsis in newborns, we are setting a new standard in the fight against this severe condition. early diagnosis and treatment monitoring are also crucial for neurological diseases. in 2023, roche made significant progress in this area. for example, our elecsys nfl test obtained breakthrough device designation from the fda. this minimally invasive test helps to detect disease activity in certain forms of multiple sclerosis and could therefore support better disease management.",
    "word_count": 490,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "strategic_initiatives": [
          {
            "keyword": "product development",
            "context": "vers 1957, head roche pharma research and early development pred dr levi garraway 1968, head global product development and chief medical officer silke h\u00f6rnstein 1975, head corporate strategy and sustainability dr aviv",
            "position": 1934,
            "sentence": "dr hans clevers 1957, head roche pharma research and early development pred dr levi garraway 1968, head global product development and chief medical officer silke h\u00f6rnstein 1975, head corporate strategy and sustainability dr aviv regev 1971, head genentech research and early development gred dr james h."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_005",
    "content": "for example, our elecsys nfl test obtained breakthrough device designation from the fda. this minimally invasive test helps to detect disease activity in certain forms of multiple sclerosis and could therefore support better disease management. we also launched the navify algorithm suite, a digital library of medical algorithms that help improve clinical decision-making through the combination of different data points. this library is already enabling better diagnoses in cardiology and oncology and is being continuously expanded. we have achieved a lot, and i would like to thank all of our more than 100,000 employees worldwide for their outstanding commitment to improving patients lives! 2023 also marks my first year as ceo of roche, a time full of exciting new challenges and opportunities. during these months, i had many in-depth, extensive and rewarding conversations with colleagues, customers, patients and other stakeholders to listen and learn. in these conversations, two important insights were reaffirmed. first, at roche we work with fantastic people who are passionate about our company and mission. i am honoured to have been part of this team for over 20 years. second, innovation remains at the core of our company. over the past ten years, we have brought more than 20 new medicines to patients and thus successfully diversified our portfolio. today, we are leading not only in cancer treatments but also in neuroscience, ophthalmology and haemophilia a. we are also the market leader in in-vitro diagnostics. in order to keep delivering innovative medicines and diagnostics, it is clear that research-driven companies like roche must continue to push scientific frontiers. therefore, my personal focus during the first few months as ceo was to work with our teams to find ways to further strengthen our pipeline and ability to innovate. together, we have laid the foundation for the future. one example is digitalisation, which includes the increased use of artificial intelligence at all stages of the drug development process. strengthening our research and development engine also forms the basis for increasing the value of our company. at roche  with pharmaceuticals, diagnostics and digital solutions under one roof  we are uniquely positioned to continue to develop breakthrough innovations for patients around the world. i would like to thank everyone who worked with us in 2023 to improve the lives of patients. and thank you, our valued shareholders, for the trust you have placed in our company. dr thomas schinecker ceo roche groupshareholder letter ceo roche group  roche 13 14  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report sustainability report 1. our approach to sustainability 16 1.1 our purpose 22 1.2 our strategy and our business model 24 2. business performance 26 2.1 roche group 28 2.2 diagnostics 30 2.3 pharmaceuticals 36 3. our reporting approach 42 3.1 our key sustainability topics 44 4. partnering with patients 46 5. access to healthcare 50 6. diversity, equity and inclusion 54 7. safety, health and well-being 60 8. ethical business practices and human rights 64 9. environment 78 10.",
    "word_count": 500,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "ey sustainability topics 44 4. partnering with patients 46 5. access to healthcare 50 6. diversity, equity and inclusion 54 7. safety, health and well-being 60 8. ethical business practices and human rights",
            "position": 3081,
            "sentence": "access to healthcare 50 6."
          }
        ]
      },
      "COMPANY_STATE": {
        "market_position": [
          {
            "keyword": "market leader",
            "context": "nly in cancer treatments but also in neuroscience, ophthalmology and haemophilia a. we are also the market leader in in-vitro diagnostics. in order to keep delivering innovative medicines and diagnostics, it is cl",
            "position": 1498,
            "sentence": "we are also the market leader in in-vitro diagnostics."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_006",
    "content": "ethical business practices and human rights 64 9. environment 78 10. global citizenship 84 11. information security 88 independent practitioner s limited assurance report 92sustainability report  roche 15 sustainability is built into our business strategy and is part of everyones job at roche. we engage regularly and systematically with our internal and external stakeholders to understand their needs and build mutual trust. our holistic approach to sustainability integrates three dimensions: society. we contribute to a better society by developing new medicines and ways of diagnosing disease which provide life-changing benefits for patients. we have a deep respect for the human rights of everyone we reach  especially patients, business partners, suppliers, local communities and, of course, our colleagues around the world. it is why we emphasise employee safety, health and development while promoting diversity, equity and inclusion, integrity, mutual respect, and equal opportunities for all. environment. respect for a healthy planet and the environment has always been a priority of the company. we are committed to halving the environmental impact of our operations and products from 2019 to 2029. and we aim to reduce our own greenhouse gas emissions to absolute zero by 2050, while partnering with our suppliers to reduce their emissions for our mutual benefit. economy. our business must meet the needs of patients and continue creating quality jobs that provide people and their families with secure livelihoods, while earning competitive returns for our investors. we do this by promoting innovation and by translating science into pioneering medicines and diagnostics that help patients live longer, better and more productive lives  enabling them to support themselves and contribute to their local economies. our commitments and initiatives roche is dedicated to working with partners across and beyond our sector to amplify our collective social and environmental impact. we are committed to several global sustainability initiatives, including:  united nations sustainable development goals roche contributes to a number of the 2030 united nations sustainable development goals sdgs and its 169 specific targets within the sphere of our work. we have a particularly important role to play in contributing to sdg 3, good health and well-being, and its associated targets. good health plays a foundational role in supporting strong societal and economic development. united nations global compact roche has been a signatory to the united nations global compact ungc since 2021. our communication on progress cop confirms our commitment to integrating the ungc principles on human rights, labour, environment and anti-corruption across our strategy, culture and day-to-day operations, and to advancing global development goals  in particular the 2030 united nations sdgs. science based targets initiative roche has committed to the science based targets initiative sbti to achieve absolute net zero for scope 1, 2 and 3 greenhouse gas emissions. the sbti drives necessary climate action in the private sector by enabling 1. our approach to sustainability our purpose is: doing now what patients need next.",
    "word_count": 481,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "he world. it is why we emphasise employee safety, health and development while promoting diversity, equity and inclusion, integrity, mutual respect, and equal opportunities for all. environment. respect for",
            "position": 924,
            "sentence": "it is why we emphasise employee safety, health and development while promoting diversity, equity and inclusion, integrity, mutual respect, and equal opportunities for all."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_007",
    "content": "the sbti drives necessary climate action in the private sector by enabling 1. our approach to sustainability our purpose is: doing now what patients need next. how we identify and meet those needs  what we do every day  must be sustainable if we are to succeed.16  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report sustainability is built into our business strategy and is part of everyones job at roche.our approach to sustainability  roche 17 organisations to set science-based emissions reduction targets. the sbti is a partnership between the carbon disclosure project cdp, the ungc, the world resources institute wri and the world wide fund for nature wwf, and its emissions reduction guidance for businesses has become recognised globally as the gold standard. sustainable markets initiative smi roche has joined the smi health systems task force to address emissions across supply chains, patient care pathways and clinical trials. the smi health systems task force launched at the 26th united nations climate change conference cop26 with the central aim of accelerating the delivery of net-zero, patient- centric healthcare systems that improve individual, societal and planetary health. the public-private partnership brings together ceos and leaders from astrazeneca, gsk, merck, novo nordisk, roche, samsung biologics, sanofi, the karolinska institutet, national health service england, the sustainable healthcare coalition, unicef, the university of pavia and the who. pharmaceutical supply chain initiative roche is a member of the pharmaceutical supply chain initiative psci, a collaboration of more than 40 pharmaceutical companies and suppliers with a shared vision to establish and promote responsible business practices that continuously improve human rights, ethics, labour, health, safety and environmentally sustainable outcomes for pharmaceutical supply chains the psci principles. our risk assessment and management process our risk management policy1 sets out roches approach to identifying, analysing, managing and reporting internal and external risks and opportunities. a consolidated group risk report covering all material risks and opportunities is discussed with the corporate executive committee and reviewed by the board of directors annually. the effectiveness of roches group risk management process is regularly monitored by the group risk advisory team. the overall process is reviewed by the audit committee of the board of directors and also externally when appropriate. risk management is embedded at all levels of the roche group. our pharmaceuticals and diagnostics divisions and global functions conduct a formal risk and opportunity assessment at least once a year and must develop response plans for their most material risks and opportunities. read more in corporate governance on page 122 . we also identify long-term business environment trends and the associated risks and opportunities on an annual basis and integrate these into our group risk management process. each year, emerging trends are identified from internal and external sources. our sustainability steering committee then evaluates and selects the trends and the associated risks and opportunities most relevant to roche.",
    "word_count": 479,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "guidance",
            "context": "e world resources institute wri and the world wide fund for nature wwf, and its emissions reduction guidance for businesses has become recognised globally as the gold standard. sustainable markets initiative",
            "position": 754,
            "sentence": "the sbti is a partnership between the carbon disclosure project cdp, the ungc, the world resources institute wri and the world wide fund for nature wwf, and its emissions reduction guidance for businesses has become recognised globally as the gold standard."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_008",
    "content": "each year, emerging trends are identified from internal and external sources. our sustainability steering committee then evaluates and selects the trends and the associated risks and opportunities most relevant to roche. sustainability risks and opportunities in focus we have also established a diligent business sustainability risk and opportunity assessment process to identify, assess and mitigate significant social, environmental and economic risks and opportunities that could impact our business objectives and protect the interests of our stakeholders in the long term. 1 go.roche.comrisk-management-policy 18  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report mistrust and scepticism in science healthcare evolution challenged by its affordabilityclimate action failure, environmental degradation with increasing biodiversity loss lasting economic instabilitywidespread increase in chronic physical and mental health conditions and infectious diseases wide, persistent spread of false information deliberate or unintended by states, populists and media can instil mistrust even in the most advanced science and knowledge. as healthcare evolves towards a continuum-of-care approach, offering a full range of solutions from prevention and detection to cure at a fair value proves more challenging.extreme weather events and ecosystem collapses aggravated by climate action failure threaten the stability of the physical business environment and the well-being of its stakeholders. lasting global macroeconomic instability leading to a potential collapse of systemically important industries creates an undercurrent of uncertainty across the business world. continuous and emerging threats to physical and mental well-being leads to rising costs for health systems, threatening societal gains in life expectancy and quality. accelerated technological transformation rapid technological transformation continues to expand opportunities across all sectors but the pace of change increases the unpredictability of its implications on business. societal crisesprogressing cyberdependency and vulnerabilitypolitical complexity and geoeconomic confrontations societal models with limited educational and economic prospects threaten societal solidarity, causing regional instabilities and disrupting interconnected global markets. mounting cyberdependency due to the ever-increasing digital interconnectedness of everyone and everything can lead to over-reliance, creating vulnerabilities. state collapse, armed conflict, regional global instability, shifting political influence and unstable political relationships add to the complexity of the business environment. future of work companies must experiment with agile organisational design and new ways of working to accommodate an increasingly virtual business world and changing workforce demands.business environment trendsour approach to sustainability  roche 19 social, environmental and economic risks and opportunities risk description our actions climate changeas we witness the effects of climate change grow in frequency and intensity, its implications on the business environment become increasingly clear . extreme and unpredictable weather events disrupt company operations and local communities, and the urgent need for climate action is changing the demands and expectations of business stakeholders worldwide. the implications of climate change on global health and the nature and spread of disease is particularly important to health-focused organisations. roche approaches the issue of climate change from a double materiality perspective  acknowledging both our impact on climate change and the influence climate change has on our business.",
    "word_count": 489,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "strategic_initiatives": [
          {
            "keyword": "transformation",
            "context": "ealth systems, threatening societal gains in life expectancy and quality. accelerated technological transformation rapid technological transformation continues to expand opportunities across all sectors but the pac",
            "position": 1922,
            "sentence": "accelerated technological transformation rapid technological transformation continues to expand opportunities across all sectors but the pace of change increases the unpredictability of its implications on business."
          },
          {
            "keyword": "transformation",
            "context": "gains in life expectancy and quality. accelerated technological transformation rapid technological transformation continues to expand opportunities across all sectors but the pace of change increases the unpredict",
            "position": 1957,
            "sentence": "accelerated technological transformation rapid technological transformation continues to expand opportunities across all sectors but the pace of change increases the unpredictability of its implications on business."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_009",
    "content": "the implications of climate change on global health and the nature and spread of disease is particularly important to health-focused organisations. roche approaches the issue of climate change from a double materiality perspective  acknowledging both our impact on climate change and the influence climate change has on our business. we assess climate change-related risk and its implications for our business, which guides our decision-making process and enables us to develop proactive mitigation strategies and enhance our resilience.roche has committed to set near- and long-term company-wide emission reductions in line with science-based net zero with the science based targets initiative sbti. based on our ambitious emissions reduction trajectory2, we outperform all the intergovernmental panel on climate change ipcc scenarios, which limit global warming to 1.5c, all without offsetting our emissions. to ensure we continue on this path, all our sites are required to develop roadmaps towards the sustainable energy future with tangible actions to achieve real zero emissions without offsetting. we are assessing climate change-related risks and are committed to disclosing the updated tcfd report3 in 2024. greenhouse gas emissionsat the 2015 un climate change conference, 196 parties signed a legally binding international treaty on climate change i.e. the paris agreement. with this, the parties committed to reducing their greenhouse gas ghg emissions to limit the effects of global warming. since the conference, countries around the world have advanced action and legislation on ghg emissions reduction, making it a priority for companies, too. guided by the european green deal, european nations and companies are leaders in the energy transition away from fossil fuels. as a result of this, combined with other factors such as the increasingly visible effects of climate change, our stakeholders are demanding emissions reduction results from us and our peers. to mitigate these risks, we are committed to maintaining low levels of ghg emissions as our business and therefore our production continues to grow. our ambitious goal is to eliminate all ghg emissions from our operations and energy purchases by 2050.as the majority of our ghg emissions originate from the transformation and use of energy, we aim to reduce our emissions by reducing our energy consumption and switching to entirely sustainable energy. we do not favour the use of carbon offsetting as an alternative to reducing our emissions. by focusing on emissions reduction and the substitution of non-sustainable energy rather than offsetting, we aim to achieve real zero emissions by 2050. we have set up action plans3 across our sites to reduce ghg emissions. this involves the implementation of innovative technologies and continuous upgrading of infrastructure. we use energy-efficient equipment, continue to evaluate employees travel needs and set the goal of a ghg emissions-free vehicle fleet by 2030. we also change work processes, which is a complex task in highly regulated and approved facilities, and we are focusing our effects on a steady transition to the use of sustainable energy. we are phasing out fossil fuel use and substitute with energies from sustainable sources.",
    "word_count": 496,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "strategic_initiatives": [
          {
            "keyword": "transformation",
            "context": "our operations and energy purchases by 2050.as the majority of our ghg emissions originate from the transformation and use of energy, we aim to reduce our emissions by reducing our energy consumption and switching",
            "position": 2285,
            "sentence": "our ambitious goal is to eliminate all ghg emissions from our operations and energy purchases by 2050.as the majority of our ghg emissions originate from the transformation and use of energy, we aim to reduce our emissions by reducing our energy consumption and switching to entirely sustainable energy."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_010",
    "content": "we also change work processes, which is a complex task in highly regulated and approved facilities, and we are focusing our effects on a steady transition to the use of sustainable energy. we are phasing out fossil fuel use and substitute with energies from sustainable sources. corruption corrupt business behaviour , such as bribery, unfair advantages, theft, fraud, embezzlement and misuse of company assets is persistent in today s interconnected and increasingly competitive world. failure to actively manage this threat has legal and financial implications. it also harms companies reputation and jeopardises their licence to operate. given the broad scope of roche operations worldwide and the different types of relationships with key stakeholders, there is exposure to corruption risk. we reject all forms of corrupt business behaviour and our key expectations regarding integrity are communicated in the roche group code of conduct.4 our behaviour in business directive outlines our approach to anti-corruption and anti-bribery.roche employees and our business-critical business partners complete a mandatory e-learning on compliance5, which covers: bribery and improper advantages, gifts and entertainment, conflict of interest, discrimination and harassment, responsible use of social media and electronic communication tools, and business partners and supply chain. all employees must complete the compliance training when they join roche and undergo periodic refreshers, including whenever the roche group code of conduct is updated. anyone who becomes aware of a potential violation of the roche group code of conduct is encouraged to bring it to the attention of our compliance experts. roche takes all reports of non-compliance seriously and is fully committed to efficiently and timely investigate the facts and take any necessary corrective action. 2 environmental goals: roche.comaboutsustainabilityenvironmentgoals-performance 3 task force on climate-related financial disclosures: go.roche.comclimate-risk-management 4 roche group code of conduct: roche.comaboutgovernancecode-of-conduct 5 behaviour in business: go.roche.combehaviour_in_business20  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report social, environmental and economic risks and opportunities continued risk description our actions human rights in a globalised world, business value chains often span across international borders, giving millions of people an opportunity to participate in the global economy, however this also brings challenges to ensuring workers human rights. as part of roche s global operations with 100,000 employees and thousands of business partners, we are at risk of being involved with negative human rights impacts. in 2023 we conducted a group human rights risk assessment for our own operations and third-party operations. for our own operations, the assessment identified data privacy, access to healthcare and a fair and safe work environment as focus areas. for our supply chain, working conditions, fair treatment and non-discrimination and a healthy work environment were identified as focus areas.roche upholds human rights principles across our own operations and our value chain.",
    "word_count": 455,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "assets",
            "context": "ss behaviour , such as bribery, unfair advantages, theft, fraud, embezzlement and misuse of company assets is persistent in today s interconnected and increasingly competitive world. failure to actively man",
            "position": 404,
            "sentence": "corruption corrupt business behaviour , such as bribery, unfair advantages, theft, fraud, embezzlement and misuse of company assets is persistent in today s interconnected and increasingly competitive world."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_011",
    "content": "for our own operations, the assessment identified data privacy, access to healthcare and a fair and safe work environment as focus areas. for our supply chain, working conditions, fair treatment and non-discrimination and a healthy work environment were identified as focus areas.roche upholds human rights principles across our own operations and our value chain. we have policies in place as well as a risk management approach to mitigate and prevent any infringement on human rights and its adverse impacts, including the assessment of whether there are reasonable grounds to suspect child labour .6 talent attraction, development and retentionthe ability to create an inclusive work environment for people with diverse backgrounds, experiences, skills and ideas is essential for any innovation- based company such as roche. the risk of not doing this well could mean being unable to attract and retain talented people with the innovation capabilities we need to deliver on our ambitions. this is especially the case in the face of an increasing skills shortage in an environment of growing competition from existing and new players and geographies. adapting how we work at roche to navigate new agile and virtual ways of working requires iterative talent strategies, new skills, differentiated leadership and a focus on well-being. we continuously monitor our progress towards our workforce goals to refine our approach and strengthen our talent pipeline.we have introduced strategic workforce planning to identify the skills needed for the future and to prepare to attract and develop employees with these skill sets.7, 8 our global employee opinion survey geos conducted every two years helps us understand employee perceptions and sentiments. we conduct an organisation-wide pay equity analysis every three years. in 2022 we also conducted a living-wage analysis9 and we will repeat this periodically in future. we offer information and programmes to support the physical and mental health and well-being10 of our employees. our oneroche learning  development portfolio enables all employees to access training and development options and become lifelong learners. our leadership commitments11 set clear expectations for all people leaders at roche and we have a series of programmes such as symbiosis designed to continually build leadership capability. several other programmes are available to help managers lead virtual and diverse global teams. 6 for more information about human rights, see page 68. 7 for more information about our dei activities, see page 54 and careers.roche.comglobalendiversity-equity-inclusion 8 roche group employment policy: go.roche.comgroup-employment-policy 9 annual report 2022, reference to living wage, page 110: roche.comar22e.pdf 10 for more information about well-being, see page 60 and careers.roche.comglobalenyour-wellbeing-matters 11 leadership commitments: go.roche.comgroup-employment-policy for all sustainability aspects that were identified as material and where roche can drive greater impact as a company, we have defined key performance indicators kpis which allow us to measure progress on actions implemented. the relevant data points can be found in each section of this report.",
    "word_count": 473,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "years helps us understand employee perceptions and sentiments. we conduct an organisation-wide pay equity analysis every three years. in 2022 we also conducted a living-wage analysis9 and we will repeat th",
            "position": 1786,
            "sentence": "we conduct an organisation-wide pay equity analysis every three years."
          },
          {
            "keyword": "equity",
            "context": "7 for more information about our dei activities, see page 54 and careers.roche.comglobalendiversity-equity-inclusion 8 roche group employment policy: go.roche.comgroup-employment-policy 9 annual report 2022",
            "position": 2613,
            "sentence": "7 for more information about our dei activities, see page 54 and careers.roche.comglobalendiversity-equity-inclusion 8 roche group employment policy: go.roche.comgroup-employment-policy 9 annual report 2022, reference to living wage, page 110: roche.comar22e.pdf 10 for more information about well-being, see page 60 and careers.roche.comglobalenyour-wellbeing-matters 11 leadership commitments: go.roche.comgroup-employment-policy for all sustainability aspects that were identified as material and where roche can drive greater impact as a company, we have defined key performance indicators kpis which allow us to measure progress on actions implemented."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_012",
    "content": "7 for more information about our dei activities, see page 54 and careers.roche.comglobalendiversity-equity-inclusion 8 roche group employment policy: go.roche.comgroup-employment-policy 9 annual report 2022, reference to living wage, page 110: roche.comar22e.pdf 10 for more information about well-being, see page 60 and careers.roche.comglobalenyour-wellbeing-matters 11 leadership commitments: go.roche.comgroup-employment-policy for all sustainability aspects that were identified as material and where roche can drive greater impact as a company, we have defined key performance indicators kpis which allow us to measure progress on actions implemented. the relevant data points can be found in each section of this report. the kpis are reassessed regularly to ensure that they are the most relevant to measure the effectiveness of the actions implemented for the defined topic and meet regulatory transparency requirements.our approach to sustainability  roche 21 1.1 our purpose we believe it is urgent to deliver medical solutions right now  even as we develop innovations for the future. we are passionate about transforming patients lives. we are courageous in both decision and action. and we believe that good business means a better world. that is why we come to work each day. we commit ourselves to scientific rigour , unassailable ethics, and access to medical innovations for all. we do this today to build a better tomorrow. we are proud of who we are, what we do and how we do it. we are many, working as one across functions, across companies and across the world. we are roche.22  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report doing now what patients need nextour purpose  roche 23 we focus on finding new medicines and diagnostics and on establishing data-based insights that evolve the practice of medicine and that help patients live longer, better lives. our business environment is undergoing tremendous change. we are facing new challenges due to the complexity of care and increasing pressure on healthcare budgets. at the same time, we see new opportunities arising from major advances in life sciences and from digitalisation in healthcare. in these turbulent times, we are guided by our common purpose: doing now what patients need next . our company has been bringing novel diagnostics and treatments to patients for more than 125 years. patients are and will remain at the core of what we do. they are the reason we come to work every day. what we do we focus on our vision of fitting treatments to patients: providing the right therapy for the right patient to ensure the best response at the right time for the right value. our approach combines our rich expertise in pharmaceuticals and diagnostics with expanded data science capabilities to drive more effective and efficient research and to enable better therapeutic decisions for patients. our pursuit of excellence in science rests on four key elements: an exceptionally broad and deep understanding of disease biology; the seamless integration of our capabilities in pharmaceuticals and diagnostics; a diversity of approaches to maximise innovation; and a long-term orientation.",
    "word_count": 495,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "7 for more information about our dei activities, see page 54 and careers.roche.comglobalendiversity-equity-inclusion 8 roche group employment policy: go.roche.comgroup-employment-policy 9 annual report 2022",
            "position": 100,
            "sentence": "7 for more information about our dei activities, see page 54 and careers.roche.comglobalendiversity-equity-inclusion 8 roche group employment policy: go.roche.comgroup-employment-policy 9 annual report 2022, reference to living wage, page 110: roche.comar22e.pdf 10 for more information about well-being, see page 60 and careers.roche.comglobalenyour-wellbeing-matters 11 leadership commitments: go.roche.comgroup-employment-policy for all sustainability aspects that were identified as material and where roche can drive greater impact as a company, we have defined key performance indicators kpis which allow us to measure progress on actions implemented."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_013",
    "content": "our approach combines our rich expertise in pharmaceuticals and diagnostics with expanded data science capabilities to drive more effective and efficient research and to enable better therapeutic decisions for patients. our pursuit of excellence in science rests on four key elements: an exceptionally broad and deep understanding of disease biology; the seamless integration of our capabilities in pharmaceuticals and diagnostics; a diversity of approaches to maximise innovation; and a long-term orientation. working in partnership with third parties, we offer integrated solutions with improved medical, health and economic benefits. we work with many different stakeholders in the healthcare ecosystem to broaden access to our offerings for people who need them and, ultimately, to provide a seamless patient journey. we will continue to concentrate our energies on prescription medicines, in vitro diagnostics and increasingly data and insights, rather than diversify into other sectors like generics, biosimilars or over-the -counter medicines. our delivery is to create value for all our stakeholders: being a partner of choice; bringing significant medical benefit for patients, doctors and payers; offering a great place to work for employees; delivering a sustainable positive contribution to society; and earning competitive returns for our investors. how we do it ultimately, delivering on our commitments takes people with integrity, courage and a passion for making a difference for patients. our people are proud to say: we are roche . our leadership inspires outcomes that matter by embracing diversity, equity and inclusion. different backgrounds, perspectives and experiences, across the entire organisation, foster innovative solutions for the benefit of patients. our ways of working enable agile and networked responses to the ever-increasing pace of change by balancing the needs for stability, speed and flexibility. our set-up is designed for innovation. our autonomous research and development centres and alliances with more than 250 external partners foster a diversity of scientific approaches and agility. our global geographical scale and reach enables us to attract talent in the leading global science clusters and to quickly bring our solutions to people who need them.1.2 our strategy and our business model24  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report our focus fitting treatments to patientsour leadership inspiring outcomes that matter our distinctiveness excellence in science our set-up built for innovationour delivery value for all stakeholdersour ways of working agile and networkedour management model our business modelour strategy and our business model  roche 25 in the diagnostics division, the strength of our portfolio combined with the commercial excellence of our affiliates resulted in strong base business growth. in the pharmaceuticals division, we experienced impressive growth in 2023 thanks to advanced medicines like vabysmo severe eye diseases, ocrevus multiple sclerosis, hemlibra haemophilia a, polivy blood cancer and phesgo breast cancer.we are especially excited about the good progress in our product pipeline, notably in oncology, ophthalmology and neurology. additionally, we have forged important partnerships through collaborations and acquisitions in areas of high unmet need. innovation will continue to be at our companys core.",
    "word_count": 496,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "e proud to say: we are roche . our leadership inspires outcomes that matter by embracing diversity, equity and inclusion. different backgrounds, perspectives and experiences, across the entire organisation,",
            "position": 1620,
            "sentence": "our leadership inspires outcomes that matter by embracing diversity, equity and inclusion."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_014",
    "content": "additionally, we have forged important partnerships through collaborations and acquisitions in areas of high unmet need. innovation will continue to be at our companys core. with our strong product portfolio in both divisions and a promising product pipeline, roche is well positioned for future growth.2. business performance 2023 was a demanding and successful year for roche. with good results in our base business, we were able to offset the sharp yet expected drop in covid-19 sales. our diagnostics base business and newer medicines continued to show strong growth.26  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report through the seamless integration of our capabilities in roche pharmaceuticals and roche diagnostics, we are uniquely positioned to achieve medical breakthroughs for patients and society.business performance  roche 27 in 2023, roche achieved sales growth of 1 -7 in chf to chf 58.7 billion, exceeding the companys guidance for the year. this increase more than made up for the expected decline in covid-19-related sales, amounting to chf 4.3 billion, and the effects of biosimilar erosion on our cancer medicines mabtherarituxan, herceptin and avastin, which totalled chf 1. 1 billion  resulting in an overall impact of chf 5.4 billion. the swiss franc significantly appreciated versus most currencies, impacting results when reported in swiss francs compared to constant exchange rates. core operating profit was down 1 -13 in chf to chf 19.2 billion. the good sales performance and a return towards a pre-covid-19 sales mix resulted in an improved gross margin. this was offset by continued investments in pharmaceutical research, development and launches of new products. additionally, the patent settlement income in japan in 2022 affected the growth rate in 2023. ifrs net income increased by 7 -9 in chf to chf 12.4 billion due to the increase in operating profit ifrs and lower income tax expenses. core earnings per share rose by 6 -9 in chf, including the positive impact from the resolution of tax disputes in 2023. sales in the pharmaceuticals division increased by 6 to chf 44.6 billion, with newer medicines for severe diseases continuing their strong growth. the top five growth drivers  vabysmo severe eye diseases, ocrevus multiple sclerosis, 2.1 roche group hemlibra haemophilia a, polivy blood cancer and phesgo breast cancer  achieved total sales of chf 14.8 billion. this represents a plus of chf 4.3 billion compared to 2022. vabysmo, launched only in early 2022, reached sales of chf 2.4 billion, and has become one of the best-selling medicines of roche. the diagnostics divisions base business sales increased by 7, with immunodiagnostic products, particularly cardiac tests, and diagnostics solutions for clinical chemistry and for advanced staining contributing significantly to this growth. overall, the diagnostics division reported sales of chf 14. 1 billion, a decline of 13. this reflects the anticipated significant drop in demand for cov id -19 -related products sales of chf 0.8 billion in 2023, compared to sales of chf 4. 1 billion in 2022.",
    "word_count": 490,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "h good results in our base business, we were able to offset the sharp yet expected drop in covid-19 sales. our diagnostics base business and newer medicines continued to show strong growth.26  contents let",
            "position": 482,
            "sentence": "with good results in our base business, we were able to offset the sharp yet expected drop in covid-19 sales."
          },
          {
            "keyword": "sales",
            "context": "dical breakthroughs for patients and society.business performance  roche 27 in 2023, roche achieved sales growth of 1 -7 in chf to chf 58.7 billion, exceeding the companys guidance for the year. this incre",
            "position": 930,
            "sentence": "our diagnostics base business and newer medicines continued to show strong growth.26  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report through the seamless integration of our capabilities in roche pharmaceuticals and roche diagnostics, we are uniquely positioned to achieve medical breakthroughs for patients and society.business performance  roche 27 in 2023, roche achieved sales growth of 1 -7 in chf to chf 58.7 billion, exceeding the companys guidance for the year."
          },
          {
            "keyword": "sales",
            "context": "guidance for the year. this increase more than made up for the expected decline in covid-19-related sales, amounting to chf 4.3 billion, and the effects of biosimilar erosion on our cancer medicines mabthe",
            "position": 1102,
            "sentence": "this increase more than made up for the expected decline in covid-19-related sales, amounting to chf 4.3 billion, and the effects of biosimilar erosion on our cancer medicines mabtherarituxan, herceptin and avastin, which totalled chf 1."
          },
          {
            "keyword": "sales",
            "context": "constant exchange rates. core operating profit was down 1 -13 in chf to chf 19.2 billion. the good sales performance and a return towards a pre-covid-19 sales mix resulted in an improved gross margin. thi",
            "position": 1550,
            "sentence": "core operating profit was down 1 -13 in chf to chf 19.2 billion."
          },
          {
            "keyword": "sales",
            "context": "wn 1 -13 in chf to chf 19.2 billion. the good sales performance and a return towards a pre-covid-19 sales mix resulted in an improved gross margin. this was offset by continued investments in pharmaceutica",
            "position": 1604,
            "sentence": "the good sales performance and a return towards a pre-covid-19 sales mix resulted in an improved gross margin."
          },
          {
            "keyword": "sales",
            "context": "are rose by 6 -9 in chf, including the positive impact from the resolution of tax disputes in 2023. sales in the pharmaceuticals division increased by 6 to chf 44.6 billion, with newer medicines for severe",
            "position": 2114,
            "sentence": "core earnings per share rose by 6 -9 in chf, including the positive impact from the resolution of tax disputes in 2023."
          },
          {
            "keyword": "sales",
            "context": ".1 roche group hemlibra haemophilia a, polivy blood cancer and phesgo breast cancer  achieved total sales of chf 14.8 billion. this represents a plus of chf 4.3 billion compared to 2022. vabysmo, launched",
            "position": 2448,
            "sentence": "the top five growth drivers  vabysmo severe eye diseases, ocrevus multiple sclerosis, 2.1 roche group hemlibra haemophilia a, polivy blood cancer and phesgo breast cancer  achieved total sales of chf 14.8 billion."
          },
          {
            "keyword": "sales",
            "context": "epresents a plus of chf 4.3 billion compared to 2022. vabysmo, launched only in early 2022, reached sales of chf 2.4 billion, and has become one of the best-selling medicines of roche. the diagnostics divi",
            "position": 2581,
            "sentence": "vabysmo, launched only in early 2022, reached sales of chf 2.4 billion, and has become one of the best-selling medicines of roche."
          },
          {
            "keyword": "sales",
            "context": "and has become one of the best-selling medicines of roche. the diagnostics divisions base business sales increased by 7, with immunodiagnostic products, particularly cardiac tests, and diagnostics solutio",
            "position": 2706,
            "sentence": "the diagnostics divisions base business sales increased by 7, with immunodiagnostic products, particularly cardiac tests, and diagnostics solutions for clinical chemistry and for advanced staining contributing significantly to this growth."
          },
          {
            "keyword": "sales",
            "context": "nced staining contributing significantly to this growth. overall, the diagnostics division reported sales of chf 14. 1 billion, a decline of 13. this reflects the anticipated significant drop in demand for",
            "position": 2949,
            "sentence": "overall, the diagnostics division reported sales of chf 14."
          },
          {
            "keyword": "sales",
            "context": "ne of 13. this reflects the anticipated significant drop in demand for cov id -19 -related products sales of chf 0.8 billion in 2023, compared to sales of chf 4. 1 billion in 2022.",
            "position": 3084,
            "sentence": "this reflects the anticipated significant drop in demand for cov id -19 -related products sales of chf 0.8 billion in 2023, compared to sales of chf 4."
          },
          {
            "keyword": "sales",
            "context": "icant drop in demand for cov id -19 -related products sales of chf 0.8 billion in 2023, compared to sales of chf 4. 1 billion in 2022.",
            "position": 3130,
            "sentence": "this reflects the anticipated significant drop in demand for cov id -19 -related products sales of chf 0.8 billion in 2023, compared to sales of chf 4."
          },
          {
            "keyword": "net income",
            "context": "additionally, the patent settlement income in japan in 2022 affected the growth rate in 2023. ifrs net income increased by 7 -9 in chf to chf 12.4 billion due to the increase in operating profit ifrs and lower",
            "position": 1862,
            "sentence": "additionally, the patent settlement income in japan in 2022 affected the growth rate in 2023."
          },
          {
            "keyword": "gross margin",
            "context": "n. the good sales performance and a return towards a pre-covid-19 sales mix resulted in an improved gross margin. this was offset by continued investments in pharmaceutical research, development and launches of n",
            "position": 1638,
            "sentence": "the good sales performance and a return towards a pre-covid-19 sales mix resulted in an improved gross margin."
          }
        ],
        "profitability": [
          {
            "keyword": "operating profit",
            "context": "rrencies, impacting results when reported in swiss francs compared to constant exchange rates. core operating profit was down 1 -13 in chf to chf 19.2 billion. the good sales performance and a return towards a pre-co",
            "position": 1481,
            "sentence": "the swiss franc significantly appreciated versus most currencies, impacting results when reported in swiss francs compared to constant exchange rates."
          },
          {
            "keyword": "operating profit",
            "context": "h rate in 2023. ifrs net income increased by 7 -9 in chf to chf 12.4 billion due to the increase in operating profit ifrs and lower income tax expenses. core earnings per share rose by 6 -9 in chf, including the posi",
            "position": 1941,
            "sentence": "ifrs net income increased by 7 -9 in chf to chf 12.4 billion due to the increase in operating profit ifrs and lower income tax expenses."
          },
          {
            "keyword": "core earnings",
            "context": "chf to chf 12.4 billion due to the increase in operating profit ifrs and lower income tax expenses. core earnings per share rose by 6 -9 in chf, including the positive impact from the resolution of tax disputes in",
            "position": 1994,
            "sentence": "ifrs net income increased by 7 -9 in chf to chf 12.4 billion due to the increase in operating profit ifrs and lower income tax expenses."
          },
          {
            "keyword": "earnings per share",
            "context": "o chf 12.4 billion due to the increase in operating profit ifrs and lower income tax expenses. core earnings per share rose by 6 -9 in chf, including the positive impact from the resolution of tax disputes in 2023. sal",
            "position": 1999,
            "sentence": "ifrs net income increased by 7 -9 in chf to chf 12.4 billion due to the increase in operating profit ifrs and lower income tax expenses."
          },
          {
            "keyword": "earnings",
            "context": "o chf 12.4 billion due to the increase in operating profit ifrs and lower income tax expenses. core earnings per share rose by 6 -9 in chf, including the positive impact from the resolution of tax disputes in",
            "position": 1999,
            "sentence": "ifrs net income increased by 7 -9 in chf to chf 12.4 billion due to the increase in operating profit ifrs and lower income tax expenses."
          },
          {
            "keyword": "profit",
            "context": "impacting results when reported in swiss francs compared to constant exchange rates. core operating profit was down 1 -13 in chf to chf 19.2 billion. the good sales performance and a return towards a pre-co",
            "position": 1491,
            "sentence": "core operating profit was down 1 -13 in chf to chf 19.2 billion."
          },
          {
            "keyword": "profit",
            "context": "2023. ifrs net income increased by 7 -9 in chf to chf 12.4 billion due to the increase in operating profit ifrs and lower income tax expenses. core earnings per share rose by 6 -9 in chf, including the posi",
            "position": 1951,
            "sentence": "ifrs net income increased by 7 -9 in chf to chf 12.4 billion due to the increase in operating profit ifrs and lower income tax expenses."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "guidance",
            "context": "27 in 2023, roche achieved sales growth of 1 -7 in chf to chf 58.7 billion, exceeding the companys guidance for the year. this increase more than made up for the expected decline in covid-19-related sales, a",
            "position": 1002,
            "sentence": "our diagnostics base business and newer medicines continued to show strong growth.26  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report through the seamless integration of our capabilities in roche pharmaceuticals and roche diagnostics, we are uniquely positioned to achieve medical breakthroughs for patients and society.business performance  roche 27 in 2023, roche achieved sales growth of 1 -7 in chf to chf 58.7 billion, exceeding the companys guidance for the year."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_015",
    "content": "this reflects the anticipated significant drop in demand for cov id -19 -related products sales of chf 0.8 billion in 2023, compared to sales of chf 4. 1 billion in 2022. with lower demand for covid-19 testing, sales in the north america, europe, middle east and africa emea and asia-pacific regions decreased by 21, 13 and 11, respectively. the divisions base business grew across all regions. outlook for 2024 roche expects an increase in group sales in the mid single digit range at constant exchange rates. core earnings per share are targeted to develop broadly in line with sales growth at constant exchange rates, excluding the impact from the resolution of tax disputes in 2023. roche expects to further increase its dividend in swiss francs. unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf.28  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 58,716 1 63,281 2 9.60 9.50 44,612 6 45,551 2 14,104 13 17,730 3 19,240 1 22,173 3 13,237 5 13,255group sales 2023 2022 dividend 2023 2022pharmaceuticals sales 2023 2022 diagnostics sales 2023 2022 core operating profit 2023 2022 rd core investments 2023 2022chf millions chfkey figures 2023   unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf. effective 1 january 2023, the group has made certain presentational and cost allocation changes to the income statement. the comparative information for 2022 has been restated accordingly.roche group  roche 29 2.2 diagnostics the diagnostics divisions base business sales increased by 7, with immunodiagnostic products, particularly cardiac tests, and diagnostics solutions for clinical chemistry and for advanced staining contributing significantly to this growth. overall, the diagnostics division reported sales of chf 14. 1 billion, a decline of 13. this reflects the anticipated significant drop in demand for covi d -19 - related products sales of chf 0.8 billion in 2023, compared to sales of chf 4. 1 billion in 2022. with lower demand for covid-19 testing, sales in the north america, europe, middle east and africa emea and asia-pacific regions decreased by 21, 13 and 11, respectively. the divisions base business grew across all regions. core lab. this customer area focuses on central labs and provides diagnostics solutions in the areas of immunoassays, clinical chemistry and custom biotech. sales increased by 9 due to the 10 growth in immunodiagnostic products, such as cardiac and oncology tests, and the 10 growth in the clinical chemistry business. sales grew across all regions, with the largest contributions to the sales growth coming from the asia-pacific and emea regions, which grew by 10 and 9, respectively. molecular lab. this customer area focuses on molecular labs and provides diagnostics solutions for the detection and monitoring of pathogens, donor screening, sexual health and genomics.",
    "word_count": 493,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "this reflects the anticipated significant drop in demand for cov id -19 -related products sales of chf 0.8 billion in 2023, compared to sales of chf 4. 1 billion in 2022. with lower demand for co",
            "position": 90,
            "sentence": "this reflects the anticipated significant drop in demand for cov id -19 -related products sales of chf 0.8 billion in 2023, compared to sales of chf 4."
          },
          {
            "keyword": "sales",
            "context": "icant drop in demand for cov id -19 -related products sales of chf 0.8 billion in 2023, compared to sales of chf 4. 1 billion in 2022. with lower demand for covid-19 testing, sales in the north america, eu",
            "position": 136,
            "sentence": "this reflects the anticipated significant drop in demand for cov id -19 -related products sales of chf 0.8 billion in 2023, compared to sales of chf 4."
          },
          {
            "keyword": "sales",
            "context": "ion in 2023, compared to sales of chf 4. 1 billion in 2022. with lower demand for covid-19 testing, sales in the north america, europe, middle east and africa emea and asia-pacific regions decreased by 21,",
            "position": 211,
            "sentence": "with lower demand for covid-19 testing, sales in the north america, europe, middle east and africa emea and asia-pacific regions decreased by 21, 13 and 11, respectively."
          },
          {
            "keyword": "sales",
            "context": "ivisions base business grew across all regions. outlook for 2024 roche expects an increase in group sales in the mid single digit range at constant exchange rates. core earnings per share are targeted to d",
            "position": 447,
            "sentence": "outlook for 2024 roche expects an increase in group sales in the mid single digit range at constant exchange rates."
          },
          {
            "keyword": "sales",
            "context": "ge at constant exchange rates. core earnings per share are targeted to develop broadly in line with sales growth at constant exchange rates, excluding the impact from the resolution of tax disputes in 2023",
            "position": 580,
            "sentence": "core earnings per share are targeted to develop broadly in line with sales growth at constant exchange rates, excluding the impact from the resolution of tax disputes in 2023."
          },
          {
            "keyword": "sales",
            "context": "16 1 63,281 2 9.60 9.50 44,612 6 45,551 2 14,104 13 17,730 3 19,240 1 22,173 3 13,237 5 13,255group sales 2023 2022 dividend 2023 2022pharmaceuticals sales 2023 2022 diagnostics sales 2023 2022 core operat",
            "position": 1156,
            "sentence": "unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf.28  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 58,716 1 63,281 2 9.60 9.50 44,612 6 45,551 2 14,104 13 17,730 3 19,240 1 22,173 3 13,237 5 13,255group sales 2023 2022 dividend 2023 2022pharmaceuticals sales 2023 2022 diagnostics sales 2023 2022 core operating profit 2023 2022 rd core investments 2023 2022chf millions chfkey figures 2023   unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf."
          },
          {
            "keyword": "sales",
            "context": "3 17,730 3 19,240 1 22,173 3 13,237 5 13,255group sales 2023 2022 dividend 2023 2022pharmaceuticals sales 2023 2022 diagnostics sales 2023 2022 core operating profit 2023 2022 rd core investments 2023 2022",
            "position": 1206,
            "sentence": "unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf.28  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 58,716 1 63,281 2 9.60 9.50 44,612 6 45,551 2 14,104 13 17,730 3 19,240 1 22,173 3 13,237 5 13,255group sales 2023 2022 dividend 2023 2022pharmaceuticals sales 2023 2022 diagnostics sales 2023 2022 core operating profit 2023 2022 rd core investments 2023 2022chf millions chfkey figures 2023   unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf."
          },
          {
            "keyword": "sales",
            "context": "13,237 5 13,255group sales 2023 2022 dividend 2023 2022pharmaceuticals sales 2023 2022 diagnostics sales 2023 2022 core operating profit 2023 2022 rd core investments 2023 2022chf millions chfkey figures",
            "position": 1234,
            "sentence": "unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf.28  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 58,716 1 63,281 2 9.60 9.50 44,612 6 45,551 2 14,104 13 17,730 3 19,240 1 22,173 3 13,237 5 13,255group sales 2023 2022 dividend 2023 2022pharmaceuticals sales 2023 2022 diagnostics sales 2023 2022 core operating profit 2023 2022 rd core investments 2023 2022chf millions chfkey figures 2023   unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf."
          },
          {
            "keyword": "sales",
            "context": "restated accordingly.roche group  roche 29 2.2 diagnostics the diagnostics divisions base business sales increased by 7, with immunodiagnostic products, particularly cardiac tests, and diagnostics solutio",
            "position": 1796,
            "sentence": "the comparative information for 2022 has been restated accordingly.roche group  roche 29 2.2 diagnostics the diagnostics divisions base business sales increased by 7, with immunodiagnostic products, particularly cardiac tests, and diagnostics solutions for clinical chemistry and for advanced staining contributing significantly to this growth."
          },
          {
            "keyword": "sales",
            "context": "nced staining contributing significantly to this growth. overall, the diagnostics division reported sales of chf 14. 1 billion, a decline of 13. this reflects the anticipated significant drop in demand for",
            "position": 2039,
            "sentence": "overall, the diagnostics division reported sales of chf 14."
          },
          {
            "keyword": "sales",
            "context": "e of 13. this reflects the anticipated significant drop in demand for covi d -19 - related products sales of chf 0.8 billion in 2023, compared to sales of chf 4. 1 billion in 2022. with lower demand for co",
            "position": 2175,
            "sentence": "this reflects the anticipated significant drop in demand for covi d -19 - related products sales of chf 0.8 billion in 2023, compared to sales of chf 4."
          },
          {
            "keyword": "sales",
            "context": "cant drop in demand for covi d -19 - related products sales of chf 0.8 billion in 2023, compared to sales of chf 4. 1 billion in 2022. with lower demand for covid-19 testing, sales in the north america, eu",
            "position": 2221,
            "sentence": "this reflects the anticipated significant drop in demand for covi d -19 - related products sales of chf 0.8 billion in 2023, compared to sales of chf 4."
          },
          {
            "keyword": "sales",
            "context": "ion in 2023, compared to sales of chf 4. 1 billion in 2022. with lower demand for covid-19 testing, sales in the north america, europe, middle east and africa emea and asia-pacific regions decreased by 21,",
            "position": 2296,
            "sentence": "with lower demand for covid-19 testing, sales in the north america, europe, middle east and africa emea and asia-pacific regions decreased by 21, 13 and 11, respectively."
          },
          {
            "keyword": "sales",
            "context": "provides diagnostics solutions in the areas of immunoassays, clinical chemistry and custom biotech. sales increased by 9 due to the 10 growth in immunodiagnostic products, such as cardiac and oncology test",
            "position": 2637,
            "sentence": "this customer area focuses on central labs and provides diagnostics solutions in the areas of immunoassays, clinical chemistry and custom biotech."
          },
          {
            "keyword": "sales",
            "context": "products, such as cardiac and oncology tests, and the 10 growth in the clinical chemistry business. sales grew across all regions, with the largest contributions to the sales growth coming from the asia-pa",
            "position": 2799,
            "sentence": "sales increased by 9 due to the 10 growth in immunodiagnostic products, such as cardiac and oncology tests, and the 10 growth in the clinical chemistry business."
          },
          {
            "keyword": "sales",
            "context": "e clinical chemistry business. sales grew across all regions, with the largest contributions to the sales growth coming from the asia-pacific and emea regions, which grew by 10 and 9, respectively. molecul",
            "position": 2868,
            "sentence": "sales grew across all regions, with the largest contributions to the sales growth coming from the asia-pacific and emea regions, which grew by 10 and 9, respectively."
          }
        ],
        "profitability": [
          {
            "keyword": "operating profit",
            "context": "sales 2023 2022 dividend 2023 2022pharmaceuticals sales 2023 2022 diagnostics sales 2023 2022 core operating profit 2023 2022 rd core investments 2023 2022chf millions chfkey figures 2023   unless otherwise stated,",
            "position": 1255,
            "sentence": "unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf.28  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 58,716 1 63,281 2 9.60 9.50 44,612 6 45,551 2 14,104 13 17,730 3 19,240 1 22,173 3 13,237 5 13,255group sales 2023 2022 dividend 2023 2022pharmaceuticals sales 2023 2022 diagnostics sales 2023 2022 core operating profit 2023 2022 rd core investments 2023 2022chf millions chfkey figures 2023   unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf."
          },
          {
            "keyword": "core earnings",
            "context": "roche expects an increase in group sales in the mid single digit range at constant exchange rates. core earnings per share are targeted to develop broadly in line with sales growth at constant exchange rates, exc",
            "position": 511,
            "sentence": "outlook for 2024 roche expects an increase in group sales in the mid single digit range at constant exchange rates."
          },
          {
            "keyword": "earnings per share",
            "context": "e expects an increase in group sales in the mid single digit range at constant exchange rates. core earnings per share are targeted to develop broadly in line with sales growth at constant exchange rates, excluding the",
            "position": 516,
            "sentence": "core earnings per share are targeted to develop broadly in line with sales growth at constant exchange rates, excluding the impact from the resolution of tax disputes in 2023."
          },
          {
            "keyword": "earnings",
            "context": "e expects an increase in group sales in the mid single digit range at constant exchange rates. core earnings per share are targeted to develop broadly in line with sales growth at constant exchange rates, exc",
            "position": 516,
            "sentence": "core earnings per share are targeted to develop broadly in line with sales growth at constant exchange rates, excluding the impact from the resolution of tax disputes in 2023."
          },
          {
            "keyword": "profit",
            "context": "3 2022 dividend 2023 2022pharmaceuticals sales 2023 2022 diagnostics sales 2023 2022 core operating profit 2023 2022 rd core investments 2023 2022chf millions chfkey figures 2023   unless otherwise stated,",
            "position": 1265,
            "sentence": "unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf.28  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 58,716 1 63,281 2 9.60 9.50 44,612 6 45,551 2 14,104 13 17,730 3 19,240 1 22,173 3 13,237 5 13,255group sales 2023 2022 dividend 2023 2022pharmaceuticals sales 2023 2022 diagnostics sales 2023 2022 core operating profit 2023 2022 rd core investments 2023 2022chf millions chfkey figures 2023   unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates cer; average rates 2022 and all total figures quoted are reported in chf."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "outlook",
            "context": "ions decreased by 21, 13 and 11, respectively. the divisions base business grew across all regions. outlook for 2024 roche expects an increase in group sales in the mid single digit range at constant exchang",
            "position": 395,
            "sentence": "the divisions base business grew across all regions."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_016",
    "content": "molecular lab. this customer area focuses on molecular labs and provides diagnostics solutions for the detection and monitoring of pathogens, donor screening, sexual health and genomics. sales declined by 30 due to lower covid-19-re lated sales for sars-cov-2 assays on the cobas 68008800 systems. growth in the underlying base business included higher sales from blood screening as well as from diagnostics solutions for the detection and monitoring of cervical cancer and from the virology base business. pathology lab. this customer area focuses on pathology labs and provides diagnostics solutions for tissue biopsies and companion diagnostics. these are targeted diagnostics to aid in the choice of specific therapies for each patient. sales increased by 14 and across all regions due to growth in the advanced staining and the companion diagnostics businesses. point of care. this customer area provides diagnostics solutions immediately at the point of care, such as in emergency rooms, general practitioners practices and directly with patients, and includes the sars-co v-2 rapid antigen test and blood gas and electrolyte bge tests. lower sales of the sars-cov-2 rapid antigen test were the main driver of the 58 sales decrease. there was growth in the base business, driven by the liat molecular point-of-care product line. diabetes care. this customer area provides diagnostics solutions for patients and healthcare professionals enabling integrated personalised diabetes management. sales decreased by 4 driven by the continued contraction of the blood glucose monitoring market in the us and major european markets, due to people switching to continuous glucose monitoring systems.30  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report core lab molecular lab pathology lab point of care diabetes care 7,750 9 2,220 30 1,388 14 1,379 58 1,367 4sales by customer area in 2023 chf millionsdiagnostics  roche 31 in 2023, we maintained our momentum of strong growth in our diagnostics base business, launching a range of new tests, platforms and digital solutions. we continued to focus our innovations on supporting healthcare professionals in prevention, diagnosis and monitoring to improve health outcomes while reducing the cost of care. we have retained our position as the worlds leader in in vitro diagnostics, with a growing portfolio of more than 500 diagnostic assays on more than 100,000 instruments around the world that deliver breakthrough innovations with the greatest possible patient and market impact. in addition to being the leader in laboratory diagnostics, we have a prominent role in bringing diagnostics closer to patients through our point- of-care innovations. for example, the handheld cobas pulse represents an industry-first professional blood glucose management solution that features mobile digital health capabilities to help improve patient care. transforming healthcare delivery to meet global challenges throughout the year, we increased our efforts to address critical health challenges, including ageing populations with increasingly complex medical needs. around the world, the number of patients over age 60 is growing. by 2030, the world health organization who estimates that one in six people will be over 60.",
    "word_count": 494,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "lutions for the detection and monitoring of pathogens, donor screening, sexual health and genomics. sales declined by 30 due to lower covid-19-re lated sales for sars-cov-2 assays on the cobas 68008800 sys",
            "position": 187,
            "sentence": "this customer area focuses on molecular labs and provides diagnostics solutions for the detection and monitoring of pathogens, donor screening, sexual health and genomics."
          },
          {
            "keyword": "sales",
            "context": "s, donor screening, sexual health and genomics. sales declined by 30 due to lower covid-19-re lated sales for sars-cov-2 assays on the cobas 68008800 systems. growth in the underlying base business include",
            "position": 239,
            "sentence": "sales declined by 30 due to lower covid-19-re lated sales for sars-cov-2 assays on the cobas 68008800 systems."
          },
          {
            "keyword": "sales",
            "context": "-cov-2 assays on the cobas 68008800 systems. growth in the underlying base business included higher sales from blood screening as well as from diagnostics solutions for the detection and monitoring of cerv",
            "position": 353,
            "sentence": "growth in the underlying base business included higher sales from blood screening as well as from diagnostics solutions for the detection and monitoring of cervical cancer and from the virology base business."
          },
          {
            "keyword": "sales",
            "context": "ostics. these are targeted diagnostics to aid in the choice of specific therapies for each patient. sales increased by 14 and across all regions due to growth in the advanced staining and the companion dia",
            "position": 741,
            "sentence": "these are targeted diagnostics to aid in the choice of specific therapies for each patient."
          },
          {
            "keyword": "sales",
            "context": "nts, and includes the sars-co v-2 rapid antigen test and blood gas and electrolyte bge tests. lower sales of the sars-cov-2 rapid antigen test were the main driver of the 58 sales decrease. there was growt",
            "position": 1149,
            "sentence": "this customer area provides diagnostics solutions immediately at the point of care, such as in emergency rooms, general practitioners practices and directly with patients, and includes the sars-co v-2 rapid antigen test and blood gas and electrolyte bge tests."
          },
          {
            "keyword": "sales",
            "context": "ctrolyte bge tests. lower sales of the sars-cov-2 rapid antigen test were the main driver of the 58 sales decrease. there was growth in the base business, driven by the liat molecular point-of-care product",
            "position": 1223,
            "sentence": "lower sales of the sars-cov-2 rapid antigen test were the main driver of the 58 sales decrease."
          },
          {
            "keyword": "sales",
            "context": "ons for patients and healthcare professionals enabling integrated personalised diabetes management. sales decreased by 4 driven by the continued contraction of the blood glucose monitoring market in the us",
            "position": 1496,
            "sentence": "this customer area provides diagnostics solutions for patients and healthcare professionals enabling integrated personalised diabetes management."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_017",
    "content": "around the world, the number of patients over age 60 is growing. by 2030, the world health organization who estimates that one in six people will be over 60. and by 2050, there will be more than 2.5 billion people in their sixties or older, with nearly half a billion people over 80. two of the most common comorbid conditions occurring in elderly people are cardiometabolic diseases and dementia. cardiovascular disease is the number one cause of mortality, accounting for 31 of all global deaths  75 of which occur in low- and middle- income countries lmics. the strong-hf study results show how our nt-probnp biomarker testing, embedded in a therapeutic strategy, is an integral part of improving care for patients with heart failure. alzheimers disease, the most common form of dementia, affects 55 million people worldwide and this number is expected to triple by 2050. however, up to 75 of people living with symptoms of alzheimers have not yet been diagnosed; those who have received a diagnosis waited, on average, 2.8 years after symptom onset. as part of our commitment to addressing the burden of alzheimers disease, in march we entered into a collaboration with eli lilly and company to support the development of our elecsys amyloid plasma panel eapp. the eapp is an innovative blood test that aims to facilitate the earlier diagnosis of alzheimers disease and potentially streamline access to future treatment options. cancer continues to be one of the worlds greatest health threats. across testing disciplines  molecular, sequencing, immunochemistry, imaging, tissue and digital diagnostics  we offer a comprehensive ecosystem of solutions to ensure laboratories and healthcare professionals have the tools they need to give patients the care they deserve. for example, 90 of women who die from cervical cancer live in lmics. the who has awarded us a prequalification for our cobas hpv test for use in lmic national cervical cancer elimination programmes. in diabetes care we continued deploying our integrated personalised diabetes management ipdm strategy, strengthening our market leadership in blood glucose monitoring bgm and thus enabling access to care for people with diabetes around the world. connectivity and digital solutions play a key role in our vision, and we proudly reached more than 5 million registered users with our diabetes management app, mysugr, while making our rochediabetes care platform for healthcare providers now available in 30 countries.innovation to improve patient outcomes32  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report active out-licensing agreementsactive in-licensing agreements analytical units placed in the cobas pure line analytical units placed in the cobas pro line roche diagnostics tests delivered to our customers 29 billion diagnostics facts 2023 diabetes care molecular labroche information solutions pathology lab diagnostics key launches 20236 21 7 new platforms tests digital solutions core lab  cobas pro is for our mid-high throughput and cobas pure is for our low-mid throughput core lab customers.",
    "word_count": 481,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_018",
    "content": "in diabetes care we continued deploying our integrated personalised diabetes management ipdm strategy, strengthening our market leadership in blood glucose monitoring bgm and thus enabling access to care for people with diabetes around the world. connectivity and digital solutions play a key role in our vision, and we proudly reached more than 5 million registered users with our diabetes management app, mysugr, while making our rochediabetes care platform for healthcare providers now available in 30 countries.innovation to improve patient outcomes32  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report active out-licensing agreementsactive in-licensing agreements analytical units placed in the cobas pure line analytical units placed in the cobas pro line roche diagnostics tests delivered to our customers 29 billion diagnostics facts 2023 diabetes care molecular labroche information solutions pathology lab diagnostics key launches 20236 21 7 new platforms tests digital solutions core lab  cobas pro is for our mid-high throughput and cobas pure is for our low-mid throughput core lab customers. these instruments are used for the measurement of over 200 parameters in blood.1,800 110 growth versus 20223,200 64 growth versus 2022325 150 9 new tests 1 new digital solution3 new digital solutions 3 new digital solutions 1 new platform 4 new tests 2 other 5 new platforms 8 new testsbusiness performance  roche 33 diagnostics  roche 33 innovative insights we have made significant progress in strengthening and expanding our efforts in healthcare digitalisation with a focus on lab insights, clinical workflow optimisation, clinical decision support and patient monitoring. these segments primarily target labs, providers and patients. our navify digital solutions  including the navify algorithm suite and navify sample tracking  securely integrate data across care settings, connecting the healthcare community and accelerating access to innovation and insights. the navify approach focuses on open digital ecosystems to address interoperability and enable a patient-centric model rather than a disease-centred approach. to support efficient product development for digital solutions, we are committed to establishing a common and scalable technology stack for all digital products for customers and patients. key launches and activities in 2023 name launch date approval indicationdisease, etc.",
    "word_count": 350,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "target",
            "context": "l workflow optimisation, clinical decision support and patient monitoring. these segments primarily target labs, providers and patients. our navify digital solutions  including the navify algorithm suite an",
            "position": 1772,
            "sentence": "these segments primarily target labs, providers and patients."
          }
        ],
        "strategic_initiatives": [
          {
            "keyword": "product development",
            "context": "ity and enable a patient-centric model rather than a disease-centred approach. to support efficient product development for digital solutions, we are committed to establishing a common and scalable technology stack for",
            "position": 2217,
            "sentence": "to support efficient product development for digital solutions, we are committed to establishing a common and scalable technology stack for all digital products for customers and patients."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_019",
    "content": "to support efficient product development for digital solutions, we are committed to establishing a common and scalable technology stack for all digital products for customers and patients. key launches and activities in 2023 name launch date approval indicationdisease, etc. systemplatform tests virsnip sars-cov-2 spike f486p26 january fda research use onlypcr test to detect sars-cov-2 xbb.1.5 variant pcr platforms lightcycler 480 ii and cobas z 480 idh1 r132h idh glioma and atrx rabbit polyclonal antibody23 february fda neuropathologyimmunohistochemistry ihc solution supporting detection of tumour cells with idh1 r132h mutation; aids pathologists in diagnosis of gliomas and identifies mutation status in patients diagnosed with brain cancerbenchmark instrument series ventana pd-l1 sp263 3 march fda label expansion identifies patients with non-small cell lung cancer nsclc who may be eligible for treatment with libtayo regeneron monotherapycompanion diagnostic for benchmark ul tra system cobas hpv test 13 june who prequalification enables lmics to use the cobas hpv test in their national cervical cancer elimination programmesroche molecular systems e.g.: cobas 4800, cobas 6800, cobas 8800 elecsys il-6 neonatal sepsis immunoassay18 october countries accepting the ce markfirst il-6 test to have a certified claim for use in diagnosis of neonatal sepsis, immunoassay with dedicated claim and supporting evidence aiding diagnosis of sepsis in neonates; potential to reduce newborn mortalitycobas e immunoassay analysers cobas hpv test 6 november fda pcr test to identify presence of hpv genotypes 16 and 18, with 12 other high-risk hpv types as a combined result; will broaden access to hpv testing in us mid-size and smaller labscobas 5800 elecsys neurofilament light chain nfl test for multiple sclerosis ms9 november fda breakthrough device designationtest to aid in detection of disease activity in adults 1855 years old with relapsing-remitting multiple sclerosis rrms or secondary progressive multiple sclerosis spmselecsys technology elecsys anti-hev igm and elecsys anti-hev igg immunoassays16 november countries accepting the ce markdetection of hepatitis e virus hev infections for treatment, monitoring and prevention of disease progression. hev testing included in who 2023 essential diagnostics list edlfully automated assays run on elecsys technology elecsys hbeag quant 27 november countries accepting the ce markimmunoassay able to determine both presence and quantity qualitative and quantitative of hepatitis b e antigen hbeag in human serum and plasma; complements existing hbv testing markerscobas e analysers34  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report key launches and activities in 2023 continued name launch date approval indicationdisease, etc.",
    "word_count": 402,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "strategic_initiatives": [
          {
            "keyword": "product development",
            "context": "to support efficient product development for digital solutions, we are committed to establishing a common and scalable technology stack for",
            "position": 21,
            "sentence": "to support efficient product development for digital solutions, we are committed to establishing a common and scalable technology stack for all digital products for customers and patients."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_020",
    "content": "systemplatform tests virsnip sars-cov-2 spike f486p26 january fda research use onlypcr test to detect sars-cov-2 xbb.1.5 variant pcr platforms lightcycler 480 ii and cobas z 480 idh1 r132h idh glioma and atrx rabbit polyclonal antibody23 february fda neuropathologyimmunohistochemistry ihc solution supporting detection of tumour cells with idh1 r132h mutation; aids pathologists in diagnosis of gliomas and identifies mutation status in patients diagnosed with brain cancerbenchmark instrument series ventana pd-l1 sp263 3 march fda label expansion identifies patients with non-small cell lung cancer nsclc who may be eligible for treatment with libtayo regeneron monotherapycompanion diagnostic for benchmark ul tra system cobas hpv test 13 june who prequalification enables lmics to use the cobas hpv test in their national cervical cancer elimination programmesroche molecular systems e.g.: cobas 4800, cobas 6800, cobas 8800 elecsys il-6 neonatal sepsis immunoassay18 october countries accepting the ce markfirst il-6 test to have a certified claim for use in diagnosis of neonatal sepsis, immunoassay with dedicated claim and supporting evidence aiding diagnosis of sepsis in neonates; potential to reduce newborn mortalitycobas e immunoassay analysers cobas hpv test 6 november fda pcr test to identify presence of hpv genotypes 16 and 18, with 12 other high-risk hpv types as a combined result; will broaden access to hpv testing in us mid-size and smaller labscobas 5800 elecsys neurofilament light chain nfl test for multiple sclerosis ms9 november fda breakthrough device designationtest to aid in detection of disease activity in adults 1855 years old with relapsing-remitting multiple sclerosis rrms or secondary progressive multiple sclerosis spmselecsys technology elecsys anti-hev igm and elecsys anti-hev igg immunoassays16 november countries accepting the ce markdetection of hepatitis e virus hev infections for treatment, monitoring and prevention of disease progression. hev testing included in who 2023 essential diagnostics list edlfully automated assays run on elecsys technology elecsys hbeag quant 27 november countries accepting the ce markimmunoassay able to determine both presence and quantity qualitative and quantitative of hepatitis b e antigen hbeag in human serum and plasma; complements existing hbv testing markerscobas e analysers34  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report key launches and activities in 2023 continued name launch date approval indicationdisease, etc. systemplatform instrumentsautomation ccm vertical 17 august global cobas connection modules: fast transport system connecting cobas p 512 and cobas p 612 to analytics and post-analyticscobas p 512 and cobas p 612 cobas pro integrated solutionsaugust china scalable, modular swa for mid- to high-volume clinical chemistry and immunochemistry testingcobas systems cobas pure integrated solutionsoctober china swa analyser bringing together three diagnostic technologies on a single platform to optimise space and resources in small to medium labscobas systems lightcycler pro 20 november ce mark; fda 510k exempt statusnew, next-generation, flexible real-time qpcr instrument with dual ivd and research mode plus enhanced system featuresnew lightcycler qpcr instrument lumiradx 29 december global roche entered into a definitive agreement to acquire lumiradx s point-of-care technology combining multiple diagnostic modalities on a single platformtransaction closing expected by mid-2024 digital solutions navify algorithm suite 11 april europe and asia-pacificsingle platform hosting library of digital medical algorithms that generate patient-centric insights; initial focus: liver disease and colon cancerembedded in existing healthcare workflows and the labhospital information system lishis and or electronic healthmedical record ehremr navify tumor board 25 october attained an overall performance score of 92.4 with hcp cloud-based digital solution streamlining workflows and multidisciplinary collaboration for oncology tumour boardsrecognition in klas research first look report  navify poc operations formally registered in most countries as cobas infinity poc25 october attained an overall performance score of 90.1 with hcp software that connects and monitors point-of-care devices roche and non-roche for device oversight and error management of test resultsrecognition in klas research first look report  navify lab operations formally registered in most countries as cobas infinity lab25 october attained an overall performance score of 89.5 with hcp lab software that consolidates data from various instruments and systems and automates lab processes for optimal lab efficiencyrecognition in klas research first look report  expanded menu of algorithms for navify algorithm suite9 november 14 ce-marked algorithms addedclinical decision support algorithms in the areas of oncology and cardiovascular metabolicsnavify algorithm suite ruo digital pathology algorithm22 december global research use onlydigital pathology algorithm for scoring pd-l1 sp142 breast samplesventana dp 200 or ventana dp 600 slide scanner stained with ventana pd-l1 sp142 assay  limited data   healthcare professionals   the 2023 best in klas software average for this category is 80.3.diagnostics  roche 35 2.3 pharmaceuticals sales in the pharmaceuticals division increased by 6 to chf 44.6 billion, with newer medicines for severe diseases continuing their strong growth.",
    "word_count": 763,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "3 best in klas software average for this category is 80.3.diagnostics  roche 35 2.3 pharmaceuticals sales in the pharmaceuticals division increased by 6 to chf 44.6 billion, with newer medicines for severe",
            "position": 5398,
            "sentence": "systemplatform instrumentsautomation ccm vertical 17 august global cobas connection modules: fast transport system connecting cobas p 512 and cobas p 612 to analytics and post-analyticscobas p 512 and cobas p 612 cobas pro integrated solutionsaugust china scalable, modular swa for mid- to high-volume clinical chemistry and immunochemistry testingcobas systems cobas pure integrated solutionsoctober china swa analyser bringing together three diagnostic technologies on a single platform to optimise space and resources in small to medium labscobas systems lightcycler pro 20 november ce mark; fda 510k exempt statusnew, next-generation, flexible real-time qpcr instrument with dual ivd and research mode plus enhanced system featuresnew lightcycler qpcr instrument lumiradx 29 december global roche entered into a definitive agreement to acquire lumiradx s point-of-care technology combining multiple diagnostic modalities on a single platformtransaction closing expected by mid-2024 digital solutions navify algorithm suite 11 april europe and asia-pacificsingle platform hosting library of digital medical algorithms that generate patient-centric insights; initial focus: liver disease and colon cancerembedded in existing healthcare workflows and the labhospital information system lishis and or electronic healthmedical record ehremr navify tumor board 25 october attained an overall performance score of 92.4 with hcp cloud-based digital solution streamlining workflows and multidisciplinary collaboration for oncology tumour boardsrecognition in klas research first look report  navify poc operations formally registered in most countries as cobas infinity poc25 october attained an overall performance score of 90.1 with hcp software that connects and monitors point-of-care devices roche and non-roche for device oversight and error management of test resultsrecognition in klas research first look report  navify lab operations formally registered in most countries as cobas infinity lab25 october attained an overall performance score of 89.5 with hcp lab software that consolidates data from various instruments and systems and automates lab processes for optimal lab efficiencyrecognition in klas research first look report  expanded menu of algorithms for navify algorithm suite9 november 14 ce-marked algorithms addedclinical decision support algorithms in the areas of oncology and cardiovascular metabolicsnavify algorithm suite ruo digital pathology algorithm22 december global research use onlydigital pathology algorithm for scoring pd-l1 sp142 breast samplesventana dp 200 or ventana dp 600 slide scanner stained with ventana pd-l1 sp142 assay  limited data   healthcare professionals   the 2023 best in klas software average for this category is 80.3.diagnostics  roche 35 2.3 pharmaceuticals sales in the pharmaceuticals division increased by 6 to chf 44.6 billion, with newer medicines for severe diseases continuing their strong growth."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_021",
    "content": "hev testing included in who 2023 essential diagnostics list edlfully automated assays run on elecsys technology elecsys hbeag quant 27 november countries accepting the ce markimmunoassay able to determine both presence and quantity qualitative and quantitative of hepatitis b e antigen hbeag in human serum and plasma; complements existing hbv testing markerscobas e analysers34  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report key launches and activities in 2023 continued name launch date approval indicationdisease, etc. systemplatform instrumentsautomation ccm vertical 17 august global cobas connection modules: fast transport system connecting cobas p 512 and cobas p 612 to analytics and post-analyticscobas p 512 and cobas p 612 cobas pro integrated solutionsaugust china scalable, modular swa for mid- to high-volume clinical chemistry and immunochemistry testingcobas systems cobas pure integrated solutionsoctober china swa analyser bringing together three diagnostic technologies on a single platform to optimise space and resources in small to medium labscobas systems lightcycler pro 20 november ce mark; fda 510k exempt statusnew, next-generation, flexible real-time qpcr instrument with dual ivd and research mode plus enhanced system featuresnew lightcycler qpcr instrument lumiradx 29 december global roche entered into a definitive agreement to acquire lumiradx s point-of-care technology combining multiple diagnostic modalities on a single platformtransaction closing expected by mid-2024 digital solutions navify algorithm suite 11 april europe and asia-pacificsingle platform hosting library of digital medical algorithms that generate patient-centric insights; initial focus: liver disease and colon cancerembedded in existing healthcare workflows and the labhospital information system lishis and or electronic healthmedical record ehremr navify tumor board 25 october attained an overall performance score of 92.4 with hcp cloud-based digital solution streamlining workflows and multidisciplinary collaboration for oncology tumour boardsrecognition in klas research first look report  navify poc operations formally registered in most countries as cobas infinity poc25 october attained an overall performance score of 90.1 with hcp software that connects and monitors point-of-care devices roche and non-roche for device oversight and error management of test resultsrecognition in klas research first look report  navify lab operations formally registered in most countries as cobas infinity lab25 october attained an overall performance score of 89.5 with hcp lab software that consolidates data from various instruments and systems and automates lab processes for optimal lab efficiencyrecognition in klas research first look report  expanded menu of algorithms for navify algorithm suite9 november 14 ce-marked algorithms addedclinical decision support algorithms in the areas of oncology and cardiovascular metabolicsnavify algorithm suite ruo digital pathology algorithm22 december global research use onlydigital pathology algorithm for scoring pd-l1 sp142 breast samplesventana dp 200 or ventana dp 600 slide scanner stained with ventana pd-l1 sp142 assay  limited data   healthcare professionals   the 2023 best in klas software average for this category is 80.3.diagnostics  roche 35 2.3 pharmaceuticals sales in the pharmaceuticals division increased by 6 to chf 44.6 billion, with newer medicines for severe diseases continuing their strong growth. in the united states, sales rose by 8. vabysmo, ocrevus and hemlibra were the main growth drivers.",
    "word_count": 497,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "3 best in klas software average for this category is 80.3.diagnostics  roche 35 2.3 pharmaceuticals sales in the pharmaceuticals division increased by 6 to chf 44.6 billion, with newer medicines for severe",
            "position": 3406,
            "sentence": "systemplatform instrumentsautomation ccm vertical 17 august global cobas connection modules: fast transport system connecting cobas p 512 and cobas p 612 to analytics and post-analyticscobas p 512 and cobas p 612 cobas pro integrated solutionsaugust china scalable, modular swa for mid- to high-volume clinical chemistry and immunochemistry testingcobas systems cobas pure integrated solutionsoctober china swa analyser bringing together three diagnostic technologies on a single platform to optimise space and resources in small to medium labscobas systems lightcycler pro 20 november ce mark; fda 510k exempt statusnew, next-generation, flexible real-time qpcr instrument with dual ivd and research mode plus enhanced system featuresnew lightcycler qpcr instrument lumiradx 29 december global roche entered into a definitive agreement to acquire lumiradx s point-of-care technology combining multiple diagnostic modalities on a single platformtransaction closing expected by mid-2024 digital solutions navify algorithm suite 11 april europe and asia-pacificsingle platform hosting library of digital medical algorithms that generate patient-centric insights; initial focus: liver disease and colon cancerembedded in existing healthcare workflows and the labhospital information system lishis and or electronic healthmedical record ehremr navify tumor board 25 october attained an overall performance score of 92.4 with hcp cloud-based digital solution streamlining workflows and multidisciplinary collaboration for oncology tumour boardsrecognition in klas research first look report  navify poc operations formally registered in most countries as cobas infinity poc25 october attained an overall performance score of 90.1 with hcp software that connects and monitors point-of-care devices roche and non-roche for device oversight and error management of test resultsrecognition in klas research first look report  navify lab operations formally registered in most countries as cobas infinity lab25 october attained an overall performance score of 89.5 with hcp lab software that consolidates data from various instruments and systems and automates lab processes for optimal lab efficiencyrecognition in klas research first look report  expanded menu of algorithms for navify algorithm suite9 november 14 ce-marked algorithms addedclinical decision support algorithms in the areas of oncology and cardiovascular metabolicsnavify algorithm suite ruo digital pathology algorithm22 december global research use onlydigital pathology algorithm for scoring pd-l1 sp142 breast samplesventana dp 200 or ventana dp 600 slide scanner stained with ventana pd-l1 sp142 assay  limited data   healthcare professionals   the 2023 best in klas software average for this category is 80.3.diagnostics  roche 35 2.3 pharmaceuticals sales in the pharmaceuticals division increased by 6 to chf 44.6 billion, with newer medicines for severe diseases continuing their strong growth."
          },
          {
            "keyword": "sales",
            "context": "ion, with newer medicines for severe diseases continuing their strong growth. in the united states, sales rose by 8. vabysmo, ocrevus and hemlibra were the main growth drivers.",
            "position": 3575,
            "sentence": "in the united states, sales rose by 8."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_022",
    "content": "in the united states, sales rose by 8. vabysmo, ocrevus and hemlibra were the main growth drivers. this increase was partly offset by declining sales of medicines with expired patents. sales in europe grew by 6, with key contributions from germany, france and the uk. the sales growth of vabysmo, phesgo, evrysdi, hemlibra and ocrevus more than compensated for the lower sales of ronapreve and medicines with expired patents. in japan, sales were down by 14, mainly due to lower supply of ronapreve to the government. excluding ronapreve, sales in japan grew by 6. this increase was fueled by the strong performance of newer medicines such as polivy and vabysmo, which effectively compensated for the impact of biosimilars. sales in the international region grew by 13, led by china, brazil and canada. in china, sales rose by 6, with tamiflu, xofluza and the cancer medicines polivy, tecentriq and perjeta being the key growth drivers, more than offsetting the impact of biosimilars and lower sales of cellcept. ocrevus chf 6.4 billion, 13. for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. there was continuously growing demand in both indications primarily driven by the us, with the growth coming from both new and retained patients. elsewhere, ocrevus continued to show high uptake, notably in germany, italy and brazil. hemlibra chf 4. 1 billion, 16. haemophilia a. sales growth continued, especially in the us in the non-inhibitor segment. in europe and the international region, sales grew across major markets, while sales in japan increased as a result of further market penetration. perjeta chf 3.8 billion, 1. her2-positive breast cancer. sales of perjeta grew by 1, with the international region, particularly china and brazil, being key growth driver. this was partly offset by a decline in sales in the us as a result of an adjustment related to us governmental plans. excluding this adjustment, perjeta sales in the us showed a growth of 1. sales of perjeta in europe were lower following the launch of phesgo. tecentriq chf 3.8 billion, 9. cancer immunotherapy either alone or in combinations for various types of cancer, e.g. lung, bladder, breast and liver cancer. sales increased by 9 with growth across all regions. in the us sales were higher driven by the non-small cell lung cancer nsclc adjuvant indication. in europe the growth was mainly driven by the small cell lung cancer and the hepatocellular carcinoma indications. in japan the sales increase came from growth in the nsclc adjuvant indication. in the international region china was the key growth driver. actemraroactemra chf 2.6 billion, 5. for rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, car t-cell-induced severe or life-threatening cytokine release syndrome and covid-19. sales increased by 5, mainly in the us, despite lower demand from hospitalised patients with cov id -19 . the demand outside of cov id -19 increased based on continued confidence in the medicine, especially in the rheumatoid arthritis segment.",
    "word_count": 488,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "in the united states, sales rose by 8. vabysmo, ocrevus and hemlibra were the main growth drivers. this increase was partly off",
            "position": 22,
            "sentence": "in the united states, sales rose by 8."
          },
          {
            "keyword": "sales",
            "context": "mo, ocrevus and hemlibra were the main growth drivers. this increase was partly offset by declining sales of medicines with expired patents. sales in europe grew by 6, with key contributions from germany,",
            "position": 144,
            "sentence": "this increase was partly offset by declining sales of medicines with expired patents."
          },
          {
            "keyword": "sales",
            "context": "owth drivers. this increase was partly offset by declining sales of medicines with expired patents. sales in europe grew by 6, with key contributions from germany, france and the uk. the sales growth of va",
            "position": 185,
            "sentence": "this increase was partly offset by declining sales of medicines with expired patents."
          },
          {
            "keyword": "sales",
            "context": "red patents. sales in europe grew by 6, with key contributions from germany, france and the uk. the sales growth of vabysmo, phesgo, evrysdi, hemlibra and ocrevus more than compensated for the lower sales",
            "position": 272,
            "sentence": "the sales growth of vabysmo, phesgo, evrysdi, hemlibra and ocrevus more than compensated for the lower sales of ronapreve and medicines with expired patents."
          },
          {
            "keyword": "sales",
            "context": "sales growth of vabysmo, phesgo, evrysdi, hemlibra and ocrevus more than compensated for the lower sales of ronapreve and medicines with expired patents. in japan, sales were down by 14, mainly due to low",
            "position": 371,
            "sentence": "the sales growth of vabysmo, phesgo, evrysdi, hemlibra and ocrevus more than compensated for the lower sales of ronapreve and medicines with expired patents."
          },
          {
            "keyword": "sales",
            "context": "ore than compensated for the lower sales of ronapreve and medicines with expired patents. in japan, sales were down by 14, mainly due to lower supply of ronapreve to the government. excluding ronapreve, sa",
            "position": 436,
            "sentence": "in japan, sales were down by 14, mainly due to lower supply of ronapreve to the government."
          },
          {
            "keyword": "sales",
            "context": "es were down by 14, mainly due to lower supply of ronapreve to the government. excluding ronapreve, sales in japan grew by 6. this increase was fueled by the strong performance of newer medicines such as p",
            "position": 539,
            "sentence": "excluding ronapreve, sales in japan grew by 6."
          },
          {
            "keyword": "sales",
            "context": "medicines such as polivy and vabysmo, which effectively compensated for the impact of biosimilars. sales in the international region grew by 13, led by china, brazil and canada. in china, sales rose by 6,",
            "position": 724,
            "sentence": "this increase was fueled by the strong performance of newer medicines such as polivy and vabysmo, which effectively compensated for the impact of biosimilars."
          },
          {
            "keyword": "sales",
            "context": "osimilars. sales in the international region grew by 13, led by china, brazil and canada. in china, sales rose by 6, with tamiflu, xofluza and the cancer medicines polivy, tecentriq and perjeta being the k",
            "position": 813,
            "sentence": "in china, sales rose by 6, with tamiflu, xofluza and the cancer medicines polivy, tecentriq and perjeta being the key growth drivers, more than offsetting the impact of biosimilars and lower sales of cellcept."
          },
          {
            "keyword": "sales",
            "context": "and perjeta being the key growth drivers, more than offsetting the impact of biosimilars and lower sales of cellcept. ocrevus chf 6.4 billion, 13. for relapsing forms of multiple sclerosis and primary pro",
            "position": 994,
            "sentence": "in china, sales rose by 6, with tamiflu, xofluza and the cancer medicines polivy, tecentriq and perjeta being the key growth drivers, more than offsetting the impact of biosimilars and lower sales of cellcept."
          },
          {
            "keyword": "sales",
            "context": "ow high uptake, notably in germany, italy and brazil. hemlibra chf 4. 1 billion, 16. haemophilia a. sales growth continued, especially in the us in the non-inhibitor segment. in europe and the internationa",
            "position": 1408,
            "sentence": "1 billion, 16."
          },
          {
            "keyword": "sales",
            "context": "ntinued, especially in the us in the non-inhibitor segment. in europe and the international region, sales grew across major markets, while sales in japan increased as a result of further market penetration",
            "position": 1523,
            "sentence": "in europe and the international region, sales grew across major markets, while sales in japan increased as a result of further market penetration."
          },
          {
            "keyword": "sales",
            "context": "n-inhibitor segment. in europe and the international region, sales grew across major markets, while sales in japan increased as a result of further market penetration. perjeta chf 3.8 billion, 1. her2-posi",
            "position": 1562,
            "sentence": "in europe and the international region, sales grew across major markets, while sales in japan increased as a result of further market penetration."
          },
          {
            "keyword": "sales",
            "context": "as a result of further market penetration. perjeta chf 3.8 billion, 1. her2-positive breast cancer. sales of perjeta grew by 1, with the international region, particularly china and brazil, being key growt",
            "position": 1687,
            "sentence": "her2-positive breast cancer."
          },
          {
            "keyword": "sales",
            "context": "ion, particularly china and brazil, being key growth driver. this was partly offset by a decline in sales in the us as a result of an adjustment related to us governmental plans. excluding this adjustment,",
            "position": 1841,
            "sentence": "this was partly offset by a decline in sales in the us as a result of an adjustment related to us governmental plans."
          },
          {
            "keyword": "sales",
            "context": "s as a result of an adjustment related to us governmental plans. excluding this adjustment, perjeta sales in the us showed a growth of 1. sales of perjeta in europe were lower following the launch of phesg",
            "position": 1955,
            "sentence": "excluding this adjustment, perjeta sales in the us showed a growth of 1."
          },
          {
            "keyword": "sales",
            "context": "to us governmental plans. excluding this adjustment, perjeta sales in the us showed a growth of 1. sales of perjeta in europe were lower following the launch of phesgo. tecentriq chf 3.8 billion, 9. cance",
            "position": 1993,
            "sentence": "excluding this adjustment, perjeta sales in the us showed a growth of 1."
          },
          {
            "keyword": "sales",
            "context": "alone or in combinations for various types of cancer, e.g. lung, bladder, breast and liver cancer. sales increased by 9 with growth across all regions. in the us sales were higher driven by the non-small",
            "position": 2220,
            "sentence": "lung, bladder, breast and liver cancer."
          },
          {
            "keyword": "sales",
            "context": "g, bladder, breast and liver cancer. sales increased by 9 with growth across all regions. in the us sales were higher driven by the non-small cell lung cancer nsclc adjuvant indication. in europe the growt",
            "position": 2283,
            "sentence": "sales increased by 9 with growth across all regions."
          },
          {
            "keyword": "sales",
            "context": "nly driven by the small cell lung cancer and the hepatocellular carcinoma indications. in japan the sales increase came from growth in the nsclc adjuvant indication. in the international region china was t",
            "position": 2497,
            "sentence": "in europe the growth was mainly driven by the small cell lung cancer and the hepatocellular carcinoma indications."
          },
          {
            "keyword": "sales",
            "context": "ll arteritis, car t-cell-induced severe or life-threatening cytokine release syndrome and covid-19. sales increased by 5, mainly in the us, despite lower demand from hospitalised patients with cov id -19 .",
            "position": 2826,
            "sentence": "for rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, car t-cell-induced severe or life-threatening cytokine release syndrome and covid-19."
          }
        ]
      },
      "COMPANY_STATE": {
        "market_position": [
          {
            "keyword": "market penetration",
            "context": "onal region, sales grew across major markets, while sales in japan increased as a result of further market penetration. perjeta chf 3.8 billion, 1. her2-positive breast cancer. sales of perjeta grew by 1, with the inte",
            "position": 1610,
            "sentence": "in europe and the international region, sales grew across major markets, while sales in japan increased as a result of further market penetration."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_023",
    "content": "sales increased by 5, mainly in the us, despite lower demand from hospitalised patients with cov id -19 . the demand outside of cov id -19 increased based on continued confidence in the medicine, especially in the rheumatoid arthritis segment. 36  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report top-selling pharmaceuticals in 2023 6,381 13 4,147 16 3,768 1 3,766 9 2,630 5 2,357 324 2 ,176 5 1,966 4 1,630 15 1,626 16ocrevus neurology hemlibra haemophilia a perjeta oncology tecentriq oncology actemraroactemra immunology vabysmo ophthalmology xolair immunology kadcyla oncology mabtherarituxan oncologyimmunology herceptin oncologychf millions 1 1 1 1 1 1 1 products launched before 2015pharmaceuticals  roche 37 innovating for patients around the world the us fda and the european commission approved columvi for people with relapsed or refractory diffuse large b-cell lymphoma based on results from phase iii pivotal data where columvi given as a fixed course induced early and long-lasting complete responses in these heavily pretreated patients. columvi is given for a fixed period of time and made to be readily available, providing patients with a treatment end date and a treatment-free period. the us fda also approved polivy in combination with r-chp for the treatment of certain types of previously untreated diffuse large b-cell lymphoma, based on the polarix trial. results of this phase iii study showed the polivy combination reduced the risk of disease progression, relapse or death by 27 compared to the standard of care, r-chop , with a comparable safety profile. this combination is the first fda-approved therapy in nearly 20 years for the first-line treatment of diffuse large b-cell lymphoma. the european commission approved the expansion of the hemlibra european union marketing authorisation. the label now includes the routine prophylaxis of bleeding episodes in people with haemophilia a without factor viii inhibitors, who have moderate disease fviii 1 and 5 with a severe bleeding phenotype. the commodore 2 study, a global phase iii programme for crovalimab in paroxysmal nocturnal haemoglobinuria pnh, a rare life-threatening blood condition, met its co-primary efficacy endpoints, showing crovalimab achieved disease control in people with pnh who have not been previously treated with complement inhibitors. the us fda accepted the companys biologics license application bla for crovalimab, for the treatment of pnh.the phase iii ocarina ii trial for ocrevus twice- a-year ten-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions. the ten-minute subcutaneous injection has the potential to improve the treatment experience and expand usage for people with multiple sclerosis ms in centres with iv capacity limitations. the pivotal phase iii imbrave050 study investigating tecentriq plus avastin in people with early-stage hepatocellular carcinoma at high risk of recurrence following surgery met the primary endpoint of recurrence-free survival. tecentriq subcutaneous sc received its first marketing authorisation in great britain and a positive opinion by the european medicines agencys committee for medicinal products for human use chmp for approval in europe.",
    "word_count": 491,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "sales increased by 5, mainly in the us, despite lower demand from hospitalised patients with cov id -19 .",
            "position": 0,
            "sentence": "sales increased by 5, mainly in the us, despite lower demand from hospitalised patients with cov id -19 ."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_024",
    "content": "the pivotal phase iii imbrave050 study investigating tecentriq plus avastin in people with early-stage hepatocellular carcinoma at high risk of recurrence following surgery met the primary endpoint of recurrence-free survival. tecentriq subcutaneous sc received its first marketing authorisation in great britain and a positive opinion by the european medicines agencys committee for medicinal products for human use chmp for approval in europe. tecentriq sc can be injected within minutes, which can free up time for patients, healthcare teams and caregivers. in the phase iii alina study, alecensa met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in disease-free survival. alecensa reduced the risk of disease recurrence or death by 76 compared with platinum-based chemotherapy in people with early-stage alk-positive non-small cell lung cancer nsclc. in a setting where treatment has curative intent, adjuvant alecensa represents an important new treatment strategy for patients with resected, stage ibiiia, alk-positive nsclc. data from the phase iii embark study showed that boys aged 47 years with duchenne muscular dystrophy dmd treated with elevidys showed an increase on the north star ambulatory assessment nsaa, a measure of motor function, compared to placebo at 52 weeks, but the primary endpoint 38  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 19 major approvals china 7japan  chugai 4 major approvals in 2023us 3 europe 5 phesgo her2-positive breast cancer  her2-positive colorectal cancer actemraroactemra cytokine release syndrome mabtherarituxan lupus nephritis mabtherarituxan antibody-mediated rejection in organ transplantation columvi diffuse large b-cell lymphoma, third-line treatment polivy diffuse large b-cell lymphoma, first-line treatment vabysmo retinal vein occlusion central vein occlusion or branched vein occlusion columvi diffuse large b-cell lymphoma, third-line treatment phesgo her2-positive breast cancer polivy diffuse large b-cell lymphoma, first-line treatment polivy diffuse large b-cell lymphoma, relapsed refractory evrysdi spinal muscular atrophy, presymptomatic paediatric 2 months x o fl u z a influenza, paediatric vabysmo neovascular or wet age-related macular degeneration  diabetic macular oedema columvi diffuse large b-cell lymphoma, third-line treatment hemlibra moderate haemophilia a evrysdi spinal muscular atrophy, presymptomatic paediatric 2 months x o fl u z a influenza, paediatric ronapreve sars-cov-2 hospitalised oncologyhaematology inflammationimmunology neurology infectious diseases ophthalmologypharmaceuticals  roche 39 pharmaceuticals clinical pipeline oncology inflammationimmunology infectious diseases metabolicsneurology ophthalmology others our pipeline of 82 new molecular entities covers a broad range of diseases, and highly innovative technologies are applied to create and produce the active molecules.4 47 3 131 2phase i phase iii phase ii registration 3 31 6 13 34 221agreements derived from existing alliances 28personalised healthcare agreements 14 technology and discovery licence agreements 10 product licence agreements 4number of new partnerships in 2023acquisitions 3 product out-licensing agreements and divestments 771 new partnerships pilot agreements 5 140  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report was not met. clinically meaningful and statistically significant treatment benefits were observed on all key pre-specified secondary functional endpoints. further evaluation of the data is ongoing.",
    "word_count": 486,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_025",
    "content": "clinically meaningful and statistically significant treatment benefits were observed on all key pre-specified secondary functional endpoints. further evaluation of the data is ongoing. the phase iii inavo120 study investigating inavolisib in combination with palbociclib and fulvestrant as a first-line treatment for people with pik3ca- mutated, hormone receptor- positive, her2- negative, endocrine-resistant, locally advanced or metastatic breast cancer met its primary endpoint. it demonstrated a statistically significant and clinically meaningful improvement in progression- free survival pfs. the inavolisib combination reduced the risk of disease worsening or death by 57, more than doubling pfs compared to palbociclib and fulvestrant alone. overall survival data were immature at this time, but a clear positive trend has been observed. follow-up will continue to the next analysis. data from the inavo120 study will be submitted to health authorities with the view of bringing this potential treatment option to patients as soon as possible. partnerships complementing our portfolio and expanding our presence in new areas roche entered a partnership with alnylam to co-develop and co-commercialise the phase ii rnai therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk. zilebesiran has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressure. in oncology, roche signed an agreement with zion pharma to continue developing and to commercialise zn-a-1041, a phase i her2 tyrosine kinase inhibitor tki with best-in-class potential. zn-a-10 41 has been specifically designed to be blood-brain barrier penetrant to address the significant unmet medical need associated with brain metastases in people with metastatic breast cancer. this tki has the potential to treat or prevent the onset of brain metastases in these patients. building on our expertise in immunology, roche signed an agreement to acquire telavant from roivant and pfizer, including the rights to rvt-3101 , an antibody with first-in-class and best-in-disease potential to treat inflammatory bowel disease. with this agreement, roche gains the right to develop, manufacture and commercialise rvt-3101 in the us and japan. genentech entered into a strategic collaboration with nvidia that couples genentechs cutting-edge artificial intelligence ai capabilities, extensive biological and molecular datasets, and research expertise with nvidias world-leading accelerated computing capabilities and ai to speed up drug discovery and development. at the end of 2023, roche entered into a definitive merger agreement to acquire carmot therapeutics including carmots innovative rd portfolio of incretin-based clinical and pre-clinical assets. the portfolio has great potential to provide new best- in-class treatments as monotherapy as well as in various combinations with other assets to treat obesity and several other indications.pharmaceuticals  roche 41 pharmaceuticals  roche 41 content the content disclosed is based on voluntary and mandatory disclosure requirements and the company strategy. the content covers non-financial matters in accordance with section six: transparency on non-f inancial matters and gri universal standards.",
    "word_count": 466,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "assets",
            "context": "therapeutics including carmots innovative rd portfolio of incretin-based clinical and pre-clinical assets. the portfolio has great potential to provide new best- in-class treatments as monotherapy as well",
            "position": 2841,
            "sentence": "at the end of 2023, roche entered into a definitive merger agreement to acquire carmot therapeutics including carmots innovative rd portfolio of incretin-based clinical and pre-clinical assets."
          },
          {
            "keyword": "assets",
            "context": "provide new best- in-class treatments as monotherapy as well as in various combinations with other assets to treat obesity and several other indications.pharmaceuticals  roche 41 pharmaceuticals  roche 41",
            "position": 2985,
            "sentence": "the portfolio has great potential to provide new best- in-class treatments as monotherapy as well as in various combinations with other assets to treat obesity and several other indications.pharmaceuticals  roche 41 pharmaceuticals  roche 41 content the content disclosed is based on voluntary and mandatory disclosure requirements and the company strategy."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_026",
    "content": "the portfolio has great potential to provide new best- in-class treatments as monotherapy as well as in various combinations with other assets to treat obesity and several other indications.pharmaceuticals  roche 41 pharmaceuticals  roche 41 content the content disclosed is based on voluntary and mandatory disclosure requirements and the company strategy. the content covers non-financial matters in accordance with section six: transparency on non-f inancial matters and gri universal standards. the content covers risk-based due diligence in our own operations and in the supply chain upstreams to identify, prevent, mitigate and account for actual and potential adverse impacts when there are reasonable grounds to suspect that products or services were manufactured or provided using child labour, in accordance with section eight: due diligence and transparency in relation to minerals and metals from conflict-affected areas and child labour under the swiss code this report has been prepared  in compliance with section six: transparency on non-financial matters and section eight: due diligence and transparency in relation to minerals and metals from conflict-affected areas and child labour of the swiss code of obligations and the respective implementing ordinance on due diligence and transparency in relation to minerals and metals from conflict-affected areas and child labour, and  in alignment with the latest global reporting initiative gri universal standards issued in 2021. reporting scope and boundaries this report covers all regions and divisions of the roche group from 1 january to 31 december 2023 with the scope as defined and outlined in the document 2023 non-financial reporting indicators definitions and scope.13. our reporting approach roche is committed to transparent reporting on our economic, social and environmental performance. 1 go.roche.comnon-financial-reporting-scope-2023  annual report 2023: ar23.roche.com  roche.comar23e.pdf  roche.comfb23e.pdf  risk management: roche.comrisk-management  key performance indicators: roche.comperformance42  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report of obligations, as well as the provisions of the ordinance on due diligence and transparency in relation to minerals and metals from conflict- affected areas and child labour. financial data mentioned in our business performance section is summarised and or aggregated information from our financial statements, prepared in accordance with international financial reporting standards ifrs, as issued by the international accounting standards board iasb. all information provided is based on a reasonably diligent data collection process with a second line of controls in order to reflect accurate information in all material aspects within the reasonable opinion of roche, taking in particular into account the size and complexity of the roche group and its operations. inadvertent errors in information may occur and inaccuracies may in particular be difficult to observe below a reasonable level of materiality. forward-looking statements are not guarantees of future performance or developments, and actual results or other developments may differ materially from the expectations expressed in the forward-looking statements. any forward- looking statement speaks only as of the date of such statement. roche does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.",
    "word_count": 497,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "assets",
            "context": "provide new best- in-class treatments as monotherapy as well as in various combinations with other assets to treat obesity and several other indications.pharmaceuticals  roche 41 pharmaceuticals  roche 41",
            "position": 136,
            "sentence": "the portfolio has great potential to provide new best- in-class treatments as monotherapy as well as in various combinations with other assets to treat obesity and several other indications.pharmaceuticals  roche 41 pharmaceuticals  roche 41 content the content disclosed is based on voluntary and mandatory disclosure requirements and the company strategy."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_027",
    "content": "any forward- looking statement speaks only as of the date of such statement. roche does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. some information provided may be based on internally developed methodology. some figures have been rounded, some percentages have been calculated using rounded numbers and non-material data have been excluded. external assurance some selected key figures of our non-financial reporting for the year ended 31 december 2023 have been subject to limited assurance procedures performed by our third-party assurance provider pricewaterhousecoopers ag pwc, in particular in the areas of: i safety, security, health and environmental protection, ii people and culture and iii grants, donations and sponsorships. see independent practitioners limited assurance report on page 92.our reporting approach  roche 43 the process and initial results of our materiality analysis were shared with the roche corporate executive committee and will be further shared for endorsement as we progress. for the purpose of this report, out of the 19 key sustainability topics, the following have been prioritised: environment  climate change, ghg and energy  air pollution  water social  product innovation and research  patient health and well-being  access and affordability  communities  employee rights and workforce dei  human rights and responsible, resilient value chains governance  corporate governance  compliance and business ethics  risk management  it, data governance, privacy and cybersecurity  transparency, accountability and reportingwe initiated a refreshed materiality assessment process, based on double materiality principles, to identify sustainability topics that have a significant impact on people, the environment and roches long-t erm business success. this ongoing assessment builds on our previous materiality assessments. the first phase of the assessment focused on a stakeholder engagement exercise. we collected quantitative data from 307 internal and 298 external stakeholders on priority sustainability topics. internal stakeholders comprised a randomly selected group of roche employees, and external stakeholders consisted of various groups including patients, caregivers, healthcare practitioners, governments and policymakers. based on the quantitative inputs and best-practice sustainability frameworks, we created a topic map. following the mapping exercise, additional quantitative and qualitative data were collected from 30 internal and 30 external stakeholders. the internal stakeholders were subject-matter experts within the organisation, and the external stakeholders comprised various groups including academia, industry bodies and associations, investors, patient organisations and suppliers. from this, we derived our 19 key sustainability topics.",
    "word_count": 391,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_028",
    "content": "the internal stakeholders were subject-matter experts within the organisation, and the external stakeholders comprised various groups including academia, industry bodies and associations, investors, patient organisations and suppliers. from this, we derived our 19 key sustainability topics. sustainability: roche.comsustainability  materiality: roche.commateriality  stakeholder engagement: roche.comstakeholder_engagement  key performance indicators: roche.comperformance  our contribution to the un sdgs: roche.comun-sdgs3.1 our key sustainability topics44  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report  subject-matter experts   non-governmental organisations   multilateral organisations19 key sustainability topics environment how we minimise our impact on the planetsocial how we contribute to a better tomorrow for allgovernance how we embed transparency and compliance in everything we do  climate change, ghg and energy  air pollution  water  biodiversity  circularity  product innovation and research  patient health and well-being  health equity  access and affordability  responsible marketing and labelling  sustainable health systems and communities  employee rights and workforce dei  human rights and responsible, resilient value chains overview of subject-matter expert segments consulted peers labsacademics and other thought leaders patient organisations suppliersindustry bodies and associations investorsngos, mlosassurance firms and other expert service providersgovernments, policymakers and regulators payers and providers internal smes corporate governance  compliance and business ethics  risk management  it, data governance, privacy and cybersecurity  transparency, accountability and reporting  stakeholder engagementour key sustainability topics  roche 45 the pharmaceutical industry is inherently science- based and rooted in the belief that good science results in good products. while advancing science is our core focus at roche, we also believe that our scientific innovations are only valuable if they serve patients in the way they want and need. over the past year, we have focused on applying this belief to our development efforts by integrating patient insights, patient experience data and patient preference into our process. through this effort, weve strived to balance our scientific discoveries with an understanding of what patients  including historically underserved, under-represented patients  need and desire in their care. this work is driven by our global patient network team and guided by our proprietary patient benefits and societal impact framework that captures prioritised, actionable insights about:  gaps patients experience in their care  current and future patient needs  patient feedback on new medicines, diagnostics and integrated healthcare solutions that are in development  benefits patients seek from their treatments and overall care embedding patient voice from end to end we strive to embed the patient voice from end to end into our disease area strategies. this work begins by empowering our early research teams to focus their discovery, partnering and development programmes on patient needs by evaluating the potential benefits and risks of their scientific discoveries for patient populations that are relevant and representative of the real-world setting. our approach to patient insight integration also involves an early assessment of the impact our innovations have on health systems so that we can prioritise our investments to advance the most beneficial molecules and diagnostics for further development.",
    "word_count": 480,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "biodiversity  circularity  product innovation and research  patient health and well-being  health equity  access and affordability  responsible marketing and labelling  sustainable health systems and comm",
            "position": 1119,
            "sentence": "sustainability: roche.comsustainability  materiality: roche.commateriality  stakeholder engagement: roche.comstakeholder_engagement  key performance indicators: roche.comperformance  our contribution to the un sdgs: roche.comun-sdgs3.1 our key sustainability topics44  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report  subject-matter experts   non-governmental organisations   multilateral organisations19 key sustainability topics environment how we minimise our impact on the planetsocial how we contribute to a better tomorrow for allgovernance how we embed transparency and compliance in everything we do  climate change, ghg and energy  air pollution  water  biodiversity  circularity  product innovation and research  patient health and well-being  health equity  access and affordability  responsible marketing and labelling  sustainable health systems and communities  employee rights and workforce dei  human rights and responsible, resilient value chains overview of subject-matter expert segments consulted peers labsacademics and other thought leaders patient organisations suppliersindustry bodies and associations investorsngos, mlosassurance firms and other expert service providersgovernments, policymakers and regulators payers and providers internal smes corporate governance  compliance and business ethics  risk management  it, data governance, privacy and cybersecurity  transparency, accountability and reporting  stakeholder engagementour key sustainability topics  roche 45 the pharmaceutical industry is inherently science- based and rooted in the belief that good science results in good products."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_029",
    "content": "this work begins by empowering our early research teams to focus their discovery, partnering and development programmes on patient needs by evaluating the potential benefits and risks of their scientific discoveries for patient populations that are relevant and representative of the real-world setting. our approach to patient insight integration also involves an early assessment of the impact our innovations have on health systems so that we can prioritise our investments to advance the most beneficial molecules and diagnostics for further development. ultimately, our goal is to create an internal ecosystem where patients are not just at the heart of our work, but they are included and integrated into our processes as partners who challenge and shape our science, enabling roche to define or redefine the standard of care for the diseases we actively focus on. making patient inclusivity a core priority for every employee, in every function, in every country is the only way we will ensure that the patient voice is embedded into our decision-making  not just at roche, but also within healthcare systems, which should be designed to address the most pressing patient needs. maintaining high standards with patient stakeholders this work, however, must be done with integrity and transparency to ensure that we do not unduly influence patient communities in relation to our innovations. for this reason, roche consistently applies high standards of conduct in its collaboration with patient stakeholders.4. partnering with patients connecting our work to patient needs requires us to move beyond patient centricity to patient inclusivity.46  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report while advancing science is our core focus at roche, we also believe that our scientific innovations are only valuable if they serve patients in the way they want and need.key sustainability topics  patient health and well-being  responsible marketing and labelling  stakeholder engagement partnering with patients  roche 47 the roche group code of conduct1, roches position on partnering with patient communities2 and the roche directive on collaborating with patient groups and patients3 establish guiding principles that govern the actions of all our employees. at their core, these documents outline our commitment to mutual value, mutual respect, integrity, equity, independence and transparency. they also form the basis of our robust training programmes provided to all employees who may interact with patients. they are based on and include elements of training offered by organisations like patient focused medicines development pfmd and the european patients academy on therapeutic innovation eupati. our commitment to these principles is further reflected in our annual disclosure of funding and non-monetary support provided to patient organisations around the world. this disclosure is a core component of our sustainability overview and a further reflection of our approach to maintaining productive and purposeful relationships.",
    "word_count": 458,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": ". at their core, these documents outline our commitment to mutual value, mutual respect, integrity, equity, independence and transparency. they also form the basis of our robust training programmes provided",
            "position": 2429,
            "sentence": "at their core, these documents outline our commitment to mutual value, mutual respect, integrity, equity, independence and transparency."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "challenges": [
          {
            "keyword": "challenge",
            "context": "t at the heart of our work, but they are included and integrated into our processes as partners who challenge and shape our science, enabling roche to define or redefine the standard of care for the diseases w",
            "position": 741,
            "sentence": "ultimately, our goal is to create an internal ecosystem where patients are not just at the heart of our work, but they are included and integrated into our processes as partners who challenge and shape our science, enabling roche to define or redefine the standard of care for the diseases we actively focus on."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_030",
    "content": "our commitment to these principles is further reflected in our annual disclosure of funding and non-monetary support provided to patient organisations around the world. this disclosure is a core component of our sustainability overview and a further reflection of our approach to maintaining productive and purposeful relationships. patient view global rankings for 2022 made available in 2023 2022 ranking of big pharma by pags that worked with us2022 ranking of all companies by pags that worked with us overall portfolio 2,207 patient organisations1st out of 15 2021: 2nd 3rd out of 42 2021: 3rd cancer overall 555 patient organisations1st out of 15 2021: 2nd 1st out of 23 2021: 2nd breast cancer 106 patient organisations1st out of 12 2021: 2nd 1st out of 14 2021: 2nd blood cancer 88 patient organisations1st out of 15 2021: 4th 1st out of 18 2021: 4th lung cancer 35 patient organisations1st out of 9 2021: 2nd1st out of 9 2021: 2nd ophthalmology 35 patient organisations1st out of 3 2021: 2ndcompanies evaluated in ophthalmology were all big pharma rare diseases 426 patient organisations1st out of 15 2021: 1st 1st out of 31 2021: 1st rare bleeding disorders 61 patient organisations1st out of 4 2021: 1st 1st out of 9 2021: 1st neurology 286 patient organisations1st out of 11 2021: 1st 1st out of 18 2021: 1st multiple sclerosis 72 patient organisations1st out of 6 2021: 1st 1st out of 9 2021: 2nd neuromuscular disorders 42 patient organisations2nd out of 3 2021: 1stcompanies evaluated in neuromuscular disorders were all big pharma  patient advocacy groups 1 roche.comaboutgovernancecode-of-conduct  2 go.roche.composition-on-partnering-with-patient-communities  3 go.roche.comcollaborating-with-patient-groups-and-patients48  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 1,604 patient organisations that engage with roche across the world chf 54 million provided in grants, sponsorships and donations to the worldwide patient community in 2023patient-focused roles healthcare system partners hsps serve as the local face of roche with key healthcare system stakeholders, such as policymakers, regulators, payers and patient organisations, to improve patient access to healthcare. hsps identify shared purpose and value with our partners to drive health system innovation and co-create solutions that will deliver value for patients and the local health ecosystem. patient partnership teams patient experience teams patient journey partners p jpsserve as primary relationship managers that build, maintain and drive roches collaborations with patient organisations as well as individual patients and their carers. patient partnership leads also known as patient advocacy leads at the country level proactively drive roches collaborations with the patient community to bring their feedback and relevant insights to our teams so that we may develop medicines, diagnostics and integrated health solutions of high value to patients. these teams work across the full lifecycle of roches innovations to shape clinical development as well as access strategies to ensure that every patient who can benefit from our companys innovations can access them.help design and implement programmes or solutions that improve the experience patients have with the roche group.",
    "word_count": 492,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_031",
    "content": "patient partnership leads also known as patient advocacy leads at the country level proactively drive roches collaborations with the patient community to bring their feedback and relevant insights to our teams so that we may develop medicines, diagnostics and integrated health solutions of high value to patients. these teams work across the full lifecycle of roches innovations to shape clinical development as well as access strategies to ensure that every patient who can benefit from our companys innovations can access them.help design and implement programmes or solutions that improve the experience patients have with the roche group. these individuals focus on understanding how patients navigate healthcare systems so that we can offer beyond the pill services, digital health solutions or end-to-end patient support programmes to enhance their experience and outcomes. are local roche representatives who work closely with patients as well as the stakeholders and organisations that directly impact the patient journey at a country level. pjps have a deep knowledge of their local health system and can identify unmet patient needs for which roche may develop solutions to add value and improve patient outcomes. patient-focused roles that help roche integrate the voice and feedback of patients into our development and commercialisation efforts 300partnering with patients  roche 49 access to healthcare is a core element of roches sustainable business strategy. we work to identify and address the root causes preventing access to innovative healthcare at global, country and local levels. we also work closely with partners to develop and deliver tailored access solutions that reflect each countrys unique healthcare needs. our commitment to sustainable healthcare is reflected in the roche group code of conduct.2 employees are expected to ensure that all access programmes are compliant with applicable laws, regulations and industry codes, and to collaborate in a transparent and responsible way with different stakeholders to enable access to our products and services. our policies provide guidance on ethical collaboration with different stakeholder groups, including patients and patient organisations, healthcare professionals, healthcare organisations and government officials. the importance of uhc and the sdgs in 2015, world leaders agreed on the united nations sdgs, a shared blueprint for peace and prosperity for people and the planet. one of the 17 goals, sdg 3, aims to ensure healthy lives and promote well-being for all at all ages. as a healthcare company, we know we have an important role to play in sdg 3, including through supporting access to our innovations. one way we facilitate access to our innovations is by supporting the expansion of universal health coverage uhc, a key component of the sdgs. uhc means that all people have access to the full range of quality health services, whenever and wherever they need them, without financial hardship. yet, as we find ourselves halfway towards the 2030 deadline for achieving the sdgs, the world is significantly off track to meet this target.",
    "word_count": 479,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "guidance",
            "context": "way with different stakeholders to enable access to our products and services. our policies provide guidance on ethical collaboration with different stakeholder groups, including patients and patient organisa",
            "position": 2112,
            "sentence": "our policies provide guidance on ethical collaboration with different stakeholder groups, including patients and patient organisations, healthcare professionals, healthcare organisations and government officials."
          },
          {
            "keyword": "target",
            "context": "towards the 2030 deadline for achieving the sdgs, the world is significantly off track to meet this target.",
            "position": 3128,
            "sentence": "yet, as we find ourselves halfway towards the 2030 deadline for achieving the sdgs, the world is significantly off track to meet this target."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_032",
    "content": "uhc means that all people have access to the full range of quality health services, whenever and wherever they need them, without financial hardship. yet, as we find ourselves halfway towards the 2030 deadline for achieving the sdgs, the world is significantly off track to meet this target. the who stated in an sdg progress report that in the wake of the pandemic, progress towards uhc has slowed while financial hardship has risen. they also reported that in 2019, around 381 million people 4.9 of the global population were pushed or further pushed into extreme poverty due to out-of-pocket payments to cover health costs. key elements to achieving uhc as a global healthcare company working in innovative therapeutics and diagnostics  and a member of the uhc2030 private sector constituency  we have made a clear commitment to support the adoption of uhc. we believe that public funding, complemented by other sustainable funding and financing mechanisms between the public and private sectors, is fundamental to achieve uhc. uhc must include non-communicable diseases ncds such as cardiovascular diseases, cancers, chronic respiratory diseases and diabetes. ncds kill approximately 41 million people each year, equivalent to 74 of all deaths globally. it is also vital that screening, early diagnosis and treatment are built into an integrated 5. access to healthcare roche supports the expansion of universal health coverage, a key component of the united nations sustainable development goals sdgs.1 1 go.roche.comun-goals  2 roche.comaboutgovernancecode-of-conduct50  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report the support for the empower programme in kenya is one of our various initiatives around the world to provide sustainable patient access to quality and affordable healthcare, and ultimately to support the expansion of uhc.key sustainability topics  patient health and well-being  health equity  access and affordability  responsible marketing and labelling  sustainable health systems and communities  stakeholder engagement access to healthcare  roche 51 healthcare system, supported by a backbone of lab-st rengthening and connected laboratory networks. with the adoption in 2023 of the who resolution on strengthening diagnostics capacity, we see growing political recognition of the value of diagnostics to deliver improved care for all, encouraging member states to adopt national diagnostics strategies as a way to ensure effective allocation of limited resources. working in partnership towards uhc roche has long supported uhc. we work at the global, regional and local levels, collaborating with multiple stakeholders to address the care gap, which ranges from working on screening programmes to healthcare workforce capacity building and beyond. we are working on initiatives around the world to provide sustainable patient access to quality and affordable healthcare, and ultimately to support the expansion of uhc:  indonesia: roche is working closely with the government and local partners on two unique projects. the first aims to strengthen oncology nursing capacity by increasing the number of trained nurses who can deliver basic and specialised oncology nursing care.",
    "word_count": 480,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "ly to support the expansion of uhc.key sustainability topics  patient health and well-being  health equity  access and affordability  responsible marketing and labelling  sustainable health systems and comm",
            "position": 1977,
            "sentence": "access to healthcare roche supports the expansion of universal health coverage, a key component of the united nations sustainable development goals sdgs.1 1 go.roche.comun-goals  2 roche.comaboutgovernancecode-of-conduct50  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report the support for the empower programme in kenya is one of our various initiatives around the world to provide sustainable patient access to quality and affordable healthcare, and ultimately to support the expansion of uhc.key sustainability topics  patient health and well-being  health equity  access and affordability  responsible marketing and labelling  sustainable health systems and communities  stakeholder engagement access to healthcare  roche 51 healthcare system, supported by a backbone of lab-st rengthening and connected laboratory networks."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "target",
            "context": "towards the 2030 deadline for achieving the sdgs, the world is significantly off track to meet this target. the who stated in an sdg progress report that in the wake of the pandemic, progress towards uhc ha",
            "position": 284,
            "sentence": "yet, as we find ourselves halfway towards the 2030 deadline for achieving the sdgs, the world is significantly off track to meet this target."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_033",
    "content": "we are working on initiatives around the world to provide sustainable patient access to quality and affordable healthcare, and ultimately to support the expansion of uhc:  indonesia: roche is working closely with the government and local partners on two unique projects. the first aims to strengthen oncology nursing capacity by increasing the number of trained nurses who can deliver basic and specialised oncology nursing care. the second project is introducing and establishing cancer patient navigator professionals to help patients and their families navigate the complex treatment journey. kenya: we are supporting the empower programme to establish clinics that provide integrated care for breast and cervical cancer, and ncds. the programme is a partnership between public, private and non-profit organisations that aims to overcome systemic healthcare challenges such as lack of screening and access to medicines. since its launch in 2019, 19 clinics have been established across kenya, with more than 42,000 women screened for breast cancer and cervical cancer. the programme has also seen over 4,000 men screened for prostate cancer. peru: in collaboration with the peruvian ministry of health, government organisations, patient advocates and other groups in peru, roche is supporting the implementation of a national cervical cancer screening programme. the goal is to ensure women have access to improved care in cities and remote villages along the amazon, where some of the highest cervical cancer rates are found. through the programme, which serves 19 sites in peru, nearly 300,000 women have been tested for hpv infection in the past two years, with more than 80 choosing sample self-collection. roche has trained around 7,500 healthcare providers in the programme and worked with the ministry of health to improve the care of high-risk hpv-p ositive patients. pakistan: we are supporting the screenher plan, a project to improve diabetes management for women. developed in partnership with greenstar social marketing guarantee limited, the project allows women in underprivileged areas to access diabetes risk assessment, education and testing that would otherwise be difficult to get. it also allows earlier diabetes diagnosis and management, improving overall health outcomes. we hope to reach over one million women in the next three years. as the world seeks to catch up on uhc implementation ahead of 2030, roche remains committed to working in partnership with private and public stakeholders around the world to address and overcome local challenges, building strong and more resilient healthcare systems for all.52  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 14 cities screenher programmemore than 40,500 patients more than 8,500 laboratory professionals we continue to work with city cancer challenge, who are now active in 14 cities worldwide reaching an estimated 66.5 million people. in pakistan was launched in partnership with greenstar social marketing guarantee limited in 2023 to improve diabetes management for women, with the goal to reach over one million individuals in the next three years.",
    "word_count": 481,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "profitability": [
          {
            "keyword": "profit",
            "context": "reast and cervical cancer, and ncds. the programme is a partnership between public, private and non-profit organisations that aims to overcome systemic healthcare challenges such as lack of screening and ac",
            "position": 798,
            "sentence": "the programme is a partnership between public, private and non-profit organisations that aims to overcome systemic healthcare challenges such as lack of screening and access to medicines."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "challenges": [
          {
            "keyword": "challenge",
            "context": "than 40,500 patients more than 8,500 laboratory professionals we continue to work with city cancer challenge, who are now active in 14 cities worldwide reaching an estimated 66.5 million people. in pakistan w",
            "position": 2890,
            "sentence": "as the world seeks to catch up on uhc implementation ahead of 2030, roche remains committed to working in partnership with private and public stakeholders around the world to address and overcome local challenges, building strong and more resilient healthcare systems for all.52  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 14 cities screenher programmemore than 40,500 patients more than 8,500 laboratory professionals we continue to work with city cancer challenge, who are now active in 14 cities worldwide reaching an estimated 66.5 million people."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_034",
    "content": "as the world seeks to catch up on uhc implementation ahead of 2030, roche remains committed to working in partnership with private and public stakeholders around the world to address and overcome local challenges, building strong and more resilient healthcare systems for all.52  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 14 cities screenher programmemore than 40,500 patients more than 8,500 laboratory professionals we continue to work with city cancer challenge, who are now active in 14 cities worldwide reaching an estimated 66.5 million people. in pakistan was launched in partnership with greenstar social marketing guarantee limited in 2023 to improve diabetes management for women, with the goal to reach over one million individuals in the next three years. in scope of our low- and lower-middle-income country llmic access goal used our core medicines in 2023, as we aim to double access from 27,000 patients between 2021 and 2026.in africa were trained through the global access program to address critical shortages of lab technicians and support the need for more quality diagnostic services. more than 52,200 children in 29 countries have been reached through the changing diabetes in children programme, a partnership with novo nordisk, since its launch in 2009.29 billion roche diagnostics tests68 of roches core medicines more than 25 million women were delivered to customers worldwide in 2023.were approved or approval was in progress in llmics, compared to 60 in 2021.were tested with roches hpv high-risk testing in 2023  more than 600,000 of these women in low- and middle-income countries. patients in 37 llmics were treated with roche medicines in 2023, compared to 33 llmics in 2021. access around the world  2023 saw a decline in the use of actemraroactemra for covid-19; however this was compensated by increases in other medicines.access to healthcare  roche 53 we see dei as a critical lever that enables innovation for our medicines and diagnostics solutions  helping millions of patients and contributing to healthier communities. as an employer, we are committed to fostering a work environment where all employees can be themselves and can thrive. the newly created global chief diversity officer role is a visible and important milestone in our efforts towards a holistic and global approach. caroline creven fourrier has been appointed in this role leading a team set up as a stand-alone group closely connected to the business and our executives. the role involves taking responsibility for roches dei strategy, strengthening our internal dei community and driving internal and external efforts to accelerate the realisation of roches dei vision and ambitions. focus on equity we recently updated our dei strategy to add equity as a critical focus area. equity has always been inherently included in our efforts and we wanted to call it out more explicitly. to roche, equity means giving people and groups fair access to opportunities, with consideration for their unique differences, to create equal outcomes.",
    "word_count": 483,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "nal and external efforts to accelerate the realisation of roches dei vision and ambitions. focus on equity we recently updated our dei strategy to add equity as a critical focus area. equity has always been",
            "position": 2779,
            "sentence": "the role involves taking responsibility for roches dei strategy, strengthening our internal dei community and driving internal and external efforts to accelerate the realisation of roches dei vision and ambitions."
          },
          {
            "keyword": "equity",
            "context": "ion of roches dei vision and ambitions. focus on equity we recently updated our dei strategy to add equity as a critical focus area. equity has always been inherently included in our efforts and we wanted t",
            "position": 2830,
            "sentence": "focus on equity we recently updated our dei strategy to add equity as a critical focus area."
          },
          {
            "keyword": "equity",
            "context": "tions. focus on equity we recently updated our dei strategy to add equity as a critical focus area. equity has always been inherently included in our efforts and we wanted to call it out more explicitly. to",
            "position": 2863,
            "sentence": "focus on equity we recently updated our dei strategy to add equity as a critical focus area."
          },
          {
            "keyword": "equity",
            "context": "ays been inherently included in our efforts and we wanted to call it out more explicitly. to roche, equity means giving people and groups fair access to opportunities, with consideration for their unique di",
            "position": 2977,
            "sentence": "equity has always been inherently included in our efforts and we wanted to call it out more explicitly."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "challenges": [
          {
            "keyword": "challenge",
            "context": "than 40,500 patients more than 8,500 laboratory professionals we continue to work with city cancer challenge, who are now active in 14 cities worldwide reaching an estimated 66.5 million people. in pakistan w",
            "position": 527,
            "sentence": "as the world seeks to catch up on uhc implementation ahead of 2030, roche remains committed to working in partnership with private and public stakeholders around the world to address and overcome local challenges, building strong and more resilient healthcare systems for all.52  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 14 cities screenher programmemore than 40,500 patients more than 8,500 laboratory professionals we continue to work with city cancer challenge, who are now active in 14 cities worldwide reaching an estimated 66.5 million people."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_035",
    "content": "equity has always been inherently included in our efforts and we wanted to call it out more explicitly. to roche, equity means giving people and groups fair access to opportunities, with consideration for their unique differences, to create equal outcomes. addressing the unmet needs of diverse patients and communities we are committed to contributing to science by advancing inclusive research for diverse patient populations globally  reducing barriers that prevent people from accessing quality care. our partnerships driving inclusive research have expanded to include sites across the us, uk, canada, south africa, kenya, morocco, nigeria and india. one example is roches partnership with omnigen to analyse health and genetic information from up to 100,000 patients in south africa. the project aims to address the relative lack of genomic data from people of african descent. better health data allows roche to develop more effective drugs, targeted therapies and novel biomarkers, and expand market access to improve patient outcomes globally. read more about our work to close representation gaps on page 110. building a workforce that reflects the societies we serve we rely on the creativity and diverse ideas of our people to create innovative healthcare solutions that improve outcomes for patients. in 2023 we made progress in improving data quality and transparency and helping employees further grow their understanding of the importance of dei around the globe. by improving our data quality and sharing data more transparently across the organisation, we encourage greater accountability and collective action towards our dei strategy and goals. in addition, we communicated our dei narrative so that all employees better understand the connection between the dei strategy and our ability to innovate on behalf of patients around the globe. 6. diversity, equity and inclusion diversity, equity and inclusion dei are key components of roche s sustainability-focused identity.54  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report key sustainability topics  employee rights and workforce dei we rely on the creativity and diverse ideas of our people to create innovative healthcare solutions that improve outcomes for patients.diversity, equity and inclusion  roche 55 roche has two corporate goals focused on gender and nationality, which catalyse action across the organisation with the aim to achieve improvement year on year. these measures serve as proxies to the numerous and often immeasurable dimensions of diversity that our people bring to roche. globally, we have set a target to increase the proportion of women in executive positions by 2, and under- represented nationalities in executive positions by 1. in 2023 we focused on building more inclusive talent pipelines and increasing equity for under-represented talent, with the aim to drive progress against our corporate diversity goals see chart on page 57. embedding dei practices to ensure everyone can be themselves, do their best work and thrive in 2023 we continued to embed dei practices across our operations to foster greater inclusion at roche. our global dei learning portfolio is accessible to more than 99 of our employees.",
    "word_count": 496,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "equity has always been inherently included in our efforts and we wanted to call it out more explicitly. to",
            "position": 0,
            "sentence": "equity has always been inherently included in our efforts and we wanted to call it out more explicitly."
          },
          {
            "keyword": "equity",
            "context": "ays been inherently included in our efforts and we wanted to call it out more explicitly. to roche, equity means giving people and groups fair access to opportunities, with consideration for their unique di",
            "position": 114,
            "sentence": "to roche, equity means giving people and groups fair access to opportunities, with consideration for their unique differences, to create equal outcomes."
          },
          {
            "keyword": "equity",
            "context": "the dei strategy and our ability to innovate on behalf of patients around the globe. 6. diversity, equity and inclusion diversity, equity and inclusion dei are key components of roche s sustainability-focu",
            "position": 1874,
            "sentence": "6."
          },
          {
            "keyword": "equity",
            "context": "y to innovate on behalf of patients around the globe. 6. diversity, equity and inclusion diversity, equity and inclusion dei are key components of roche s sustainability-focused identity.54  contents letter",
            "position": 1906,
            "sentence": "diversity, equity and inclusion diversity, equity and inclusion dei are key components of roche s sustainability-focused identity.54  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report key sustainability topics  employee rights and workforce dei we rely on the creativity and diverse ideas of our people to create innovative healthcare solutions that improve outcomes for patients.diversity, equity and inclusion  roche 55 roche has two corporate goals focused on gender and nationality, which catalyse action across the organisation with the aim to achieve improvement year on year."
          },
          {
            "keyword": "equity",
            "context": "our people to create innovative healthcare solutions that improve outcomes for patients.diversity, equity and inclusion  roche 55 roche has two corporate goals focused on gender and nationality, which cata",
            "position": 2318,
            "sentence": "diversity, equity and inclusion diversity, equity and inclusion dei are key components of roche s sustainability-focused identity.54  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report key sustainability topics  employee rights and workforce dei we rely on the creativity and diverse ideas of our people to create innovative healthcare solutions that improve outcomes for patients.diversity, equity and inclusion  roche 55 roche has two corporate goals focused on gender and nationality, which catalyse action across the organisation with the aim to achieve improvement year on year."
          },
          {
            "keyword": "equity",
            "context": "utive positions by 1. in 2023 we focused on building more inclusive talent pipelines and increasing equity for under-represented talent, with the aim to drive progress against our corporate diversity goals",
            "position": 2877,
            "sentence": "in 2023 we focused on building more inclusive talent pipelines and increasing equity for under-represented talent, with the aim to drive progress against our corporate diversity goals see chart on page 57."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "target",
            "context": "often immeasurable dimensions of diversity that our people bring to roche. globally, we have set a target to increase the proportion of women in executive positions by 2, and under- represented nationaliti",
            "position": 2661,
            "sentence": "globally, we have set a target to increase the proportion of women in executive positions by 2, and under- represented nationalities in executive positions by 1."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_036",
    "content": "embedding dei practices to ensure everyone can be themselves, do their best work and thrive in 2023 we continued to embed dei practices across our operations to foster greater inclusion at roche. our global dei learning portfolio is accessible to more than 99 of our employees. the portfolio, available on our global learning platform, includes trainings on bias awareness, intercultural awareness and psychological safety to help employees expand their understanding and build skills to support the dei strategy. our ongoing awareness campaign  dei: it starts with me  helps raise awareness of important issues and creates lasting, positive change across roche by driving doable, incremental and actionable changes across 100,000 employees. the 2023 campaign reached 50 more people than previous campaigns. through the inclusion index in the 2023 global employee opinion survey geos, we measured the perception of inclusion at roche, focusing on inclusion, authenticity and respect. our 2023 score was 77, remaining stable from 2021. our inclusive culture is strengthened by the collective efforts of our diversity networks. forty-five new diversity networks formed in 2023, bringing the total to 127 see page 57. advancing positive change in society through diverse partnerships our dei strategy encourages the development of local partnerships with diverse stakeholders to create a positive ripple effect in communities across the globe. in 2023 roche strengthened partnerships that add value to patients, society, healthcare and roche  fostering greater appreciation for dei globally and locally. one example is mission leapfrog, an initiative that aims to transform patient well-being and population health in asia. by partnering with people across the region to co-create breakthroughs, the project hopes to trigger transformative leapfrog progress that improves health outcomes for underserved populations. proactively addressing demographic shifts, workplace expectations and policy changes the dei landscape is constantly evolving and requires continued focus and investment. with global demographic shifts such as population growth in low- and middle-income countries, along with a generational shift in the workforce, we expect our current and future organisational needs to mirror these dynamics. roche is also proactively taking steps to meet changing regulatory requirements that call for additional focus on dei, with particular attention to health equity, disability, ethnicity and age. supporting global dei commitments roche is committed to creating a diverse, equitable and inclusive workplace where human rights are respected and safe working conditions are ensured. 56  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report q1 2021 q1 2022 q1 2023 q3 2021 q3 2022 q3 2023 q4 2021 q4 2022 q4 2023 goal q2 2021 q2 2022 q2 202335.436.1 15.516.215.817.834.335.9 35.9 35.637.335.837.1 36.7 36.7 36.938.7 14.215.816.2 15.9 16.5 15.6 13.6 13.6 13.9  includes individuals from countries in asia, latin america, eastern europe, middle east and africa. excludes chugai and workday lite companies these companies do not use the roche workday system as their leading hr system due to our arms-length alliance and mergeracquisition agreements.",
    "word_count": 481,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "regulatory requirements that call for additional focus on dei, with particular attention to health equity, disability, ethnicity and age. supporting global dei commitments roche is committed to creating a",
            "position": 2464,
            "sentence": "roche is also proactively taking steps to meet changing regulatory requirements that call for additional focus on dei, with particular attention to health equity, disability, ethnicity and age."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_037",
    "content": "56  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report q1 2021 q1 2022 q1 2023 q3 2021 q3 2022 q3 2023 q4 2021 q4 2022 q4 2023 goal q2 2021 q2 2022 q2 202335.436.1 15.516.215.817.834.335.9 35.9 35.637.335.837.1 36.7 36.7 36.938.7 14.215.816.2 15.9 16.5 15.6 13.6 13.6 13.9  includes individuals from countries in asia, latin america, eastern europe, middle east and africa. excludes chugai and workday lite companies these companies do not use the roche workday system as their leading hr system due to our arms-length alliance and mergeracquisition agreements. illustrative map of the diversity networks and chapters; not exhaustivediversity networks are grassroots, self-organised groups of employees coming together to contribute to the dei mission of our organisation and are specifically aimed at embracing the unique power of each person to transform the lives of patients and society. agegeneration raceethnicity disability gender lgbtq dei veterans intersectional127 diversity networks and chapters around the globeglobal dei corporate goals we have set the 2023 target of achieving 2 share of women in executive positions and 1 of under-represented nationalities in executive positions as per our q4 2022 baseline. additionally, we invite leaders across roche to make an additional commitment which is relevant in the local culture and context. women under-represented nationalitiesdiversity, equity and inclusion  roche 57 103,605 latin america 4,981australianew zealand 652north america 28,661 europe 44,920africa 1,171asia 23,219by regionemployees part-time 11.5 full-time 88.5  number of employees expressed in full-time equivalents, on 31 december 2023  operating divisional group4,435 5,3098,202 9,306 858 29978 345,130 4,1473,240 2,576 6,171 5,752 9,033 9,0897,397 7,090 9,749 10,281 male female303450545559 20244044 353960 and over 25294549 19 and under age distribution by genderpharmaceuticals 45,239 chugai 7,499 diagnostics 38,173 corporate and other 12,694 employees by divisionodg58  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 58  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report as a united nations global compact ungc signatory, we commit to integrate the universal principles in the areas of human rights, labour, environment and anti-corruption into our business strategy, culture and daily operations. our valuable 5001 commitment supports disability inclusion and we are a signatory of the un standards of conduct for business on tackling discrimination against lgbtq people.2 we also recently signed the zero health gaps pledge3 from the world economic forum wef. this pledge aligns with our commitment to address barriers to clinical trial participation, diversify genetic data for scientific discovery and increase access to innovative diagnostic and therapeutic solutions by advancing inclusive research4 read more about our work in this area on page 110.",
    "word_count": 432,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "which is relevant in the local culture and context. women under-represented nationalitiesdiversity, equity and inclusion  roche 57 103,605 latin america 4,981australianew zealand 652north america 28,661 eur",
            "position": 1465,
            "sentence": "women under-represented nationalitiesdiversity, equity and inclusion  roche 57 103,605 latin america 4,981australianew zealand 652north america 28,661 europe 44,920africa 1,171asia 23,219by regionemployees part-time 11.5 full-time 88.5  number of employees expressed in full-time equivalents, on 31 december 2023  operating divisional group4,435 5,3098,202 9,306 858 29978 345,130 4,1473,240 2,576 6,171 5,752 9,033 9,0897,397 7,090 9,749 10,281 male female303450545559 20244044 353960 and over 25294549 19 and under age distribution by genderpharmaceuticals 45,239 chugai 7,499 diagnostics 38,173 corporate and other 12,694 employees by divisionodg58  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 58  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report as a united nations global compact ungc signatory, we commit to integrate the universal principles in the areas of human rights, labour, environment and anti-corruption into our business strategy, culture and daily operations."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "target",
            "context": "127 diversity networks and chapters around the globeglobal dei corporate goals we have set the 2023 target of achieving 2 share of women in executive positions and 1 of under-represented nationalities in ex",
            "position": 1134,
            "sentence": "agegeneration raceethnicity disability gender lgbtq dei veterans intersectional127 diversity networks and chapters around the globeglobal dei corporate goals we have set the 2023 target of achieving 2 share of women in executive positions and 1 of under-represented nationalities in executive positions as per our q4 2022 baseline."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_038",
    "content": "our valuable 5001 commitment supports disability inclusion and we are a signatory of the un standards of conduct for business on tackling discrimination against lgbtq people.2 we also recently signed the zero health gaps pledge3 from the world economic forum wef. this pledge aligns with our commitment to address barriers to clinical trial participation, diversify genetic data for scientific discovery and increase access to innovative diagnostic and therapeutic solutions by advancing inclusive research4 read more about our work in this area on page 110. our approach to dei is outlined for employees in the roche group code of conduct5 and the roche group employment policy.6 we communicate our expectations to suppliers through the roche directive on human rights due diligence for business partners.7 roche acknowledges and is committed to internationally respected standards and guidelines, including:  the fundamental principles and rights at work stipulated by the international labour organization ilo, specifically the conventions no. 138 and no. 182 and the ilo-ioe child labour guidance tool for business  the ten principles of the united nations global compact  the united nations guiding principles on business and human rights ungps  the universal declaration of human rights udhr mechanisms to mitigate risk related to dei we take a holistic approach to ensuring employees are compensated fairly, diversely represented, provided equitable opportunities and work in a safe and fulfilling environment, free from discrimination. in addition to what is described in the ethical business practices and human rights, and safety, health and well-being chapters, there are two additional key mechanisms we use:  we continuously track and communicate progress against our corporate goals and refine our approach to achieving them, including quarterly reviews by the corporate executive committee and regular engagement with the people  culture teams most directly involved. we conduct an organisation-wide pay equity analysis every three years. in 2022 we also conducted a living-wage analysis and will repeat this periodically in future. 1 go.roche.comroche-the-valuable-500  2 go.roche.comunfe-standards  3 go.roche.comzero-health-gaps-pledge  4 go.roche.comadvancing-inclusive-research  5 roche.comaboutgovernancecode-of-conduct  6 go.roche.comroche-group-employment-policy  7 go.roche.comhuman-rights-due-diligence-for-businessdiversity, equity and inclusion  roche 59 diversity, equity and inclusion  roche 59 we are committed to maintaining the safety, security, health and environmental she principles and practices outlined in the roche group code of conduct.1 these principles establish a uniform minimum standard for she across all roche companies, workplaces and employees. we expect our suppliers and service providers to uphold these same standards in their own operations. mental health is top of mind at roche, we take mental health seriously and strive to create a culture where everyone can thrive, feeling supported and psychologically safe. the responsibility for workplace mental health is shared at the global and local levels and is supported by senior management. as a leader, it is my responsibility to prioritise the mental health and well-being of my people. helping people thrive is a non-negotiable part of a people leaders job. by fostering an open dialogue, we create a culture where everyone can flourish, says thomas schinecker, roche ceo.",
    "word_count": 491,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "gagement with the people  culture teams most directly involved. we conduct an organisation-wide pay equity analysis every three years. in 2022 we also conducted a living-wage analysis and will repeat this p",
            "position": 2019,
            "sentence": "we conduct an organisation-wide pay equity analysis every three years."
          },
          {
            "keyword": "equity",
            "context": "e.comroche-group-employment-policy  7 go.roche.comhuman-rights-due-diligence-for-businessdiversity, equity and inclusion  roche 59 diversity, equity and inclusion  roche 59 we are committed to maintaining t",
            "position": 2451,
            "sentence": "1 go.roche.comroche-the-valuable-500  2 go.roche.comunfe-standards  3 go.roche.comzero-health-gaps-pledge  4 go.roche.comadvancing-inclusive-research  5 roche.comaboutgovernancecode-of-conduct  6 go.roche.comroche-group-employment-policy  7 go.roche.comhuman-rights-due-diligence-for-businessdiversity, equity and inclusion  roche 59 diversity, equity and inclusion  roche 59 we are committed to maintaining the safety, security, health and environmental she principles and practices outlined in the roche group code of conduct.1 these principles establish a uniform minimum standard for she across all roche companies, workplaces and employees."
          },
          {
            "keyword": "equity",
            "context": "oche.comhuman-rights-due-diligence-for-businessdiversity, equity and inclusion  roche 59 diversity, equity and inclusion  roche 59 we are committed to maintaining the safety, security, health and environmen",
            "position": 2493,
            "sentence": "1 go.roche.comroche-the-valuable-500  2 go.roche.comunfe-standards  3 go.roche.comzero-health-gaps-pledge  4 go.roche.comadvancing-inclusive-research  5 roche.comaboutgovernancecode-of-conduct  6 go.roche.comroche-group-employment-policy  7 go.roche.comhuman-rights-due-diligence-for-businessdiversity, equity and inclusion  roche 59 diversity, equity and inclusion  roche 59 we are committed to maintaining the safety, security, health and environmental she principles and practices outlined in the roche group code of conduct.1 these principles establish a uniform minimum standard for she across all roche companies, workplaces and employees."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "guidance",
            "context": "our organization ilo, specifically the conventions no. 138 and no. 182 and the ilo-ioe child labour guidance tool for business  the ten principles of the united nations global compact  the united nations guid",
            "position": 1092,
            "sentence": "182 and the ilo-ioe child labour guidance tool for business  the ten principles of the united nations global compact  the united nations guiding principles on business and human rights ungps  the universal declaration of human rights udhr mechanisms to mitigate risk related to dei we take a holistic approach to ensuring employees are compensated fairly, diversely represented, provided equitable opportunities and work in a safe and fulfilling environment, free from discrimination."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_039",
    "content": "helping people thrive is a non-negotiable part of a people leaders job. by fostering an open dialogue, we create a culture where everyone can flourish, says thomas schinecker, roche ceo. in 2023, we continued establishing an effective, efficient and holistic global mental health and well-being programme. the programme is centred on three pillars:  protection. the assessment of psycho-social risk factors at work is part of the comprehensive workplace risk assessment mandated for all roche workplaces. promotion. we promote mental health and well-being as part of roches global well-being initiative livewellroche. support. every employee has access to a local employee assistance or counselling programme, including counselling for psychological stress at work as well as in their home life. we also offer a network of dedicated mental health champions and mental health first aiders to help reduce the stigma surrounding mental health conditions and create a safe space for employees. since 2020 we have reported on the maturity of health risk assessments and management, in particular for psycho-social risks, and have set ambitious goals for 20202025 see illustration on page 63. roche was rated as one of the top improvers in the 2023 ccla corporate mental health benchmark, which ranks companies based on the strength of their management commitments and public reporting on mental health. we ranked in tier 3 of the benchmark. well-being as a company actively shaping the present and future of healthcare, we are passionate about fostering a health and well-being culture at work. roches holistic approach to well-being takes both organisational and individual perspectives 7. safety, health and well-being roche strives to be an innovative company that our employees are proud to be part of and our partners trust. 1 roche.comaboutgovernancecode-of-conduct60  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report while actively shaping the present and future of healthcare, roche considers the safety and well-being of its employees a top priority. key sustainability topics  employee rights and workforce deisafety, health and well-being  roche 61 into account. our global live well hub offers over 30 well-being resources for individuals and teams on topics including psychological safety, mental health, mindfulness and gratitude. we measure and report on employee well-being primarily through our global employee opinion survey geos see table. livewellroche each year our sites hold two live well weeks to promote healthy lifestyles and physical, mental and emotional well-being. in 2023, we offered over 50 global events with thousands of employees attending, where we celebrated genuine connections, fostered a sense of community and ignited our sense of purpose. we placed particular emphasis on the topic of womens health, especially menopause, offering keynotes, awareness sessions and guidelines. in addition, we have a global live well community that supports employees to care for themselves and others as much as we care for patients.",
    "word_count": 465,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_040",
    "content": "we placed particular emphasis on the topic of womens health, especially menopause, offering keynotes, awareness sessions and guidelines. in addition, we have a global live well community that supports employees to care for themselves and others as much as we care for patients. over 250 dedicated live well champions across the roche network help boost awareness and impact.total body well-being in each country we operate in, we create and support safe and inspirational spaces where employees can have fun, challenge themselves and share their passion. we offer a range of wellness resources tailored to our employees needs and stage of life, including meditation and mindfulness resources, sleep tools, resilience training, coaching and counselling sessions, as well as fitness options. many of these initiatives are driven by our employees. safety in the workplace all forms of work at roche must be safe, whether the tasks are urgent, complex or routine. we aim to minimise the number of occupational accidents per year and the number of accidents causing absence from work lost time accident frequency rate per 200,000 worked hours. our approach to safety at the workplace has been recognised in the dow jones sustainability indices, where roche was rated in the 97th percentile for occupational health and safety compared to the industry benchmark. employee health and well-being in the global employee opinion survey geos indices 2023 2021 2019 environment and culture1, 276 75 76 health and well-being1, 373 72 na impact on overall health1, 466 66 na na  not applicable 1 the measures have been gathered according to the independent third party that provides the services for the geos survey. roche aims to continuously improve the used survey measures. 2 currently, measured through the following three items: roche takes a genuine interest in the employees well-being, i am able to successfully balance my work and personal life, roche offers me a healthy workplace 3 currently, measured through the following two items: my current state of well-being allows me to perform my job effectively, i am able to cope effectively with work-related stress 4 currently, measured through the following item: the impact of work at roche on my overall health is positive62  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report employee health and safetyemployee psycho-social risk assessment and management total number of lost time accidents lost time accident frequency rate scores for 2023 five-year she goal 2025 maximum score 2019 2020 2021 2022334 277 270 238 0.3750.297 0.2850.251 2023200 0.2070 0 0 10 75 159.2 55 14.2 9.556 13.5 culture commitment approachgoal reachedsafety, health and well-being  roche 63 the roche group code of conduct clearly expresses roches expectations as an employer relating to ethical business practices and human rights and provides our employees with practical guidance, examples and references to further useful information. to ensure our high ethical standards are upheld, roche relies on a robust and comprehensive compliance management programme.",
    "word_count": 484,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "guidance",
            "context": "r relating to ethical business practices and human rights and provides our employees with practical guidance, examples and references to further useful information. to ensure our high ethical standards are up",
            "position": 2960,
            "sentence": "2 currently, measured through the following three items: roche takes a genuine interest in the employees well-being, i am able to successfully balance my work and personal life, roche offers me a healthy workplace 3 currently, measured through the following two items: my current state of well-being allows me to perform my job effectively, i am able to cope effectively with work-related stress 4 currently, measured through the following item: the impact of work at roche on my overall health is positive62  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report employee health and safetyemployee psycho-social risk assessment and management total number of lost time accidents lost time accident frequency rate scores for 2023 five-year she goal 2025 maximum score 2019 2020 2021 2022334 277 270 238 0.3750.297 0.2850.251 2023200 0.2070 0 0 10 75 159.2 55 14.2 9.556 13.5 culture commitment approachgoal reachedsafety, health and well-being  roche 63 the roche group code of conduct clearly expresses roches expectations as an employer relating to ethical business practices and human rights and provides our employees with practical guidance, examples and references to further useful information."
          }
        ],
        "challenges": [
          {
            "keyword": "challenge",
            "context": "ry we operate in, we create and support safe and inspirational spaces where employees can have fun, challenge themselves and share their passion. we offer a range of wellness resources tailored to our employee",
            "position": 509,
            "sentence": "over 250 dedicated live well champions across the roche network help boost awareness and impact.total body well-being in each country we operate in, we create and support safe and inspirational spaces where employees can have fun, challenge themselves and share their passion."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_041",
    "content": "2 currently, measured through the following three items: roche takes a genuine interest in the employees well-being, i am able to successfully balance my work and personal life, roche offers me a healthy workplace 3 currently, measured through the following two items: my current state of well-being allows me to perform my job effectively, i am able to cope effectively with work-related stress 4 currently, measured through the following item: the impact of work at roche on my overall health is positive62  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report employee health and safetyemployee psycho-social risk assessment and management total number of lost time accidents lost time accident frequency rate scores for 2023 five-year she goal 2025 maximum score 2019 2020 2021 2022334 277 270 238 0.3750.297 0.2850.251 2023200 0.2070 0 0 10 75 159.2 55 14.2 9.556 13.5 culture commitment approachgoal reachedsafety, health and well-being  roche 63 the roche group code of conduct clearly expresses roches expectations as an employer relating to ethical business practices and human rights and provides our employees with practical guidance, examples and references to further useful information. to ensure our high ethical standards are upheld, roche relies on a robust and comprehensive compliance management programme. the programme covers all relevant areas including proper compliance training and communication, risk and opportunity management, anti-corruption policy, due diligence when dealing with business partners and suppliers, and mechanisms for identifying, reporting and investigating compliance concerns  including protection of whistleblowers against retaliation. embedding our strong ethics culture into everything we do remains the main focus of our compliance programme. we know that our success in this area depends on how comprehensive and accessible the compliance programme is to all our employees. our compliance ambitions reflect this aspiration see table. with this in mind, our actions in 2023 focused on effective education and culture of integrity, simplification of directives and processes, as well as solutions and tools that enable the implementation of our business strategy. a good example of this is the launch of a roche group directive on employees engaging in external commitments that clarifies our expectations in regard to handling potential conflicts of interest, and establishes a digital tool making the process more consistent, transparent and simple for the employees. our efforts to radically simplify our directive on personal use of social media, with the aim to ensure effective and compliant use of social media by employees, is another example: a multidisciplinary task force updated the directive, refreshing the content and modernising the look and feel to make it clearer and more accessible to all employees. and an example of a solution-oriented collaboration enabling the implementation of our business strategy is the successful roll-out of our business partner management checklist, which provides guidance on the proper management of external business partners and allows affiliates to test their maturity level in regard to this process, including important elements such as due diligence and human rights.8.",
    "word_count": 491,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "guidance",
            "context": "r relating to ethical business practices and human rights and provides our employees with practical guidance, examples and references to further useful information. to ensure our high ethical standards are up",
            "position": 1197,
            "sentence": "2 currently, measured through the following three items: roche takes a genuine interest in the employees well-being, i am able to successfully balance my work and personal life, roche offers me a healthy workplace 3 currently, measured through the following two items: my current state of well-being allows me to perform my job effectively, i am able to cope effectively with work-related stress 4 currently, measured through the following item: the impact of work at roche on my overall health is positive62  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report employee health and safetyemployee psycho-social risk assessment and management total number of lost time accidents lost time accident frequency rate scores for 2023 five-year she goal 2025 maximum score 2019 2020 2021 2022334 277 270 238 0.3750.297 0.2850.251 2023200 0.2070 0 0 10 75 159.2 55 14.2 9.556 13.5 culture commitment approachgoal reachedsafety, health and well-being  roche 63 the roche group code of conduct clearly expresses roches expectations as an employer relating to ethical business practices and human rights and provides our employees with practical guidance, examples and references to further useful information."
          },
          {
            "keyword": "guidance",
            "context": "ss strategy is the successful roll-out of our business partner management checklist, which provides guidance on the proper management of external business partners and allows affiliates to test their maturity",
            "position": 3125,
            "sentence": "and an example of a solution-oriented collaboration enabling the implementation of our business strategy is the successful roll-out of our business partner management checklist, which provides guidance on the proper management of external business partners and allows affiliates to test their maturity level in regard to this process, including important elements such as due diligence and human rights.8."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_042",
    "content": "our efforts to radically simplify our directive on personal use of social media, with the aim to ensure effective and compliant use of social media by employees, is another example: a multidisciplinary task force updated the directive, refreshing the content and modernising the look and feel to make it clearer and more accessible to all employees. and an example of a solution-oriented collaboration enabling the implementation of our business strategy is the successful roll-out of our business partner management checklist, which provides guidance on the proper management of external business partners and allows affiliates to test their maturity level in regard to this process, including important elements such as due diligence and human rights.8. ethical business practices and human rights roche is convinced that integrity is essential to the success and sustainability of our business. our compliance ambitions we have a strong culture of integrity at roche. we drive compliance leadership and an ethical mindset via continuous education for line managers and promoting ownership. our leaders are role models on compliance behaviour in an agile environment. our compliance programme is simple and supports quick decisions. we regularly revise and modernise our existing processes and policies. we develop compliance digital solutions in the spirit of oneroche. we develop oneroche data and digital strategy for healthcare compliance. we enable the implementation of our business strategy through solution-oriented collaboration. we effectively collaborate across functions to accelerate learning. we base our decisions and focus areas on the outcome of our comprehensive risk and opportunity management process. we continuously develop our compliance community to serve business needs.64  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report we are convinced that integrity is essential to the success and sustainability of our business. to ensure our high ethical standards are upheld, we rely on a robust and comprehensive compliance management programme.key sustainability topics  human rights and responsible, resilient value chains  compliance and business ethics  risk managementethical business practices and human rights  roche 65 compliance business conduct culture roche is convinced that integrity is essential to ensuring the success and sustainability of our business. the roche group code of conduct is developed in alignment with the roche values of integrity, courage and passion. the code contains guidance in the areas of products and services, personal integrity, corporate integrity, employment, company assets, responsible business and comprehensive compliance management. it also provides questions and answers, examples and information on where to find more detailed guidance on the various topics. all employees and all others acting on behalf of roche must comply with the roche group code of conduct, regardless of their location and the nature of their work. following the oneroche approach principle, the standards are equally binding for group functions, the pharmaceuticals and the diagnostics division. roche.comaboutgovernancecode-of-conduct policies and targets on business conduct our behaviour in business directive defines our expectations on business conduct.",
    "word_count": 479,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "assets",
            "context": "in the areas of products and services, personal integrity, corporate integrity, employment, company assets, responsible business and comprehensive compliance management. it also provides questions and answe",
            "position": 2697,
            "sentence": "the code contains guidance in the areas of products and services, personal integrity, corporate integrity, employment, company assets, responsible business and comprehensive compliance management."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "guidance",
            "context": "ss strategy is the successful roll-out of our business partner management checklist, which provides guidance on the proper management of external business partners and allows affiliates to test their maturity",
            "position": 543,
            "sentence": "and an example of a solution-oriented collaboration enabling the implementation of our business strategy is the successful roll-out of our business partner management checklist, which provides guidance on the proper management of external business partners and allows affiliates to test their maturity level in regard to this process, including important elements such as due diligence and human rights.8."
          },
          {
            "keyword": "guidance",
            "context": "s developed in alignment with the roche values of integrity, courage and passion. the code contains guidance in the areas of products and services, personal integrity, corporate integrity, employment, company",
            "position": 2588,
            "sentence": "the code contains guidance in the areas of products and services, personal integrity, corporate integrity, employment, company assets, responsible business and comprehensive compliance management."
          },
          {
            "keyword": "guidance",
            "context": "nt. it also provides questions and answers, examples and information on where to find more detailed guidance on the various topics. all employees and all others acting on behalf of roche must comply with the",
            "position": 2863,
            "sentence": "it also provides questions and answers, examples and information on where to find more detailed guidance on the various topics."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_043",
    "content": "following the oneroche approach principle, the standards are equally binding for group functions, the pharmaceuticals and the diagnostics division. roche.comaboutgovernancecode-of-conduct policies and targets on business conduct our behaviour in business directive defines our expectations on business conduct. it defines business integrity as both the actual and the perception of ethical behaviour in business that is in line with the roche group code of conduct and our commitment to run our business in a socially responsible way. go.roche.combehaviour_in_business prevention and detection of corruption and bribery roche rejects all forms of corrupt business behaviour , such as bribery, improper advantages, theft, fraud, embezzlement and misuse of company assets. while the key expectations regarding integrity are set forth in the roche group code of conduct, the behaviour in business directive specifies and provides explanations on the specific aspects of anti-corruption and anti-bribery. go.roche.combehaviour_in_business anti-corruption and anti-bribery trainingroche employees, as well as business-critical business partners, are trained on the key compliance principles through a global mandatory e-learning. the e-learning focuses on the following topics: bribery and improper advantages, gifts and entertainment, conflict of interest, discrimination and harassment, responsible use of social media and electronic communication tools, and business partners and supply chain. all employees are required to complete this e-learning when they join roche, as well as periodic refreshers and when the roche group code of conduct gets updated. roche.comaboutgovernancecode-of-conduct anti-competitive behaviour prevention and detectionthe maintenance of high ethical standards in adhering to national and international laws is one of the fundamental roche corporate principles. it is the policy of the company to comply strictly, in all respects, with competition laws, and roche supports all efforts to promote and protect competition. the behaviour in competition directive is designed to make both management and employees aware of the basic rules, and how these rules affect their business behaviour in making commercial decisions. go.roche.combehaviour_in_business66  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report in 2023, 240 employees and 63 externals used the roche group speakup line, which is operated by an external provider. of these, 78 qualified as alleged violations of the code of conduct. the chief compliance officer received in total, from all channels, 760 reports of alleged violations of the code of conduct via the business ethics incident management system. of these, 316 were unfounded, 285 were founded, and 159 are still under investigation. compliance continued handling non- compliance events including corruption, bribery andor anti-competitive events anyone who becomes aware of a potential violation of the roche group code of conduct can and should bring it to the attention of our compliance experts. roche employees and contractors can use the following reporting channels:  the chief compliance officer and the compliance officers network worldwide;  the roche group code of conduct help  advice line in case of compliance questions or uncertainties;  the roche group speakup line to report in good faith a suspected violation.",
    "word_count": 482,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "assets",
            "context": "behaviour , such as bribery, improper advantages, theft, fraud, embezzlement and misuse of company assets. while the key expectations regarding integrity are set forth in the roche group code of conduct, t",
            "position": 763,
            "sentence": "go.roche.combehaviour_in_business prevention and detection of corruption and bribery roche rejects all forms of corrupt business behaviour , such as bribery, improper advantages, theft, fraud, embezzlement and misuse of company assets."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_044",
    "content": "compliance continued handling non- compliance events including corruption, bribery andor anti-competitive events anyone who becomes aware of a potential violation of the roche group code of conduct can and should bring it to the attention of our compliance experts. roche employees and contractors can use the following reporting channels:  the chief compliance officer and the compliance officers network worldwide;  the roche group code of conduct help  advice line in case of compliance questions or uncertainties;  the roche group speakup line to report in good faith a suspected violation. roche expects employees to speak up when they believe in good faith that someone has done, is doing, or may be about to do something that violates the roche group code of conduct. the roche group speakup line comprises a web and telephone service that enables reporting compliance concerns confidentially and anonymously. it is also available for everyone who is not a roche employee or contractor . the roche group speakup line operates in 103 countries and 53 languages, making it available worldwide. any employee who raises a compliance concern in good faith acts in the interest of roche and deserves acknowledgement. roche does not tolerate any retaliation against an employee who raises a compliance concern in good faith. roche takes all non-compliance reports seriously and is fully committed to efficiently and timely investigate them, to assess the facts and, if necessary, to take adequate corrective measures and sanctions. our business ethics incident management system beims enables our management, the chief compliance officer and the chief audit  risk advisory executive to capture, track and monitor alleged violations, from initial reports through to resolution. roche.comaboutgovernancecode-of-conduct as a result, 115 employment contracts and 4 contracts with business partners were terminated. the increase in the numbers of reported alleged violations compared to last year is i due to the opening of our speak-up line to external people and ii still due to a broadening of the scope of the definition of a business ethics incident, with the removal of the materiality criterion as of 1 march 2022.roche group code of conduct violations  annual report 2022, reference to roche group code of conduct violations, page 157: roche.comar22e.pdfethical business practices and human rights  roche 67 human rights 1 roche.comaboutgovernancecode-of-conduct  2 go.roche.comgroup-employment-policy  3 go.roche.comrespecting-human-rights  4 go.roche.comsupplier-code-of-conduct  5 go.roche.comhuman-rights-due-diligence-for-businessour commitments roche fosters human rights globally, both in our own operations and across our value chain. we are evolving our holistic approach in the value chain towards a proactive approach in improving human rights by committing to doing no harm and making an impactful positive contribution to society. roche has been supporting and implementing the united nations un guiding principles on business and human rights and became a signatory to the un global compact. we are equally committed to supporting: the ten un global compact principles; the universal declaration of human rights; and the international labour organization ilo declaration on fundamental principles and rights at work and the conventions no. 138 and no. 182.",
    "word_count": 494,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_045",
    "content": "138 and no. 182. these commitments are embodied in our roche group code of conduct1 and the roche group employment policy.2 in 2023 we updated our roche position on respecting human rights3, the supplier code of conduct4 and the roche directive on human rights due diligence for business partners.5 this section of the report covers the obligations on due diligence and transparency in relation to human rights and the report on child labour in compliance with section eight: due diligence and transparency in relation to minerals and metals from conflict-affected areas and child labour under the swiss code of obligations, as well as the provisions of the implementing ordinance on due diligence and transparency in relation to minerals and metals from conflict-affected areas and child labour. roche is out of scope of the due diligence and reporting obligations on minerals and metals from conflict-affected and high-risk areas under article 9 of said ordinance. risk management we have a risk management approach designed to systematically identify, assess, mitigate and adequately manage the risk of human rights violations, including the assessment of whether there are reasonable grounds to suspect child labour. in 2023 we conducted a group human rights risk assessment for our own operations and third-party operations. the purpose was to identify and assess the potential negative human rights impacts of our activities and business relationships with a focus on own operations and the upstream supply chain.68  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report assess communicate integrate track  identify human rights risks roche may potentially cause or contribute to through its own activities, or directly linked to its operations, products or services by its business relationships  consolidate and prioritise impact-based risks  define risk mitigation strategiesplans  coordinate with relevant internal functions the risk responsibility risk owners, budget allocations and processes  put mitigation strategiesplans into action  establish appropriate qualitative and quantitative indicators monitor risk mitigation strategiesplans  collect feedback from both internal and external affected stakeholders leverage materiality assessment process when possible establish form and frequency of communication accessible to all intended audiences  educate internal and external stakeholdersthree-year cycle, review and update annual cycle group human rights risk assessmentethical business practices and human rights  roche 69 the following focus areas based on impact were identified in our own operations focus areas background and commitments prevention and mitigation data privacy data is a valuable element for developing innovative treatments and diagnostic solutions for patients and a driver for business excellence. we strive to be a respected and preferred partner to all who may provide such data, like our employees, patients and healthcare stakeholders. roche is committed to collecting and using data in a lawful, fair , legitimate and ethical way, and will always respect the privacy of individuals in order to earn and deserve their trust.roche collects data in compliance with applicable data privacy laws e.g. swiss federal act on data protection, eu general data protection regulation and the us health insurance portability and accountability act.",
    "word_count": 497,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_046",
    "content": "roche is committed to collecting and using data in a lawful, fair , legitimate and ethical way, and will always respect the privacy of individuals in order to earn and deserve their trust.roche collects data in compliance with applicable data privacy laws e.g. swiss federal act on data protection, eu general data protection regulation and the us health insurance portability and accountability act. the same is expected from our service providers and collaboration partners. a comprehensive risk assessment and mitigation process ensures privacy by design and default and that privacy principles are always considered. roche applies appropriate governance and safeguards measures to protect individuals privacy rights. the group privacy officer together with the global privacy office coordinates a global network with subject-matter experts and privacy coordinators in roche affiliates and in global and regional business functions in close collaboration with global it security and privacy governance and other global functions. access to healthcareaccess to healthcare is part of the sdg 3 to ensure healthy lives. as a healthcare company, roche plays a role in collaborating with different stakeholders in improving the prevention, treatment and management of non-communicable diseases and infectious diseases, such as hiv, tuberculosis and hepatitis c. we are also accelerating our ongoing efforts with our goal to double the number of patients being treated with our innovative therapies in low- and lower-middle-income countries llmics by the end of 2026. and it is also our ambition to double patient access to novel, high-m edical-value diagnostics for people around the world.through trusted partnerships with global, regional and local stakeholders, we help governments address relevant access gaps and build strong and resilient healthcare systems, including in llmics where, according to the world bank, 75 of the world s population live. every country has a different situation, and their healthcare systems present unique challenges. so we work closely with partners to develop and deliver tailored access solutions that reflect each country s individual healthcare needs. our global access program was created to enable access to reliable diagnostics for patients in llmics, leveraging our world-class expertise and innovation as a core component to help control and eliminate diseases such as hivaids, tuberculosis, hepatitis c, covid-19 and human papillomavirus hpv  cervical cancer . fair and safe work environmentroche is committed to fair working conditions, and respecting human rights. these commitments are reflected in the roche group code of conduct and roche group employment policy. roche condemns all forms of child, forced or compulsory labour . roche tolerates the employment of juveniles only where it is lawful and only under conditions that adequately safeguard their well-being. roche does not tolerate:  any form of psychological, physical or sexual harassment, or any other violation of the dignity and respect of employees in the workplace. any form of workplace discrimination based on gender , age, ethnicity, national origin, religion, disability, sexual orientation, hivaids status, citizenship, generic information or any other relevant characteristics protected under the applicable law.",
    "word_count": 489,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_047",
    "content": "roche does not tolerate:  any form of psychological, physical or sexual harassment, or any other violation of the dignity and respect of employees in the workplace. any form of workplace discrimination based on gender , age, ethnicity, national origin, religion, disability, sexual orientation, hivaids status, citizenship, generic information or any other relevant characteristics protected under the applicable law. at roche, prevention is the key element for all activities, decisions and measures aimed at ensuring safety, security, health and environmental protection she. we have a holistic approach to well-b eing, taking both the organisational aspects and the individual perspective into account.roche aims to prevent non-compliant behaviour by fostering a culture of openness to questions. we provide designated contacts to address uncertainties on the roche group code of conduct. all roche companies have to ensure that the roche group employment policy is properly implemented in their local employment practices and that local policies are developed and communicated to meet the minimum standards. roche observes all regulations in the she area, in respect of all its employees and of anyone else potentially affected by its activities. workplace risk assessments with mitigation plans are performed in every affiliate. a management system approach is in place to identify and control safety, security, health and environmental risks. exposure of workers to occupational health hazards are prevented or adequately controlled. the risks and the measures taken to control them is documented in workplace health risk assessments. workers are offered health surveillance exams and are provided with information and training.70  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report these expectations are covered in the supplier code of conduct, which our suppliers are contractually obligated to adhere to. in 2023, we shared an updated version of the supplier code of conduct with our suppliers, containing the human rights aspects of freely chosen labour, child labour and young workers, fair treatment and non-discrimination, wages, benefits and working hours, forced or compulsory labour, and responsible sourcing of minerals and metals. to ensure the protection of human rights throughout the roche value chain, these human rights aspects are an integral part of the risk-based due diligence process in our upstream supply chain and with potential and existing suppliers and business partners. we have a formal process and methodology to identify, prevent, mitigate and account for actual and potential adverse impacts on human rights. to enhance transparency within our sphere of influence, we also expect suppliers and business partners to actively assess and manage human rights risks of their own business partners.respecting human rights in our supply chain roche holds our suppliers to high performance expectations concerning human rights that are aligned with our own values and principles. our human rights commitment for business partners is based on the pharmaceutical supply chain initiative psci principles, which we are committed to. the principles are referenced in all roche contracts and embedded in the provisions of the roche supplier code of conduct, which all our suppliers commit to.",
    "word_count": 498,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_048",
    "content": "our human rights commitment for business partners is based on the pharmaceutical supply chain initiative psci principles, which we are committed to. the principles are referenced in all roche contracts and embedded in the provisions of the roche supplier code of conduct, which all our suppliers commit to. we focus on the following human rights aspects:  freely chosen employment  no child labour  legal treatment of young workers  fair treatment and non-discrimination  working conditions wages, benefits, working hours  freedom of association and right of collective bargaining  health and safety the following focus areas based on impact were identified in our supply chain focus areas background and commitments prevention and mitigation working conditions suppliers are committed to pay workers according to applicable wage laws, including minimum wages, overtime hours and mandated benefits, and consider remuneration in accordance with the skills, performance and experience of their workers based on local competitive conditions.we require our suppliers to explicitly acknowledge and adhere to the principles embodied in the supplier code of conduct. suppliers must ensure that their own suppliers appropriately ensure compliance with these principles along their own supply chains. suppliers shall also ensure that roche can verify compliance with the supplier code of conduct through our psci-based supplier sustainability assurance visit ssav programme. business partners identified as being at higher risk for human rights violations are included in a list of business partner auditable entities and scheduled for psci-based audits. suppliers that fail to meet roche s expectations on the topics outlined in the roche supplier code of conduct might be disqualified from working with roche. for current suppliers when expectations are not met a mitigation plan is put in place, and in the event of non-compliance it may lead to termination. healthy working environmentsuppliers are expected to be committed to protecting human health, to understanding relevant workplace hazards and to effectively communicating such hazards and related protection to all potentially impacted workers. fair treatment and non-discriminationsuppliers are expected to be committed to providing a workplace free of harsh and inhumane treatment, and a workplace free of harassment and discrimination. given the type of business relationship that roche has with its suppliers, this focus area is particularly relevant for migrant workers for reasons such as national origin. pharmaceutical supply chain initiative psci: go.roche.compscinitiative ethical business practices and human rights  roche 71 the roche directive on human rights due diligence for business partners6 sets forth the framework and principles to ensure the protection of human rights across the roche value chain. global guidance on the due diligence process, including instruction on how to develop and implement appropriate due diligence for local markets, is provided. roches due diligence process for protecting human rights for business partners includes:  identification of risks and impact assessment considering any actual and potential risks for human rights violations in our own operations, in our business partners and activities related to our business adequately weighted and prioritised according to their severity and likelihood.",
    "word_count": 491,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "guidance",
            "context": "mework and principles to ensure the protection of human rights across the roche value chain. global guidance on the due diligence process, including instruction on how to develop and implement appropriate due",
            "position": 2880,
            "sentence": "pharmaceutical supply chain initiative psci: go.roche.compscinitiative ethical business practices and human rights  roche 71 the roche directive on human rights due diligence for business partners6 sets forth the framework and principles to ensure the protection of human rights across the roche value chain."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_049",
    "content": "global guidance on the due diligence process, including instruction on how to develop and implement appropriate due diligence for local markets, is provided. roches due diligence process for protecting human rights for business partners includes:  identification of risks and impact assessment considering any actual and potential risks for human rights violations in our own operations, in our business partners and activities related to our business adequately weighted and prioritised according to their severity and likelihood. roche provides mechanisms to raise concerns from roche employees and business partners  initiating and implementing corrective and remedial measures if needed. systematic and regular review of the risk identification and impact assessment: the identification and active management of risk is a continuous process undertaken with the active engagement of all stakeholders potentially impacted. supportive documentation evidencing the adequate due diligence process is stored in line with roches corporate records management programme requirements and applicable laws. reporting of relevant and legally binding human rights-related activities and related key performance indicators kpis are maintained to ensure proper record-keeping and transparency with all stakeholders. pre-contract our roche risk management programme is designed to systematically identify, assess, mitigate and adequately manage the risk of human rights violations and to ensure that business partners meet roches expectations throughout the procurement life cycle. the assessment of human rights risk is embedded in our standardised due diligence process conducted before engaging new business partners. roche procurement professionals considering offering opportunities to business partners use an online tool developed by roche to create a risk profile of the business partner that includes an initial assessment of the business partners risk of human rights violations. the methodology used mirrors the methodology described in the next section. no supplier can be engaged without having been assessed accordingly with regards to potential human rights adverse impacts. 6 go.roche.comhuman-rights-due-diligence-for-business 72  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report identification of business partners subject to human rights audits supplier sustainability assurance visit ssav programme we have a formal, annual process and methodology for assessing business partners in order to identify those at higher risk for human rights violations. business partners at high risk are subject to formal audits under the programme established to assess business partners against compliance with the roche supplier code of conduct.",
    "word_count": 382,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "guidance",
            "context": "global guidance on the due diligence process, including instruction on how to develop and implement appropriate due",
            "position": 7,
            "sentence": "global guidance on the due diligence process, including instruction on how to develop and implement appropriate due diligence for local markets, is provided."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_050",
    "content": "6 go.roche.comhuman-rights-due-diligence-for-business 72  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report identification of business partners subject to human rights audits supplier sustainability assurance visit ssav programme we have a formal, annual process and methodology for assessing business partners in order to identify those at higher risk for human rights violations. business partners at high risk are subject to formal audits under the programme established to assess business partners against compliance with the roche supplier code of conduct. criteria used include the following:  being associated with an industry that is likely to employ vulnerable populations  being located in a region at higher risk for human rights violations, per respected human rights indices  being associated with government, media or internal reports of alleged behaviour or operations that indicate real or potential non-compliance with the roche supplier code of conduct inputs to our automated human rights risk assessment methodology that allows for traceability in the supply chain include an external perspective with risk assessment depending of four main externally available and recognised indexes: kidsrights index, global slavery index, oecd index and global rights index, using the following data:  nature of product or service procurement category code identifying the suppliers exact industry and the nature of its product or service  to assess associated human rights risk. we are looking for activities typically associated with vulnerable populations such as children, underage workers, migrants, local underprivileged communities and people with low levels of education. exact location of the business partners operations to assess if that area or region is associated with higher levels of human rights violations i.e. limited regulation or enforcement. history or new information on potential risk data input on external reports or concerns raised about a particular business partner, region or industry business partners identified as being at higher risk for human rights violations are included in a list of business partner auditable entities. these are scheduled for psci-based audits as part of our ssav programme.as mentioned, depending on the circumstances, further risk-based due diligence actions may be undertaken to ensure that issues such as human rights violations are detected and addressed, as per the risk-based approach principles of the oecd due diligence guidance for responsible business of 30 may 2018. we conduct on-site audits at high-risk suppliers through which we directly evaluate supplier human rights compliance and overall supplier performance against the requirements of the roche supplier code of conduct via our psci-based ssav programme. key characteristics of ssav include the following:  a regularly updated list of auditable suppliers, identified for inclusion on the list by the risk-based method previously described  an annual audit plan that is communicated to all relevant internal stakeholders e.g.",
    "word_count": 447,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "guidance",
            "context": "ons are detected and addressed, as per the risk-based approach principles of the oecd due diligence guidance for responsible business of 30 may 2018. we conduct on-site audits at high-risk suppliers through w",
            "position": 2557,
            "sentence": "these are scheduled for psci-based audits as part of our ssav programme.as mentioned, depending on the circumstances, further risk-based due diligence actions may be undertaken to ensure that issues such as human rights violations are detected and addressed, as per the risk-based approach principles of the oecd due diligence guidance for responsible business of 30 may 2018."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_051",
    "content": "we conduct on-site audits at high-risk suppliers through which we directly evaluate supplier human rights compliance and overall supplier performance against the requirements of the roche supplier code of conduct via our psci-based ssav programme. key characteristics of ssav include the following:  a regularly updated list of auditable suppliers, identified for inclusion on the list by the risk-based method previously described  an annual audit plan that is communicated to all relevant internal stakeholders e.g. supplier relationship managers, global procurement leadership and risk managers  use of psci-approved independent auditors  documented audit reports using psci templates and following psci standard for classifying findings based on level of risk  documented action plans submitted by the audited suppliers and monitored to timely closure  follow-up audits to ensure both adequacy of action plans and continuous improvement  disclosure of programme kpis through various roche public reporting mechanisms, including roche s external website  a documented ssav programme manual describing all aspects of the programme the ssav programme also embeds sub-tier oversight per psci protocols, based on the transparency obligations our suppliers commit to according to the roche supplier code of conduct. therefore, ssav audits include the following:  a review of the supplier programmes and management systems in place to ensure that the human rights of the supplier s own suppliers are adequately protected  the direct assessment of human rights and labour compliance associated with any sub-tier suppliers working at supplier sites during the time of the audit where suppliers are found to not be in compliance with these principles or where other serious concerns related to a supplier s ability to meet roche performance expectations exist, roche demands immediate corrective action or , where immediate corrective action is not possible, a concept to correct issues including a concrete time schedule. as a last resort, when there are severe issues and a supplier is not able or willing to correct those, roche will terminate business relationships with the supplier and disqualify them from future opportunities.ongoing human rights risk managementethical business practices and human rights  roche 73 grievance mechanism employees as well as business partners are encouraged to speak up in good faith if they believe that a human rights violation has occurred. this also covers any reasonable concerns about the existence of a potential or actual adverse impact related to child labour. the roche group speakup line is available for everyone internally and externally to report compliance concerns. our local and regional compliance officers also serve as contacts for allegations, which are then reported to the chief compliance officer via the business ethics incident management system beims. human rights violations, especially by our suppliers, can also be identified by the procurement department.all allegations are taken seriously and are objectively investigated. full protection to any retaliation practice against the person who spoke up identified or anonymous is provided. if the allegation is substantiated, we take appropriate remedial measures. our reporting in 2023, 27 substantiated incidents related to human rights violations triggered terminations of contracts.",
    "word_count": 495,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "future opportunities",
            "context": "rrect those, roche will terminate business relationships with the supplier and disqualify them from future opportunities.ongoing human rights risk managementethical business practices and human rights  roche 73 grievance",
            "position": 2207,
            "sentence": "as a last resort, when there are severe issues and a supplier is not able or willing to correct those, roche will terminate business relationships with the supplier and disqualify them from future opportunities.ongoing human rights risk managementethical business practices and human rights  roche 73 grievance mechanism employees as well as business partners are encouraged to speak up in good faith if they believe that a human rights violation has occurred."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_052",
    "content": "if the allegation is substantiated, we take appropriate remedial measures. our reporting in 2023, 27 substantiated incidents related to human rights violations triggered terminations of contracts. all the incidents were related to discrimination and harassment, 25 involving roche employees, 1 a contractor and 1 a business partner. in addition, we assess supplier compliance with our human rights standards through our ssav audit programme.74  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report facilities and utilities 5contract research organisations 5 laboratory supplies 13 logistics and transportation 32 waste management and cleaning 2it and telecommunication 7ssavs per industry 2023 temporary labour 3 the most common critical or major findings categories: excessive overtime and incorrect overtime compensation 10, not granted enough days off or annual leave 4, delayed payment of wages 3 and improper maintenance of hr and payroll documentation 3  safety, security, health and environment  supplier sustainability assurance visit she and ssav audits 2023number of supplier she audits conducted with contract manufacturers 37supplier sustainability audits 69 sustainability audits triggered by high human rights risk: 26 sustainability audits with findings related to human rights and labour: 36 construction and building 2ethical business practices and human rights  roche 75 construction and building 9 contract research organisations 6 laboratory supplies 16logistics and transportation 62 temporary labour 8 it and telecommunication 5human rights-related findings per industry 2023 waste management and cleaning services 1facilities and utilities 4 a number of findings regarding child labour and young workers 7 b number of findings regarding forced labour 20 c number of findings regarding overtime payments 18 d total of all findings with any human rights impacts including a to c 11176  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report between 2021 and 2022, roche observed findings related to human rights and fair labour practices notably within the logistics industry segment. audits performed within the ssav programme highlighted several situations within the logistics industry where companies did not introduce and manage appropriate policies and procedures to protect the rights of employees. a recurring problem was the lack of appropriate control mechanisms regarding the working conditions especially overtime and days off of truck drivers and warehouse workers. all non-compliances were noted in the final audit report and reflected within the corrective action plan cap addressing proper actions to remove them. the cap contained the implementation of appropriate policies, systems and procedures to secure employee rights. these include the implementation of electronic successful collaboration with business partners to avoid negative impacts on human rights working time registration systems or appropriate control mechanisms within the existing operational processes, as well as the implementation of dedicated training for managers and operational team leaders to raise their awareness within the area of human rights and labour. the effectiveness and efficiency of the actions implemented within the cap have been confirmed during the follow-up audits by an independent external auditor.",
    "word_count": 483,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_053",
    "content": "these include the implementation of electronic successful collaboration with business partners to avoid negative impacts on human rights working time registration systems or appropriate control mechanisms within the existing operational processes, as well as the implementation of dedicated training for managers and operational team leaders to raise their awareness within the area of human rights and labour. the effectiveness and efficiency of the actions implemented within the cap have been confirmed during the follow-up audits by an independent external auditor. at roche, we are aware that throughout the supply chain we must actively cooperate with our suppliers and business partners to minimise the risk of non-compliance, especially related to human rights and fair labour practices. at the same time, we are constantly improving our internal due diligence processes and procedures, which guide our activities and risk analysis beyond the tier-1 level.risk-assessed suppliers significant suppliers assessed in relation to the ssav programme 30 70 100 20 60 90 0 40 10 50 80100100  significant suppliers are those that are assessed with the risk-based methodology for supplier sustainability assurance visits ssavs.ethical business practices and human rights  roche 77 environmental protection is nothing new to roche. for many years, we have been working to minimise our ecological footprint and increase the use of renewable resources while expanding the global business. to achieve this, we have embedded our procedures for environmental protection throughout our operations. roche aims to mitigate environmental risks via a multidisciplinary system of prevention and a successful environmental risk management system. expert teams at each roche site identify risks and develop mitigation plans. they communicate our policy and guidelines to employees and other stakeholders and motivate them to implement the necessary measures. we approach prevention with the same sense of responsibility and just as methodically as we approach issues concerning quality, productivity and cost-efficiency. our environmental programme has operational strategies covering climate change mitigation, reducing greenhouse gas ghg emissions and increasing resource efficiency, the environmental aspects of procurement, and water and waste management. we complement these strategies by setting tangible and quantitative medium-term 2025 and long-term 2050 goals. we continuously monitor our environmental performance against a range of key performance indicators kpis. this gives us greater oversight and control of our impacts and allows us to identify areas for improvement  helping ensure compliance with our high standards and meet our objectives. minimising our ecological footprint as part of our commitment to sustainable development, we strive to use new and more sustainable technologies and processes to minimise our impact on the environment. we measure our impact on the environment using the eco-balance metric developed by the swiss federal office for the environment. by 2025, we want to improve our eco-balance by at least 36 compared to 2019. in 2023, we report an overall improvement of 32.8 in our eco-balance compared to 2019. this achievement was reflected by a 2 improvement observed in 2023 when compared to 2022.",
    "word_count": 485,
    "keyword_analysis": {
      "COMPANY_STATE": {
        "operational_efficiency": [
          {
            "keyword": "productivity",
            "context": "the same sense of responsibility and just as methodically as we approach issues concerning quality, productivity and cost-efficiency. our environmental programme has operational strategies covering climate change",
            "position": 2072,
            "sentence": "we approach prevention with the same sense of responsibility and just as methodically as we approach issues concerning quality, productivity and cost-efficiency."
          }
        ]
      },
      "RISK_FACTORS": {
        "operational_risks": [
          {
            "keyword": "environmental risk",
            "context": "aims to mitigate environmental risks via a multidisciplinary system of prevention and a successful environmental risk management system. expert teams at each roche site identify risks and develop mitigation plans. the",
            "position": 1695,
            "sentence": "roche aims to mitigate environmental risks via a multidisciplinary system of prevention and a successful environmental risk management system."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_054",
    "content": "in 2023, we report an overall improvement of 32.8 in our eco-balance compared to 2019. this achievement was reflected by a 2 improvement observed in 2023 when compared to 2022. this improvement was attributed to a reduction in phosphorus emissions, increased use of sustainable energy and a decrease in water use. greenhouse gas emissions the pharmaceuticals and diagnostics industry  as a contributor to global ghg emissions  must take appropriate measures to reduce its impact. roche adheres to international agreements that define targets and schedules for reducing emissions, such as the paris agreement, as well as national legislation at site level. ghg emissions are an integral part of roches environmental impact, and therefore we have set ambitious but realistic reduction targets in line with the latest climate science. we have committed ourselves through the science based targets initiative sbti and will submit our targets for approval. our long-term goal is to reduce scope 1 and 2 ghg emissions to real zero by 2050. this means reaching zero operational emissions by 9. environment roche s progressive approach to environmental protection and management reflects our strong commitment to risk mitigation and is intrinsic to our business.78  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report expert teams at each roche site identify environmental risks and develop mitigation plans. they communicate our policy and guidelines to employees and other stakeholders and motivate them to implement the necessary measures.key sustainability topics  climate change  air pollution  water  circularityenvironment  roche 79 focusing on our own reduction efforts, rather than relying on carbon offsets. our short-term goal is to reduce total scope 1 and 2 ghg emissions by 40 by 2025 from 2019 levels. in 2023, our scope 1 and 2 emissions decreased by 6.9 due to an increase in the use of sustainable energy. our scope 3 ghg programme value chain emissions are a significant part of our total footprint. in 2023 we began developing our decarbonisation roadmap. partnering with suppliers, industry, health systems and financial institutions, we are accelerating progress to reach net zero emissions. through the sustainable markets initiative smi health systems taskforce, our immediate focus is on identifying key hotspots, decarbonising healthcare supply chains and patient care pathways, and delivering digital solutions for sustainable clinical research. supplier engagement is a crucial part of our approach. through the smi and the pharmaceutical supply chain initiative psci we are communicating our expectations to suppliers, including on emissions disclosure and commitment to science-based targets. in 2023, our scope 3 emissions decreased by 7.4 overall. emissions from business flights, waste and use of sold products diagnostic instruments increased in the reporting period. supply chain emissions decreased in line with a lower third-party spend, especially for the covid-19 portfolio, and due to restatement using more granular activity-based emission factors. environmental compliance a dedicated team of roche employees around the globe identifies potential risks to people, goods, the environment and roches reputation.",
    "word_count": 486,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_055",
    "content": "supply chain emissions decreased in line with a lower third-party spend, especially for the covid-19 portfolio, and due to restatement using more granular activity-based emission factors. environmental compliance a dedicated team of roche employees around the globe identifies potential risks to people, goods, the environment and roches reputation. the corporate safety, security, health and environmental protection audit team inspects our pharmaceuticals and diagnostics manufacturing facilities for environmental performance and implementation of our environmental policy in line with legal requirements and internal standards. we expect contract manufacturers, suppliers and service providers to meet the same standards as we do. to ensure compliance, we inspect the operations of our suppliers and make recommendations for improvement. in the event of non-compliance, we either ask for improvements, which we actively monitor and support, or terminate the contract. improving data quality roche plays a pivotal role in advancing healthcare  bringing life-saving medications, treatments and diagnostics to millions of people worldwide. amidst the pursuit of innovation and therapeutic breakthroughs, it is crucial that we prioritise the safety and well-being of our workforce alongside environmental sustainability. accurate and reliable employee safety and environmental data are key to enabling ethical, sustainable and responsible practices. accurate employee safety and environmental performance data help us identify potential risks and hazards so we can implement preventive measures and reduce the likelihood of workplace accidents, injuries and environmental incidents. they are also essential for demonstrating compliance. over the last year, roche has been reviewing its data collection processes. as part of this journey, we have made significant changes to data practices and systems across the organisation. this includes aligning processes and platforms that enable more efficient and accurate safety, health and environmental data collection. these efficiency gains have allowed us to focus on workplace safety initiatives that enable our people to deliver patient outcomes and reduce environmental impacts at the same time. access to real-time data has also allowed roche to extract meaningful insights in a more dynamic way than was previously possible. roche plans to expand on this work in the coming years by continuing to explore innovative technologies within safety, health and environment.80  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report emissions to water natural gaswater consumption 1.4 emissions to air business air travellingcompany vehicleslandfilled waste 1.1noise pollution 1.4 energy consumption electricity roche eco-balance 2023 energy use by selected types 2023by 2030, all vehicles will operate using energy from sustainable sources.83.63.09.5 26.3 we look for ways to reduce energy consumption and improve energy efficiency, and we aim to be using 100 renewable electricity by 2025. 13.0 video and teleconferencing facilities have been established at all sites and are widely used. employees are encouraged to use trains and to consolidate several business trips into one.4.8 23.9environment  roche 81 98,820 29.1 1 direct emissions from within operations  2 indirect emissions from purchased energy  3 emissions resulting from activities within our supply chain  4 the calculation methodology is based on the ghg protocol following a hybrid activity-based approach.",
    "word_count": 500,
    "keyword_analysis": {
      "RISK_FACTORS": {
        "operational_risks": [
          {
            "keyword": "workplace safety",
            "context": "afety, health and environmental data collection. these efficiency gains have allowed us to focus on workplace safety initiatives that enable our people to deliver patient outcomes and reduce environmental impacts at",
            "position": 2114,
            "sentence": "these efficiency gains have allowed us to focus on workplace safety initiatives that enable our people to deliver patient outcomes and reduce environmental impacts at the same time."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_056",
    "content": "13.0 video and teleconferencing facilities have been established at all sites and are widely used. employees are encouraged to use trains and to consolidate several business trips into one.4.8 23.9environment  roche 81 98,820 29.1 1 direct emissions from within operations  2 indirect emissions from purchased energy  3 emissions resulting from activities within our supply chain  4 the calculation methodology is based on the ghg protocol following a hybrid activity-based approach. 303,925 7.24,214,069 92.5 240,610 70.93,299, 154 78.3 scope 2 market based 98,820 2.2 waste generated in operations 4 4,149 1.0 business travel 12 9,18 3 3.1 use of sold products 172,960 4.1fuel- and energy-related activities 89,026 2 .1scope 1 240,610 5.3 upstream transportation 175,672 4.2scope 33 ghg emissions t co2scope 11, 22, 33 ghg emissions t co2scope 11, 22 ghg emissions t co2scope 3 scope 2 market based capital goods4 scope 1purchased goods and services482  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report energy consumption in terajoules 2023 2022 2021 2020 total scope 1 and scope 2, market based 8,438 8,396 8,306 8,420 energy scope 1 and scope 2, market based consumption gjemployee 76 78 79 81 gj  gigajoule emissions into the air in tonnes 2023 2022 2021 2020 vocs 79 80 86 73 particulates 17 16 18 16 nitrogen oxides 100 113 118 113 sulphur dioxide 3 2 4 3  volatile organic compoundshalogenated hydrocarbons in tonnes 2023 2022 2021 2020 inventory 74.1 85.1 88.6 92.0 releases 1.5 3.5 1.5 1.5  global inventory including chugai, genentech and ventana  includes data from additional roche sites as well as a wider scope of halogenated hydrocarbons than in previous years. landfilled and incinerated waste in tonnes 2023 2022 2021 2020 non-hazardous 10,538 9,087 10,357 11,139 hazardous 17,051 14,587 15,110 13,332  in 2023, one of our affiliates reevaluated its waste disposal classification which resulted in an increase in the reported numbers. the increase in hazardous waste was due to the reallocation of electronic waste to hazardous waste.water usage and discharge 2023 2022 2021 2020 water withdrawn million m3 16.7 14.9 15.4 14.9 water consumed million m3 2.5 2.9 2.7 2.8 organic matter discharged to waterways after treatment t 49 80 76 76 heavy metals discharged to waterways after treatment kg 418 137 131 174  the increase in heavy metals was due to additional reporting of iron and manganese. environmental data from spark therapeutics and flatiron health are not included in the roche environmental results.environment  roche 83 what does it mean to be a good global corporate citizen? for roche, it means contributing to making a difference in communities where we live and work to help make them healthier, more resilient and more sustainable. we aim to create a lasting impact across our philanthropic endeavours. we cant achieve this alone. from the moment we first ventured into philanthropy with the international committee of the red cross icrc back in 1918, we have collaborated with trusted partners. today, in a fast-changing external environment, partnerships are more important than ever.",
    "word_count": 498,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "inventory",
            "context": "r dioxide 3 2 4 3  volatile organic compoundshalogenated hydrocarbons in tonnes 2023 2022 2021 2020 inventory 74.1 85.1 88.6 92.0 releases 1.5 3.5 1.5 1.5  global inventory including chugai, genentech and vent",
            "position": 1510,
            "sentence": "303,925 7.24,214,069 92.5 240,610 70.93,299, 154 78.3 scope 2 market based 98,820 2.2 waste generated in operations 4 4,149 1.0 business travel 12 9,18 3 3.1 use of sold products 172,960 4.1fuel- and energy-related activities 89,026 2 .1scope 1 240,610 5.3 upstream transportation 175,672 4.2scope 33 ghg emissions t co2scope 11, 22, 33 ghg emissions t co2scope 11, 22 ghg emissions t co2scope 3 scope 2 market based capital goods4 scope 1purchased goods and services482  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report energy consumption in terajoules 2023 2022 2021 2020 total scope 1 and scope 2, market based 8,438 8,396 8,306 8,420 energy scope 1 and scope 2, market based consumption gjemployee 76 78 79 81 gj  gigajoule emissions into the air in tonnes 2023 2022 2021 2020 vocs 79 80 86 73 particulates 17 16 18 16 nitrogen oxides 100 113 118 113 sulphur dioxide 3 2 4 3  volatile organic compoundshalogenated hydrocarbons in tonnes 2023 2022 2021 2020 inventory 74.1 85.1 88.6 92.0 releases 1.5 3.5 1.5 1.5  global inventory including chugai, genentech and ventana  includes data from additional roche sites as well as a wider scope of halogenated hydrocarbons than in previous years."
          },
          {
            "keyword": "inventory",
            "context": "arbons in tonnes 2023 2022 2021 2020 inventory 74.1 85.1 88.6 92.0 releases 1.5 3.5 1.5 1.5  global inventory including chugai, genentech and ventana  includes data from additional roche sites as well as a wid",
            "position": 1573,
            "sentence": "303,925 7.24,214,069 92.5 240,610 70.93,299, 154 78.3 scope 2 market based 98,820 2.2 waste generated in operations 4 4,149 1.0 business travel 12 9,18 3 3.1 use of sold products 172,960 4.1fuel- and energy-related activities 89,026 2 .1scope 1 240,610 5.3 upstream transportation 175,672 4.2scope 33 ghg emissions t co2scope 11, 22, 33 ghg emissions t co2scope 11, 22 ghg emissions t co2scope 3 scope 2 market based capital goods4 scope 1purchased goods and services482  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report energy consumption in terajoules 2023 2022 2021 2020 total scope 1 and scope 2, market based 8,438 8,396 8,306 8,420 energy scope 1 and scope 2, market based consumption gjemployee 76 78 79 81 gj  gigajoule emissions into the air in tonnes 2023 2022 2021 2020 vocs 79 80 86 73 particulates 17 16 18 16 nitrogen oxides 100 113 118 113 sulphur dioxide 3 2 4 3  volatile organic compoundshalogenated hydrocarbons in tonnes 2023 2022 2021 2020 inventory 74.1 85.1 88.6 92.0 releases 1.5 3.5 1.5 1.5  global inventory including chugai, genentech and ventana  includes data from additional roche sites as well as a wider scope of halogenated hydrocarbons than in previous years."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_057",
    "content": "from the moment we first ventured into philanthropy with the international committee of the red cross icrc back in 1918, we have collaborated with trusted partners. today, in a fast-changing external environment, partnerships are more important than ever. increasingly, we work in a more integrated way with several stakeholders at once. we have an established policy1 to ensure the projects we endorse meet specific quality, innovation and sustainability criteria, and strictly adhere to the high integrity standards set in the roche group code of conduct. our sustainability group reporting system gaia ensures internal documentation and monitoring of assets spent on philanthropy. in 2023, we drove many projects with potential for lasting impact across our four key pillars: community and environment, humanitarian and social, science and education, and arts and culture. community and environment the roche childrens walk  our biggest employee engagement and philanthropy initiative  celebrated its 20th anniversary in 2023. more than chf 23 million in donations have supported childhood development and education projects over the last 20 years.2 employee volunteering is vital for our philanthropic efforts. our secondment programme draws upon a broad pool of employee specialists for skills-based volunteering with non-governmental organisations ngos across two domains: science and education, and humanitarian and health. one initiative saw over 40 members of our gps digital excellence team from around the world volunteer more than 400 hours for swisscontact, an ngo fostering sustainable development in developing countries. the insights provided by the roche team enabled a digital strategy to help swisscontact grow its reach and reputation. rapid and collaborative disaster response is more important than ever. we work closely with our affiliates to identify the best ways to support local efforts with relief organisations and to help disaster-affected communities rebuild and prepare for the future. after an earthquake hit areas of t\u00fcrkiye and syria in february 2023, roche joined international partners to help ensure uninterrupted access to healthcare. in t\u00fcrkiye, we helped establish six field health units in four cities and a fully equipped family health centre in ad\u0131yaman, one of the hardest-hit cities. in syria, we supplied two highly specialised mobile health units. 10. global citizenship from communities to arts and culture, from environment to education, our philanthropic programmes are united by one goal: partnering to create a lasting impact. 1 go.roche.comdonations-and-non-commercial-sponsorship  2 see our feature on the anniversary on page 118 of this report. 84  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report roche continents programme students participate in a workshop for sustainable colour dyeing at atelier luma, a design research programme of luma arles in france.key sustainability topics  sustainable health systems and communities  stakeholder engagement global citizenship  roche 85 since 2017, roche has supported the icrc in its drive to improve access to clean water and essential services for hundreds of thousands of vulnerable people in mali, many cut off from other humanitarian organisations. in total, over 300,000 people have received improved access to drinking water as of 2023.",
    "word_count": 496,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "assets",
            "context": "ct. our sustainability group reporting system gaia ensures internal documentation and monitoring of assets spent on philanthropy. in 2023, we drove many projects with potential for lasting impact across our",
            "position": 654,
            "sentence": "our sustainability group reporting system gaia ensures internal documentation and monitoring of assets spent on philanthropy."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_058",
    "content": "84  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report roche continents programme students participate in a workshop for sustainable colour dyeing at atelier luma, a design research programme of luma arles in france.key sustainability topics  sustainable health systems and communities  stakeholder engagement global citizenship  roche 85 since 2017, roche has supported the icrc in its drive to improve access to clean water and essential services for hundreds of thousands of vulnerable people in mali, many cut off from other humanitarian organisations. in total, over 300,000 people have received improved access to drinking water as of 2023. we have contributed to similar projects with the icrc since 2006 across several other countries, including pakistan, ethiopia, liberia, uganda, burundi, eritrea and guinea. science and education we are passionate about nurturing the next generation of scientific leaders in a collaborative environment. we support the international chemistry olympiad icho, an annual competition for the worlds most talented chemistry students. in 2023, the competition was held in switzerland for the first time since it began in 1968. we are proud that vivian michael huber, a 2023 first-place winner, is completing an apprenticeship at roche in the field of synthesis. we continue to champion education programmes to train the next generation of healthcare providers. this is vital in a world experiencing health system labour shortages. we fund a wide range of scholarships in emerging markets, providing education and training for new nurses  such as training for oncology nurses in indonesia  health workers, lab technicians and more. arts and culture roche has a long tradition of cultivating interdisciplinary exchanges to foster creativity and innovation. for example, the roche continents programme brings together talented international students studying at european universities for an immersion into a diverse world of arts and science. in 2023, roche continents was held in arles, france, in partnership with the luma arles centre of arts and culture. the focus in 2023 was on climate change, sustainability and human capital, with input from both artists and scientists. severin schwan, chairman of the roche board of directors, andr\u00e9 hoffmann, vice-chairman, and hans clevers, head of roche pharma research and early development, inspired and engaged students in discussions about science, sustainability and the importance of ethical and responsible business. the parallels between arts and science were also apparent in the ten-year anniversary of roche young commissions where we partnered once more with the lucerne festival to commission new works from young composers and paired them with two of our scientists, eoin oconnor and shanon seger. having visited the roche labs, young composers david moliner and hovik sardaryan premiered their incredible composition at the kkl luzern concert hall. just like our own work at roche, young commissions shows that working together, across disciplines, perspectives and countries, leads to creativity and innovation. the intersection between science and arts was explored in an opening dialogue between hans clevers and a composer, and in a welcome speech provided by teresa graham, ceo roche pharmaceuticals.",
    "word_count": 498,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_059",
    "content": "just like our own work at roche, young commissions shows that working together, across disciplines, perspectives and countries, leads to creativity and innovation. the intersection between science and arts was explored in an opening dialogue between hans clevers and a composer, and in a welcome speech provided by teresa graham, ceo roche pharmaceuticals. at roche we celebrate multiculturalism, a value that speaks to our own diverse and inclusive culture. that is why we are proud to support culturescapes, a biennial festival promoting arts, cross-cultural dialogue and networking. the 2023 theme was sahara, and roche played an integral role in supporting the festival, including hosting the opening event  a dance production called c la vie by serge aim \u00e9 coulibaly, a renowned dancer and choreographer from burkina faso. the dance, like the event, was a tribute to pluralism and the uniqueness of life. such events offer a unique opportunity for our employees and the community to experience the rich artistic and cultural diversity we cherish.86  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report  illustrative map of participating sites; not exhaustive170 sites in 75 countries joined the roche childrens walk 2023 over 20 years  chf 23 millions raised  1,000 projects supported  total attendance: 315,000 employees incl. 23,000 in 2023 15 from 2022 roche commissions culturescapes unicefroger federer foundation 12 renowned composers were paired with roche scientists and featured at the lucerne festival. 17 arts and culture celebrations fostered dialogue, diversity and inclusion.450,000 children received educational support. 30,000 children accessed early childhood development programmes.67,000 children were enrolled in the school readiness initiative.enduring alliances and long-standing partners to drive sustainable impact 20 years of partnership with rocheglobal citizenship  roche 87 our work revolves around data, and the integrity of that data must be protected. information security allows us to proceed swiftly in developing medical advancements, unhindered by potentially damaging cyberattacks that can take companies offline for seconds, minutes or even months. it also preserves the security of our partners  healthcare organisations that can only collaborate with third parties whose systems they know will not compromise their devices, products and, most importantly, patient data. patient safety and data privacy patient safety and data privacy are of the utmost importance to roche, and we comply with applicable global, regional and local laws, regulations, standards, policies and contractual obligations. our robust list of certifications provides assurance that roche is maintaining a comprehensive information security management system with strong security governance, state-of- the-art risk management, effective security controls and processes, appropriate it and information security operations, commitment at all levels of management, and very high employee awareness of best practices in cybersecurity, data and privacy protection. built-in security and data privacy our navify digital solutions securely integrate data across care settings, connecting the healthcare community and accelerating access to innovation and insights. we employ multi-layer security through state-of-the-art controls to protect customers and patients sensitive data while complying with jurisdictional data privacy regulations, such as hipaa us and gdpr eu.",
    "word_count": 497,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_060",
    "content": "built-in security and data privacy our navify digital solutions securely integrate data across care settings, connecting the healthcare community and accelerating access to innovation and insights. we employ multi-layer security through state-of-the-art controls to protect customers and patients sensitive data while complying with jurisdictional data privacy regulations, such as hipaa us and gdpr eu. making security simple while cybersecurity is a shared responsibility, we work to ensure our researchers and partners can operate without the constant fear of security breaches. as tim ehrhart, roches chief information security officer, puts it candidly, the security teams goal is to be delightfully boring and inconspicuous. were in the background, creating an environment where our employees and partners can focus on what they need to prioritise rather than worry about their cyber safety. our security approach enables safe collaboration from anywhere, any time. while many organisations require employees to switch out laptops when travelling internationally and forbid the use of personal devices, we believe restrictive policies complicate the work of employees without offering a meaningful boost in safety. particularly in todays post-covid era, people demand  and deserve  the freedom to connect wherever they may be. this is achieved by taking the necessary measures to ensure a simple user experience by embedding safety by design. fundamentally safe by design our informatics system is fundamentally safe by design. in practical terms, we minimise usage of virtual private networks, using cloud computing to compartmentalise data and follow a policy of just-in-time access where system and application access is granted for predetermined periods of time 11. information security for roche, security goes beyond compliance. it is a strategic advantage and central to our goal of developing the medicines, diagnostics and insights that help people live longer , better lives.88  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report security is more than policies and structures  it is people, too. at roche, all 100,000 employees around the world, along with our partners and stakeholders, work together to protect the integrity and confidentiality of our systems and data. key sustainability topics  compliance and business ethics  it, data governance, privacy and cybersecurityinformation security  roche 89 and on an as-needed basis to help minimise risk. if a breach does occur, it is contained and therefore does not pose a threat to our wider systems. safety by design means we are better equipped to handle potential breaches, which cause minor inconvenience rather than a major incident. this approach relieves users of as much of the security burden as possible. it is also more sustainable, requiring fewer total devices, which lowers our environmental impact. the result is a cost-effective, resilient security posture that supports sustainable innovation and empowers our workforce to be adaptable within a secure environment. developing and empowering people security is more than policies and structures  it is people, too. at roche, all 100,000 employees around the world, along with our partners and stakeholders, work together to protect the integrity and confidentiality of our systems and data.",
    "word_count": 499,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_061",
    "content": "developing and empowering people security is more than policies and structures  it is people, too. at roche, all 100,000 employees around the world, along with our partners and stakeholders, work together to protect the integrity and confidentiality of our systems and data. information security awareness training and roche privacy awareness training are mandatory for all of our employees. additionally, we invest heavily in continuous development opportunities so our technical experts stay ahead of both industry trends and constantly evolving cyberthreats. this helps ensure we are prepared and proactive in mitigating threat risks.growing our security capabilities in-house as fully integrated members of our organisation and culture, roche information security experts are as dedicated to our healthcare mission as any roche employee. they bring a diverse array of experience across the telecommunications, finance, government and healthcare industries. embedding security into our business strategy means that, unlike many of our competitors, we do not outsource the majority of our information security organisation. instead, we prioritise growing our security capabilities in-house. by cultivating a supportive, fulfilling work environment, we increase our ability to attract and retain top security talent, says tim. constantly testing and improving because threats are constantly evolving, our team is constantly improving our security posture using a multi-pronged approach. we conduct penetration tests, web security vulnerability tests and daily network perimeter tests. we benefit from external expertise both through our strong network of partners including security experts from healthcare, government, technology vendors and private entities.90  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report compliance and certifications patient safety and privacy are of the utmost importance to roche, and we comply with applicable global, regional and local laws, regulations, standards and policies. the certifications on the right provide assurance that roche maintains a comprehensive information security management ism framework with strong security governance, state- of-the-art risk management, effective security controls and processes, and appropriate it and information security organisation operations.certifications iso 27001 iso 27701 soc 2 type 2 cyber essentials uk hitrustvendor security and privacy assessments completed 430 security incidents resolved 2,400information security and privacy risk assessments performed 1,500 critical vulnerability alerts released 220 95 of employees feel aware and contributing towards preventing it security risks and cyber threats. usd 143,000 in rewards were given to external security researchers in 2023.information security 2023 bug bounty reports received and remediated 300information security  roche 91 pricewaterhousecoopers ag, birchstrasse 160, postfach, ch-8050 zurich telephone: 41 58 792 44 00, www.pwc.ch pricewaterhousecoopers ag is a member of the global pricewaterhousecoopers network of firms, each of which is a separate and independent legal entity.we have been engaged by the corporate governance and sustainability committee to perform assurance procedures to provide limited assurance on selected non-financial information including the greenhouse gas ghg emissions of roche holding ltd and its consolidated subsidiaries roche group for the period from 1 january 2023 to 31 december 2023 disclosed in the annual report 2023 report.",
    "word_count": 488,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_062",
    "content": "the certifications on the right provide assurance that roche maintains a comprehensive information security management ism framework with strong security governance, state- of-the-art risk management, effective security controls and processes, and appropriate it and information security organisation operations.certifications iso 27001 iso 27701 soc 2 type 2 cyber essentials uk hitrustvendor security and privacy assessments completed 430 security incidents resolved 2,400information security and privacy risk assessments performed 1,500 critical vulnerability alerts released 220 95 of employees feel aware and contributing towards preventing it security risks and cyber threats. usd 143,000 in rewards were given to external security researchers in 2023.information security 2023 bug bounty reports received and remediated 300information security  roche 91 pricewaterhousecoopers ag, birchstrasse 160, postfach, ch-8050 zurich telephone: 41 58 792 44 00, www.pwc.ch pricewaterhousecoopers ag is a member of the global pricewaterhousecoopers network of firms, each of which is a separate and independent legal entity.we have been engaged by the corporate governance and sustainability committee to perform assurance procedures to provide limited assurance on selected non-financial information including the greenhouse gas ghg emissions of roche holding ltd and its consolidated subsidiaries roche group for the period from 1 january 2023 to 31 december 2023 disclosed in the annual report 2023 report. scope and subject matter our assurance engagement relates to limited level of assurance on the selected non-financial information including the ghg emissions from 1 january 2023 to 31 december 2023 disclosed in the report 2023. the following selected non-financial information including the ghg emissions published in the report is within the scope of our limited assurance engagement:  the following people key figures, in all material aspects, disclosed in the report:  number of employees expressed in ftes, part-time and full-time employees as well as employees by divisionoperating divisional group odg in the diagram on page 58 of the report;  share of women in executive positions in the graph on page 57 of the report; and  the following safety, security, health and environmental protection she key figures including ghg emissions for scope 1  2 and scope 3 resulting from business travel, in all material aspects, disclosed in the report:  employee health and safety in the graph on page 63 of the report;  roche eco-balance and energy use by selected types in the diagrams on page 81 of the report;  all key figures in the tables and graphs on pages 82 and 83 except scope 3: capital goods, purchased goods and services, fuel- and energy-related activities, upstream transportation, waste generated in operations, use of sold products. criteria the selected 2023 non-financial information including the ghg emissions was prepared by the corporate governance and sustainability committee of roche holding ltd based on the document 2023 non-financial reporting indicators definitions and scope the suitable criteria which is available on the roche website go.roche.comnon-financial-reporting-scope-2023 . inherent limitations the accuracy and completeness of the selected 2023 non-financial information including the ghg emissions are subject to inherent limitations given their nature and methods for determining, calculating and estimating such data.",
    "word_count": 495,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_063",
    "content": "criteria the selected 2023 non-financial information including the ghg emissions was prepared by the corporate governance and sustainability committee of roche holding ltd based on the document 2023 non-financial reporting indicators definitions and scope the suitable criteria which is available on the roche website go.roche.comnon-financial-reporting-scope-2023 . inherent limitations the accuracy and completeness of the selected 2023 non-financial information including the ghg emissions are subject to inherent limitations given their nature and methods for determining, calculating and estimating such data. in addition, the greenhouse gas quantification is subject to inherent uncertainty because of incomplete scientific knowledge used to determine factors related to the values needed to combine emissions of different gases. our assurance report will therefore have to be read in connection with the document 2023 non-financial reporting indicators definitions and scope used by roche group, its definitions and procedures as well as on the independent practitioners limited assurance report on selected 2023 non-financial information to the corporate governance and sustainability committee of roche holding ltd, basel92  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report related third-party guidelines used to present the selected 2023 non-financial information. corporate governance and sustainability committees responsibility the corporate governance and sustainability committee of roche holding ltd is responsible for the preparation and presentation of the non- financial information including the ghg emissions in accordance with the document 2023 non- financial reporting indicators definitions and scope. this responsibility includes the design, implementation and maintenance of the internal control system related to the preparation of the selected non-financial information that are free of material misstatement, whether due to fraud or error. furthermore, the corporate governance and sustainability committee is responsible for the selection and application of the document basis for preparation of non-financial information 2023 and adequate record keeping. independence and quality management we are independent of roche holding ltd in accordance with the international code of ethics for professional accountants including international independence standards issued by the international ethics standards board for accountants iesba code. we have fulfilled our ethical responsibilities in accordance with the iesba code, which is founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behaviour. pricewaterhousecoopers ag applies international standard on quality management 1, which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.practitioners responsibility our responsibility is to perform a limited assurance engagement and to express a conclusion on the selected 2023 non-financial information including the ghg emissions of roche group disclosed in the report. we conducted our engagement in accordance with the international standard on assurance engagements isae 3000 revised assurance engagements other than audits or reviews of historical financial information and the international standard on assurance engagements 3410, assurance engagements on greenhouse gas statements isae 3410, issued by the international auditing and assurance standards board.",
    "word_count": 488,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_064",
    "content": "pricewaterhousecoopers ag applies international standard on quality management 1, which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.practitioners responsibility our responsibility is to perform a limited assurance engagement and to express a conclusion on the selected 2023 non-financial information including the ghg emissions of roche group disclosed in the report. we conducted our engagement in accordance with the international standard on assurance engagements isae 3000 revised assurance engagements other than audits or reviews of historical financial information and the international standard on assurance engagements 3410, assurance engagements on greenhouse gas statements isae 3410, issued by the international auditing and assurance standards board. those standards require that we plan and perform our procedures to obtain limited assurance whether anything has come to our attention that causes us to believe that the selected 2023 non-financial information including the ghg emissions was prepared, in all material aspects, in accordance with the document 2023 non-financial reporting indicators definitions and scope. based on risk and materiality considerations, we performed our procedures to obtain sufficient and appropriate assurance evidence. the procedures selected depend on the assurance practitioners judgement. a limited assurance engagement under isae 3000 revised and isae 3410 is substantially less in scope than a reasonable assurance engagement in relation to both the risk assessment procedures, including an understanding of internal control, and the procedures performed in response to the assessed risks. consequently, the nature, timing and extent of procedures for gathering sufficient appropriate evidence are deliberately limited relative to a reasonable assurance engagement and therefore less assurance is obtained with a limited assurance engagement than for a reasonable assurance engagement.independent practitioners limited assurance report  roche 93 we performed the following assurance procedures, among others:  review of the application of roche group guidelines reviewing the application of the roche group selected non-financial reporting guidelines as per the document 2023 non-financial reporting indicators definitions and scope;  site visits and management inquiry visiting selected pharmaceuticals and diagnostics sites in china, germany, italy and the usa.",
    "word_count": 350,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_065",
    "content": "a limited assurance engagement under isae 3000 revised and isae 3410 is substantially less in scope than a reasonable assurance engagement in relation to both the risk assessment procedures, including an understanding of internal control, and the procedures performed in response to the assessed risks. consequently, the nature, timing and extent of procedures for gathering sufficient appropriate evidence are deliberately limited relative to a reasonable assurance engagement and therefore less assurance is obtained with a limited assurance engagement than for a reasonable assurance engagement.independent practitioners limited assurance report  roche 93 we performed the following assurance procedures, among others:  review of the application of roche group guidelines reviewing the application of the roche group selected non-financial reporting guidelines as per the document 2023 non-financial reporting indicators definitions and scope;  site visits and management inquiry visiting selected pharmaceuticals and diagnostics sites in china, germany, italy and the usa. the selection was based on quantitative and qualitative criteria; interviewing personnel responsible for internal non-financial reporting and data collection at the sites we visited and at the group level to determine the understanding and application of roche groups non-financial reporting guidelines as per the document 2023 non-financial reporting indicators definitions and scope;  assessment of the key figures performing tests on a sample basis of evidence supporting selected people and she key figures concerning completeness, accuracy, adequacy and consistency;  review of documentation and analysis of relevant policies and principles reviewing relevant documentation on a sample basis, including roche group non-financial reporting policies, management of reporting structures and documentation; and  assessment of the processes and data consolidation reviewing the management and non-financial reporting processes for selected people and she key figures; and assessing the aggregation process of data at roche group level.we believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion. conclusion based on the work we performed, nothing has come to our attention that causes us to believe that the selected 2023 non-financial information including the ghg emissions of roche group for the period from 1 january 2023 to 31 december 2023 disclosed in the report is not prepared, in all material respects, in accordance with the document 2023 non-financial reporting indicators definitions and scope. intended users and purpose of the report this report is prepared for, and only for, the corporate governance and sustainability committee of roche holding ltd, and solely for the purpose of reporting to them on selected 2023 non-financial information including the ghg emissions disclosed in the report and no other purpose. we do not, in giving our conclusion, accept or assume responsibility legal or otherwise or accept liability for, or in connection with, any other purpose for which our report including the conclusion may be used, or to any other person to whom our report is shown or into whose hands it may come, and no other persons shall be entitled to rely on our conclusion.",
    "word_count": 485,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_066",
    "content": "intended users and purpose of the report this report is prepared for, and only for, the corporate governance and sustainability committee of roche holding ltd, and solely for the purpose of reporting to them on selected 2023 non-financial information including the ghg emissions disclosed in the report and no other purpose. we do not, in giving our conclusion, accept or assume responsibility legal or otherwise or accept liability for, or in connection with, any other purpose for which our report including the conclusion may be used, or to any other person to whom our report is shown or into whose hands it may come, and no other persons shall be entitled to rely on our conclusion. we permit the disclosure of our report, in full only and in combination with the suitable criteria, to enable the corporate governance and sustainability committee to demonstrate that they have discharged their governance responsibilities by commissioning an independent assurance report over the selected 2023 non-financial information including the ghg emissions, without assuming or accepting any responsibility or liability to any third parties on our part. to the fullest extent permitted by law, we do not accept 94  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report or assume responsibility to anyone other than the corporate governance and sustainability committee of roche holding ltd for our work or this report. pricewaterhousecoopers ag bruno rossi raphael rutishauser zurich, 31 january 2024 the maintenance and integrity of roche holding ltds website and its content are the responsibility of the corporate governance and sustainability committee; the work carried out by the assurance provider does not involve consideration of the maintenance and integrity of roche holding ltds website, accordingly, the assurance provider accepts no responsibility for any changes that may have occurred to the specified non-financial information or suitable criteria since they were initially presented on the website.independent practitioners limited assurance report  roche 95 96  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report through our commitment to innovation and collaboration, we bring meaningful change to patients, people and communities across the globe. the stories behind our advancements capture the reach and impact of our people s work. how we contributehow we contribute  roche 97 as a roche patient expert since 2019, antoine has helped roche colleagues better understand the experiences of people with multiple sclerosis ms.98  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report when antoine learned in 2009 that he had relapsing remitting multiple sclerosis, he felt shocked but also relieved. he had sought help after losing vision in one eye, feeling pins and needles in his head and suspecting he might have a fatal illness. i felt happy not to have a brain tumour, he recalls. he decided to keep his diagnosis private.",
    "word_count": 470,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_067",
    "content": "i felt happy not to have a brain tumour, he recalls. he decided to keep his diagnosis private. at his engineering job at a medical devices plant in his native france, he kept a smile on his face even as he struggled to focus and steady himself going up and down the stairs. when it came time for his annual review, his boss told him that his performance had declined and the company wanted to let him go. they didnt know i had ms, antoine, 44, recalls. i cracked and i cried. the experience was early in antoines journey with ms, an immune-mediated disease that affects 2.9 million people1 and is the leading cause of non- traumatic disability in young people. but antoine has since embraced transparency. today, as one of the 1,500 members of carering, an internal community of employees who are also patients or caregivers, he regularly shares details about his life with ms to help roche improve delivery of care. the carering community is designed to create a safe, trusting space for members to share their experiences, connect and contribute to projects related to relevant disease areas. collaborating with patient communities including patient organisations, patients and their families, etc. enables us to better understand unmet needs and co-create solutions that support personalised healthcare from an early stage of drug development through to the delivery of care. as a roche patient expert since 2019, antoines courage, honesty and passion for sharing a patient perspective has contributed to valuable outcomes. his feedback has ensured that our patient-facing materials are easy to understand and that roches integrated strategic plan isp for ms is focused on meeting patient needs. antoine was a great person to have on the team as he brought not only his own lived experiences but also a broader perspective from the patient community, said marco parisi, who led the development of the isp for ms. he has helped us build a strategy that is based on the needs of patients and what a win in ms looks like for them. antoines voice has also helped roche colleagues better understand the experiences of people with ms and has been a valued addition to our training we provide on ocrevus, our ms therapy. a true inspiration to everyone antoine joined roche on a work placement organised through a government-run scheme that provides reintegration opportunities and financial support for people with disabilities. roche is committed to advancing the inclusion of people with disabilities through our valuable 500 pledge. antoines placement was facilitated by the rocheability network, which promotes disability inclusion, and was one of the first of its kind for roche. since then, he has been consulting with us for about four hours a week when he feels well enough and is not attending rehabilitation for his ms. having a patient on our team is something unique across the industry, says christine eighteen, roches global patient partnership leader in ms, who works closely with antoine.",
    "word_count": 495,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "strategic_initiatives": [
          {
            "keyword": "strategic plan",
            "context": "ack has ensured that our patient-facing materials are easy to understand and that roches integrated strategic plan isp for ms is focused on meeting patient needs. antoine was a great person to have on the team as h",
            "position": 1636,
            "sentence": "his feedback has ensured that our patient-facing materials are easy to understand and that roches integrated strategic plan isp for ms is focused on meeting patient needs."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_068",
    "content": "since then, he has been consulting with us for about four hours a week when he feels well enough and is not attending rehabilitation for his ms. having a patient on our team is something unique across the industry, says christine eighteen, roches global patient partnership leader in ms, who works closely with antoine. im proud that roche provides people living with diseases like ms the opportunity to continue to work and im grateful for the value they add to our business. sharing his journey with multiple sclerosis, antoine helps us improve care for people with ms 1 go.roche.comatlasofms-number-of-people-with-mshow we contribute  roche 99 working with roche has given me a sense of relief because i dont feel that i have a handicap, says antoine. as a patient expert, i am talking about ms, i am using my brain and i can help people. and that is really important for me. i help people better understand this disease. setbacks along the way antoines ability to confront his disease with positivity has encouraged us in our work and commitment to improving the lives of those living with ms. when he was first diagnosed, antoine met with neurologists, physiotherapists and a psychologist to help him with the less visible effects of his disease. ms is not only linked to physical symptoms, antoine says. you may see i am struggling to walk, losing my balance, struggling with fatigue, but you cant see my mental state, the fact i forget things more easily. the effects of a disease like ms are multifaceted. like other people with ms, antoine spent the early part of his journey working with doctors to find a treatment that worked best for him. he learned to self-administer injections  an act that wasnt easy for me to accept because it was a frequent injection and a constant reminder that i had ms, antoine says. he approaches setbacks and difficult days with positivity. i have a daughter and i dont want to show her that papa is sick, papa is tired, papa struggles to do lots of things. so even if i had a bad night, i always greet her with a smile, he says. as antoine adjusted to life with ms, he moved to basel where his wife, katie, found work with roche. he began looking for work, too, and started seeing a new medical team. recently, however, antoine and his medical team have begun to suspect that his ms may be evolving to secondary progressive ms, which is characterised by a gradual worsening of symptoms with no definite periods of remission. this worries him because treatment options are limited in this type of ms. in response to antoines emerging cognitive challenges, his roche colleagues have implemented strategies to ensure he can track his tasks. when he requires rehabilitation, which can be last-minute and time-intensive, roche adapts to accommodate his absence.",
    "word_count": 479,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_069",
    "content": "in response to antoines emerging cognitive challenges, his roche colleagues have implemented strategies to ensure he can track his tasks. when he requires rehabilitation, which can be last-minute and time-intensive, roche adapts to accommodate his absence. we always remain flexible as an organisation because his availability changes depending on his health, and his health is always our priority, says christine. readapting to a new reality to prioritise the aspects of his health he can control, antoine has recently given up alcohol and changed his diet. i have a daughter, i have a family, i can still work, i can still do lots of things. so i try to focus now on what i can do and not what ive lost. antoine continues to advance roches understanding of life with ms, enabling better patient care. he is a valued colleague who inspires with his commitment to supporting his peers and with his ability to adapt to his changing life. readaptation is an important word for me and for all ms patients. since ive had this condition, ive been working to readapt myself to the new me. today, antoine says he has become more comfortable asking for help and has a new perspective on life. having ms puts things into perspective; i dont sweat the small stuff. it changes your way of thinking and your behaviour. it changed my behaviour drastically  for the better i think.100  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report antoine continues to advance roches understanding of life with ms, enabling better patient care. his feedback has ensured that our patient-f acing materials are easy to understand.how we contribute  roche 101 human model systems and related cutting-edge technologies have the potential to reduce reliance on animal testing and significantly speed up the drug development process.102  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report we are at an inflection point in healthcare. human model systems  miniature, simplified versions of human tissues and organs  are poised to transform the way we discover and develop new therapies. although still in its infancy, the technology has the potential to reduce reliance on animal testing and significantly speed up the drug development process without sacrificing patient safety. the institute of human biology ihb, launched in may 2023, is the latest example of roches commitment to advance human model systems. the institute combines the best of exploratory research with the translational power of industry to solve the real-life challenges of drug discovery and development. established by our roche pharma research and early development pred innovation engine, the ihb provides a platform for cutting- edge collaboration among experts in exploratory biology, biomedicine, engineering, computational and data science. no other institute in the world unites all these areas under one roof.",
    "word_count": 465,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_070",
    "content": "established by our roche pharma research and early development pred innovation engine, the ihb provides a platform for cutting- edge collaboration among experts in exploratory biology, biomedicine, engineering, computational and data science. no other institute in the world unites all these areas under one roof. partnerships with academic institutions including the swiss federal institute of technology eth zurich ensure we foster the next generation of translational bioengineering talent and equip them to address future healthcare challenges.one key area of interest for the ihb is organoids  tiny tissue cultures that mimic properties of in vivo organs. they can be derived from a patients own tissues, enabling individualised diagnosis and treatment. the applications of this technology are far-reaching. for example, cystic fibrosis centres in the netherlands and beyond now routinely use organoids to determine patient eligibility for cystic fibrosis therapies. this work was led by hans clevers, head of pred at roche, who brings considerable expertise in organoids to the ihb. roches pred has already had success with organoids in testing anti-cancer drugs. using organoids to assess drug response, scientists progressed drugs into the clinical trial stage without animal testing. our capacity to create sustainable solutions for patients that are safer, more effective and more personalised is our key differentiator. human model systems have the potential to transform healthcare, but there is still a way to go before they reach widespread application. the ihb will play a key role in advancing this technology  contributing to our long-term vision to revolutionise industry drug discovery and development.accelerating drug discovery and development through the institute of human biologyhow we contribute  roche 103 the mystoryforchange illustrations capture the experiences and challenges women all over the world have encountered throughout their healthcare journey.104  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report for too long women1 have been overlooked by healthcare systems that see men as the default. research into womens health has been chronically underfunded, leaving women facing inequities in treatment, access and care. women are 50 more likely to be misdiagnosed with a heart attack, for example. the disparities are bigger for women of colour, with black women suffering 41 higher mortality for breast cancer compared to white women. recognition of this systemic blindness to the experiences and needs of women has catalysed a movement to amplify and empower womens voices. the mystoryforchange campaign from roches xproject aims to do just this. since its launch in early 2023, over 630 women from around the world have shared stories about their healthcare experiences. i had endometriosis that was left undiagnosed for about five years  by the time it was found i had a mass twice the size of my uterus, shared one woman. my mother, a biracial medical doctor, was grossly dismissed by her peers. it took hours of advocating for herself until she received life-saving care, said another of her mothers heart attack.",
    "word_count": 482,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_071",
    "content": "my mother, a biracial medical doctor, was grossly dismissed by her peers. it took hours of advocating for herself until she received life-saving care, said another of her mothers heart attack. together driving change roche has a long-standing history in womens health, pioneering diagnostics and treatments for conditions that primarily address women. xproject represents this continued commitment. it is an ongoing initiative aiming to close the gaps in womens health through partnerships, funding and action to create better health outcomes for everyone. the x in xproject represents the female chromosome that has historically been overlooked. the project has grown into a number of initiatives spanning health, technology and financing. teresa graham, ceo of roche pharmaceuticals, together with passionate colleagues, has been a major driving force for the project. outside of roche, momentum has also been building. in march 2023, the united nations population fund unfpa launched the equity 2030 alliance, of which roche is a founding member. the global commitment brings together leaders in the private sector, academia and government to close gender equity gaps. technology is key femtech plays a crucial role in the prevention, diagnosis and management of womens diseases. roche looks to harness the power of innovative technologies to improve patient outcomes  including those specifically designed to collect womens health data. in partnership with microsoft2 we developed a tool that uses artificial intelligence and cloud technologies to improve breast cancer diagnosis in the middle east to 96 accuracy. we continue to support femtech innovations, for example by participating in the annual femtechnology summit, which brings together leaders across the industry, and tech4eva, an acceleration programme for womens health start-ups. womens health is not a niche issue. and if women are doing better, society is, too. by amplifying womens voices and advancing gender-inclusive solutions in health, technology and financing, we can provide better outcomes for even more people around the world. closing the gaps on womens health equity with xproject 1 we use the terms woman and women to refer to people who biologically have two x chromosomes xx. however, inclusivity is at the core of xproject and we recognise that these individuals may not all identify as female. we respect that gender identities are diverse and are striving for an equitable health system for all. 2 roche.comxprojectxstoriestechnology-for-womens-healthhow we contribute  roche 105 in the last 15 years, ieepo has become the cornerstone of our engagement with the worldwide patient community.106  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report our patient partnership model prioritises the integration of patient insights and feedback into early- and late-stage research where we believe the patient voice can have the greatest impact. but the value of this work extends well beyond the development setting and is key to helping shape effective policy, as well as healthcare systems.",
    "word_count": 468,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "mentum has also been building. in march 2023, the united nations population fund unfpa launched the equity 2030 alliance, of which roche is a founding member. the global commitment brings together leaders i",
            "position": 991,
            "sentence": "in march 2023, the united nations population fund unfpa launched the equity 2030 alliance, of which roche is a founding member."
          },
          {
            "keyword": "equity",
            "context": "l commitment brings together leaders in the private sector, academia and government to close gender equity gaps. technology is key femtech plays a crucial role in the prevention, diagnosis and management of",
            "position": 1159,
            "sentence": "the global commitment brings together leaders in the private sector, academia and government to close gender equity gaps."
          },
          {
            "keyword": "equity",
            "context": "an provide better outcomes for even more people around the world. closing the gaps on womens health equity with xproject 1 we use the terms woman and women to refer to people who biologically have two x chr",
            "position": 2142,
            "sentence": "closing the gaps on womens health equity with xproject 1 we use the terms woman and women to refer to people who biologically have two x chromosomes xx."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_072",
    "content": "2 roche.comxprojectxstoriestechnology-for-womens-healthhow we contribute  roche 105 in the last 15 years, ieepo has become the cornerstone of our engagement with the worldwide patient community.106  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report our patient partnership model prioritises the integration of patient insights and feedback into early- and late-stage research where we believe the patient voice can have the greatest impact. but the value of this work extends well beyond the development setting and is key to helping shape effective policy, as well as healthcare systems. this work is closely connected with our mission to help patient communities play a more influential and purposeful role in healthcare  a mission we have championed for the last 15 years through our international experience exchange with patient organisations ieepo. we are proud that ieepo has become the cornerstone of our engagement with the worldwide patient community. the platform enables us to help patient organisations identify synergies in their markets and programmes, support them as they build their capabilities to amplify their voice, and collaborate with them on urgent topics with the goal of making healthcare accessible to all. with more than 1,000 patient community stakeholders participating in the platform and its related events from over 95 countries, ieepo is central to our vision of ensuring that patients have a seat at decision-making tables with an informed and active voice that will shape how healthcare is delivered across the globe. at its core, the mission of ieepo is to humanise healthcare through coordinated action on five key topics:  improving health literacy  advocating for universal health coverage in all geographies and markets  improving the collection and utilisation of health data to support decision-making  focusing on prevention and cure with a 50:50 model  prioritising diversity, equity and inclusion in healthcare while each of these topics is complex on its own, and has different implications in every country, we know that sharing knowledge, experience and learnings with and within the patient community ultimately drives change. by thinking globally, we have built our collective capacity to act locally, empowering every person  regardless of their age, sex, gender, race, ethnicity, socioeconomic status, health literacy and geography  to take control of their health. engaging with the patient community: thinking globally, acting locallyhow we contribute  roche 107 roche has a bold ambition to radically improve breast cancer diagnosis and treatment by 2030, so that eight in ten women in africa will survive five years after diagnosis.108  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report breast and cervical cancer currently constitute over half the cancer burden for women in sub- saharan africa, with 60 to 70 of women with these cancers in african countries diagnosed at a late stage. only five in ten women diagnosed with breast cancer in an african country will survive five years, compared to nine in ten in high-income countries.",
    "word_count": 481,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "upport decision-making  focusing on prevention and cure with a 50:50 model  prioritising diversity, equity and inclusion in healthcare while each of these topics is complex on its own, and has different imp",
            "position": 1987,
            "sentence": "at its core, the mission of ieepo is to humanise healthcare through coordinated action on five key topics:  improving health literacy  advocating for universal health coverage in all geographies and markets  improving the collection and utilisation of health data to support decision-making  focusing on prevention and cure with a 50:50 model  prioritising diversity, equity and inclusion in healthcare while each of these topics is complex on its own, and has different implications in every country, we know that sharing knowledge, experience and learnings with and within the patient community ultimately drives change."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_073",
    "content": "engaging with the patient community: thinking globally, acting locallyhow we contribute  roche 107 roche has a bold ambition to radically improve breast cancer diagnosis and treatment by 2030, so that eight in ten women in africa will survive five years after diagnosis.108  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report breast and cervical cancer currently constitute over half the cancer burden for women in sub- saharan africa, with 60 to 70 of women with these cancers in african countries diagnosed at a late stage. only five in ten women diagnosed with breast cancer in an african country will survive five years, compared to nine in ten in high-income countries. roche has identified breast cancer as a priority condition to be addressed as part of our long- term strategy in africa, as we believe it will not only support people with the disease but may also support the delivery of other non-communicable diseases and support health equity strategies. roche has a bold ambition to radically improve breast cancer diagnosis and treatment by 2030, so that eight in ten women in africa will survive five years after diagnosis. to achieve this monumental ambition, roche is working with a consortium of influential stakeholders, uniting governments, civil society, development finance institutions, private sector entities, multilateral organisations, community leaders and healthcare professionals. all are bringing their own expertise and resources to this fight. in september 2023, the world health organization who regional office for africa announced a pilot to support better access to breast and cervical cancer services in three african countries. roche is supporting the who regional office for africa with funding to provide integrated breast and cervical services at six sites across kenya, c\u00f4te divoire and zimbabwe. the initiative includes health promotion, screening, early diagnosis and treatment, as well as general primary care and screening for other non-communicable diseases. early detection services will be integrated into existing cervical cancer screening clinics to ensure both old and new systems are unified. the aim is to provide an integrated and holistic system of healthcare that will contribute to addressing the burden of breast and cervical cancer in the african region. the initiative also seeks to increase healthcare workers ability to provide cancer care within communities through training, and will supply and deliver the necessary equipment and essential supplies to support women at primary healthcare level. this programme marks an exciting and tangible step on the path to true health equity in africa and demonstrates a new way in which the public and private sector can work together to drive real change within healthcare systems, said maturin tchoumi, roche pharma international area head for africa, at the time of the launch. collaborations are absolutely vital to enable long-t erm, sustainable access to healthcare that goes from screening to diagnosis through to treatment. roche is proud to support the who regional office for africa on this initiative.",
    "word_count": 485,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "the disease but may also support the delivery of other non-communicable diseases and support health equity strategies. roche has a bold ambition to radically improve breast cancer diagnosis and treatment by",
            "position": 1010,
            "sentence": "roche has identified breast cancer as a priority condition to be addressed as part of our long- term strategy in africa, as we believe it will not only support people with the disease but may also support the delivery of other non-communicable diseases and support health equity strategies."
          },
          {
            "keyword": "equity",
            "context": "ary healthcare level. this programme marks an exciting and tangible step on the path to true health equity in africa and demonstrates a new way in which the public and private sector can work together to dr",
            "position": 2702,
            "sentence": "this programme marks an exciting and tangible step on the path to true health equity in africa and demonstrates a new way in which the public and private sector can work together to drive real change within healthcare systems, said maturin tchoumi, roche pharma international area head for africa, at the time of the launch."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_074",
    "content": "collaborations are absolutely vital to enable long-t erm, sustainable access to healthcare that goes from screening to diagnosis through to treatment. roche is proud to support the who regional office for africa on this initiative. supporting breast and cervical cancer services in africahow we contribute  roche 109 roche has been conducting clinical trials for 25 years and continues to work across africa to close representation gaps in trial and research data. 110  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report africa has the worlds fastest-growing population and is the birthplace of all of humanity. yet less than 2 of human genome data comes from people of african descent. this important population is also under-represented in clinical trials, reducing opportunities for scientists to research diseases and develop medicines that are equally effective across global populations. as a science-driven healthcare company striving to improve health outcomes for all patients, roche is committed to addressing barriers that prevent people from accessing quality healthcare. one of the key ways we work to do this is by ensuring inclusion and increasing representation of historically excluded populations in research and development to help optimise health outcomes for all patients worldwide. with our commitment in africa, for example, roche has been conducting clinical trials for 25 years and continues to work across the continent and its diaspora to close representation gaps in trial and research data. there is a growing momentum across the continent, powered by african scientists and a broad network of partners including ngos, academia, the public sector and the private sector  including roche. through these partnerships, and with recent advances in technology, we are closer than ever to closing these data gaps and ultimately working towards a healthier future for all. at roche, we are proud of our commitment in africa and taking part in this momentous push forward.in addition, through the african genomics program, we are expanding equitable data access in africa and accelerating research. in 2023, a number of initiatives were underway to enhance capacity on the continent for the genomics ecosystem. two key programmes initiated in 2023 include together for change, a collaborative effort with several industry peers and meharry medical college to create the largest african genomic database to date, comprising up to 425,000 samples from people of african descent in the us and africa. the globally available data will increase opportunities to discover new human biology and better diagnose, prevent and treat disease. additionally, in the discover me south africa collaborative research initiative, we will access and analyse health and genetic information from up to 100,000 patients in south africa. at the same time, we are building the capacity of the next generation of african scientists by offering fellowships focused on clinical pharmacology, pathology and human genetics.",
    "word_count": 463,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_075",
    "content": "additionally, in the discover me south africa collaborative research initiative, we will access and analyse health and genetic information from up to 100,000 patients in south africa. at the same time, we are building the capacity of the next generation of african scientists by offering fellowships focused on clinical pharmacology, pathology and human genetics. we understand that there is still much work ahead, but we are committed to continue to improve inclusion of understudied patients in clinical research, generating data that enables us to assess the safety and efficacy of our innovations in under-re presented demographic groups, and reducing barriers to equitable care for diverse patients everywhere.working towards a healthier future for allhow we contribute  roche 111 roche is committed to helping to improve global diagnostics capacity to enable access to affordable, high-quality healthcare services for all people around the world.112  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report diagnostics are essential to decision-making along every step of a patients health, wellness and disease journey. a diagnostic test alone can help clinicians change the course of someones healthcare experience  and their life. as a leader in diagnostics, roche is committed to not only advancing solutions that can support clinicians in making critical decisions for their patients health, but also improving the way these tools are integrated into health systems around the world. healthcare professionals increasingly depend on laboratory tests to make diagnostic and treatment decisions. more than 29 billion tests were performed on roche diagnostics platforms in 2023. but the role of the lab goes far beyond the actual test  empowering doctors to make the right decisions at the right time, giving people greater control over their health and well-being, and helping payers and policymakers use resources more efficiently. stronger labs not only help healthcare systems make savings in the routine management of population health  like cancer, cardiovascular disease and dementia; but investing in them also helps reduce costs and prepare for any future public health crises  like pandemics. a study in germany found pcr and antigen testing during the covid-19 pandemic helped reduce the incidence of infection by 40, resulting in 62,000 fewer deaths and eur 2.8 billion in healthcare cost savings.1 insufficient resources and underfunding are two of the greatest challenges facing labs today. despite the importance of laboratory systems, they lack the political and financial support needed. it is estimated that although lab results drive around 70 of clinical decisions, labs account for only 5 of hospital spend. roche is committed to helping improve diagnostics capacity around the world by investing in laboratory infrastructure innovations that increase lab efficiency. we are also continuing our support for programmes that train new laboratory professionals and enhance the skills of those already working in the lab. yet many countries do not have laboratory capacity to meet current needs, let alone those of the future. the challenges are greater in low-income, rural communities.",
    "word_count": 487,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_076",
    "content": "yet many countries do not have laboratory capacity to meet current needs, let alone those of the future. the challenges are greater in low-income, rural communities. it is thought that 81 of people in low- a nd middle-income countries lmics have little or no access to life-saving diagnostics. many of these countries lack an integrated laboratory network that can provide high-quality, accessible and efficient lab testing services. in may 2023, roche welcomed the adoption of the resolution on strengthening diagnostics capacity by the world health assembly wha. the resolution supports diagnostics as a core pillar of universal health coverage uhc  a guarantee that all people have access to affordable, high-quality health services. the adoption of the resolution represents an important step towards increasing global access to novel, high-medical-value diagnostics solutions. with added momentum from the wha resolution, roche is partnering with stakeholders through advocacy and public-private partnerships to implement and drive greater diagnostics capacity globally  focusing on lmics where access is most critical. one example is our partnership with the global fund that helps improve the diagnosis of hiv and tuberculosis in lmics by building local diagnostics capacity. we will continue to advocate political commitment to strengthening laboratories as a key driver to achieving uhc.improving access to diagnostics through strengthened labs 1 go.roche.comimpact-corona-testing-economy-and-health-carehow we contribute  roche 113 roches years-long engagement with uruguays haemophilia stakeholders was instrumental in establishing the foundation for universal coverage. 114  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report hemlibra is approved in 120 countries for people living with haemophilia a inhibitors and in 108 countries for people with no inhibitors. to increase access to innovative treatment options, patient organisations, treatment centres and pharmaceutical companies must work together with governments to make clinically informed decisions that help to improve the lives of patients. in latin america, roche has spent years listening to the haemophilia community to better understand their needs and provide integral solutions, thus being considered as a trusted and ethical partner. the provided solutions based on continuous collaboration between different sectors resulted in a first-of-its-kind agreement in uruguay to offer coverage of the treatment option to paediatric patients and adults with inhibitors to factor viii. roches years-long engagement with uruguays haemophilia stakeholders, including supporting the haemophilia patient association to develop a population census, was instrumental in establishing the foundation for universal coverage. this was originally expected to be achieved by 2024. but negotiations accelerated after a young boy with haemophilia wrote to the countrys president in 2021, describing life lacking access to treatment and asking for therapy for every child with haemophilia who needed treatment in uruguay. to innovate a solution, roche put together a team of colleagues from access, pricing, medical and compliance. expanding access to innovative treatment options under budget constraints required both an innovative payment model and an unwavering commitment to transparently and ethically co-create the model with the patient organisation, physicians, opinion leaders, healthcare providers, payers and the government.",
    "word_count": 493,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_077",
    "content": "to innovate a solution, roche put together a team of colleagues from access, pricing, medical and compliance. expanding access to innovative treatment options under budget constraints required both an innovative payment model and an unwavering commitment to transparently and ethically co-create the model with the patient organisation, physicians, opinion leaders, healthcare providers, payers and the government. as we mark the 75th anniversary of roche in uruguay, we are proud of the trusted reputation weve maintained in the country, which enabled us to bring innovative treatments to people.innovative and novel access solutions for a treatment option in uruguayhow we contribute  roche 115 roche has expanded its architectural focus to include sustainable construction principles, aiming to set a benchmark for the industry.116  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report the construction sector accounts for around 60 of global waste and half of the worlds energy consumption. recognising our role as a global entity, roche is determined to help mitigate these impacts. building on its rich tradition of architectural excellence, roche has expanded its focus to include sustainable construction principles, aiming to set a benchmark for the industry. sustainability in construction is a necessity, and roche has risen to this challenge. using our own novel sustainable construction methodology, roche has seamlessly integrated sustainable building into our ethos. this approach not only promotes sustainability through reduced environmental impact but also encourages productivity and community contribution. three key pillars underpin roches sustainable construction approach: 1. applying circularity principles to reduce waste and increase resource reuse and recycling. 2. cutting greenhouse gas ghg emissions with the aim of reducing the buildings carbon footprint. 3. designing to enhance the productivity and well-b eing of the buildings occupants. roche has developed a software tool to make it possible to carry out construction projects in compliance with all relevant sustainable construction requirements. the tool evaluates a buildings entire sustainability performance from the planning stage through to the end of life. the new buildings are designed to conserve energy while fostering an environment that boosts employee efficiency and prioritises their health and comfort. evaluations revealed that sustainable buildings at roche require on average 25 less energy compared to standard buildings, and users show 25 higher productivity. collaboration is central to roches vision for sustainable construction. for example, our work with the science based targets initiative sbti to set ghg reduction targets in line with climate science demonstrates our commitment to reducing our impact and underscores the broader significance and urgency of sustainable construction in todays world. our sustainable construction approach is a competitive differentiator and helps us generate long-term value. one example of this commitment is the re-use for kids initiative. in collaboration with the canton of basel-stadt and the bern university of applied sciences, our site in basel is testing the reuse of old building components to build two kindergartens for the city.",
    "word_count": 480,
    "keyword_analysis": {
      "COMPANY_STATE": {
        "operational_efficiency": [
          {
            "keyword": "productivity",
            "context": "approach not only promotes sustainability through reduced environmental impact but also encourages productivity and community contribution. three key pillars underpin roches sustainable construction approach: 1.",
            "position": 1647,
            "sentence": "this approach not only promotes sustainability through reduced environmental impact but also encourages productivity and community contribution."
          },
          {
            "keyword": "productivity",
            "context": "ghg emissions with the aim of reducing the buildings carbon footprint. 3. designing to enhance the productivity and well-b eing of the buildings occupants. roche has developed a software tool to make it possible",
            "position": 1976,
            "sentence": "designing to enhance the productivity and well-b eing of the buildings occupants."
          },
          {
            "keyword": "productivity",
            "context": "at roche require on average 25 less energy compared to standard buildings, and users show 25 higher productivity. collaboration is central to roches vision for sustainable construction. for example, our work with",
            "position": 2615,
            "sentence": "evaluations revealed that sustainable buildings at roche require on average 25 less energy compared to standard buildings, and users show 25 higher productivity."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "challenges": [
          {
            "keyword": "challenge",
            "context": "chmark for the industry. sustainability in construction is a necessity, and roche has risen to this challenge. using our own novel sustainable construction methodology, roche has seamlessly integrated sustaina",
            "position": 1405,
            "sentence": "sustainability in construction is a necessity, and roche has risen to this challenge."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_078",
    "content": "one example of this commitment is the re-use for kids initiative. in collaboration with the canton of basel-stadt and the bern university of applied sciences, our site in basel is testing the reuse of old building components to build two kindergartens for the city. this innovative project not only demonstrates our commitment to sustainability but also contributes to the well-being and connection of the community. building on our architectural heritage, roches holistic approach to sustainable construction positions us as a role model in the industry. with a focus on environmental protection and community engagement, our buildings stand as symbols of roches values  each one marking a step towards a more circular and decarbonised economy.taking a holistic approach to sustainable building construction how we contribute  roche 117 the funds roche employees raise through the roche childrens walk go to react which supports early childhood development and education with partners like selam childrens village in ethiopia left and unicef projects right,  unicefuni160400ose around the world.118  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report every child has the right to education. but girls in malawi miss 12 to 26 days of school each year on average due to the stigma and discrimination they face for menstruating. to help keep girls in school, unicef runs a programme to create awareness for menstrual health and help reduce stigma and discrimination. the roche employee action and charity trust react, an independent entity funded by roche employees through the childrens walk, has supported this unicef programme since 2020. since then, the programme has educated 5,600 school and community members in menstrual health and hygiene and provided 6,800 girls with reusable pads and other supplies. i dont view menses as a curse anymore, said one of the young women who received education about menstrual health through the programme. my schoolmates and i freely talk about it and support each other, so everyone can learn in peace. the work in malawi is just one example of the many projects supported by react. the charity is rooted in our tradition of philanthropy and reflects our commitment to act as global citizens contributing to local efforts to build stronger and healthier communities. in 2023, we were proud to celebrate 20 years of the roche childrens walk. over the years, more than 315,000 roche employees have participated in the event, raising over chf 23 million for children in need. partnering for progress since the childrens walk started in 2003, react has partnered with a range of non-p rofit organisations to support early childhood development and education efforts around the world. from the beginning, our partnership with unicef has supported access to education for children from disadvantaged backgrounds. in total, over 450,000 children have benefitted from unicef educational programmes across ethiopia, malawi, nepal and the philippines.",
    "word_count": 468,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_079",
    "content": "from the beginning, our partnership with unicef has supported access to education for children from disadvantaged backgrounds. in total, over 450,000 children have benefitted from unicef educational programmes across ethiopia, malawi, nepal and the philippines. other partners include childs dream, an organisation working to improve education access for children in cambodia; selam charity, that supports orphans in ethiopia; and the roger federer foundation, that supports a range of childhood development initiatives. roche employees making it possible our collaboration with these incredible organisations is only possible through our employees dedication to the childrens walk. in 2023 alone, over 23,000 employees participated across 170 roche sites in 75 countries, raising more than chf 1 million. over the last 20 years, 166 leading roche fundraisers and contributors have experienced first-hand the impact of funds raised by the childrens walk as ambassadors. in 2023, six ambassadors visited cambodia to see the work childs dream has done to improve school infrastructure, create computer facilities and provide high-school scholarships. eight ambassadors travelled to ethiopia to see the selam childrens village, supported by react since 2017 to fund orphan homes and youth vocational training, and to malawi to visit some of the essential educational projects led by unicef. the stories shared by our ambassadors, partners and especially the children they serve remind us of the incredible impact that education can have on childrens lives. twenty years of impact for children how we contribute  roche 119 we aspire to deliver the security and privacy that our regulators require, our customers expect and our patients deserve.120  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report we believe data is integral to improving the lives of patients, the physicians who treat them and the health systems that care for them. in 2023, we focused on strengthening our zero-trust network and refining our shared-responsibility model to help protect our data and enable our entire organisation to achieve our mission of doing now what patients need next. zero-trust networking the industrys historical security model can be compared to a castle and a moat. the inside was assumed to be safe because all the dangers were kept outside. unfortunately, that model never really worked. an attack on one computer could put everything at risk at once. that is, an attacker who got past the moat had a chance to take the whole castle. the solution to this problem is a model called zero-trust networking, which assumes every activity comes with some level of risk and that any device could be attacked or misused. instead of assuming no bad actors will make it across the moat and intrinsically trusting the corporate network, our model doesnt trust networks at all. instead, it trusts identities. this means we make sure we know who is accessing what data and when. the benefit of this approach is that, in the event of a breach, damage is contained. a compromised device is much less likely to pose a threat to the company at large.",
    "word_count": 499,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_080",
    "content": "the benefit of this approach is that, in the event of a breach, damage is contained. a compromised device is much less likely to pose a threat to the company at large. under zero-trust, attackers trying to breach the castle get stuck in the stables. shared-responsibility model at roche, cybersecurity is a shared responsibility. in our shared-responsibility model we clearly define who is responsible for which tasks to ensure smooth, efficient operation. roche security teams partner closely to follow governance and risk management processes, ensuring security privacy end to end. our security experts ensure effective vulnerability and incident management and promote security and privacy awareness, supported by training. we hold our partners and vendors to the same high standards we set for ourselves. through a rigorous assessment process, we mitigate risks and ensure our partners meet stringent cybersecurity and compliance requirements. finally, we report on product security and privacy and integrate customer feedback into product requirements. looking ahead todays world is more digitally connected than ever before, but with that comes network fragility. attacks have become more sophisticated and the proliferation of connected devices has increased the threat surface. to put it in terms of the castle and the moat: the castle stores more treasure, the invaders have learned to swim, and the moats water level is dropping. to achieve our mission in this environment, weve traded the castle and moat for a model of zero-t rust networking and shared responsibility. through a sensible and thoughtful approach, we balance the realities of todays modern workforce with a pragmatic security approach that understands the threat landscape and user behaviour. this allows us to focus on what drives us each day: doing now what patients need next.privacy and security that regulators require, customers expect and patients deservehow we contribute  roche 121 122  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report corporate governance principles 124 board of directors 126 corporate executive committee 130 group structure and shareholders 134 capital structure 136 board of directors and corporate executive committee 137 remuneration, shareholdings and loans 142 participatory rights of shareholders 143 change of control and defensive measures 143 relationship to statutory auditors 144 relationship to the independent proxy 145 information policy 146 chief compliance officer and compliance officers network 146 non-applicabilitynegative disclosure 147corporate governance  roche 123 business activities with a focus on sustainable value creation and innovation, a management culture conforming to recognised standards of good corporate governance and a policy of transparent communication embody roches corporate governance principles, which build the basis for the successful implementation of roches commitment to serving all its stakeholders. a strong board of directors which represents the interests of the shareholders and all other stakeholders, and highly skilled managers who act with integrity are extremely important. roche ranked as one of the top three most sustainable healthcare companies in the pharmaceuticals index of the dow jones sustainability indices djsi for the 15th year running.",
    "word_count": 490,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_081",
    "content": "a strong board of directors which represents the interests of the shareholders and all other stakeholders, and highly skilled managers who act with integrity are extremely important. roche ranked as one of the top three most sustainable healthcare companies in the pharmaceuticals index of the dow jones sustainability indices djsi for the 15th year running. this recognition is based on an in-depth analysis of economic, social and environmental performance. sustainability is at the core of our business practices and this award reflects our commitment to running our business in a way that is ethical, responsible and creates long-term value for stakeholders. this corporate governance report sets out the structures, processes and rules which roche takes as the basis for well-functioning corporate governance. in doing so, roche complies with all relevant corporate governance requirements, in particular with all applicable laws, the swiss stock exchange six swiss exchange directives and the swiss code of best practice for corporate governance promulgated by the swiss business federation economiesuisse. the companys internal governance framework, particularly its articles of incorporation and bylaws, embodies all the principles needed to ensure that the companys businesses are managed and supervised in a manner consistent with good corporate governance, including the necessary checks and balances.1 the printed annual report contains selected links to the roche website  https: www.roche.com . readers are thus provided not only with a snapshot of our company at the reporting date but are also directed to sources which they can consult at any time for up-to-date information about corporate governance at roche. whereas each annual report covers a single financial year ending 31 december, our website contains information of a more permanent nature, as well as the latest roche news. the companys articles of incorporation, bylaws and the curricula vitae of current and former members of the board of directors and the corporate executive committee are published on our website status as per end of term and as at the reporting date on 31 december of each year, at least of the last ten years.principles 1 https: www.roche.comaboutgovernance124  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report annual general meeting enlarged corporate executive committeecorporate executive committeeboard of directors and board committeesannual general meeting board of directors chairmansnomination committeeboard committees corporate governance and sustainability committeeremuneration committee audit committee enlarged corporate executive committee gred global product developmentcommunications general counsel corporate strategy and sustainabilitypharma partnering predcorporate executive committee ceo roche groupceo roche diagnosticschief people officerceo roche pharmaceuticalschief financial and information officercorporate governance  roche 125 review agm 2023 under the chair of roches now-resigned chairman, dr christoph franz, the 105th ordinary annual general meeting agm of roche holding ltd was held on 14 march 2023 for the first time since 2019 without any covid -19 restrictions and with shareholders attending in person again.",
    "word_count": 467,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_082",
    "content": "whereas each annual report covers a single financial year ending 31 december, our website contains information of a more permanent nature, as well as the latest roche news. the companys articles of incorporation, bylaws and the curricula vitae of current and former members of the board of directors and the corporate executive committee are published on our website status as per end of term and as at the reporting date on 31 december of each year, at least of the last ten years.principles 1 https: www.roche.comaboutgovernance124  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report annual general meeting enlarged corporate executive committeecorporate executive committeeboard of directors and board committeesannual general meeting board of directors chairmansnomination committeeboard committees corporate governance and sustainability committeeremuneration committee audit committee enlarged corporate executive committee gred global product developmentcommunications general counsel corporate strategy and sustainabilitypharma partnering predcorporate executive committee ceo roche groupceo roche diagnosticschief people officerceo roche pharmaceuticalschief financial and information officercorporate governance  roche 125 review agm 2023 under the chair of roches now-resigned chairman, dr christoph franz, the 105th ordinary annual general meeting agm of roche holding ltd was held on 14 march 2023 for the first time since 2019 without any covid -19 restrictions and with shareholders attending in person again. as successor of dr christoph franz, shareholders elected dr severin schwan as a member of the board of directors member since 2013 and as the new chairman of the board of directors for a term of one year as provided by the articles of incorporation. at the same time with this election, dr severin schwan resigned as a member of the corporate executive committee member since 2006 and as the ceo roche group since 2008. furthermore, the agm re-elected andr\u00e9 hoffmann, dr j\u00f6rg duschmal\u00e9, dr patrick frost, anita hauser, prof. dr richard p . lifton, dr jemilah mahmood, bernard poussot and dr claudia suessmuth dyckerhoff as members of the board of directors for a term of one year as provided by the articles of incorporation. moreover, prof. dr akiko iwasaki and dr mark schneider were elected as new members of the board of directors for a term of one year. in addition, the agm re-elected andr\u00e9 hoffmann, prof. dr richard p . lifton, bernard poussot and elected dr j\u00f6rg duschmal\u00e9 and anita hauser as members of the remuneration committee for a term of one year.review on reporting year at its organising meeting immediately following the agm, the board of directors determined the structure and composition of its remaining committees as shown on page 129 see also page 8 and page 137 board of directors and corporate executive committee. outlook agm 2024 on 12 march 2024, at the forthcoming agm the board of directors nominates dr severin schwan as its chairman for re-election. the board of directors further nominates all other remaining members of the board of directors for re-election. moreover, the board of directors nominates andr\u00e9 hoffmann, dr j\u00f6rg duschmal\u00e9, anita hauser and prof. dr richard p .",
    "word_count": 499,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "outlook",
            "context": "hown on page 129 see also page 8 and page 137 board of directors and corporate executive committee. outlook agm 2024 on 12 march 2024, at the forthcoming agm the board of directors nominates dr severin schwa",
            "position": 2929,
            "sentence": "lifton, bernard poussot and elected dr j\u00f6rg duschmal\u00e9 and anita hauser as members of the remuneration committee for a term of one year.review on reporting year at its organising meeting immediately following the agm, the board of directors determined the structure and composition of its remaining committees as shown on page 129 see also page 8 and page 137 board of directors and corporate executive committee."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_083",
    "content": "moreover, the board of directors nominates andr\u00e9 hoffmann, dr j\u00f6rg duschmal\u00e9, anita hauser and prof. dr richard p . lifton for re-election to the remuneration committee at the agm in 2024. the board of directors nominates testaris ag for election as independent proxy by the agm in 2024 for the period from 2024 until the conclusion of the 2025 ordinary agm of shareholders.board of directors126  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report board of directors and board committeesboard of directors chairmansnomination committeeboard committees corporate governance and sustainability committeeremuneration committee audit committeecorporate governance  roche 127 3 6 2nationality 45 2france 1 austria 1switzerland 5 us 4 germany 3malaysia 1 age tenure55 years 5565 years 65 yearsboard of directors11 members 610 years 5 years 10 years average tenure years 7.64  incl. 2 dual citizen and 1 triple citizen   calculated from year of first election to 2024male 63.64female 36.36128  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report a corporate governance and sustainability committee andr\u00e9 hoffmann chair prof. dr akiko iwasaki dr jemilah mahmood dr claudia suessmuth dyckerhoffboard of directors committeesc remuneration committee andr\u00e9 hoffmann chair dr j\u00f6rg duschmal\u00e9 anita hauser prof. dr richard p . lifton bernard poussotb audit committee dr patrick frost chair dr j\u00f6rg duschmal\u00e9 dr mark schneider dr claudia suessmuth dyckerhoffd chairmansnomination committee dr severin schwan chair andr\u00e9 hoffmann anita hausercomposition as at 31.12.2023 name year of birth nationalitycommittee membership chairnon- executive in- dependent member function first elected board of directors dr severin schwan 1967 ch, at, de d  e chairman 2013 as a member 2023 as chairman andr\u00e9 hoffmann 1958 representative of the shareholder group with pooled voting rightsch a, c , d e, g vice- chairman1996 dr j\u00f6rg duschmal\u00e9 1984 representative of the shareholder group with pooled voting rightsch b, c e, g member 2020 dr patrick frost 1968 ch b e, g member 2020 anita hauser 1969 ch c, d e, g member 2017 prof. dr akiko iwasaki 1970 us a e, g member 2023 prof. dr richard p . lifton 1953 us c e, g member 2015 dr jemilah mahmood 1959 my a e, g member 2022 bernard poussot 1952 us, fr c e, g member 2015 dr mark schneider 1965 us, de b e, g member 2023 dr claudia suessmuth dyckerhoff 1967 de a, b e, g member 2016 secretary to the board of directorsper-olof attinger 1960 a corporate governance and sustainability committee b audit committee c remuneration committee d chairmansnomination committee e non-executive director f executive director  currently no member g independent member of the board of directors  committee chairperson roches board of directors independence definition is based on the definition in the swiss code of best practice for corporate governance of economiesuisse see https: www.economiesuisse.chsitesdefaultfilespublicationsswisscode_e_web.pdf  and is complemented by specific preceding criteria see https: www.roche.comabout governanceboard-of-directors .",
    "word_count": 475,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_084",
    "content": "dr richard p . lifton 1953 us c e, g member 2015 dr jemilah mahmood 1959 my a e, g member 2022 bernard poussot 1952 us, fr c e, g member 2015 dr mark schneider 1965 us, de b e, g member 2023 dr claudia suessmuth dyckerhoff 1967 de a, b e, g member 2016 secretary to the board of directorsper-olof attinger 1960 a corporate governance and sustainability committee b audit committee c remuneration committee d chairmansnomination committee e non-executive director f executive director  currently no member g independent member of the board of directors  committee chairperson roches board of directors independence definition is based on the definition in the swiss code of best practice for corporate governance of economiesuisse see https: www.economiesuisse.chsitesdefaultfilespublicationsswisscode_e_web.pdf  and is complemented by specific preceding criteria see https: www.roche.comabout governanceboard-of-directors . members of the board of directors: cvs and mandates detailed information is available as follows: a current members: https: www.roche.comaboutgovernanceboard-of-directors b former members at least of the last ten years: https: www.roche.comaboutgovernanceec-bod-former c information at the reporting date on 31 december of each year at least of the last ten years: https: www.roche.comaboutgovernancearchiv-former-cvs information of the members of the board of directors shown is in accordance with the directive on information relating to corporate governance dcg, https: www.ser-ag.comdam downloadsregulationlistingdirectivesdcg-en.pdf  and also specifically includes mandates in accordance with article 734e and article 626 para. 2 point 1 of the federal act on the amendment of the swiss civil code part five: the code of obligations co that may be carried out in comparable positions in other undertakings with commercial objects. rules on mandates applying for members of the board of directors and the corporate executive committee are in accordance with 22.4 of the articles of incorporation of roche holding ltd https: assets.cwp.roche.comf126832xbb7e156602roche-statuten-2023-en.pdf  and are explained on page 137.corporate governance  roche 129 in 2023, memberships of the corporate executive committee and of the enlarged corporate executive committee changed as follows. corporate executive committee with his election as the new chairman of the board of directors of roche holding ltd on 14 march 2023, dr severin schwan resigned as a member of the corporate executive committee member since 2006 and as the ceo roche group since 2008. effective 14 march 2023, the board of directors appointed dr thomas schinecker, former ceo roche diagnostics, as dr schwans successor as the ceo roche group. due to bill andersons resignation as ceo roche pharmaceuticals effective 31 december 2022, dr thomas schinecker became in addition the ad interim ceo roche pharmaceuticals as of 1 january 2023 until 28 february 2023. effective 1 january 2023, matt sause, former head of roche diagnostics north america region, succeeding dr thomas schinecker, became ceo roche diagnostics and a member of the corporate executive committee.",
    "word_count": 458,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "assets",
            "context": "committee are in accordance with 22.4 of the articles of incorporation of roche holding ltd https: assets.cwp.roche.comf126832xbb7e156602roche-statuten-2023-en.pdf  and are explained on page 137.corporate",
            "position": 2052,
            "sentence": "rules on mandates applying for members of the board of directors and the corporate executive committee are in accordance with 22.4 of the articles of incorporation of roche holding ltd https: assets.cwp.roche.comf126832xbb7e156602roche-statuten-2023-en.pdf  and are explained on page 137.corporate governance  roche 129 in 2023, memberships of the corporate executive committee and of the enlarged corporate executive committee changed as follows."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_085",
    "content": "due to bill andersons resignation as ceo roche pharmaceuticals effective 31 december 2022, dr thomas schinecker became in addition the ad interim ceo roche pharmaceuticals as of 1 january 2023 until 28 february 2023. effective 1 january 2023, matt sause, former head of roche diagnostics north america region, succeeding dr thomas schinecker, became ceo roche diagnostics and a member of the corporate executive committee. effective 1 march 2023, teresa graham, former head of global product strategy for roche pharmaceuticals, was appointed ceo roche pharmaceuticals and became a member of the corporate executive committee.enlarged corporate executive committee effective 1 march 2023, dr levi garraway, head of global product development and chief medical officer, became a new member of the enlarged corporate executive committee. as of 1 april 2023, silke h\u00f6rnstein, former head of global strategy and transformation for roche diagnostics, became head of corporate strategy and sustainability as well as secretary to the corporate executive committee and a new member of the enlarged corporate executive committee. information on each member of the corporate executive committee and of the enlarged corporate executive committee is listed on page 133 see also page 12 and page 137 board of directors and corporate executive committee.corporate executive committee130  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report enlarged corporate executive committeecorporate executive committee enlarged corporate executive committee gred global product developmentcommunications general counsel corporate strategy and sustainabilitypharma partnering predcorporate executive committee ceo roche groupceo roche diagnosticschief people officerceo roche pharmaceuticalschief financial and information officercorporate governance  roche 131 2nationality 13 1us 3germany 2 switzerland 1austria 1 age tenurecorporate executive committee5 members 610 years 5 years 10 years average tenure years 5.60  incl. 2 dual citizen   calculated from first year of membership in the corporate executive committee to 2024male 60female 40 3 55 years 5565 years132  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report composition as at 31.12.2023 name year of birth nationality position since corporate executive committee dr thomas schinecker 1975 at, de ceo roche group 2019 as a member 2023 as ceo teresa graham 1973 us ceo roche pharmaceuticals 2023 matt sause 1977 us ceo roche diagnostics 2023 dr alan hippe 1967 ch, de chief financial and information officer 2011 cristina a. wilbur 1967 us chief people officer 2016 enlarged corporate executive committeeclaudia b\u00f6ckstiegel 1964 ch, de general counsel 2020 prof. dr hans clevers 1957 nl head roche pharma research and early development pred2022 dr levi garraway 1968 us head global product development and chief medical officer2023 silke h\u00f6rnstein 1975 de head corporate strategy and sustainability2023 dr aviv regev 1971 il, us head genentech research and early development gred2020 dr james h. sabry 1958 ca, us global head pharma partnering 2018 barbara sch\u00e4dler 1962 de head group communications 2019 secretary to the corporate executive committeesilke h\u00f6rnstein 1975 de 2023 statutory auditors of roche holding ltdkpmg klynveld peat marwick goerdeler sa reporting years 20042008 kpmg ag since 2009 auditor in charge: john a.",
    "word_count": 495,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "strategic_initiatives": [
          {
            "keyword": "transformation",
            "context": "porate executive committee. as of 1 april 2023, silke h\u00f6rnstein, former head of global strategy and transformation for roche diagnostics, became head of corporate strategy and sustainability as well as secretary to",
            "position": 907,
            "sentence": "as of 1 april 2023, silke h\u00f6rnstein, former head of global strategy and transformation for roche diagnostics, became head of corporate strategy and sustainability as well as secretary to the corporate executive committee and a new member of the enlarged corporate executive committee."
          },
          {
            "keyword": "product development",
            "context": "tee.enlarged corporate executive committee effective 1 march 2023, dr levi garraway, head of global product development and chief medical officer, became a new member of the enlarged corporate executive committee. as of",
            "position": 721,
            "sentence": "effective 1 march 2023, teresa graham, former head of global product strategy for roche pharmaceuticals, was appointed ceo roche pharmaceuticals and became a member of the corporate executive committee.enlarged corporate executive committee effective 1 march 2023, dr levi garraway, head of global product development and chief medical officer, became a new member of the enlarged corporate executive committee."
          },
          {
            "keyword": "product development",
            "context": "7 nl head roche pharma research and early development pred2022 dr levi garraway 1968 us head global product development and chief medical officer2023 silke h\u00f6rnstein 1975 de head corporate strategy and sustainability202",
            "position": 2941,
            "sentence": "dr hans clevers 1957 nl head roche pharma research and early development pred2022 dr levi garraway 1968 us head global product development and chief medical officer2023 silke h\u00f6rnstein 1975 de head corporate strategy and sustainability2023 dr aviv regev 1971 il, us head genentech research and early development gred2020 dr james h."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_086",
    "content": "dr hans clevers 1957 nl head roche pharma research and early development pred2022 dr levi garraway 1968 us head global product development and chief medical officer2023 silke h\u00f6rnstein 1975 de head corporate strategy and sustainability2023 dr aviv regev 1971 il, us head genentech research and early development gred2020 dr james h. sabry 1958 ca, us global head pharma partnering 2018 barbara sch\u00e4dler 1962 de head group communications 2019 secretary to the corporate executive committeesilke h\u00f6rnstein 1975 de 2023 statutory auditors of roche holding ltdkpmg klynveld peat marwick goerdeler sa reporting years 20042008 kpmg ag since 2009 auditor in charge: john a. morris 20042010 ian starkey 20112017 mark baillache 20182021 fran\u00e7ois rouiller since 2022 chief compliance officer pascale schmidt 1973 2020 members of the corporate executive committee: cvs and mandates detailed information is available as follows: a current members: https: www.roche.comaboutgovernanceexecutive-committee b former members at least ten years back: https: www.roche.comaboutgovernanceec-bod-former c information at the reporting date on 31 december of each year at least of the last ten years: https: www.roche.comaboutgovernancearchiv-former-cvs information of the members of the corporate executive committee shown is in accordance with the directive on information relating to corporate governance dcg, https: www.ser-ag.com damdownloadsregulationlistingdirectivesdcg-en.pdf  and also specifically includes mandates in accordance with article 734e and article 626 para. 2 point 1 of the federal act on the amendment of the swiss civil code part five: the code of obligations co that may be carried out in comparable positions in other undertakings with commercial objects. rules on mandates applying for members of the board of directors and the corporate executive committee are in accordance with 22.4 of the articles of incorporation of roche holding ltd https: assets.cwp.roche.comf126832xbb7e156602roche-statuten-2023-en.pdf  and are explained on page 137. corporate governance  roche 133 roches operating businesses are organised into two divisions: pharmaceuticals and diagnostics. the pharmaceuticals division comprises the two business segments roche pharmaceuticals including genentech in the united states and chugai. in 2021, the diagnostics division replaced the previous business area structure of its four business areas with new customer areas. sales are presented by the following customer areas: core lab, molecular lab, point of care, pathology lab, diabetes care for details see finance report, page 26. business activities are carried out through group subsidiaries and associated companies. detailed information on roche holding ltd and on significant subsidiaries and associated companies including company name, listing information, domicile, share capital and equity interest is listed in the finance report, note 33 to the roche group consolidated financial statements list of subsidiaries and associates, page 143 . major shareholders are listed in the finance report, notes 22 and 32 to the roche group consolidated financial statements equity attributable to roche shareholders and related parties, pages 100 and 140 , and in note 4 to the financial statements of roche holding ltd significant shareholders, page 190 . in addition, significant shareholders are published on the relevant webpage see link below  of the disclosure office of six exchange regulation.",
    "word_count": 492,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "n replaced the previous business area structure of its four business areas with new customer areas. sales are presented by the following customer areas: core lab, molecular lab, point of care, pathology la",
            "position": 2448,
            "sentence": "in 2021, the diagnostics division replaced the previous business area structure of its four business areas with new customer areas."
          }
        ],
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "s and associated companies including company name, listing information, domicile, share capital and equity interest is listed in the finance report, note 33 to the roche group consolidated financial stateme",
            "position": 2872,
            "sentence": "detailed information on roche holding ltd and on significant subsidiaries and associated companies including company name, listing information, domicile, share capital and equity interest is listed in the finance report, note 33 to the roche group consolidated financial statements list of subsidiaries and associates, page 143 ."
          },
          {
            "keyword": "equity",
            "context": "listed in the finance report, notes 22 and 32 to the roche group consolidated financial statements equity attributable to roche shareholders and related parties, pages 100 and 140 , and in note 4 to the fi",
            "position": 3152,
            "sentence": "major shareholders are listed in the finance report, notes 22 and 32 to the roche group consolidated financial statements equity attributable to roche shareholders and related parties, pages 100 and 140 , and in note 4 to the financial statements of roche holding ltd significant shareholders, page 190 ."
          },
          {
            "keyword": "assets",
            "context": "committee are in accordance with 22.4 of the articles of incorporation of roche holding ltd https: assets.cwp.roche.comf126832xbb7e156602roche-statuten-2023-en.pdf  and are explained on page 137. corporate",
            "position": 1952,
            "sentence": "rules on mandates applying for members of the board of directors and the corporate executive committee are in accordance with 22.4 of the articles of incorporation of roche holding ltd https: assets.cwp.roche.comf126832xbb7e156602roche-statuten-2023-en.pdf  and are explained on page 137."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "strategic_initiatives": [
          {
            "keyword": "product development",
            "context": "7 nl head roche pharma research and early development pred2022 dr levi garraway 1968 us head global product development and chief medical officer2023 silke h\u00f6rnstein 1975 de head corporate strategy and sustainability202",
            "position": 119,
            "sentence": "dr hans clevers 1957 nl head roche pharma research and early development pred2022 dr levi garraway 1968 us head global product development and chief medical officer2023 silke h\u00f6rnstein 1975 de head corporate strategy and sustainability2023 dr aviv regev 1971 il, us head genentech research and early development gred2020 dr james h."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_087",
    "content": "major shareholders are listed in the finance report, notes 22 and 32 to the roche group consolidated financial statements equity attributable to roche shareholders and related parties, pages 100 and 140 , and in note 4 to the financial statements of roche holding ltd significant shareholders, page 190 . in addition, significant shareholders are published on the relevant webpage see link below  of the disclosure office of six exchange regulation. group structure and shareholders  six exchange regulation: https: www.ser-ag.comenresourcesnotifications-market-participantssignificant-shareholders.htmlpharmaceuticalsroche pharmaceuticals incl. genentech diagnostics composition as at 31.12.2023molecular lab point of carecore lab pathology lab diabetes carechugai134  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report andr\u00e9 hoffmann above, chairman of the corporate governance and sustainability committee and of the remuneration committee, and dr j\u00f6rg duschmal\u00e9 below, member of the audit committee and of the remuneration committee andr\u00e9 hoffmann vice-chairman of the board of directors, chairman of the remuneration committee and of the boards corporate governance and sustainability committee and member of the boards chairmansnomination committee and dr j\u00f6rg duschmal\u00e9 member of the board of directors, of the boards audit committee and of the remuneration committee serve in their respective capacities on the board and its committees as representatives of the shareholder group with pooled voting rights and receive the remuneration set forth in the remuneration report on page 162 and in the finance report, note 32 to the roche group consolidated financial statements related parties, page 140 . no other relationships exist with the shareholders with pooled voting rights. there are no cross-shareholdings.corporate governance  roche 135 information on roches capital structure is provided in the finance report, notes to the financial statements of roche holding ltd page 187 . additional details are contained in the articles of incorporation of roche holding ltd.2 movement in recognised amounts during the last three financial years are detailed in the finance report, notes to the financial statements of roche holding ltd page 189 . the company has a share capital of chf 106,691,000, divided into 106,691,000 fully paid bearer shares with a nominal value of chf 1 each. there are no restrictions on the exercise of the voting rights of these bearer shares. there is no authorised or conditional capital. in addition, 702,562,700 non-voting equity securities nes have been issued in bearer form. they do not form part of the share capital and confer no voting rights. each nes confers the same rights as one share to participate in available earnings and in any liquidation proceeds following repayment of the share capital. roches nes and the rights pertaining thereto including the provisions protecting the interests of nes holders are described in 4 of the articles of incorporation of roche holding ltd.capital structure 2 https: www.roche.comaboutgovernancearticle-of-incorporationinformation on debt instruments which have been issued and on outstanding bonds is provided in the finance report, note 21 to the roche group consolidated financial statements debt, page 94.",
    "word_count": 484,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "profitability": [
          {
            "keyword": "earnings",
            "context": "confer no voting rights. each nes confers the same rights as one share to participate in available earnings and in any liquidation proceeds following repayment of the share capital. roches nes and the rights",
            "position": 2824,
            "sentence": "each nes confers the same rights as one share to participate in available earnings and in any liquidation proceeds following repayment of the share capital."
          }
        ],
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "listed in the finance report, notes 22 and 32 to the roche group consolidated financial statements equity attributable to roche shareholders and related parties, pages 100 and 140 , and in note 4 to the fi",
            "position": 122,
            "sentence": "major shareholders are listed in the finance report, notes 22 and 32 to the roche group consolidated financial statements equity attributable to roche shareholders and related parties, pages 100 and 140 , and in note 4 to the financial statements of roche holding ltd significant shareholders, page 190 ."
          },
          {
            "keyword": "equity",
            "context": "e bearer shares. there is no authorised or conditional capital. in addition, 702,562,700 non-voting equity securities nes have been issued in bearer form. they do not form part of the share capital and conf",
            "position": 2623,
            "sentence": "in addition, 702,562,700 non-voting equity securities nes have been issued in bearer form."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_088",
    "content": "each nes confers the same rights as one share to participate in available earnings and in any liquidation proceeds following repayment of the share capital. roches nes and the rights pertaining thereto including the provisions protecting the interests of nes holders are described in 4 of the articles of incorporation of roche holding ltd.capital structure 2 https: www.roche.comaboutgovernancearticle-of-incorporationinformation on debt instruments which have been issued and on outstanding bonds is provided in the finance report, note 21 to the roche group consolidated financial statements debt, page 94. information on employee stock options is provided in the finance report, note 27 to the roche group consolidated financial statements equity compensation plans, page 114, including detailed information on the stock-settled stock appreciation rights s-sars plan, the restricted stock units rsus plan, roche connect and the roche option plan. roche has issued no options apart from employee stock options as described in the finance report, note 27 to the roche group consolidated financial statements equity compensation plans, page 114, and options issued in connection with debt instruments. neither the options awarded to employees nor the debt instruments which have been issued have any effect on roches share capital.136  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report information on each member of the board of directors and on each member of the corporate executive committee is listed on pages 129 and 133 . members of the board of directors have no age limit or restriction on their term of office. curricula vitae cvs of all current and former members of at least the last ten years of both bodies and other information including information on the years of their first election, board memberships, additional positions, memberships and activities are available and continuously updated on the internet. in addition, the status of the cvs of both bodies at the relevant reporting date on 31 december of at least the last ten years is separately available, too.3 rules pursuant to article 626 para. 2 point 1 of the federal act on the amendment of the swiss civil code part five: the code of obligations co on the number of permitted activities of the board of directors and the corporate executive committee members are outlined in 22.4 of the articles of incorporation of roche holding ltd.4  no member of the board of directors may assume more than 10 additional mandates, of which no more than 4 may be in publicly listed companies. no member of the corporate executive committee may assume more than 5 additional mandates, of which no more than 1 may be in a publicly listed company. these restrictions do not apply to: a. mandates at companies controlled by the company or which control it. b. mandates which a member of the board of directors or of the corporate executive committee assumes by order of the company or by order of companies controlled by the company. c. mandates at associations, foundations, family foundations and employee welfare foundations.",
    "word_count": 497,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "profitability": [
          {
            "keyword": "earnings",
            "context": "each nes confers the same rights as one share to participate in available earnings and in any liquidation proceeds following repayment of the share capital. roches nes and the rights",
            "position": 74,
            "sentence": "each nes confers the same rights as one share to participate in available earnings and in any liquidation proceeds following repayment of the share capital."
          }
        ],
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "ons is provided in the finance report, note 27 to the roche group consolidated financial statements equity compensation plans, page 114, including detailed information on the stock-settled stock appreciatio",
            "position": 744,
            "sentence": "information on employee stock options is provided in the finance report, note 27 to the roche group consolidated financial statements equity compensation plans, page 114, including detailed information on the stock-settled stock appreciation rights s-sars plan, the restricted stock units rsus plan, roche connect and the roche option plan."
          },
          {
            "keyword": "equity",
            "context": "ns as described in the finance report, note 27 to the roche group consolidated financial statements equity compensation plans, page 114, and options issued in connection with debt instruments. neither the o",
            "position": 1110,
            "sentence": "roche has issued no options apart from employee stock options as described in the finance report, note 27 to the roche group consolidated financial statements equity compensation plans, page 114, and options issued in connection with debt instruments."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_089",
    "content": "c. mandates at associations, foundations, family foundations and employee welfare foundations. mandates shall mean mandates in comparable functions at other companies with an economic purpose. mandates in different legal entities that are under joint control or same beneficial ownership are deemed as a single mandate. since 2014, the annual general meeting has elected all members of the board of directors, the chairman of the board of directors and the members of the remuneration committee on an annual basis in elections in which each nominee is voted on separately see 18 of the articles of incorporation of roche holding ltd4 and the minutes of the 105th ordinary annual general meeting of roche holding ltd, held on 14 march 20235. with the exception of dr severin schwan, none of the members of the board of directors in office at the end of 2023 was a member of roches corporate executive committee or served in an executive capacity at any group subsidiary during the three financial years preceding the current reporting period and they are for lack of existing business connections with the group or any group subsidiary independent. roches board of directors independence definition is based on the definition in the swiss code of best practice for corporate governance of economiesuisse see https: www. economiesuisse.chsitesdefaultfilespublications swisscode_e_web.pdf  and is complemented by specific preceding criteria see https: www.roche. comaboutgovernanceboard-of-directors . the principles of governance principles of delegation and competence, reservation of powers and management of a group of companies of the executive bodies of the company include economic, environmental and social topics. the principles together with the internal organisation of the board of directors, the division of authority board of directors and corporate executive committee 3 https: www.roche.comaboutgovernanceboard-of-directors and https:www.roche.comaboutgovernanceexecutive-committee , in addition see pages 129, 133 and 151. 4 https: www.roche.comaboutgovernancearticle-of-incorporation 5 https: www.roche.comaboutgovernanceannual-general-meetingscorporate governance  roche 137 and responsibilities between the board and management, the remits of the board committees, and the information and control mechanisms available to the board in its dealings with corporate management, are governed by the bylaws.6 the board of directors of roche holding ltd is organised so as to ensure that the group conducts its businesses responsibly and with a focus on long- term value creation. to this end, the roche board has delegated certain responsibilities to several committees.7 their composition and chairpersons as at 31 december 2023 are described on pages 8 and 129. each committees authorities and responsibilities are defined in detail in the bylaws of the board of directors.8 all the committees with the exception of the chairmansnomination committee are chaired by independent directors. according to the bylaws of the board of directors, a board meeting may be convened without the chairman present at the request of any of its members. the roche board meets once a year to assess the chairmans performance.",
    "word_count": 468,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_090",
    "content": "according to the bylaws of the board of directors, a board meeting may be convened without the chairman present at the request of any of its members. the roche board meets once a year to assess the chairmans performance. this meeting, which is not attended by the chairman, is chaired by the vice-chairman.as part of the management information system mis, the board has access to an electronic information platform which provides timely information to the board of directors and the board committees as does the system of controls as set forth below. the board of directors has established a system of controls which is continuously monitored by the audit committee, by the corporate governance and sustainability committee and by the board of directors and consists of the following elements:  report on operating and financial risks risk management system the roche group has established a risk management process covering the entire company with a system in place to identify and manage all types of risks and opportunities potentially affecting its business including economic, environmental and social impacts. the board of directors is the highest governance body involved. roches risk management policy sets out the approach and accompanying responsibilities. roches pharmaceuticals and diagnostics divisions and group functions conduct a formal assessment process at least once a year and must develop management plans for their most material risks and opportunities. these risk management 6 https: www.roche.comaboutgovernancearticle-of-incorporation 7 https: www.roche.comaboutgovernancecommittees 8 https: www.roche.comaboutgovernancearticle-of-incorporationcorporate executive committeeboard of directors and board committeesboard of directors chairmansnomination committeeboard committees corporate governance and sustainability committeeremuneration committee audit committee corporate executive committee ceo roche groupceo roche diagnosticschief people officerceo roche pharmaceuticalschief financial and information officer138  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report plans are monitored and deviations reviewed in regular performance dialogues. the consolidated group risk report including target risk profile is discussed by the corporate executive committee and approved together with the group business plan by the board of directors. all material risks are reviewed by the board on a yearly basis. the effectiveness of the risk management process is monitored by the group risk advisory team and the overall process is regularly reviewed by external auditors, with findings presented to the audit committee and the full board. for details on risk management and the risk management policy, see risk management on our website.9 financial risk management is described in the finance report.10  system of internal controls over financial reporting see page 162 of the finance report  internal audit group audit reports administratively to the general counsel, has direct access and gives regular briefings to the audit committee, to the corporate governance and sustainability committee and to the chairman of the board of directors about ongoing activities and audit reports. the chief audit  risk advisory executive attends the audit committee and partly the corporate governance and sustainability committee meetings, as do the external auditors.",
    "word_count": 481,
    "keyword_analysis": {
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "target",
            "context": "deviations reviewed in regular performance dialogues. the consolidated group risk report including target risk profile is discussed by the corporate executive committee and approved together with the group",
            "position": 2282,
            "sentence": "the consolidated group risk report including target risk profile is discussed by the corporate executive committee and approved together with the group business plan by the board of directors."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_091",
    "content": "for details on risk management and the risk management policy, see risk management on our website.9 financial risk management is described in the finance report.10  system of internal controls over financial reporting see page 162 of the finance report  internal audit group audit reports administratively to the general counsel, has direct access and gives regular briefings to the audit committee, to the corporate governance and sustainability committee and to the chairman of the board of directors about ongoing activities and audit reports. the chief audit  risk advisory executive attends the audit committee and partly the corporate governance and sustainability committee meetings, as do the external auditors. group audit is an independent appraisal function which evaluates and reviews the groups activities as a service to the board of directors and to management. the annual audit plan with yearly defined focus areas is validated by senior management and approved by the audit committee. the roche group is committed to maintaining a high standard of internal control throughout its worldwide operations. management is responsible for assessing the business risks in all aspects of its operation and for implementing effective and efficient processes and controls whilst ensuring compliance with internal and external rules and regulations. by conducting operational audits, group audit determines managements response to the risks surrounding business processes and systems, and evaluates the appropriateness, completeness and efficiency of the processes and controls. action plans to implement necessary changes and enhancements are developed together with the businessauditee and are tracked to completion. statutory auditors, see page 144  chief compliance officer and compliance officers in subsidiaries, see page 146  safety, security, health and environmental protection department11  corporate sustainability steering committee12  scientific ethics advisory group seag13 the members of the corporate executive committee are invited to attend meetings of the board of directors for, and report in person on, those agenda items concerning them. when the situation warrants, members of the enlarged corporate executive committee may also be invited to attend. the board committees invite the chairman of the board and corporate executive committee members to deliver reports at committee meetings and may elect to commission independent expert reports and call on the services of consultants. each year several black-out periods are imposed during which members of the board of directors and senior managers and certain other employees are prohibited from trading in company stock. the following black-out periods arewere in effect for 2024 and 2023, respectively: black-out periods 2024 2023 26 december 2023 to 1 february 202426 december 2022 to 3 february 2023 1 april to 24 april 2024 1 april to 26 april 2023 26 june to 25 july 2024 26 june to 27 july 2023 1 october to 23 october 20241 october to 19 october 2023 black-out periods can be changed by the chairman of the board of directors if circumstances warrant.",
    "word_count": 470,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_092",
    "content": "each year several black-out periods are imposed during which members of the board of directors and senior managers and certain other employees are prohibited from trading in company stock. the following black-out periods arewere in effect for 2024 and 2023, respectively: black-out periods 2024 2023 26 december 2023 to 1 february 202426 december 2022 to 3 february 2023 1 april to 24 april 2024 1 april to 26 april 2023 26 june to 25 july 2024 26 june to 27 july 2023 1 october to 23 october 20241 october to 19 october 2023 black-out periods can be changed by the chairman of the board of directors if circumstances warrant. roche employees involved in the preparation of regular publicity events in particular annual and half-year reports and media conferences, quarterly sales releases or having otherwise access to such potentially share price sensitive information of roche are subject to these black-out periods. 9 https: www.roche.comaboutsustainabilityapproachrisk-management 10 additional information is provided in the finance report, note 31 to the roche group consolidated financial statements, risk management, page 126. 11 https: www.roche.comaboutsustainabilityenvironment 12 https: www.roche.comaboutsustainability 13 https: www.roche.cominnovationethical-standardsadvisorycorporate governance  roche 139 dr patrick frost, chairman of the audit committee irrespective of whether the relevant information is share price sensitive for roche or not, during the black-out periods these persons shall keep the relevant information confidential and must not i disclose it to any non-insider within or outside roche including family members, ii buy, sell or otherwise trade in equity securities of roche shares, non-voting equity securities as well as options or similar instruments and derivatives based thereon, or iii provide trading recommendations thereon. the automatic execution of predefined periodic purchase orders under the roche connect programme is not subject to these black-out periods. for addressees, scope and exceptions with regard to the black-out periods please refer to the roche group insider directive  https: assets.cwp. roche.comf126832x3e96b30141group-insider- policy.pdf . in the reporting year, no exceptions to the general rules were granted. in 2023, the board of directors met for 10 meetings: meetings from 1 to 8 hours in length, including a 14 remuneration committee members recuse themselves from deliberations and decisions on matters that affect their interests. these figures indicate the actual length of meetings and do not include the directors extensive pre-meeting preparations and post-meeting follow-up activities.full-day meeting. in addition, the board went on a 5-day trip to a major non-european affiliate. the board committees met as follows in 2023:  chairmansnomination committee: 7 meetings approx. 2 hours each   remuneration committee: 3 meetings14 approx. 2 hours each   audit committee: 5 meetings approx. 3 to 4 hours each   corporate governance and sustainability committee: 3 meetings approx. 2 to 3 hours each  the board of directors regularly conducts an assessment self-assessment  assessment by third parties via electronic survey and personal interviews of its performance. in 2023, a third-party assessment took place. members of the corporate executive committee have a maximum ordinary notice period of twelve months. there are no change-of-control clauses in the employment contracts.",
    "word_count": 497,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "egular publicity events in particular annual and half-year reports and media conferences, quarterly sales releases or having otherwise access to such potentially share price sensitive information of roche",
            "position": 775,
            "sentence": "roche employees involved in the preparation of regular publicity events in particular annual and half-year reports and media conferences, quarterly sales releases or having otherwise access to such potentially share price sensitive information of roche are subject to these black-out periods."
          }
        ],
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "ny non-insider within or outside roche including family members, ii buy, sell or otherwise trade in equity securities of roche shares, non-voting equity securities as well as options or similar instruments",
            "position": 1687,
            "sentence": "11 https: www.roche.comaboutsustainabilityenvironment 12 https: www.roche.comaboutsustainability 13 https: www.roche.cominnovationethical-standardsadvisorycorporate governance  roche 139 dr patrick frost, chairman of the audit committee irrespective of whether the relevant information is share price sensitive for roche or not, during the black-out periods these persons shall keep the relevant information confidential and must not i disclose it to any non-insider within or outside roche including family members, ii buy, sell or otherwise trade in equity securities of roche shares, non-voting equity securities as well as options or similar instruments and derivatives based thereon, or iii provide trading recommendations thereon."
          },
          {
            "keyword": "equity",
            "context": "ng family members, ii buy, sell or otherwise trade in equity securities of roche shares, non-voting equity securities as well as options or similar instruments and derivatives based thereon, or iii provide",
            "position": 1733,
            "sentence": "11 https: www.roche.comaboutsustainabilityenvironment 12 https: www.roche.comaboutsustainability 13 https: www.roche.cominnovationethical-standardsadvisorycorporate governance  roche 139 dr patrick frost, chairman of the audit committee irrespective of whether the relevant information is share price sensitive for roche or not, during the black-out periods these persons shall keep the relevant information confidential and must not i disclose it to any non-insider within or outside roche including family members, ii buy, sell or otherwise trade in equity securities of roche shares, non-voting equity securities as well as options or similar instruments and derivatives based thereon, or iii provide trading recommendations thereon."
          },
          {
            "keyword": "assets",
            "context": "ions with regard to the black-out periods please refer to the roche group insider directive  https: assets.cwp. roche.comf126832x3e96b30141group-insider- policy.pdf . in the reporting year, no exceptions to",
            "position": 2144,
            "sentence": "for addressees, scope and exceptions with regard to the black-out periods please refer to the roche group insider directive  https: assets.cwp."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_093",
    "content": "members of the corporate executive committee have a maximum ordinary notice period of twelve months. there are no change-of-control clauses in the employment contracts. there are no management contracts which fall within the scope of subsection 4.4 annex of the six directive on information relating to corporate governance.140  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report attendance at board and board committee meetings in 2023 boardchairmans nomination committeeremuneration committeeaudit committeecorporate governance and sustainability committee number of meetings 10 7 3 5 3 s. schwan 10 5 2 3 5 3 a. hoffmann 10 7 3  3 j. duschmal\u00e9 10  2 5  p. f r o s t 10  1 5  a. hauser 10 5 2  1 a. iwasaki member of the board since march 2023 8    2 r. p . lifton 10  3   j. mahmood 10    3 b. poussot 10  3   m. schneider member of the board since march 2023 9   4  c. suessmuth dyckerhoff 10   5 3 c. franz member of the board until march 2023 1 2 1    not a member of that committee  member since march 2023  member until march 2023  guestcorporate governance  roche 141 all details regarding remuneration, shareholdings and loans content and method of determining the compensation and the shareholding programmes, basic principles and elements of compensation and shareholding programmes for serving and former members of the board of directors and corporate executive committee, together with a description of the authorities and procedure for determining such are set forth in the separate remuneration report on pages 148 to 177 and in the finance report, notes 22 and 32 to the roche group consolidated financial statements equity attributable to roche shareholders and related parties, pages 100 and 140 , and are listed in note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191. the following rules on remuneration, shareholdings and loans for the board of directors board and the corporate executive committee cec are set forth in the articles of incorporation aoi:15rules in aoi 15 for content board cec rules on the principles applicable to performance- related pay24.15 24.25 rules on the principles to the allocation of equity securities, convertible rights and options24 24 additional amount for payments to members of the corporate executive committee appointed after the vote on pay at the annual general meeting of shareholders  23.5 rules on loans, credit facilities and post-employment benefits24.1 and 25.124.2 and 25.2 rules on the vote on pay at the annual general meeting 23 23 15 https: www.roche.comaboutgovernancearticle-of-incorporationremuneration, shareholdings and loans142  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 16 https: www.roche.comaboutgovernancearticle-of-incorporationchange of control and defensive measures the articles of incorporation contain no provisions on the mandatory bid rule. swiss law applies. there are no change-of-control clauses.",
    "word_count": 466,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "177 and in the finance report, notes 22 and 32 to the roche group consolidated financial statements equity attributable to roche shareholders and related parties, pages 100 and 140 , and are listed in note",
            "position": 1698,
            "sentence": "franz member of the board until march 2023 1 2 1    not a member of that committee  member since march 2023  member until march 2023  guestcorporate governance  roche 141 all details regarding remuneration, shareholdings and loans content and method of determining the compensation and the shareholding programmes, basic principles and elements of compensation and shareholding programmes for serving and former members of the board of directors and corporate executive committee, together with a description of the authorities and procedure for determining such are set forth in the separate remuneration report on pages 148 to 177 and in the finance report, notes 22 and 32 to the roche group consolidated financial statements equity attributable to roche shareholders and related parties, pages 100 and 140 , and are listed in note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191."
          },
          {
            "keyword": "equity",
            "context": "ples applicable to performance- related pay24.15 24.25 rules on the principles to the allocation of equity securities, convertible rights and options24 24 additional amount for payments to members of the co",
            "position": 2246,
            "sentence": "the following rules on remuneration, shareholdings and loans for the board of directors board and the corporate executive committee cec are set forth in the articles of incorporation aoi:15rules in aoi 15 for content board cec rules on the principles applicable to performance- related pay24.15 24.25 rules on the principles to the allocation of equity securities, convertible rights and options24 24 additional amount for payments to members of the corporate executive committee appointed after the vote on pay at the annual general meeting of shareholders  23.5 rules on loans, credit facilities and post-employment benefits24.1 and 25.124.2 and 25.2 rules on the vote on pay at the annual general meeting 23 23 15 https: www.roche.comaboutgovernancearticle-of-incorporationremuneration, shareholdings and loans142  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 16 https: www.roche.comaboutgovernancearticle-of-incorporationchange of control and defensive measures the articles of incorporation contain no provisions on the mandatory bid rule."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_094",
    "content": "swiss law applies. there are no change-of-control clauses. those components of remuneration based on roche non-voting equity securities would be terminated in the event of an acquisition, and vesting period restrictions on pre-existing awards would be removed, so that all such options could be exercised immediately.participatory rights of shareholders the participatory rights of shareholders are defined in roches articles of incorporation.16 as roche shares are issued to bearer, there are no restrictions on admission to annual general meetings, with the exception that shares must be deposited within a specified period before the date of a meeting and an admittance card must be issued in the shareholders name, as provided in 12 of the articles of incorporation. any shareholder can elect to be represented by a third party at an annual general meeting. the articles of incorporation contain no restrictions on the exercise of voting rights, and the only quorum requirements are those stipulated in 16, in conformity with the swiss code of obligations co.under 10.2 of the articles of incorporation, shareholders who, alone or together, hold at least 0.5 of the share capital or the votes may until but no later than 36 days before the annual general meeting request that an item be included on the agenda or that a motion relating to an agenda item be included in the notice convening the annual general meeting. the rules on the issue of instructions to the independent proxy and rules on the electronic participation in the annual general meeting are laid down in the corresponding invitation to the annual general meeting and are not regulated in the articles of incorporation.corporate governance  roche 143 at the annual general meeting of roche holding ltd on 14 march 2023, the shareholders voted to appoint kpmg ag kpmg as statutory auditors. based on the existing legal requirements of the swiss code of obligations article 730a concerning the maximum term of office of seven years of the auditor in charge, fran\u00e7ois rouiller has been the auditor in charge since the business year 2022 information on how long the auditor in charge has been serving in this capacity is provided on page 133 . the statutory auditors participate in audit committee meetings. they prepare written and oral reports on the results of their audits. the audit committee oversees and assesses the auditors and makes recommendations to the board for information on the authorities and responsibilities of the audit committee, see article 8. 1 of the bylaws17. the statutory auditors participated in all five meetings of the audit committee in 2023. the performance of kpmg is assessed based on different elements such as affiliate surveys to evaluate the service level at the country level, interviews with roche key stakeholders and the self-evaluation of the kpmg internal processes to ensure compliance with the federal audit oversight authority faoa audit committee guide. kpmgs independence is ensured by limiting kpmg from providing certain non-audit services.",
    "word_count": 485,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "there are no change-of-control clauses. those components of remuneration based on roche non-voting equity securities would be terminated in the event of an acquisition, and vesting period restrictions on p",
            "position": 118,
            "sentence": "those components of remuneration based on roche non-voting equity securities would be terminated in the event of an acquisition, and vesting period restrictions on pre-existing awards would be removed, so that all such options could be exercised immediately.participatory rights of shareholders the participatory rights of shareholders are defined in roches articles of incorporation.16 as roche shares are issued to bearer, there are no restrictions on admission to annual general meetings, with the exception that shares must be deposited within a specified period before the date of a meeting and an admittance card must be issued in the shareholders name, as provided in 12 of the articles of incorporation."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_095",
    "content": "the performance of kpmg is assessed based on different elements such as affiliate surveys to evaluate the service level at the country level, interviews with roche key stakeholders and the self-evaluation of the kpmg internal processes to ensure compliance with the federal audit oversight authority faoa audit committee guide. kpmgs independence is ensured by limiting kpmg from providing certain non-audit services. furthermore, permitted services cannot exceed in total 20 of the audit fee unless they are explicitly rewieved and approved by the audit committee. the company has a formal policy governing the engagement of the statutory auditor for non-audit services of which limits for certain permitted other services are agreed by the audit committee. each potential non-audit service engagement is reviewed against this policy before any authority to proceed is given. the auditors have direct access to the audit committee and its chair as well as the chief audit  risk advisory executive to discuss relevant issues. the reports of the statutory auditor on the consolidated financial statements and on the financial statements can be found on pages 163 and 195 , respectively, of the finance report. kpmg received the following remuneration for their services as statutory auditors of roche holding ltd and as the auditors of other roche companies including chugai: 2023 2022 millions of chf audit services 22.2 21.4 audit-related services  assurance 0.7 0.7 tax services 2.5 2.8 other services 0.5 0.4 total 25.9 25.3 the audit fee is reviewed by the chief audit  risk advisory executive and approved by the audit committee every year and takes into consideration changes in roches business, as well as changes in financial reporting and audit standards and regulations.relationship to statutory auditors 17 https: www.roche.comaboutgovernancearticle-of-incorporation144  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report the statutory auditors are elected each year by the annual general meeting. audit services are provided as legally required. audit-related services include assurance and accounting services provided by auditors but which are not necessarily provided by the statutory auditor. these services, which go beyond the legal requirements, could include other attestation services, comfort letters and consultations. tax services include services with respect to compliance, tax returns and tax advice except those services related to the audit of tax.other services include advice relating to process improvements, regulations and trainings. an external audit services tender, completed in 2022, for the external auditing services starting with the 2024 financial year, in which four audit firms were invited to participate, conluded based on the assessment of the audit firms as part of the tender process to reappoint kpmg as the external auditor for the 2024 financial year. relationship to the independent proxy since 2019, testaris ag has served as the independent proxy and at the annual general meeting on 14 march 2023, shareholders elected testaris ag as the independent proxy for the period from 2023 until the conclusion of the 2024 ordinary annual general meeting of shareholders.",
    "word_count": 488,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_096",
    "content": "an external audit services tender, completed in 2022, for the external auditing services starting with the 2024 financial year, in which four audit firms were invited to participate, conluded based on the assessment of the audit firms as part of the tender process to reappoint kpmg as the external auditor for the 2024 financial year. relationship to the independent proxy since 2019, testaris ag has served as the independent proxy and at the annual general meeting on 14 march 2023, shareholders elected testaris ag as the independent proxy for the period from 2023 until the conclusion of the 2024 ordinary annual general meeting of shareholders. testaris ag was paid for its services for the annual general meeting 2023 according to expenditure totalling chf 16,085 2022: chf 15,974. the board of directors nominates testaris ag for election as independent proxy by the annual general meeting 2024 for the period from 2024 until the conclusion of the 2025 ordinary annual general meeting of shareholders. the rules on the issue of instructions to the independent proxy and the rules on the electronic participation in the annual general meeting are laid down in the corresponding invitation to the annual general meeting and are not regulated in the articles of incorporation.corporate governance  roche 145 information policy as provided by 30 of the articles of incorporation18, corporate notices are published in the swiss official gazette of commerce and in other daily newspapers designated by the board of directors basler zeitung, finanz und wirtschaft, l agefi, le temps, neue z\u00fcrcher zeitung. roche reports its half-year and full-year results in business reports published in print andor online formats and at media events. in addition, detailed first-quarter and nine-month sales figures are published each year in april and october. the most current list of publication dates is available on the internet.19, 20 all relevant information and documents, including all media releases19, investor updates20 and presentations to analyst and investor conferences are available on the internet.20 further publications are available on https: www.roche.compublications or can be ordered by e-mail : materials.management.mm1roche.com or fax: 41 061 688 69 02 the contact address for investor relations is: f. hoffmann-la roche ltd, investor relations, group finance, 4070 basel, switzerland tel.: 41 061 688 88 80 fax: 41 061 691 00 14 additional information, including details on specific contact persons, is available on the internet.21 chief compliance officer and compliance officers network the chief compliance officer with the compliance officers network is committed to ensuring that the roche group code of conduct22 is consistently complied with throughout the roche group. the chief compliance officer also serves as a contact person for shareholders, employees, business partners, customers, suppliers and the general public on issues relating to the implementation of and compliance with this code.",
    "word_count": 459,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "print andor online formats and at media events. in addition, detailed first-quarter and nine-month sales figures are published each year in april and october. the most current list of publication dates is",
            "position": 1789,
            "sentence": "in addition, detailed first-quarter and nine-month sales figures are published each year in april and october."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_097",
    "content": "hoffmann-la roche ltd, investor relations, group finance, 4070 basel, switzerland tel.: 41 061 688 88 80 fax: 41 061 691 00 14 additional information, including details on specific contact persons, is available on the internet.21 chief compliance officer and compliance officers network the chief compliance officer with the compliance officers network is committed to ensuring that the roche group code of conduct22 is consistently complied with throughout the roche group. the chief compliance officer also serves as a contact person for shareholders, employees, business partners, customers, suppliers and the general public on issues relating to the implementation of and compliance with this code. employees and other parties who become aware of violations of the roche group code of conduct can bring them to the attention of their managers or supervisors, to the local compliance officer or report them to the chief compliance officer23 ms pascale schmidt, e-mail: global.compliance_administrationroche.com . such disclosures will be treated confidentially. in addition, employees and third parties may anonymously report irregularities or complaints in their mother tongue via the roche group speakup line. as part of the continuous enhancement of roches human rights programme and in compliance with applicable laws and regulations, any interested party can report its allegations through the same channel if they believe in good faith that an actual 18 https: www.roche.comaboutgovernancearticle-of-incorporation 19 https: www.roche.commedia 20 https: www.roche.cominvestors 21 https: www.roche.comcontactinvestor-contacts 22 https: www.roche.comaboutgovernancecode-of-conduct 23 https: www.roche.comaboutgovernancecode-of-conductcompliance-officer 146  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report non-applicabilitynegative disclosure it is expressly noted that any information not contained or mentioned herein is either non-applicable or its omission is to be construed as a negative declaration as provided in the six swiss exchange directive on information relating to corporate governance and the commentary thereto. 24 https: www.roche.comaboutgovernancecode-of-conductor potential human right violation has occurred in roche or in roches value chain. in case of questions or uncertainties about the interpretation of the roche group code of conduct and its reference documents, employees may reach out to their line managers, the local compliance officer or the chief compliance officer, or contact the roche group code of conduct help  advice line  global.helpandadviceroche.com . this compliance tool also serves as a platform for ideas and suggestions concerning those documents. in addition, roche has established a business ethics incident management system beims which enables the chief compliance officer to capture, track and monitor alleged violations, from initial reports through to resolution.business ethics incidents are recorded in the system when the internal investigations team or the regionallocal management receives specific and concrete information about an alleged violation of the roche group code of conduct in one of certain predefined categories.24 the corporate governance and sustainability committee and the audit committee of the board of directors are regularly informed of substantial violations and managements corrective actions taken.",
    "word_count": 470,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_098",
    "content": "this compliance tool also serves as a platform for ideas and suggestions concerning those documents. in addition, roche has established a business ethics incident management system beims which enables the chief compliance officer to capture, track and monitor alleged violations, from initial reports through to resolution.business ethics incidents are recorded in the system when the internal investigations team or the regionallocal management receives specific and concrete information about an alleged violation of the roche group code of conduct in one of certain predefined categories.24 the corporate governance and sustainability committee and the audit committee of the board of directors are regularly informed of substantial violations and managements corrective actions taken. the chief compliance officer reports to the general counsel and also submits regular reports to the corporate governance and sustainability committee and as needed to the audit committee of the board of directors.corporate governance  roche 147 148  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report remuneration report 1. principles 150 2. remuneration decision process and approval framework 152 3. remuneration components 156 4. remuneration of the board of directors 161 5. remuneration of the corporate executive committee 168 statutory auditor s report 178remuneration report  roche 149 1.1 overview motivation, expertise and performance of employees are key to the success of roche as an innovative and agile company. this conviction forms the basis of our compensation policy. roche aims to remunerate all employees fairly, transparently and in line with market conditions, in order to enable them to participate appropriately in the companys success. we pursue this goal by providing equitable, competitive, performance- based and results-oriented compensation. we strive for a balanced mix of fixed and variable compensation components geared to each employees position and management responsibility. firstly, the variable components are intended to create additional financial incentives to achieve corporate goals and to keep innovation at a consistently high level while increasing the value that the company creates for all stakeholder groups. secondly, in order to allow employees and managers to participate in the companys business success, variable compensation components are key. both objectives are incentivised by annual bonus payments and long-term securities-based programmes.for a global company like roche, market- competitive remuneration plays a key role along with a performance- and success-based, transparent compensation structure. to ensure that compensation packages are competitive, both the structure and individual components are regularly benchmarked based on the relevant swiss, european and international market criteria. our remuneration guidelines and their underlying principles are also subject to regular outside comparisons. however, our compensation policy is only one factor in safeguarding roches future success. the key element is a corporate culture that offers employees conditions in which they can make their best possible contribution to the shared corporate goal of improving healthcare for patients. this includes a sound and a sustainability-oriented value system that is based on integrity, courage and passion.",
    "word_count": 479,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_099",
    "content": "the key element is a corporate culture that offers employees conditions in which they can make their best possible contribution to the shared corporate goal of improving healthcare for patients. this includes a sound and a sustainability-oriented value system that is based on integrity, courage and passion. at the same time, our decentralised management approach plays a major role with its wide scope for individual decision-making, respectful interactions, openness to diversity, wide- ranging training and development opportunities and an attractive working environment. a unidimensional diminishment to questions on remuneration would fall by far too short.1. principles roche, the place to work: https: careers.roche.comglobalen150  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report board of directors corporate executive committee a current members https :www.roche.comabout governanceboard-of-directorshttps :www.roche.comabout governanceexecutive-committee b former members at least of the last ten yearshttps :www.roche.comaboutgovernanceec-bod-former c information at the reporting date on 31 december of each year at least of the last ten yearshttps :www.roche.comaboutgovernancearchiv-former-cvs  the audited information on activities at other companies in accordance with art. 734e co can be found under link c. information of the members of the board of directors and of the corporate executive committee shown is in accordance with the directive on information relating to corporate governance dcg  https :www.ser-ag.comdam downloadsregulationlistingdirectivesdcg-en. pdf and also specifically includes mandates in accordance with article 734e and article 626 para. 2 point 1 of the federal act on the amendment of the swiss civil code part five: 1.2 members of the board of directors and the corporate executive committee: cvs and mandates detailed information is available as follows: the code of obligations co that may be carried out in comparable positions in other undertakings with commercial objects. rules on mandates applying for members of the board of directors and the corporate executive committee are in accordance with 22.4 of the articles of incorporation of roche holding ltd  https :assets.cwp. roche.comf126832xbb7e156602roche-statuten- 2023-en.pdf , in addition see page 137 .auditedremuneration report  roche 151 2.1 overview each year the remuneration committee of roches board of directors decides the remuneration of board members and the members of the groups corporate executive committee. chairman, group ceo and all other members of the groups corporate executive committee must not be present when the remuneration committee decides their corresponding compensation and have no right to a say in decisions. the decision right is reserved to remuneration committee members only.2. remuneration decision process and approval framework remuneration decision process and approval framework as of 2023 beneficiary remuneration componentsboard of directors bod chairman c corporate executive committee cecdecision by approval by base pay  basic remuneration   remuneration committee annual general meetingbonus   stock-settled stock appreciation rights s-sars  restricted stock units rsus   pension  c only  the remuneration committee tracks market data on salaries at other leading global pharmaceutical companies1 and at major swiss companies2 and reports its findings to the full board. the external consulting firm pricewaterhousecoopers ag pwc assists the remuneration committee of roche in performing market comparisons and as an advisor.",
    "word_count": 499,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "assets",
            "context": "committee are in accordance with 22.4 of the articles of incorporation of roche holding ltd  https :assets.cwp. roche.comf126832xbb7e156602roche-statuten- 2023-en.pdf , in addition see page 137 .auditedremu",
            "position": 2283,
            "sentence": "rules on mandates applying for members of the board of directors and the corporate executive committee are in accordance with 22.4 of the articles of incorporation of roche holding ltd  https :assets.cwp."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_100",
    "content": "remuneration decision process and approval framework remuneration decision process and approval framework as of 2023 beneficiary remuneration componentsboard of directors bod chairman c corporate executive committee cecdecision by approval by base pay  basic remuneration   remuneration committee annual general meetingbonus   stock-settled stock appreciation rights s-sars  restricted stock units rsus   pension  c only  the remuneration committee tracks market data on salaries at other leading global pharmaceutical companies1 and at major swiss companies2 and reports its findings to the full board. the external consulting firm pricewaterhousecoopers ag pwc assists the remuneration committee of roche in performing market comparisons and as an advisor. pwc has additional mandates in the roche group. information on the remuneration committees remit, powers and procedures for making remuneration decisions can be found in the bylaws of the roche board of directors3 and in the articles of incorporation.4 they are also outlined in the sections below on the principles governing specific remuneration components see 3..total aggregate amounts that are based on these decisions are submitted to the general meeting for approval. the general meeting shall vote annually and with binding effect on the approval of the remuneration that the board of directors has resolved of the board of directors and the corporate executive committee for details see 4. and 5.. 1 peer set 2023: abbott laboratories, abbvie, amgen, astrazeneca, bristol-myers squibb, danaher, eli lilly, glaxosmithkline, johnson  johnson, medtronic, merck  co., novartis, novo nordisk, pfizer, sanofi 2 peer set 2023: abb, alcon, holcim, lonza, nestl\u00e9, richemont, ubs, zurich 3 https: www.roche.comaboutgovernancearticle-of-incorporation 4 https: www.roche.comaboutgovernancearticle-of-incorporation152  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report market comparison companies for salary assessment pharma peer set major swiss companiespeer set for 2023 abb alcon holcim lonza nestl\u00e9 richemont ubs zurichabbott laboratories abbvie amgen astrazeneca bristol-myers squibb danaher eli lilly glaxosmithkline johnson  johnson medtronic merck  co. novartis novo nordisk pfizer sanofi peer set for 2023rocheremuneration report  roche 153 2.2 procedure for submitting total board and executive remuneration for shareholder approval at the annual general meeting each year at the annual general meeting agm shareholders approve the total remuneration for the board of directors and for the corporate executive committee as decided by the board of directors remuneration committee and the board of directors, respectively. according to the approval at the agm 2014, roche has committed itself to obtaining separate and binding shareholder approvals of the total remuneration paid to the board of directors and to the corporate executive committee as follows:retrospective approval total aggregate bonus amounts for the corporate executive committee and the chairman of the board of directors for 2023 for the resigned chairman only for the financial year just ended will be submitted retrospectively at each ordinary agm for separate and binding approval. prospective approval all other board and executive aggregate remuneration will be submitted prospectively to the agm for separate and binding approval for the period between two ordinary agms.",
    "word_count": 481,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_101",
    "content": "according to the approval at the agm 2014, roche has committed itself to obtaining separate and binding shareholder approvals of the total remuneration paid to the board of directors and to the corporate executive committee as follows:retrospective approval total aggregate bonus amounts for the corporate executive committee and the chairman of the board of directors for 2023 for the resigned chairman only for the financial year just ended will be submitted retrospectively at each ordinary agm for separate and binding approval. prospective approval all other board and executive aggregate remuneration will be submitted prospectively to the agm for separate and binding approval for the period between two ordinary agms. this remuneration report shall be submitted to an advisory vote by the shareholders at the agm 2024.andr\u00e9 hoffmann, chairman of the remuneration committee154  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 1.1.2023 1.1.2024 1.1.2025agm 2023 agm 2024 agm 2025approval of total remuneration retrospective: chairman c of the board of directors bod:  bonus for financial year 2023 total amount, for 2023 to resigned c only corporate executive committee cec:  bonus for financial year 2023 total amount prospective: board of directors bod: aggregate total remuneration agm 2024agm 2025  basic remuneration corporate executive committee cec: aggregate total remuneration agm 2024agm 2025  base pay  stock-settled stock appreciation rights s-sars  restricted stock units rsus  indirect benefits advisory vote retrospective:  advisory vote on the 2023 remuneration report at the agm 2024financial year 2023 financial year 2024 approval of total remuneration at the annual general meeting agm 2024 c bonus cec bonus remuneration report 2023bod basic remuneration cec base pay s-sars rsus indirect benefitsremuneration report  roche 155 3.1 overview of remuneration elements the remuneration to the members of the board of directors and the corporate executive committee is composed of the following elements: the corporate executive committees fixed base salary is complemented with the annual variable bonus as short-term incentive sti and with perennial remuneration elements s-sars, rsus as long-term incentive lti . the remuneration components are linked to the employees performance, the companys financial performance and non-financial success5 and thus align the interests of roche and its employees with those of shareholders. societal and environmental objectives6 are also taken into account. the lti remuneration components are intended to sustainably, homogenously and in a long-term- oriented perspective align managements interest with those of shareholders and holders of non- voting equity securities and to give participating managers an additional incentive to achieve sustainable shareholder value growth.3. remuneration components 5 https: www.roche.cominvestorsreportsperformance 6 https: www.roche.comaboutsustainabilityenvironmentgoals-performancecomposition of remuneration to the board of directors and the corporate executive committee board of directors corporate executive committee annual remuneration elements c bod ceo roche group cec base pay  basic remuneration s e e 3.1.1 cash and for ten years blocked non-voting equity securities andor shares cash  cash  cash bonus s e e 3.1.2   cash or non-voting equity securities andor shares cash pensions, etc.",
    "word_count": 484,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "iented perspective align managements interest with those of shareholders and holders of non- voting equity securities and to give participating managers an additional incentive to achieve sustainable shareh",
            "position": 2783,
            "sentence": "the lti remuneration components are intended to sustainably, homogenously and in a long-term- oriented perspective align managements interest with those of shareholders and holders of non- voting equity securities and to give participating managers an additional incentive to achieve sustainable shareholder value growth.3."
          },
          {
            "keyword": "equity",
            "context": "roche group cec base pay  basic remuneration s e e 3.1.1 cash and for ten years blocked non-voting equity securities andor shares cash  cash  cash bonus s e e 3.1.2   cash or non-voting equity securities a",
            "position": 3333,
            "sentence": "remuneration components 5 https: www.roche.cominvestorsreportsperformance 6 https: www.roche.comaboutsustainabilityenvironmentgoals-performancecomposition of remuneration to the board of directors and the corporate executive committee board of directors corporate executive committee annual remuneration elements c bod ceo roche group cec base pay  basic remuneration s e e 3.1.1 cash and for ten years blocked non-voting equity securities andor shares cash  cash  cash bonus s e e 3.1.2   cash or non-voting equity securities andor shares cash pensions, etc."
          },
          {
            "keyword": "equity",
            "context": "d non-voting equity securities andor shares cash  cash  cash bonus s e e 3.1.2   cash or non-voting equity securities andor shares cash pensions, etc.",
            "position": 3420,
            "sentence": "remuneration components 5 https: www.roche.cominvestorsreportsperformance 6 https: www.roche.comaboutsustainabilityenvironmentgoals-performancecomposition of remuneration to the board of directors and the corporate executive committee board of directors corporate executive committee annual remuneration elements c bod ceo roche group cec base pay  basic remuneration s e e 3.1.1 cash and for ten years blocked non-voting equity securities andor shares cash  cash  cash bonus s e e 3.1.2   cash or non-voting equity securities andor shares cash pensions, etc."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_102",
    "content": "the lti remuneration components are intended to sustainably, homogenously and in a long-term- oriented perspective align managements interest with those of shareholders and holders of non- voting equity securities and to give participating managers an additional incentive to achieve sustainable shareholder value growth.3. remuneration components 5 https: www.roche.cominvestorsreportsperformance 6 https: www.roche.comaboutsustainabilityenvironmentgoals-performancecomposition of remuneration to the board of directors and the corporate executive committee board of directors corporate executive committee annual remuneration elements c bod ceo roche group cec base pay  basic remuneration s e e 3.1.1 cash and for ten years blocked non-voting equity securities andor shares cash  cash  cash bonus s e e 3.1.2   cash or non-voting equity securities andor shares cash pensions, etc. see 3.1.5    perennial remuneration elements stock-settled stock appreciation rights s-sars s e e 3.1.3    restricted stock units rsus see 3.1.4   156  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report corporate executive committee lti mix s-sarsrsus fixed base for calculation vesting period cliff vesting expiration period 80 s-sarsbased on the individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year4 years 4 years 10 years 20 rsus 4 years 4 years  the remaining participants of the s-sars and rsus programme are offered on a yearly basis a choice of three combinations to determine the mix of restricted stock units rsus and stock-settled stock appreciation rights s-sars, options are used instead of s-sars in some countries. the following options are available: choice 1 choice 2 choice 3 80 s-sars 50 s-sars 20 s-sars 20 rsus 50 rsus 80 rsusoffering this level of choice empowers participants to engage more fully in their total rewards, enables them to better understand a critical element of their compensation and increases the value of the programme. this attractively designed roche long-term incentive programme enables roche to attract, motivate and retain the best talent and keep it aligned with the companys long-term success. the lti of the corporate executive committee and the enlarged corporate executive committee is composed of 80 s-sars and 20 rsus based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year. vesting and expiration periods are aligned for any newly issued s-sars and rsus see below. unlike all other participants of the two programmes, members of the corporate executive committee have no choice in determining the mix of rsus and s-sars, which since 2019 have a four-year cliff vesting.remuneration report  roche 157 3.1.1 base pay fixed base pay  basic remuneration is determined for each position based on salary market data of other leading global pharmaceutical companies see footnote 1 and of other major swiss companies see footnote 2 and reflects individuals abilities, experience and performance over time. pay adjustments are likewise linked to individual performance and take into account prevailing market conditions and the companys overall financial situation.",
    "word_count": 498,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "iented perspective align managements interest with those of shareholders and holders of non- voting equity securities and to give participating managers an additional incentive to achieve sustainable shareh",
            "position": 196,
            "sentence": "the lti remuneration components are intended to sustainably, homogenously and in a long-term- oriented perspective align managements interest with those of shareholders and holders of non- voting equity securities and to give participating managers an additional incentive to achieve sustainable shareholder value growth.3."
          },
          {
            "keyword": "equity",
            "context": "roche group cec base pay  basic remuneration s e e 3.1.1 cash and for ten years blocked non-voting equity securities andor shares cash  cash  cash bonus s e e 3.1.2   cash or non-voting equity securities a",
            "position": 746,
            "sentence": "remuneration components 5 https: www.roche.cominvestorsreportsperformance 6 https: www.roche.comaboutsustainabilityenvironmentgoals-performancecomposition of remuneration to the board of directors and the corporate executive committee board of directors corporate executive committee annual remuneration elements c bod ceo roche group cec base pay  basic remuneration s e e 3.1.1 cash and for ten years blocked non-voting equity securities andor shares cash  cash  cash bonus s e e 3.1.2   cash or non-voting equity securities andor shares cash pensions, etc."
          },
          {
            "keyword": "equity",
            "context": "d non-voting equity securities andor shares cash  cash  cash bonus s e e 3.1.2   cash or non-voting equity securities andor shares cash pensions, etc. see 3.1.5    perennial remuneration elements stock-sett",
            "position": 833,
            "sentence": "remuneration components 5 https: www.roche.cominvestorsreportsperformance 6 https: www.roche.comaboutsustainabilityenvironmentgoals-performancecomposition of remuneration to the board of directors and the corporate executive committee board of directors corporate executive committee annual remuneration elements c bod ceo roche group cec base pay  basic remuneration s e e 3.1.1 cash and for ten years blocked non-voting equity securities andor shares cash  cash  cash bonus s e e 3.1.2   cash or non-voting equity securities andor shares cash pensions, etc."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "target",
            "context": "ase for calculation vesting period cliff vesting expiration period 80 s-sarsbased on the individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured o",
            "position": 1306,
            "sentence": "see 3.1.5    perennial remuneration elements stock-settled stock appreciation rights s-sars s e e 3.1.3    restricted stock units rsus see 3.1.4   156  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report corporate executive committee lti mix s-sarsrsus fixed base for calculation vesting period cliff vesting expiration period 80 s-sarsbased on the individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year4 years 4 years 10 years 20 rsus 4 years 4 years  the remaining participants of the s-sars and rsus programme are offered on a yearly basis a choice of three combinations to determine the mix of restricted stock units rsus and stock-settled stock appreciation rights s-sars, options are used instead of s-sars in some countries."
          },
          {
            "keyword": "target",
            "context": "e executive committee is composed of 80 s-sars and 20 rsus based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured o",
            "position": 2445,
            "sentence": "the lti of the corporate executive committee and the enlarged corporate executive committee is composed of 80 s-sars and 20 rsus based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_103",
    "content": "unlike all other participants of the two programmes, members of the corporate executive committee have no choice in determining the mix of rsus and s-sars, which since 2019 have a four-year cliff vesting.remuneration report  roche 157 3.1.1 base pay fixed base pay  basic remuneration is determined for each position based on salary market data of other leading global pharmaceutical companies see footnote 1 and of other major swiss companies see footnote 2 and reflects individuals abilities, experience and performance over time. pay adjustments are likewise linked to individual performance and take into account prevailing market conditions and the companys overall financial situation. the remuneration committee makes and reviews the final decision on the basic remuneration paid to the chairman of the board of directors and on the individual base pay to members of the corporate executive committee and on the remuneration of the other members of the board.3.1.2 bonuses variable bonuses are annually awarded for individual contributions of value creation in a business year and are meant to be an incentive to strive for outstanding results and to create new business opportunities. bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to the achievement of measurable and qualitative individual or functional performance objectives. for competitive reasons, roche does not disclose the individual performance objectives of members of its corporate executive committee and of its chairman. employer contribution of social securities beneficial partsfixed base pay  basic remuneration indirect benefits employer contribution:  pensions and insurance contributions  roche connect  tax consulting services expense allowances others:  childrens schooling costs  foreign tax obligation  ahvivalvsti:  bonus lti:  stock-settled stock appreciation rights  restricted stock units variable, long-termroche remuneration components 7 https: www.roche.comaboutpeople-culture 8 https: www.roche.comaboutsustainabilityenvironmentgoals-performance and she goals 20202025 for the roche group: https: assets.cwp.roche.comf126832x70206811f520200331-she-goals-2020-2025-communication.pdf158  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report in december at the end of a reporting year or in january following a reporting year, the remuneration committee decides on the bonuses and their amounts payable to the members of the corporate executive committee and to the chairman of the board for 2023 to the resigned chairman only in respect of the relevant reporting year, based on performance against the aforementioned objectives. at the same time, the remuneration committee also decides in what form bonuses will be awarded, i.e. cash payments andor blocked if applicable non-voting equity securities andor shares. the remuneration committee uses its discretion appropriately in the weighting of each criterion and in the bonus allocation. in 2023 in total, 84,279 employees were eligible for a bonus under the roche bonus program.",
    "word_count": 473,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "o create new business opportunities. bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operati",
            "position": 1256,
            "sentence": "bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to the achievement of measurable and qualitative individual or functional performance objectives."
          }
        ],
        "profitability": [
          {
            "keyword": "operating profit",
            "context": "s amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting eq",
            "position": 1297,
            "sentence": "bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to the achievement of measurable and qualitative individual or functional performance objectives."
          },
          {
            "keyword": "operating profit",
            "context": ", sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, prod",
            "position": 1354,
            "sentence": "bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to the achievement of measurable and qualitative individual or functional performance objectives."
          },
          {
            "keyword": "core earnings",
            "context": "constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development",
            "position": 1372,
            "sentence": "bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to the achievement of measurable and qualitative individual or functional performance objectives."
          },
          {
            "keyword": "earnings per share",
            "context": "ant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline,",
            "position": 1377,
            "sentence": "bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to the achievement of measurable and qualitative individual or functional performance objectives."
          },
          {
            "keyword": "earnings",
            "context": "ant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development",
            "position": 1377,
            "sentence": "bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to the achievement of measurable and qualitative individual or functional performance objectives."
          },
          {
            "keyword": "profit",
            "context": "are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting eq",
            "position": 1307,
            "sentence": "bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to the achievement of measurable and qualitative individual or functional performance objectives."
          },
          {
            "keyword": "profit",
            "context": "owth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, prod",
            "position": 1364,
            "sentence": "bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to the achievement of measurable and qualitative individual or functional performance objectives."
          }
        ],
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "it after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employee",
            "position": 1411,
            "sentence": "bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to the achievement of measurable and qualitative individual or functional performance objectives."
          },
          {
            "keyword": "equity",
            "context": "des in what form bonuses will be awarded, i.e. cash payments andor blocked if applicable non-voting equity securities andor shares. the remuneration committee uses its discretion appropriately in the weight",
            "position": 3182,
            "sentence": "cash payments andor blocked if applicable non-voting equity securities andor shares."
          },
          {
            "keyword": "assets",
            "context": "maboutsustainabilityenvironmentgoals-performance and she goals 20202025 for the roche group: https: assets.cwp.roche.comf126832x70206811f520200331-she-goals-2020-2025-communication.pdf158  contents letters",
            "position": 2437,
            "sentence": "employer contribution of social securities beneficial partsfixed base pay  basic remuneration indirect benefits employer contribution:  pensions and insurance contributions  roche connect  tax consulting services expense allowances others:  childrens schooling costs  foreign tax obligation  ahvivalvsti:  bonus lti:  stock-settled stock appreciation rights  restricted stock units variable, long-termroche remuneration components 7 https: www.roche.comaboutpeople-culture 8 https: www.roche.comaboutsustainabilityenvironmentgoals-performance and she goals 20202025 for the roche group: https: assets.cwp.roche.comf126832x70206811f520200331-she-goals-2020-2025-communication.pdf158  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report in december at the end of a reporting year or in january following a reporting year, the remuneration committee decides on the bonuses and their amounts payable to the members of the corporate executive committee and to the chairman of the board for 2023 to the resigned chairman only in respect of the relevant reporting year, based on performance against the aforementioned objectives."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "development pipeline",
            "context": "re earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to th",
            "position": 1474,
            "sentence": "bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to the achievement of measurable and qualitative individual or functional performance objectives."
          }
        ],
        "strategic_initiatives": [
          {
            "keyword": "product development",
            "context": "ofit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are lin",
            "position": 1466,
            "sentence": "bonus amounts are linked to group and divisional core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers7 and environmental goals.8 additionally, they are linked to the achievement of measurable and qualitative individual or functional performance objectives."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_104",
    "content": "the remuneration committee uses its discretion appropriately in the weighting of each criterion and in the bonus allocation. in 2023 in total, 84,279 employees were eligible for a bonus under the roche bonus program. 3.1.3 stock-settled stock appreciation rights s-sars long-term the s-sars proportion of the lti of the corporate executive committee is 80 based on the individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year. s-sars entitle holders to benefit financially from any increase in the value of roches non-voting equity securities between the grant date and the exercise date. s-sars granted all vest together after four years and then have to be exercised within ten years of the grant date. unexercised s-sars lapse without compensation. the fair value of s-sars is calculated at the grant date using the trinomial model for american call options for details see page 171. s-sars to the corporate executive committee are allocated individually at the remuneration committees discretion. in 2023 in total, 24,221 employees received s-sars.3.1.4 restricted stock units rsus long-term the proportion of restricted stock units rsus of the members of the corporate executive committee is 20 of the total lti based on the individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year. rsus contain rights to receive non-voting equity securities andor shares after a four-year vesting period plus a value adjustment being the amount equivalent to the sum of the dividend paid during the vesting period attributable to the number of non-voting equity securities andor shares for which an individual award has been granted. they will all be vested to the recipient for the corporate executive committee after four years only. thereafter, resulting non-voting equity securities andor shares may remain blocked for up to ten years. rsu awards are allocated individually for the corporate executive committee at the remuneration committees discretion. in 2023, rsus served as a remuneration component for 24,395 eligible roche employees. 3.1.5 indirect benefits as shown in 5.8 5.3 for the ceo roche group and 4.3 for the chairman, respectively, members of the corporate executive committee additionally received indirect benefits pension funds  insurance contributions, roche connect, payments for foreign tax obligation and tax consulting services and annual expense allowances.",
    "word_count": 393,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": ". s-sars entitle holders to benefit financially from any increase in the value of roches non-voting equity securities between the grant date and the exercise date. s-sars granted all vest together after fou",
            "position": 607,
            "sentence": "s-sars entitle holders to benefit financially from any increase in the value of roches non-voting equity securities between the grant date and the exercise date."
          },
          {
            "keyword": "equity",
            "context": "of 133.33 of a base pay measured on 1 january of a year. rsus contain rights to receive non-voting equity securities andor shares after a four-year vesting period plus a value adjustment being the amount e",
            "position": 1494,
            "sentence": "rsus contain rights to receive non-voting equity securities andor shares after a four-year vesting period plus a value adjustment being the amount equivalent to the sum of the dividend paid during the vesting period attributable to the number of non-voting equity securities andor shares for which an individual award has been granted."
          },
          {
            "keyword": "equity",
            "context": "to the sum of the dividend paid during the vesting period attributable to the number of non-voting equity securities andor shares for which an individual award has been granted. they will all be vested to",
            "position": 1709,
            "sentence": "rsus contain rights to receive non-voting equity securities andor shares after a four-year vesting period plus a value adjustment being the amount equivalent to the sum of the dividend paid during the vesting period attributable to the number of non-voting equity securities andor shares for which an individual award has been granted."
          },
          {
            "keyword": "equity",
            "context": "pient for the corporate executive committee after four years only. thereafter, resulting non-voting equity securities andor shares may remain blocked for up to ten years. rsu awards are allocated individual",
            "position": 1923,
            "sentence": "thereafter, resulting non-voting equity securities andor shares may remain blocked for up to ten years."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "target",
            "context": "the s-sars proportion of the lti of the corporate executive committee is 80 based on the individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured o",
            "position": 380,
            "sentence": "3.1.3 stock-settled stock appreciation rights s-sars long-term the s-sars proportion of the lti of the corporate executive committee is 80 based on the individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year."
          },
          {
            "keyword": "target",
            "context": "of the members of the corporate executive committee is 20 of the total lti based on the individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured o",
            "position": 1323,
            "sentence": "in 2023 in total, 24,221 employees received s-sars.3.1.4 restricted stock units rsus long-term the proportion of restricted stock units rsus of the members of the corporate executive committee is 20 of the total lti based on the individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_105",
    "content": "in 2023, rsus served as a remuneration component for 24,395 eligible roche employees. 3.1.5 indirect benefits as shown in 5.8 5.3 for the ceo roche group and 4.3 for the chairman, respectively, members of the corporate executive committee additionally received indirect benefits pension funds  insurance contributions, roche connect, payments for foreign tax obligation and tax consulting services and annual expense allowances. individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion.",
    "word_count": 463,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "ives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operati",
            "position": 1088,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ],
        "profitability": [
          {
            "keyword": "operating profit",
            "context": "mance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting eq",
            "position": 1129,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "operating profit",
            "context": ", sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, prod",
            "position": 1186,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "core earnings",
            "context": "constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development",
            "position": 1204,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "earnings per share",
            "context": "ant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline,",
            "position": 1209,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "earnings",
            "context": "ant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development",
            "position": 1209,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "profit",
            "context": "individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting eq",
            "position": 1139,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "profit",
            "context": "owth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, prod",
            "position": 1196,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ],
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "it after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employee",
            "position": 1243,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "development pipeline",
            "context": "re earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performanc",
            "position": 1306,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "target",
            "context": "elti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objecti",
            "position": 883,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "target",
            "context": "formance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured o",
            "position": 1859,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "target",
            "context": "shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to th",
            "position": 2380,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ],
        "strategic_initiatives": [
          {
            "keyword": "product development",
            "context": "ofit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by p",
            "position": 1298,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_106",
    "content": "3.1.5 indirect benefits as shown in 5.8 5.3 for the ceo roche group and 4.3 for the chairman, respectively, members of the corporate executive committee additionally received indirect benefits pension funds  insurance contributions, roche connect, payments for foreign tax obligation and tax consulting services and annual expense allowances. individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion. the remuneration is in the form of cash payments and is annually tracked against market data on directors pay at other leading global pharmaceutical companies see footnote 1 and other major swiss companies see footnote 2, and is assisted by the consultancy of pwc.",
    "word_count": 494,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "ives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operati",
            "position": 1002,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ],
        "profitability": [
          {
            "keyword": "operating profit",
            "context": "mance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting eq",
            "position": 1043,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "operating profit",
            "context": ", sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, prod",
            "position": 1100,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "core earnings",
            "context": "constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development",
            "position": 1118,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "earnings per share",
            "context": "ant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline,",
            "position": 1123,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "earnings",
            "context": "ant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development",
            "position": 1123,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "profit",
            "context": "individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting eq",
            "position": 1053,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "profit",
            "context": "owth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, prod",
            "position": 1110,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ],
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "it after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employee",
            "position": 1157,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "development pipeline",
            "context": "re earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performanc",
            "position": 1220,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "target",
            "context": "elti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objecti",
            "position": 797,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "target",
            "context": "formance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured o",
            "position": 1773,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "target",
            "context": "shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to th",
            "position": 2294,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ],
        "strategic_initiatives": [
          {
            "keyword": "product development",
            "context": "ofit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by p",
            "position": 1212,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_107",
    "content": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion. the remuneration is in the form of cash payments and is annually tracked against market data on directors pay at other leading global pharmaceutical companies see footnote 1 and other major swiss companies see footnote 2, and is assisted by the consultancy of pwc. as in the previous years, the board of directors will submit the total aggregate bonus of the resigned chairman of the board of directors for the 2023 financial year to the general meeting 2024 for retrospective binding approval.",
    "word_count": 484,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "ives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operati",
            "position": 659,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ],
        "profitability": [
          {
            "keyword": "operating profit",
            "context": "mance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting eq",
            "position": 700,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "operating profit",
            "context": ", sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, prod",
            "position": 757,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "core earnings",
            "context": "constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development",
            "position": 775,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "earnings per share",
            "context": "ant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline,",
            "position": 780,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "earnings",
            "context": "ant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development",
            "position": 780,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "profit",
            "context": "individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting eq",
            "position": 710,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "profit",
            "context": "owth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, prod",
            "position": 767,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ],
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "it after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employee",
            "position": 814,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "development pipeline",
            "context": "re earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performanc",
            "position": 877,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "target",
            "context": "elti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objecti",
            "position": 454,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "target",
            "context": "formance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured o",
            "position": 1430,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          },
          {
            "keyword": "target",
            "context": "shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to th",
            "position": 1951,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ],
        "strategic_initiatives": [
          {
            "keyword": "product development",
            "context": "ofit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by p",
            "position": 869,
            "sentence": "individual members of the corporate executive committee received payments as shown in 5.9.remuneration report  roche 159 3.3 ratio of variable remuneration components relative to fixed base pay of the corporate executive committee 2023 ratio of variable remuneration components bonuses, s-sars and rsus relative to  of value of fixed base pay sti variablelti long-term total: 133.33  criteria bonus s-sars 80 of total lti rsus 20 of total lti individual target value  100 106.66  26.66  minimum 0 0 0 maximum 200 106.66 26.66 performance criteria group objectives group and divisional business performance and individual objectives; considering core profits, sales growth at constant exchange rates, operating profit after capital charge opac based on core operating profit, core earnings per share and non-voting equity security nes growth at constant exchange rates, product development pipeline, diversity of employees and managers, environmental goalsvalue development determined by performance of nes after grant value development determined by performance plus a value adjustment for dividends of nes after grant split in  a group objectives b individual objectives 70 30 na na na na weighting criteria  decision on objectivesat the remuneration committees discretion na  not applicable  assessed in consideration of the performance of competitors and the macroeconomic development  based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year for all further details please refer to the following sections of this remuneration report.9 9 see also in the finance report note 32 to the roche group consolidated financial statements related parties, page 140 and note 6 to the financial statements of roche holding ltd board and executive shareholdings, page 191.3.2 weighting fixed  variable, long-term of 2023 remuneration components at target and as percentage of total remuneration in 2023 the variable, long-term remuneration paid out to the members of the corporate executive committee ranged from 57 to 84 of the total compensation.board of directors including chairman corporate executive committee including ceo roche group fixed variable, long-term30 70 100 20 60 90 0 40 10 50 8033 67100160  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 10 for a list of members, their positions and their committee memberships and chairmanships see page 129.4.1 resolution and approval remuneration of the chairman of the board of directors and of members of the board of directors is decided at the remuneration committees discretion."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_108",
    "content": "the remuneration is in the form of cash payments and is annually tracked against market data on directors pay at other leading global pharmaceutical companies see footnote 1 and other major swiss companies see footnote 2, and is assisted by the consultancy of pwc. as in the previous years, the board of directors will submit the total aggregate bonus of the resigned chairman of the board of directors for the 2023 financial year to the general meeting 2024 for retrospective binding approval. for the new, incumbent chairman of the board of directors, from 2023 the base remuneration determined by the remuneration committee will consist of a cash component and a new component in the form of shares blocked for ten years. at the same time, the bonus component will no longer apply to the incumbent chairman of the board of directors from 2023. the maximum amount of the total aggregate remuneration of the board of directors for the period between the ordinary general meeting 2024 and the ordinary general meeting 2025 will be tabled separately in 2024 as in the previous years for the general meetings prospective binding approval see 2.2.4. remuneration of the board of directors 4.2 amount of remuneration to the members of the board of directors in 2023, the members of the board of directors10 received remuneration and additional compensation as shown in the remuneration of members of the board of directors 2023 table on page 162 for their board activities. roche paid employer contributions totalling chf 139,063 2022: chf 201,074 to social security agencies for the members of the board of directors beside the legally required contributions separately stated for the incumbent and the resigned chairman of the board of directors. the basic remuneration of the board of directors excluding the chairman has remained unchanged since 2001. with the exception of the resigned chairman of the board of directors bonus in the form of blocked shares and the incumbent chairman of the board of directors award of blocked shares as part of the basic remuneration, members of the board of directors were not awarded any shares, non-voting equity securities, s-sars or rsus. there are no loans or credits granted to the members of the board of directors. in 2023, for their advisory service on the genentech scientific resource board, prof. dr akiko iwasaki and prof. dr richard p . lifton received honoraria amounting to usd 22,000 chf 19,773  and to usd 22,000 chf 19,773 , respectively. auditedremuneration report  roche 161 auditedremuneration of members of the board of directors 2023 in chf basic remunerationadditional remuneration for committee memberschairs 11additional special remunerationadditional bvg costs total remuneration s. schwan, chairman see 4.3 total remuneration paid to the incumbent and the resigned chairman of the board of directors a. hoffmann, vice-chairman 400,000 12  2,815 402,815 j. duschmal\u00e9 300,000 60,000  4,592 364,592 p. f r o s t 300,000 60,000   360,000 a. hauser 300,000 60,000  6,293 366,293 a. iwasaki since march 202313 250,000 22,500 19,773 see page 161 292,273 r.",
    "word_count": 499,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "f the basic remuneration, members of the board of directors were not awarded any shares, non-voting equity securities, s-sars or rsus. there are no loans or credits granted to the members of the board of di",
            "position": 2144,
            "sentence": "with the exception of the resigned chairman of the board of directors bonus in the form of blocked shares and the incumbent chairman of the board of directors award of blocked shares as part of the basic remuneration, members of the board of directors were not awarded any shares, non-voting equity securities, s-sars or rsus."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_109",
    "content": "hauser 300,000 60,000  6,293 366,293 a. iwasaki since march 202313 250,000 22,500 19,773 see page 161 292,273 r. p . lifton 300,000 30,000 19,773 see page 161 349,773 j. mahmood 300,000 30,000   330,000 b. poussot 300,000 30,000   330,000 m. schneider since march 202313 250,000 22,500   272,500 c. suessmuth dyckerhoff 300,000 60,000  7,392 367,392 total 143,000,000 375,000 39,546 21,092 3,435,638 resigned member: c. franz until april 2023 see 4.3 total remuneration paid to the incumbent and the resigned chairman of the board of directors  costs under the provisions of the swiss federal occupational old age, survivors and invalidity pension act bvg. in accordance with the minimum requirements for insurance benefits under bvg, half of the costs for four members of the board of directors who are subject to compulsory insurance are borne by the company. 11 with the exception of members of the chairmans committee chairman, vice-chairman, board members receive chf 30,000year for each committee they serve on and chf 60,000year for each committee they chair. 12 remuneration for serving as vice-chairman of the board 13 prorated remuneration for the period from march to december 2023 14 additionally, employer contribution to ahvivalv totalling chf 570,084 including the chairman was paid that does not form part of remuneration. 162  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report remuneration of members of the board of directors 2022 in chf basic remunerationadditional remuneration for committee memberschairs 15additional special remunerationadditional bvg costs total remuneration c. franz, chairman see annual report 2022, page 196, 4.3 total remuneration paid to the chairman of the board of directors a. hoffmann, vice-chairman 400,000 16  6,734 406,734 j. duschmal\u00e9 300,000 30,000  4,475 334,475 p. f r o s t 300,000 60,000   360,000 a. hauser 300,000 30,000  6,159 336,159 r. p . lifton 300,000 30,000 16,709  346,709 j. mahmood since march 202217 250,000 22,500   272,500 b. poussot 300,000 30,000   330,000 s. schwan see annual report 2022, page 200, 5.3 highest total remuneration paid to dr severin schwan as a member of the corporate executive committee, remuneration received in his primary function as ceo roche group is reflected in total remuneration for the corporate executive committee c. suessmuth dyckerhoff 300,000 60,000  7,019 367,019 members until march september 2022 18 p . bulcke until march 2022 75,000 7,500   82,500 h. clevers until march 2022 75,000 7,500   82,500 j. brown until september 2022 225,000 45,000   270,000 total 192,825,000 322,500 16,709 24,387 3,188,596  costs under the provisions of the swiss federal occupational old age, survivors and invalidity pension act bvg. in accordance with the minimum requirements for insurance benefits under bvg, half of the costs for four members of the board of directors who are subject to compulsory insurance are borne by the company. 15 with the exception of members of the chairmans committee chairman, vice-chairman, board members receive chf 30,000year for each committee they serve on and chf 60,000year for each committee they chair.",
    "word_count": 485,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_110",
    "content": "in accordance with the minimum requirements for insurance benefits under bvg, half of the costs for four members of the board of directors who are subject to compulsory insurance are borne by the company. 15 with the exception of members of the chairmans committee chairman, vice-chairman, board members receive chf 30,000year for each committee they serve on and chf 60,000year for each committee they chair. 16 remuneration for serving as vice-chairman of the board 17 prorated remuneration for the period from march to december 2022 18 prorated remuneration for the period from january to march 2022 and from january to september 2022, respectively 19 additionally, employer contribution to ahvivalv totalling chf 461,365 including the chairman was paid that does not form part of remuneration. auditedremuneration report  roche 163 4.3 total remuneration paid to the incumbent and the resigned chairman of the board of directors as resigned chairman, dr christoph franz received total remuneration listed below until his resignation in april 2023.since his election in march 2023, dr severin schwan as incumbent chairman received total remuneration for 2023 as shown.auditedtotal remuneration paid to the incumbent chairman of the board of directors dr severin schwan in chf  2023 2022 base salary  in cash  in shares 2,001,818 1,564,910 na dr severin schwan, executive member of the board of directors, received his remuneration in 2022 in his primary function as ceo roche group.pension funds  insurances  annual expense allowances  children and education allowance including employer contribution of social securities beneficial parts976,660 total 204,543,388 na  not applicable  remuneration since april 2023 as chairman of the board of directors; for remuneration as resigned ceo from january to march 2023 see 5.2, 5.45.10, respectively. in the form of shares blocked for ten years calculation of number of shares based on the price at the date of transfer; calculation of value in consideration of reduction of value due to blocking period of ten years reduced market value: 55.839 20 additionally, employer contribution to ahvivalv of chf 224,367 was paid that does not form part of remuneration.auditedtotal remuneration paid to the resigned chairman of the board of directors dr christoph franz in chf  2023 2022 base salary in cash 1,167,000 3,500,000 bonus subject to approval of the annual general meeting 583,334  1,750,000  pension funds  insurances  annual expense allowances  other remuneration  including employer contribution of social securities beneficial parts328,398 669,777 total 212,078,732 5,919,777  remuneration until april 2023 as chairman of the board of directors: as per terms of his resignation agreement, dr christoph franz remained at roche until end of april to ensure a smooth handover to his successor and received his remuneration until 30 april 2023.",
    "word_count": 436,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_111",
    "content": "auditedremuneration report  roche 163 4.3 total remuneration paid to the incumbent and the resigned chairman of the board of directors as resigned chairman, dr christoph franz received total remuneration listed below until his resignation in april 2023.since his election in march 2023, dr severin schwan as incumbent chairman received total remuneration for 2023 as shown.auditedtotal remuneration paid to the incumbent chairman of the board of directors dr severin schwan in chf  2023 2022 base salary  in cash  in shares 2,001,818 1,564,910 na dr severin schwan, executive member of the board of directors, received his remuneration in 2022 in his primary function as ceo roche group.pension funds  insurances  annual expense allowances  children and education allowance including employer contribution of social securities beneficial parts976,660 total 204,543,388 na  not applicable  remuneration since april 2023 as chairman of the board of directors; for remuneration as resigned ceo from january to march 2023 see 5.2, 5.45.10, respectively. in the form of shares blocked for ten years calculation of number of shares based on the price at the date of transfer; calculation of value in consideration of reduction of value due to blocking period of ten years reduced market value: 55.839 20 additionally, employer contribution to ahvivalv of chf 224,367 was paid that does not form part of remuneration.auditedtotal remuneration paid to the resigned chairman of the board of directors dr christoph franz in chf  2023 2022 base salary in cash 1,167,000 3,500,000 bonus subject to approval of the annual general meeting 583,334  1,750,000  pension funds  insurances  annual expense allowances  other remuneration  including employer contribution of social securities beneficial parts328,398 669,777 total 212,078,732 5,919,777  remuneration until april 2023 as chairman of the board of directors: as per terms of his resignation agreement, dr christoph franz remained at roche until end of april to ensure a smooth handover to his successor and received his remuneration until 30 april 2023. in the form of shares blocked for ten years calculation of number of shares based on the price at the date of transfer in march 2024 and 2023, respectively, after approval at the agm 2024  agm 2023, respectively; calculation of value in consideration of reduction of value due to blocking period of ten years reduced market value: 55.839 to be submitted for shareholder approval at the agm 2024  as approved at the agm 2023, respectively  including fee to dr christoph franz in 2023 amounting to a total of jpy 15.47 million chf 98,971 received for serving as a member of the board of directors of chugai pharmaceutical co., ltd. 21 additionally, employer contribution to ahvivalv of chf 206,654 2022: chf 260,291 was paid that does not form part of remuneration. the remuneration committees bonus proposal for the resigned chairman in respect of the 2023 financial year in the form of shares blocked for ten years, payable in march 2024 will be put for shareholder binding vote at the 2024 ordinary annual general meeting see 4.6.",
    "word_count": 487,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_112",
    "content": "21 additionally, employer contribution to ahvivalv of chf 206,654 2022: chf 260,291 was paid that does not form part of remuneration. the remuneration committees bonus proposal for the resigned chairman in respect of the 2023 financial year in the form of shares blocked for ten years, payable in march 2024 will be put for shareholder binding vote at the 2024 ordinary annual general meeting see 4.6. both total remunerations are contained in the total remuneration of the board of directors in 4.4.164  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 4.4 total remuneration paid to the board of directors for the 2023 calendar year the members of the board of directors including the incumbent and the resigned chairman of the board of directors received remuneration including bonus for the resigned chairman and employer contribution of social securities beneficial parts totalling chf 10, 107,396 2022: chf 9, 150,679, excluding additional employer contribution paid to social securities totalling chf 570,084 2022: chf 461,365. 4.5 remuneration paid to the former members of the board of directors no remuneration was paid. 4.6 board remuneration subject to approval at the annual general meeting 4.6.1 submission of the resigned chairmans total aggregate bonus for a binding retrospective vote at the annual general meeting 2024 remuneration to the resigned chairman of the board of directors includes a bonus award of chf 583,334, in the form of shares blocked for ten years as shown in the table in section 4.3 total remuneration paid to the incumbent and the resigned chairman of the board of directors. the board of directors will submit the remuneration committees bonus proposal for the resigned chairman in respect of the 2023 financial year in the form of shares blocked for ten years, payable in march 2024, excluding legally required employer contributions to ahvivalv for retrospective binding shareholder vote at the 2024 ordinary annual general meeting agm.4.6.2 submission of the boards total aggregate future remuneration for the period between the 2024 ordinary agm and the 2025 ordinary agm for a prospective binding shareholder vote at the 2024 agm the board of directors proposes that the 2024 ordinary agm approve board remuneration totalling not more than chf 12,000,000 excluding legally required employer contributions to ahvivalv for the period between the 2024 ordinary agm and the 2025 ordinary agm. the compensation of the members of the board of directors is paid in cash, and for the chairman of the board of directors, compensation consists of a component in cash and a component in the form of shares blocked for ten years calculation of value in consideration of reduction of value due to blocking period of ten years reduced market value: 55.839 as determined by the remuneration committee.",
    "word_count": 455,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_113",
    "content": "the board of directors will submit the remuneration committees bonus proposal for the resigned chairman in respect of the 2023 financial year in the form of shares blocked for ten years, payable in march 2024, excluding legally required employer contributions to ahvivalv for retrospective binding shareholder vote at the 2024 ordinary annual general meeting agm.4.6.2 submission of the boards total aggregate future remuneration for the period between the 2024 ordinary agm and the 2025 ordinary agm for a prospective binding shareholder vote at the 2024 agm the board of directors proposes that the 2024 ordinary agm approve board remuneration totalling not more than chf 12,000,000 excluding legally required employer contributions to ahvivalv for the period between the 2024 ordinary agm and the 2025 ordinary agm. the compensation of the members of the board of directors is paid in cash, and for the chairman of the board of directors, compensation consists of a component in cash and a component in the form of shares blocked for ten years calculation of value in consideration of reduction of value due to blocking period of ten years reduced market value: 55.839 as determined by the remuneration committee. 4.6.3 reconciliation of the reported remuneration with the shareholders prospectively approved remuneration for the members of the board of directors the 2022 ordinary agm prospectively approved board remuneration totalling not more than chf 10,000,000 excluding legally required employer contributions to ahvivalv and excluding bonuses for the period ending at the 2023 ordinary agm. for comparison, from the 2022 ordinary agm to the 2023 ordinary agm actual remuneration amounted to chf 7,859,786 excluding legally required employer contributions to ahvivalv and excluding bonuses and remained within the approved total remuneration limit.auditedremuneration report  roche 165 the 2023 ordinary agm approved board remuneration totalling not more than chf 10,000,000 excluding legally required employer contributions to ahvivalv and excluding bonuses for the period ending at the 2024 ordinary agm. with the change of the chairman of the board of directors, the remuneration components have been changed as of 2023 insofar as, on the one hand, there is no longer a bonus remuneration for the chairman of the board of directors, but on the other hand, the base compensation increases, which now consists of a component in cash and a component in the form of shares blocked for ten years calculation of value in consideration of reduction of value due to blocking period of ten years reduced market value: 55.839 as per the remuneration committees decision see 4.3. from the 2023 ordinary agm to the 2024 ordinary agm actual remuneration excluding legally required employer contributions to ahvivalv, including the reduction for the blocking period remained within the approved total remuneration limit. as before, detailed calculation will be made and reported after the end of the aforementioned period.4.7 security holdings directors andr\u00e9 hoffmann and dr j\u00f6rg duschmal\u00e9 and members of the founders families who are closely associated with them belong to a contractually bound shareholder group with pooled voting rights.",
    "word_count": 496,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_114",
    "content": "from the 2023 ordinary agm to the 2024 ordinary agm actual remuneration excluding legally required employer contributions to ahvivalv, including the reduction for the blocking period remained within the approved total remuneration limit. as before, detailed calculation will be made and reported after the end of the aforementioned period.4.7 security holdings directors andr\u00e9 hoffmann and dr j\u00f6rg duschmal\u00e9 and members of the founders families who are closely associated with them belong to a contractually bound shareholder group with pooled voting rights. at the end of 2023 this group held 69,318,000 shares 64.97 of issued shares. detailed information about this group can be found in the finance report, note 32 to the roche group consolidated financial statements related parties, page 140  and in note 4 to the financial statements of roche holding ltd significant shareholders, page 190 . in addition, as at 31 december 2023 as at 31 december 2022, respectively the members of the board of directors and persons closely associated with them held roche shares, non- voting equity securities nes and american depositary receipts adrs  as shown in the table 4.7. 1 security holdings shares, nes, adrs below. 4.7.1 security holdings shares, nes, adrs as at 31 december 2023 as at 31 december 2022 shares numbernon-voting equity securities nes numberothers number typeclose relatives security holdings numbertypeshares numbernon-voting equity securities nes numberothers number typeclose relatives security holdings numbertype board of directors s. schwan 244,786 97,876   215,956 91,966   a. hoffmann   200     200   j. duschmal\u00e9           p. f r o s t 2,000    2,000    a. hauser 3,000 150  20 nes 3,000 150  20 nes a. iwasaki     na na na na r. p . lifton   300 adrs     300 adrs   j. mahmood         b. poussot 500 500   500 500   m. schneider 2,500 2,500   na na na na c. suessmuth dyckerhoff  2,710      2,710     total 252,786 103,936 300 adrs  20 nes 221,456 95,526 300 adrs  20 nes na  not applicable  shares held by the shareholder group with pooled voting rights not listed  jointly held with close relative  roches adr american depositary receipt listed on otcqx  https: www.otcmarkets.comstockrhhbyquote  international premier under the symbol rhhby, isin us771195104. traded in usd, eight 8 adrs represent one 1 underlying nes.audited166  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report as chairman, dr severin schwan is not entitled to receive new ltis s-sars and rsus. his ltis awarded in his former role as ceo are listed audited audited4.7.2 stock-settled stock appreciation rights s-sars number of s-sars held on 31 december 2023 2023 2022 2021 2020 2019 2018 2017 s. schwan awarded in former role as ceo 115,095 75,635 100,746 103,260 122,322 100,677 85,476 price chf 263.65 359.70 306.45 308.05 271.65 220.80 251.90 market price per nes on 31 december 2023 chf 244.50 expiry date 10.3.2033 17.3.2032 18.3.2031 19.3.2030 15.3.2029 15.3.2025 16.3.2024 grant value per s-sar chf since 1.1.2012:  trinomial model for american call options37.07 56.41 42.35 41.32 34.88 26.49 31.20 4.7.3 restricted stock units rsus number of rsus held on 31 december 2023 2023 2022 2021 2020 s.",
    "word_count": 499,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "s of the board of directors and persons closely associated with them held roche shares, non- voting equity securities nes and american depositary receipts adrs  as shown in the table 4.7. 1 security holding",
            "position": 1081,
            "sentence": "in addition, as at 31 december 2023 as at 31 december 2022, respectively the members of the board of directors and persons closely associated with them held roche shares, non- voting equity securities nes and american depositary receipts adrs  as shown in the table 4.7."
          },
          {
            "keyword": "equity",
            "context": "ty holdings shares, nes, adrs as at 31 december 2023 as at 31 december 2022 shares numbernon-voting equity securities nes numberothers number typeclose relatives security holdings numbertypeshares numbernon",
            "position": 1326,
            "sentence": "4.7.1 security holdings shares, nes, adrs as at 31 december 2023 as at 31 december 2022 shares numbernon-voting equity securities nes numberothers number typeclose relatives security holdings numbertypeshares numbernon-voting equity securities nes numberothers number typeclose relatives security holdings numbertype board of directors s."
          },
          {
            "keyword": "equity",
            "context": "ies nes numberothers number typeclose relatives security holdings numbertypeshares numbernon-voting equity securities nes numberothers number typeclose relatives security holdings numbertype board of direct",
            "position": 1440,
            "sentence": "4.7.1 security holdings shares, nes, adrs as at 31 december 2023 as at 31 december 2022 shares numbernon-voting equity securities nes numberothers number typeclose relatives security holdings numbertypeshares numbernon-voting equity securities nes numberothers number typeclose relatives security holdings numbertype board of directors s."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_115",
    "content": "his ltis awarded in his former role as ceo are listed audited audited4.7.2 stock-settled stock appreciation rights s-sars number of s-sars held on 31 december 2023 2023 2022 2021 2020 2019 2018 2017 s. schwan awarded in former role as ceo 115,095 75,635 100,746 103,260 122,322 100,677 85,476 price chf 263.65 359.70 306.45 308.05 271.65 220.80 251.90 market price per nes on 31 december 2023 chf 244.50 expiry date 10.3.2033 17.3.2032 18.3.2031 19.3.2030 15.3.2029 15.3.2025 16.3.2024 grant value per s-sar chf since 1.1.2012:  trinomial model for american call options37.07 56.41 42.35 41.32 34.88 26.49 31.20 4.7.3 restricted stock units rsus number of rsus held on 31 december 2023 2023 2022 2021 2020 s. schwan awarded in former role as ceo 4,046 2,965 3,481 3,463 grant value per rsu chf 263.65 nes closing price at grant date on 10 march 2023chf 359.70 nes closing price at grant date on 17 march 2022chf 306.45 nes closing price at grant date on 18 march 2021chf 308.05 nes closing price at grant date on 19 march 2020below in the tables 4.7.2 stock-settled stock appreciation rights s-sars and 4.7.3 restricted stock units rsus.remuneration report  roche 167 5.1 resolution and approval remuneration of the members of the corporate executive committee was decided at the remuneration committees discretion, taking into account market comparisons. as in the previous years, in 2024 the board of directors will separately submit the total aggregate bonuses of the corporate executive committee for the 2024 financial year to the general meeting for retrospective binding approval. the maximum amounts of the total other aggregate remuneration of the corporate executive committee for the period between the ordinary general meeting 2024 and the ordinary general meeting 2025 will be tabled separately in 2024 as in the previous years for the general meetings prospective binding approval see 2.2. 5.2 amount of remuneration to members of the corporate executive committee the general provisions assigning authority for decisions on corporate executive committee 5. remuneration of the corporate executive committee remuneration to the remuneration committee and to the board of directors are outlined on page 152 , 2. remuneration decision process and approval framework. in 2023, members of the corporate executive committee received remuneration for their work as shown in 5.45. 10. the amount of remuneration for the ceo roche group, dr thomas schinecker, is explained in 5.3 in detail. total remuneration of the corporate executive committee in 2023 is shown in 5. 11. remuneration in 2023 to dr severin schwan in his role as the resigned ceo roche group is reflected in the remuneration components see 5.45. 10 and is included and aggregated in the total remuneration of the corporate executive committee see 5.",
    "word_count": 445,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_116",
    "content": "remuneration in 2023 to dr severin schwan in his role as the resigned ceo roche group is reflected in the remuneration components see 5.45. 10 and is included and aggregated in the total remuneration of the corporate executive committee see 5. 11.168  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 5.4 base pay of the other members of the corporate executive committee audited audited5.3 highest total remuneration paid to dr thomas schinecker as a member of the corporate executive committee as ceo roche group including as ad interim ceo roche pharmaceuticals, januarymarch 2023, dr thomas schinecker received the highest in his role as the ceo roche group in 2023, dr severin schwan received chf 697, 103 as base salary.remuneration paid to a member of the corporate executive committee as reflected in the following chart and included in the total amount paid to the corporate executive committee see 5. 11 total remuneration paid to the members of the corporate executive committee, page 174. base pay in chf 2023 2022 t. graham 1,250,000 na a. hippe 1,600,008 1,600,000 m. sause 1,009,624 na c. a. wilbur 1,026,039 1,006,167 total 4,885,671 na  not applicablehighest total remuneration paid to dr thomas schinecker, incumbent ceo roche group, as a member of the corporate executive committee in chf 2023 2022 base salary 3,000,000 na in 2022, dr thomas schinecker received his remuneration in his role as ceo roche diagnostics.bonus subject to approval of the total aggregate bonuses for the corporate executive committee by the annual general meeting 3,200,000  s-sars 222,534,697 rsus 23446,768 roche connect 32,499 pension funds  insurances 341,490  other payments incl. expense allowance  for tax consulting services 50,325 total 249,605,779 na  not applicable  including employer contribution of social securities beneficial parts  in the form of shares calculation of number of shares based on the price at the date of transfer in march 2024 after approval at the agm 2024 22 s-sars 2023: number: 79,169, grant value according to the trinomial model for american call options: chf 40.42. trinomial model for american call options value as described in 5.6 stock-settled stock appreciation rights s-sars of the other members of the corporate executive committee, page 170. s-sars 2023 are blocked for four years and may thereafter be exercised only, whilst non-voting equity securities resulting from exercise are automatically blocked for an additional four years calculation of value of non-voting equity securities in consideration of reduction of value due to additional blocking period of four years; reduced market value: 79.209. 23 calculation of rsus value 2023: number of rsus: 3,062, multiplied by grant value of chf 261.30 nes closing price at grant date on 16 march 2023 per rsu calculation of value of non-voting equity securitiesshares in consideration of reduction of value due to blocking period of ten years; reduced market value: 55.839. 24 includes an annual expense allowance chf 30,000, payments for tax consulting services chf 7,215, family, children and education allowance chf 13,110.",
    "word_count": 491,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "170. s-sars 2023 are blocked for four years and may thereafter be exercised only, whilst non-voting equity securities resulting from exercise are automatically blocked for an additional four years calculati",
            "position": 2447,
            "sentence": "s-sars 2023 are blocked for four years and may thereafter be exercised only, whilst non-voting equity securities resulting from exercise are automatically blocked for an additional four years calculation of value of non-voting equity securities in consideration of reduction of value due to additional blocking period of four years; reduced market value: 79.209."
          },
          {
            "keyword": "equity",
            "context": "exercise are automatically blocked for an additional four years calculation of value of non-voting equity securities in consideration of reduction of value due to additional blocking period of four years;",
            "position": 2579,
            "sentence": "s-sars 2023 are blocked for four years and may thereafter be exercised only, whilst non-voting equity securities resulting from exercise are automatically blocked for an additional four years calculation of value of non-voting equity securities in consideration of reduction of value due to additional blocking period of four years; reduced market value: 79.209."
          },
          {
            "keyword": "equity",
            "context": "261.30 nes closing price at grant date on 16 march 2023 per rsu calculation of value of non-voting equity securitiesshares in consideration of reduction of value due to blocking period of ten years; reduce",
            "position": 2905,
            "sentence": "23 calculation of rsus value 2023: number of rsus: 3,062, multiplied by grant value of chf 261.30 nes closing price at grant date on 16 march 2023 per rsu calculation of value of non-voting equity securitiesshares in consideration of reduction of value due to blocking period of ten years; reduced market value: 55.839."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_117",
    "content": "23 calculation of rsus value 2023: number of rsus: 3,062, multiplied by grant value of chf 261.30 nes closing price at grant date on 16 march 2023 per rsu calculation of value of non-voting equity securitiesshares in consideration of reduction of value due to blocking period of ten years; reduced market value: 55.839. 24 includes an annual expense allowance chf 30,000, payments for tax consulting services chf 7,215, family, children and education allowance chf 13,110. additionally, employer contribution to ahvivalv of chf 280,852 was paid that does not form part of remuneration.remuneration report  roche 169 bonus in chf 2023 2022 subject to approval of the total aggregate bonuses of the corporate executive committee by the annual general meeting 2024 t. graham 1,700,000 na a. hippe 2,000,000 2,000,000 m. sause 1,200,000 na c. a. wilbur 1,350,000 1,300,000 total 6,250,000 na  not applicablereceive the bonus 2023 as a 100 cash payment. dr thomas schinecker will receive the bonus in the form of roche shares. bonus payment is due in march 2024. for his role as the ceo roche group in 2023, dr severin schwan will receive the bonus award of chf 550,74125 in the form of roche shares which are blocked for ten years. the bonus is part of the total aggregate amount of bonuses to the corporate executive committee which will be brought forward for a binding vote by the annual general meeting 2024.5.5 bonuses of the other members of the corporate executive committee the remuneration committee of the board of directors determined the corporate executive committee members bonuses based on the 2023 performance against the agreed objectives. the remuneration committee uses its discretion appropriately in the weighting of each criterion and in the bonus allocation. the total aggregate amount of bonuses will be brought forward for a binding vote by the annual general meeting 2024. except for dr thomas schinecker, all members of the corporate executive committee will audited 5.6 stock-settled stock appreciation rights s-sars of the other members of the corporate executive committee s-sars to the members of the corporate executive committee are allocated individually at the remuneration committees discretion. the s-sars shown in the 5. 15.2 stock-settled stock appreciation rights s-sars table on page 177 entitle holders to benefit financially from any increase in the value of roches non-voting equity securities nes between the grant date and the exercise date. the strike price for s-sars under the terms of this multi-year plan is the closing price for roche nes at grant date. all s-sars since 2019 vest four previously granted s-sars three years after the grant date. vested s-sars can be exercised converted into nes within ten previously granted s-sars within seven years of the grant date. unexercised s-sars lapse without compensation. 25 shares blocked for ten years calculation of number of shares based on the share price at the date of transfer in march 2024 after approval at the agm 2024.",
    "word_count": 484,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "261.30 nes closing price at grant date on 16 march 2023 per rsu calculation of value of non-voting equity securitiesshares in consideration of reduction of value due to blocking period of ten years; reduce",
            "position": 190,
            "sentence": "23 calculation of rsus value 2023: number of rsus: 3,062, multiplied by grant value of chf 261.30 nes closing price at grant date on 16 march 2023 per rsu calculation of value of non-voting equity securitiesshares in consideration of reduction of value due to blocking period of ten years; reduced market value: 55.839."
          },
          {
            "keyword": "equity",
            "context": "page 177 entitle holders to benefit financially from any increase in the value of roches non-voting equity securities nes between the grant date and the exercise date. the strike price for s-sars under the",
            "position": 2416,
            "sentence": "15.2 stock-settled stock appreciation rights s-sars table on page 177 entitle holders to benefit financially from any increase in the value of roches non-voting equity securities nes between the grant date and the exercise date."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_118",
    "content": "unexercised s-sars lapse without compensation. 25 shares blocked for ten years calculation of number of shares based on the share price at the date of transfer in march 2024 after approval at the agm 2024. calculation of shares in consideration of reduction of value due to blocking period of ten years reduced market value: 55.839170  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 26 for further information on the trinomial model for american call options: please refer to boyle, phelim p .: a lattice framework for option pricing with two state variables, the journal of financial and quantitative analysis, volume 23, issue 1 mar 1988, 112, https: assets.cwp.roche.comf126832xe1222fd9e5trinomial_model.pdf 27 s-sars 2023 see 4.7.2, page 167: number: 115,095, grant value according to the trinomial model for american call options: chf 37.07. s-sars 2023 are blocked for four years and may thereafter be exercised only, whilst non-voting equity securities resulting from exercise are automatically blocked for an additional four years calculation of value of non-voting equity securities in consideration of reduction of value due to additional blocking period of four years; reduced market value: 79.209. auditedstock-settled stock appreciation rights s-sars 2023 2022 numbergrant value per s-sar in chf value in chf numbergrant value per s-sar in chf value in chf t. graham 27,249 40.42 1,101,405 na na na a. hippe 42,224 40.42 1,706,694 30,255 56.41 1,706,685 m. sause 26,389 40.42 1,066,643 na na na c. a. wilbur 26,390 40.42 1,066,684 18,910 56.41 1,066,713 total 122,252 40.42 4,941,426 price: chf 261.30, expiry date: 16.3.2033 price: chf 359.70, expiry date: 17.3.2032 na  not applicablesince 2019, the s-sars proportion of the lti of the corporate executive committee is 80 based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year. the fair value of the s-sars is calculated at the grant date using the trinomial model for american call options. the trinomial model is an effective method for valuation of american call options, as it considers the possibility of exercising the option any time prior to maturity called american option, as compared to a european option, which only allows exercise at its maturity date.26 the numbers of s-sars, the strike prices, expiry dates and grant values for s-sars are shown below and in the 5. 15.2 stock-settled stock appreciation rights s-sars table on page 177. the numbers of s-sars as calculated at the time of issue have been entered as values in the tables on page 169 and below.",
    "word_count": 428,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": ".07. s-sars 2023 are blocked for four years and may thereafter be exercised only, whilst non-voting equity securities resulting from exercise are automatically blocked for an additional four years calculati",
            "position": 1009,
            "sentence": "s-sars 2023 are blocked for four years and may thereafter be exercised only, whilst non-voting equity securities resulting from exercise are automatically blocked for an additional four years calculation of value of non-voting equity securities in consideration of reduction of value due to additional blocking period of four years; reduced market value: 79.209."
          },
          {
            "keyword": "equity",
            "context": "exercise are automatically blocked for an additional four years calculation of value of non-voting equity securities in consideration of reduction of value due to additional blocking period of four years;",
            "position": 1141,
            "sentence": "s-sars 2023 are blocked for four years and may thereafter be exercised only, whilst non-voting equity securities resulting from exercise are automatically blocked for an additional four years calculation of value of non-voting equity securities in consideration of reduction of value due to additional blocking period of four years; reduced market value: 79.209."
          },
          {
            "keyword": "assets",
            "context": "ables, the journal of financial and quantitative analysis, volume 23, issue 1 mar 1988, 112, https: assets.cwp.roche.comf126832xe1222fd9e5trinomial_model.pdf 27 s-sars 2023 see 4.7.2, page 167: number: 115,",
            "position": 720,
            "sentence": "calculation of shares in consideration of reduction of value due to blocking period of ten years reduced market value: 55.839170  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 26 for further information on the trinomial model for american call options: please refer to boyle, phelim p .: a lattice framework for option pricing with two state variables, the journal of financial and quantitative analysis, volume 23, issue 1 mar 1988, 112, https: assets.cwp.roche.comf126832xe1222fd9e5trinomial_model.pdf 27 s-sars 2023 see 4.7.2, page 167: number: 115,095, grant value according to the trinomial model for american call options: chf 37.07."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "target",
            "context": "tion of the lti of the corporate executive committee is 80 based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured o",
            "position": 1895,
            "sentence": "wilbur 26,390 40.42 1,066,684 18,910 56.41 1,066,713 total 122,252 40.42 4,941,426 price: chf 261.30, expiry date: 16.3.2033 price: chf 359.70, expiry date: 17.3.2032 na  not applicablesince 2019, the s-sars proportion of the lti of the corporate executive committee is 80 based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_119",
    "content": "15.2 stock-settled stock appreciation rights s-sars table on page 177. the numbers of s-sars as calculated at the time of issue have been entered as values in the tables on page 169 and below. in 2023 for his role as ceo roche group, dr severin schwan received s-sars totalling chf 3,379,509.27remuneration report  roche 171 5.7 restricted stock units rsus of the other members of the corporate executive committee since 2019, the proportion of restricted stock units rsus of the members of the corporate executive committee is 20 of the total lti based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year. rsu awards are allocated individually for the corporate executive committee at the remuneration committees discretion. rsus contain rights to receive non-voting equity securities andor shares after a since 2019 newly defined four-year vesting period plus a value adjustment being the amount equivalent to the sum of the dividend paid during the vesting period attributable to the number of non-voting equity securities andor shares for which an individual award has been granted. they will be vested to the recipient for the corporate executive committee after four years only. thereafter, resulting non-voting equity securities andor shares may remain blocked for up to ten years. in 2023 for his role as ceo roche group, dr severin schwan received rsus totalling chf 595,650.28auditedrestricted stock units rsus 2023 2022 numbervalue at grant in chf value in chf numbervalue at grant in chf value in chf t. graham 1,054 261.30 275,410 na na na a. hippe 1,633 261.30 238,267  1,186 359.70 238,212  m. sause 1,021 261.30 266,787 na na na c. a. wilbur 1,021 261.30 266,787 741 359.70 266,538 total 4,729 261.30 1,047,251  na  not applicable  calculation of value in consideration of reduction of value due to an additional blocking period of ten years reduced market value: 55.839 28 calculation of rsus value 2023 see 4.7.3, page 167: number of rsus: 4,046, multiplied by grant value of chf 263.65 nes closing price at grant date on 10 march 2023 per rsu calculation of value of non-voting equity securities  shares in consideration of reduction of value due to blocking period of ten years; reduced market value: 55.839.172  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 5.8 indirect benefits of the other members of the corporate executive committee employer contributions made in 2023 to social security schemes, pension plans and a group-wide employee stock purchase plan roche connect in respect of members of the corporate executive committee are shown in the indirect benefits employer contributions table below and in the table on page 169. roche connect is a voluntary stock purchase plan offering employees the opportunity to buy roche non-voting equity securities nes up to an amount equal to 10 of their annual base salary at a 20 discount.",
    "word_count": 487,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "tive committee at the remuneration committees discretion. rsus contain rights to receive non-voting equity securities andor shares after a since 2019 newly defined four-year vesting period plus a value adju",
            "position": 879,
            "sentence": "rsus contain rights to receive non-voting equity securities andor shares after a since 2019 newly defined four-year vesting period plus a value adjustment being the amount equivalent to the sum of the dividend paid during the vesting period attributable to the number of non-voting equity securities andor shares for which an individual award has been granted."
          },
          {
            "keyword": "equity",
            "context": "to the sum of the dividend paid during the vesting period attributable to the number of non-voting equity securities andor shares for which an individual award has been granted. they will be vested to the",
            "position": 1119,
            "sentence": "rsus contain rights to receive non-voting equity securities andor shares after a since 2019 newly defined four-year vesting period plus a value adjustment being the amount equivalent to the sum of the dividend paid during the vesting period attributable to the number of non-voting equity securities andor shares for which an individual award has been granted."
          },
          {
            "keyword": "equity",
            "context": "pient for the corporate executive committee after four years only. thereafter, resulting non-voting equity securities andor shares may remain blocked for up to ten years. in 2023 for his role as ceo roche g",
            "position": 1329,
            "sentence": "thereafter, resulting non-voting equity securities andor shares may remain blocked for up to ten years."
          },
          {
            "keyword": "equity",
            "context": "263.65 nes closing price at grant date on 10 march 2023 per rsu calculation of value of non-voting equity securities  shares in consideration of reduction of value due to blocking period of ten years; redu",
            "position": 2208,
            "sentence": "wilbur 1,021 261.30 266,787 741 359.70 266,538 total 4,729 261.30 1,047,251  na  not applicable  calculation of value in consideration of reduction of value due to an additional blocking period of ten years reduced market value: 55.839 28 calculation of rsus value 2023 see 4.7.3, page 167: number of rsus: 4,046, multiplied by grant value of chf 263.65 nes closing price at grant date on 10 march 2023 per rsu calculation of value of non-voting equity securities  shares in consideration of reduction of value due to blocking period of ten years; reduced market value: 55.839.172  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 5.8 indirect benefits of the other members of the corporate executive committee employer contributions made in 2023 to social security schemes, pension plans and a group-wide employee stock purchase plan roche connect in respect of members of the corporate executive committee are shown in the indirect benefits employer contributions table below and in the table on page 169."
          },
          {
            "keyword": "equity",
            "context": "nnect is a voluntary stock purchase plan offering employees the opportunity to buy roche non-voting equity securities nes up to an amount equal to 10 of their annual base salary at a 20 discount.",
            "position": 2943,
            "sentence": "roche connect is a voluntary stock purchase plan offering employees the opportunity to buy roche non-voting equity securities nes up to an amount equal to 10 of their annual base salary at a 20 discount."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "target",
            "context": "f the corporate executive committee is 20 of the total lti based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured o",
            "position": 589,
            "sentence": "in 2023 for his role as ceo roche group, dr severin schwan received s-sars totalling chf 3,379,509.27remuneration report  roche 171 5.7 restricted stock units rsus of the other members of the corporate executive committee since 2019, the proportion of restricted stock units rsus of the members of the corporate executive committee is 20 of the total lti based on the already existing individual target value of the total lti for corporate executive committee members of 133.33 of a base pay measured on 1 january of a year."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_120",
    "content": "wilbur 1,021 261.30 266,787 741 359.70 266,538 total 4,729 261.30 1,047,251  na  not applicable  calculation of value in consideration of reduction of value due to an additional blocking period of ten years reduced market value: 55.839 28 calculation of rsus value 2023 see 4.7.3, page 167: number of rsus: 4,046, multiplied by grant value of chf 263.65 nes closing price at grant date on 10 march 2023 per rsu calculation of value of non-voting equity securities  shares in consideration of reduction of value due to blocking period of ten years; reduced market value: 55.839.172  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 5.8 indirect benefits of the other members of the corporate executive committee employer contributions made in 2023 to social security schemes, pension plans and a group-wide employee stock purchase plan roche connect in respect of members of the corporate executive committee are shown in the indirect benefits employer contributions table below and in the table on page 169. roche connect is a voluntary stock purchase plan offering employees the opportunity to buy roche non-voting equity securities nes up to an amount equal to 10 of their annual base salary at a 20 discount. nes purchased under this plan are subject to a holding period, which is four years in switzerland. in addition, members of the corporate executive committee received annual expense allowances and some members payments for foreign tax obligations and tax consulting services as shown in the table below. payments employer contributions of indirect benefits payments for pension funds, insurances, expense allowance, family, children and education allowances, roche connect, tax consulting fees and including employer contribution of social securities beneficial parts in 2023 to dr severin schwan amounted to chf 176,458.audited auditedindirect benefits employer contributions in chf 2023 2022 pension funds  insurances annual expense allowancesroche connectpayments for tax  tax consulting servicespension funds  insurances annual expense allowancesroche connectpayments for tax  tax consulting services t. graham 285,757 25,000 7,000 37,921 na na na na a. hippe 435,864 30,000 39,996 4,136 425,494 30,000 39,996 10,884 m. sause 341,490 30,000  29,904 na na na na c. a. wilbur 435,864 30,000 18,744 513,187 425,494 30,000 18,744 141,119 total 1,498,975 115,000 65,740 585,148 na  not applicable  including employer contribution of social securities beneficial parts audited 5.9 other remuneration and loans of members of the corporate executive committee to meet contractual obligations, in 2023 roche paid a total of chf 37,328 for relocation costs. these additional payments are included in the total remuneration to members of the corporate executive committee.the company granted no loans or credits to the members of the corporate executive committee. the maximum regular period of notice for members of the corporate executive committee is 12 months.",
    "word_count": 451,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "263.65 nes closing price at grant date on 10 march 2023 per rsu calculation of value of non-voting equity securities  shares in consideration of reduction of value due to blocking period of ten years; redu",
            "position": 446,
            "sentence": "wilbur 1,021 261.30 266,787 741 359.70 266,538 total 4,729 261.30 1,047,251  na  not applicable  calculation of value in consideration of reduction of value due to an additional blocking period of ten years reduced market value: 55.839 28 calculation of rsus value 2023 see 4.7.3, page 167: number of rsus: 4,046, multiplied by grant value of chf 263.65 nes closing price at grant date on 10 march 2023 per rsu calculation of value of non-voting equity securities  shares in consideration of reduction of value due to blocking period of ten years; reduced market value: 55.839.172  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 5.8 indirect benefits of the other members of the corporate executive committee employer contributions made in 2023 to social security schemes, pension plans and a group-wide employee stock purchase plan roche connect in respect of members of the corporate executive committee are shown in the indirect benefits employer contributions table below and in the table on page 169."
          },
          {
            "keyword": "equity",
            "context": "nnect is a voluntary stock purchase plan offering employees the opportunity to buy roche non-voting equity securities nes up to an amount equal to 10 of their annual base salary at a 20 discount. nes purcha",
            "position": 1181,
            "sentence": "roche connect is a voluntary stock purchase plan offering employees the opportunity to buy roche non-voting equity securities nes up to an amount equal to 10 of their annual base salary at a 20 discount."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_121",
    "content": "these additional payments are included in the total remuneration to members of the corporate executive committee.the company granted no loans or credits to the members of the corporate executive committee. the maximum regular period of notice for members of the corporate executive committee is 12 months. there are no change-of-control clauses in the employment contracts.remuneration report  roche 173 5.10 remuneration to former members of the corporate executive committee in 2023, to meet legal and contractual obligations, roche paid remuneration of chf 771,776 excluding legally required employer contributions to ahvivalv of chf 256, 135 to bill anderson, who had resigned from the corporate executive committee at the end of december 2022. in 2023, no other payments to former members of the corporate executive committee were made. 5.11 total remuneration paid to the members of the corporate executive committee for the 2023 calendar year, members of the corporate executive committee including dr severin schwan as resigned ceo received remuneration including bonuses, employer contribution of social securities beneficial parts totalling chf 34,431,779 2022: chf 37, 181,576, excluding additional employer contribution paid to ahvivalv totalling chf 1, 104,210 2022: chf 1,819,906 that does not form part of remuneration. no additional remuneration other than the above-mentioned payments was paid to current or former members of the corporate executive committee. 5.12 the corporate executive committees remuneration subject to approval at the annual general meeting 5.12.1 submission of the corporate executive committees total aggregate bonuses in respect of the 2023 financial year for a retrospective binding approval at the annual general meeting 2024the board of directors proposes awarding the members of the corporate executive committee bonuses for dr severin schwan as resigned ceo in the form of roche shares which are blocked for ten years, for dr thomas schinecker as the incumbent ceo of the roche group in the form of shares and for all other members of the corporate executive committee as a 100 cash payment, see 5.3 and 5.5 totalling chf 10,000,741 in respect of the 2023 financial year 2022: chf 10,691,950, excluding legally required employer contributions to social security agencies, and will submit this proposed total amount to the ordinary annual general meeting agm 2024 for a retrospective approval vote. 5.12.2 submission of the corporate executive committees total future aggregate remuneration for the period between the 2024 ordinary agm and the 2025 ordinary agm for a prospective binding shareholder approval at the annual general meeting 2024 the board of directors proposes that the 2024 ordinary agm approve remuneration for the corporate executive committee totalling not more than chf 38,000,000 excluding legally required employer contributions to ahvivalv and excluding bonuses for the period between the 2024 ordinary agm and the 2025 ordinary agm. the amount of the corporate executive committees total future aggregate remuneration is composed of base pay, long-term incentives s-sars calculated at grant value and rsus see 3.",
    "word_count": 475,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_122",
    "content": "5.12.2 submission of the corporate executive committees total future aggregate remuneration for the period between the 2024 ordinary agm and the 2025 ordinary agm for a prospective binding shareholder approval at the annual general meeting 2024 the board of directors proposes that the 2024 ordinary agm approve remuneration for the corporate executive committee totalling not more than chf 38,000,000 excluding legally required employer contributions to ahvivalv and excluding bonuses for the period between the 2024 ordinary agm and the 2025 ordinary agm. the amount of the corporate executive committees total future aggregate remuneration is composed of base pay, long-term incentives s-sars calculated at grant value and rsus see 3. 1.4, calculated at the time of reservation of non-voting equity securities or shares, pension benefits excluding legally required employer contributions to ahvivalv as well as contributions for expenses, payments for foreign tax obligations, tax consulting services and roche connect.audited174  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 5.12.3 reconciliation of the reported remuneration with the shareholders prospectively approved remuneration for the members of the corporate executive committee the 2022 ordinary agm approved remuneration for the corporate executive committee totalling not more than chf 38,000,000 excluding legally required employer contributions to ahvivalv and excluding bonuses for the period ending at the 2023 ordinary agm. for comparison, from the 2022 ordinary agm to the 2023 ordinary agm actual remuneration amounted to chf 34,026,906 excluding legally required employer contributions to ahvivalv and excluding bonuses in total and remained within the approved total amount. as before, detailed calculation of the actual remuneration for comparison to the remuneration for the corporate executive committee approved at the 2023 ordinary agm totalling not more than chf 38,000,000 excluding legally required employer contributions to ahvivalv and excluding bonuses for the period ending at the 2024 ordinary agm will be made and reported after the end of the aforementioned period. 5.13 clawback in addition to applicable statutory provisions, roches long-term incentive plans include the option to partially reclaim distributed compensation as a result of special circumstances clawback. if the employee voluntarily serves notice of termination of employment, s-sars see 5. 15.2 and rsus see 5. 15.3 which are unvested at the date of termination of employment lapse immediately without any compensation. upon termination of employment as a result of serious misconduct, all s-sars and rsus granted and outstanding, whether vested or unvested, shall lapse immediately without any compensation.",
    "word_count": 403,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "calculated at grant value and rsus see 3. 1.4, calculated at the time of reservation of non-voting equity securities or shares, pension benefits excluding legally required employer contributions to ahvival",
            "position": 795,
            "sentence": "1.4, calculated at the time of reservation of non-voting equity securities or shares, pension benefits excluding legally required employer contributions to ahvivalv as well as contributions for expenses, payments for foreign tax obligations, tax consulting services and roche connect.audited174  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 5.12.3 reconciliation of the reported remuneration with the shareholders prospectively approved remuneration for the members of the corporate executive committee the 2022 ordinary agm approved remuneration for the corporate executive committee totalling not more than chf 38,000,000 excluding legally required employer contributions to ahvivalv and excluding bonuses for the period ending at the 2023 ordinary agm."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_123",
    "content": "15.3 which are unvested at the date of termination of employment lapse immediately without any compensation. upon termination of employment as a result of serious misconduct, all s-sars and rsus granted and outstanding, whether vested or unvested, shall lapse immediately without any compensation. according to the s-sars plan rules, serious misconduct by the participant may include inter alia:  activity leading to serious disciplinary action  repeated or willful failure to perform such duties as have been reasonably assigned by roche  violation of any law or public regulation  commission of a crime  gross negligence or willful misconduct in employment  engaging in conduct bringing disgrace or disrepute to roche andor any of its subsidiaries  violation of any of roches directives and guidelines relating to business conductremuneration report  roche 175 type of security value to be acquired ceo roche group shares andor nes 500 of annual base salary members of the corporate executive committee shares andor nes 200 of annual base salary5.14 guidelines for security holdings since 2012 members of the corporate executive committee are required to hold roche securities. members of the corporate executive committee are required to hold roche securities equivalent in value to 200 of their respective annual base salary. this requirement must be fulfilled within five years from 15 march 2022 or, in the case of new members, within five years from the start of employment. the requirement of roche security holdings for the ceo roche group remains unchanged at 500 of his annual base salary, without a five-year limitation new. 5.15 security holdings as at 31 december 2023 as at 31 december 2022, respectively the members of the corporate executive committee and persons closely associated with them held securities as shown in the following tables shares and non-voting equity securities nes, stock-settled stock appreciation rights s-sars and restricted stock units rsus. 5.15.1 shares and non-voting equity securities nes as at 31 december 2023 as at 31 december 2022 shares numbernes numberclose relatives security holdings numbertypeshares numbernes numberclose relatives security holdings numbertype corporate executive committee shares nes shares nes t. schinecker  3,599    2,752   t. graham  6,459   na na na na a. hippe 6,970 43,124  21 6,970 40,390  21 m. sause  3,516   na na na na c. a. wilbur  16,010    14,640   total 6,970 72,708  21 6,970 57,782  21 na  not applicableaudited176  contents letters to shareholders sustainability report how we contribute corporate governance remuneration report 5.15.2 stock-settled stock appreciation rights s-sars number of s-sars held on 31 december 2023 2023 2022 2021 2020 2019 2018 2017 corporate executive committee t. schinecker 79,169 20,801 22,669 20,652 3,872   t. graham 27,249 4,412 13,344 14,180 8,960 8,304 3,975 a. hippe 42,224 30,255 40,300 41,304 48,930 40,275 2,191 m. sause 26,389 4,020 4,256 3,105 2,931   c. a.",
    "word_count": 451,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "balance_sheet": [
          {
            "keyword": "equity",
            "context": "closely associated with them held securities as shown in the following tables shares and non-voting equity securities nes, stock-settled stock appreciation rights s-sars and restricted stock units rsus. 5.1",
            "position": 1881,
            "sentence": "5.15 security holdings as at 31 december 2023 as at 31 december 2022, respectively the members of the corporate executive committee and persons closely associated with them held securities as shown in the following tables shares and non-voting equity securities nes, stock-settled stock appreciation rights s-sars and restricted stock units rsus."
          },
          {
            "keyword": "equity",
            "context": "tled stock appreciation rights s-sars and restricted stock units rsus. 5.15.1 shares and non-voting equity securities nes as at 31 december 2023 as at 31 december 2022 shares numbernes numberclose relatives",
            "position": 2013,
            "sentence": "5.15.1 shares and non-voting equity securities nes as at 31 december 2023 as at 31 december 2022 shares numbernes numberclose relatives security holdings numbertypeshares numbernes numberclose relatives security holdings numbertype corporate executive committee shares nes shares nes t."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "challenges": [
          {
            "keyword": "limitation",
            "context": "ngs for the ceo roche group remains unchanged at 500 of his annual base salary, without a five-year limitation new. 5.15 security holdings as at 31 december 2023 as at 31 december 2022, respectively the members",
            "position": 1621,
            "sentence": "the requirement of roche security holdings for the ceo roche group remains unchanged at 500 of his annual base salary, without a five-year limitation new."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_124",
    "content": "sause 26,389 4,020 4,256 3,105 2,931   c. a. wilbur 26,390 18,910 25,187 25,815 29,052 21,402 16,032 total 201,421 78,398 105,756 107,987 90,814 69,981 22,198 price chf 261.30 359.70 306.45 308.05 335.45271.65 220.80 251.90 market price per nes on 31 december 2023 chf 244.50 expiry date 16.3.2033 17.3.2032 18.3.2031 19.3.2030 30.4.203015.3.2029 15.3.2025 16.3.2024 grant value per s-sar chf since 1.1.2012:  trinomial model for american call options40.42 56.41 42.35 41.32 44.7134.88 26.49 31.20 5.15.3 restricted stock units rsus number of rsus held on 31 december 2023 2023 2022 2021 2020 corporate executive committee t. schinecker 3,062 815 783 693 t. graham 1,054 2,076 922 475 a. hippe 1,633 1,186 1,392 1,385 m. sause 1,021 1,890 1,176 555 521 c. a. wilbur 1,021 741 870 866 total 7,791 6,708 5,143 4,495 grant value per rsu chf 261.30 nes closing price at grant date on 16 march 2023chf 359.70 nes closing price at grant date on 17 march 2022chf 306.45 nes closing price at grant date on 18 march 2021chf 308.05 chf 335.45 nes closing price at grant date on 19 march 2020 and 30 april 2020 , respectively audited auditedremuneration report  roche 177 to the general meeting of roche holding ltd, basel report on the audit of the remuneration report opinion we have audited the remuneration report of roche holding ltd the company for the year ended 31 december 2023. the audit was limited to the information pursuant to art. 734a734f of the swiss code of obligations co in the sections marked with a grey line and audited, including the respective footnotes, on pages 148 to 177 of the remuneration report. in our opinion, the information pursuant to art. 734a734f co in the accompanying remuneration report complies with swiss law and the companys articles of incorporation. basis for opinion we conducted our audit in accordance with swiss law and swiss standards on auditing sa-ch. our responsibilities under those provisions and standards are further described in the auditors responsibilities for the audit of the remuneration report section of our report. we are independent of the company in accordance with the provisions of swiss law and the requirements of the swiss audit profession, and we have fulfilled our other ethical responsibilities in accordance with these requirements. we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. other information the board of directors is responsible for the other information. the other information comprises the information included in the annual report, but does not include the sections marked audited in the remuneration report, the consolidated financial statements, the stand-alone financial statements and our auditors reports thereon.our opinion on the remuneration report does not cover the other information and we do not express any form of assurance conclusion thereon.",
    "word_count": 461,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_125",
    "content": "other information the board of directors is responsible for the other information. the other information comprises the information included in the annual report, but does not include the sections marked audited in the remuneration report, the consolidated financial statements, the stand-alone financial statements and our auditors reports thereon.our opinion on the remuneration report does not cover the other information and we do not express any form of assurance conclusion thereon. in connection with our audit of the remuneration report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the audited financial information in the remuneration report or our knowledge obtained in the audit or otherwise appears to be materially misstated. if, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. we have nothing to report in this regard. board of directors responsibilities for the remuneration report the board of directors is responsible for the preparation of a remuneration report in accordance with the provisions of swiss law and the companys articles of incorporation, and for such internal control as the board of directors determines is necessary to enable the preparation of a remuneration report that is free from material misstatement, whether due to fraud or error. the board of directors is also responsible for designing the remuneration system and defining individual remuneration packages. auditors responsibilities for the audit of the remuneration report our objectives are to obtain reasonable assurance about whether the information pursuant to art. 734a734f co is free from material misstatement, whether due to fraud or error, and to issue an auditors report that includes our opinion. reasonable assurance is a high level of 178 kpmg ag, grosspeteranlage 5, ch-4002 basel  2024 kpmg ag, a swiss corporation, is a subsidiary of kpmg holding ag, which is a member of the kpmg global organisation of independent member firms affiliated with kpmg international limited, a private english company limited by guarantee. all rights reserved.kpmg ag fran\u00e7ois rouiller paul nichols licensed audit expert auditor in charge basel, 29 january 2024assurance, but is not a guarantee that an audit conducted in accordance with swiss law and sa-ch will always detect a material misstatement when it exists. misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this remuneration report. as part of an audit in accordance with swiss law and sa-ch, we exercise professional judgement and maintain professional skepticism throughout the audit. we also:  identify and assess the risks of material misstatement in the remuneration report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.",
    "word_count": 488,
    "keyword_analysis": {},
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_126",
    "content": "as part of an audit in accordance with swiss law and sa-ch, we exercise professional judgement and maintain professional skepticism throughout the audit. we also:  identify and assess the risks of material misstatement in the remuneration report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. the risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the companys internal control. evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made. we communicate with the board of directors or its relevant committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. we also provide the board of directors or its relevant committee with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and, where applicable, actions taken to eliminate threats or safeguards applied. statutory auditors report  roche 179 imprint cautionary statement regarding forward-looking statements this annual report contains certain forward-looking statements. these forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche. all trademarks are legally protected.",
    "word_count": 495,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "profitability": [
          {
            "keyword": "earnings per share",
            "context": "y executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earni",
            "position": 3114,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings per share",
            "context": "share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earning",
            "position": 3227,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings per share",
            "context": "2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche. all trademarks are legally protected.",
            "position": 3350,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings",
            "context": "y executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earning",
            "position": 3114,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings",
            "context": "arnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the histor",
            "position": 3215,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings",
            "context": "share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical publish",
            "position": 3227,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings",
            "context": "r share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche. all trademarks are legally protected.",
            "position": 3338,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings",
            "context": "2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche. all trademarks are legally protected.",
            "position": 3350,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "profit",
            "context": "d 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023",
            "position": 3149,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "forecast",
            "context": "verse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any su",
            "position": 3156,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          }
        ],
        "challenges": [
          {
            "keyword": "limitation",
            "context": "overy, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or ma",
            "position": 2700,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  },
  {
    "chunk_id": "roche_2023_127",
    "content": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche. all trademarks are legally protected. links to third-party pages are provided for convenience only. we do not express any opinion on the content of any third-party pages and expressly disclaim any liability for all third-party information and the use thereof. the roche annual report is published in german and english. our reporting consists of the actual annual report and of the finance report and contains the annual financial statements and the consolidated financial statements. printed on non-chlorine bleached, fsc-certified paper. published by f. hoffmann-la roche ltd group communications 4070 basel, switzerland tel.: 41 061 688 11 11 www.roche.com to orderdownload publications internet: www.roche .compublications e-mail: materials.management.mm1roche.com fax: 41 061 688 69 02 media relations tel.: 41 061 688 88 88 e-mail: media.relationsroche.com investor relations tel.: 41 061 688 88 80 e-mail: investor.relationsroche.com group sustainability e-mail: corporate.sustainabilityroche.comkey dates for 2024 annual general meeting 12 march 2024 first-quarter sales 24 april 2024 half-year results 25 july 2024 nine-month sales 23 october 2024 f. hoffmann-la roche ltd 4070 basel, switzerland  2024 all trademarks are legally protected. www.roche.com 77 265 745sharing his journey with multiple sclerosis, antoine helps us improve care for people with ms. since 2019, serving as a patient expert, he has brought a valuable perspective to roche, contributing to several significant outcomes. read his story on page 98 of this annual report.",
    "word_count": 406,
    "keyword_analysis": {
      "FINANCIAL_METRICS": {
        "revenue_terms": [
          {
            "keyword": "sales",
            "context": "porate.sustainabilityroche.comkey dates for 2024 annual general meeting 12 march 2024 first-quarter sales 24 april 2024 half-year results 25 july 2024 nine-month sales 23 october 2024 f. hoffmann-la roche",
            "position": 2335,
            "sentence": "hoffmann-la roche ltd group communications 4070 basel, switzerland tel.: 41 061 688 11 11 www.roche.com to orderdownload publications internet: www.roche .compublications e-mail: materials.management.mm1roche.com fax: 41 061 688 69 02 media relations tel.: 41 061 688 88 88 e-mail: media.relationsroche.com investor relations tel.: 41 061 688 88 80 e-mail: investor.relationsroche.com group sustainability e-mail: corporate.sustainabilityroche.comkey dates for 2024 annual general meeting 12 march 2024 first-quarter sales 24 april 2024 half-year results 25 july 2024 nine-month sales 23 october 2024 f."
          },
          {
            "keyword": "sales",
            "context": "l meeting 12 march 2024 first-quarter sales 24 april 2024 half-year results 25 july 2024 nine-month sales 23 october 2024 f. hoffmann-la roche ltd 4070 basel, switzerland  2024 all trademarks are legally p",
            "position": 2397,
            "sentence": "hoffmann-la roche ltd group communications 4070 basel, switzerland tel.: 41 061 688 11 11 www.roche.com to orderdownload publications internet: www.roche .compublications e-mail: materials.management.mm1roche.com fax: 41 061 688 69 02 media relations tel.: 41 061 688 88 88 e-mail: media.relationsroche.com investor relations tel.: 41 061 688 88 80 e-mail: investor.relationsroche.com group sustainability e-mail: corporate.sustainabilityroche.comkey dates for 2024 annual general meeting 12 march 2024 first-quarter sales 24 april 2024 half-year results 25 july 2024 nine-month sales 23 october 2024 f."
          }
        ],
        "profitability": [
          {
            "keyword": "earnings per share",
            "context": "y executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earni",
            "position": 997,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings per share",
            "context": "share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earning",
            "position": 1110,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings per share",
            "context": "2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche. all trademarks are legally protected. links to third-party pages are provided for conveni",
            "position": 1233,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings",
            "context": "y executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earning",
            "position": 997,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings",
            "context": "arnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the histor",
            "position": 1098,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings",
            "context": "share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical publish",
            "position": 1110,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings",
            "context": "r share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche. all trademarks are legally protected. links to third-party pages ar",
            "position": 1221,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "earnings",
            "context": "2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche. all trademarks are legally protected. links to third-party pages are provided f",
            "position": 1233,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          },
          {
            "keyword": "profit",
            "context": "d 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023",
            "position": 1032,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          }
        ]
      },
      "BUSINESS_OUTLOOK": {
        "future_prospects": [
          {
            "keyword": "forecast",
            "context": "verse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any su",
            "position": 1039,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          }
        ],
        "challenges": [
          {
            "keyword": "limitation",
            "context": "overy, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or ma",
            "position": 583,
            "sentence": "various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this annual report, such as: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.the statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that roches earnings or earnings per share for 2023 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of roche."
          }
        ]
      }
    },
    "company": "roche",
    "year": "2023",
    "source": "roche_2023.pdf",
    "processing_date": "2024-11-03T20:45:16.976474"
  }
]